aripiprazole profile

Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	60795
CHEMBL ID	1112
CHEBI ID	31236
SCHEMBL ID	8255
SCHEMBL ID	5335696
SCHEMBL ID	12961254
MeSH ID	M000602020

Synonym
AC-1554
CHEMBL1112 ,
aripiprex
nsc-759266
abilify mycite
AKOS005558247
HY-14546
HMS3393I18
AB00639935-09
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one
gtpl34
aristada (aripiprazole lauroxil)
abilify
abilify od
2(1h)-quinolinone, 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-
7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
aripiprazole [usan]
7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
aripiprazole depot
opc 14597
7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1h)-quinolinone
hsdb 7320
abilitat
7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1h)-quinolinone
abilify discmelt
bms-337039
opc-14597
opc-31
discmelt
opc 31
aripiprazole
129722-12-9
MLS001424078
24-29-3
smr000466383
MLS000759517
cpd000466383
NCGC00159510-02
DB01238
NCGC00159510-03
aripiprazole (jan/usp/inn)
D01164
abilify (tn)
aripiprazolum
aripiprazol
MLS001165779
CHEBI:31236 ,
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1h)-one
MLS001195621
HMS2051I18
HMS2093F22
HMS2089M20
bdbm50130293
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-quinolin-2-one
L001339
FT-0662279
FT-0662278
STK625160
A19454
abilify maintena
aripiprazole [usan:inn:ban]
nsc 759266
unii-82vfr53i78
82vfr53i78 ,
abilify maintena kit
abilify digital
dtxcid1026083
tox21_111728
cas-129722-12-9
dtxsid3046083 ,
BCP9000317
pharmakon1600-01505851
nsc759266
7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1h)-quinolinone
HMS2230M18
CCG-100891
FT-0600352
NCGC00159510-04
AB07660
CS-0766
S1975
2(1h)-quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-
HMS3373D04
aripiprazole [mart.]
aripiprazole [who-dd]
aripiprazole [ema epar]
aripiprazole [vandf]
aripiprazole [mi]
aripiprazole [inn]
aripiprazole [usp-rs]
aripiprazole [ep monograph]
abilify mycite kit
aripiprazole [usp monograph]
aripiprazole [jan]
aripiprazole [hsdb]
aripiprazole [orange book]
DL-178
NC00141
AM20090766
BBL029082
SCHEMBL8255
tox21_111728_1
NCGC00159510-05
KS-1030 ,
7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]3,4-dihydro-2(1h)-quinolinone
7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy)-3,4-dihydrocarbostyril
7-{4-[-4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril
7-[4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy]-3,4-dihydro-2(1h)-quinolinone
7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3, 4-dihydrocarbostyril
SCHEMBL5335696
MLS006011892
7-{4-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1h-quinolin-2-one
7-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy)-3,4-dihydroquinolin-2(1h)-one
pripiprazole
arpizol
SCHEMBL12961254
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1h)-one
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-quinolin-2(1h)-one
AB00639935_11
AB00639935_10
J-005707
SR-01000759353-4
SR-01000759353-6
sr-01000759353
HMS3657K13
aripiprazole 1.0 mg/ml in acetonitrile
SBI-0206870.P001
HMS3715J07
7-{4-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1h-quinol in-2-one
1026778-41-5
SW197521-3
BCP04902
Q411188
aripiprazole; 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
mfcd00892072
SY053146
Z1521553846
aripiprazole (abilify)
asprito
BRD-K70358946-001-06-6
EN300-119521
7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1h-quinolin-2-one
9sc ,
HMS3884E18
HMS3744A13
129722-12-9 (free base)
BA164218
aripiprazole- bio-x
aripiprazole-d8(butyl-d8)
ps25 - aripiprazole/dehydroaripiprazole
ariprazoleimpurity
aripiprazole (mart.)
aripiprazole (ep monograph)
7-(4-(4-(2,3-bis(chloranyl)phenyl)piperazin-1-yl)butoxy)-3,4-dihydro-1h-quinolin-2-one
aripiprazole (usp-rs)
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-1,2,3,4-tetrahydroquinolin-2-one
aripiprazole orally disintegrating
n05ax12
2(1h)-quinolinone, 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro- list acronyms
aripiprazole (usp monograph)
aripiprazole, 1mg/ml in acetonitrile

Excerpt	Reference	Relevance
"Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D(2)-dopamine receptor partial agonist."	( Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Arrington, E; Chiodo, LA; Liu, LX; Mailman, R; Renock, S; Roth, BL; Shapiro, DA; Sibley, DR, 2003)	2.48
"Aripiprazole is an atypical FDA-approved anti-psychotic drug with potential against AD."	( Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model. Choi, JY; Jeong, YJ; Ko, YG; Lee, HJ; Oh, SJ; Park, HJ; Son, Y, 2021)	1.65
"Aripiprazole is an antipsychotic drug used to treat schizophrenia and bipolar disorder. "	( The antipsychotic aripiprazole induces peripheral antinociceptive effects through PI3Kγ/NO/cGMP/K Aguiar, DC; de Almeida, DL; Duarte, IDG; Ferreira, RCM; Moreira, FA; Romero, TRL, 2022)	2.5
"Aripiprazole was found to be an effective first-line antidepressant in LLD. "	( Aripiprazole as First-Line Therapy for Late-Life Depression: A Case Note Review. Sonal, A; Srivastava, S, )	3.02
"Aripiprazole is a second-generation antipsychotic, efficacious in patients with schizophrenia during acute episodes. "	( Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. Alamome, I; Azorin, JM; Drapier, D; El Hage, W; Fakra, É; Jardri, R; Llorca, PM; Mouchabac, S; Nuss, P; Rabbani, M; Simon, N; Vacheron, MN, 2022)	2.42
"Aripiprazole is an antipsychotic with a partial agonism of dopamine D"	( Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice. Alamo, C; Almenta Gallego, D; Arques-Egea, S; Fraguas, D; Gómez-Revuelta, M; Hernández Huerta, D; Núñez Arias, D; Oda Plasencia-García, B; Parro Torres, C; Romero-Guillena, SL; Ros Cucurul, E; Sánchez-Lafuente, CG, 2023)	3.8
"Aripiprazole is an atypical antipsychotic drug, which is prescribed for many psychiatric diseases such as schizophrenia and mania in bipolar disorder. "	( Block of Voltage-Gated Sodium Channels by Aripiprazole in a State-Dependent Manner. Fauler, M; Föhr, KJ; Jungwirth, B; Messerer, DAC; Rapp, M; Zimmer, T, 2022)	2.43
"Aripiprazole seems to be an effective and well-tolerated antipsychotic drug in the treatment of CS accompanying autism."	( Aripiprazole Used to Treat Capgras Syndrome in an Adolescent Diagnosed With Autism. Baykal, S; Mutlu, C, )	3.02
"Aripiprazole (APZ) is an atypical antipsychotic that can safeguard mice against autism-like behavior induced by valproic acid (VPA)."	( Maternal treatment with aripiprazole prevents the development of a valproic acid-induced autism-like phenotype in juvenile male mice. de Andrade, GM; de Barros Viana, GS; de Oliveira Ferreira, E; Lima, FAV; Neves, KRT; Pessoa Gomes, JM, 2023)	1.94
"Aripiprazole is a medication used to treat psychotic symptoms in schizophrenia or bipolar I disorder (BP-I) that can be taken orally or injected into the muscle. "	( A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. Harlin, M; Jan, M; Jin, N; Larsen, F; Madera-McDonough, J; Such, P; Watkin, S; Yildirim, M, 2023)	2.56
"Aripiprazole (ARI) is an atypical antipsychotic that improves some cognitive functions."	( Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. Bai, M; Chen, H; Kang, L; Li, Q; Li, S; Lin, Y; Lu, C; Tang, Z; Xiong, P; Zhang, H, 2023)	3.07
"Aripiprazole is an antipsychotic medicine used to treat a variety of mental disorders, including irritability linked with autism disorder in children. "	( Application of a nucleophilic substitution reaction for spectrofluorimetric determination of aripiprazole in pharmaceutical dosage form and plasma matrix; greenness assessment. Abdullah, O; Alaqel, SL; Alharbi, A; Almalki, AH; Almrasy, AA; Althobaiti, YS; Alturki, MS; Ramzy, S, 2023)	2.57
"Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. "	( Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review. Benites-Zapata, VA; Campos-Rodriguez, SK; Fernández, MF; Ortiz-Saavedra, B; Pino-Zavaleta, DA; Valdivieso-Jiménez, G, 2023)	2.66
"Aripiprazole is a better choice to avoid relevant short-term weight gain."	( An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. Cai, S; Cheng, Z; Correll, CU; Deng, H; Han, X; Lu, Z; Wang, C; Xiang, Y; Yang, F; Yang, L; Yu, X; Yuan, Y; Zhao, J, 2019)	1.5
"Aripiprazole, which is a quinolinone derivative, has been widely used to treat schizophrenia, major depressive disorder, and bipolar disorder."	( Optimization of Processing Parameters of Nanoemulsion Containing Aripiprazole Using Response Surface Methodology. Ahmad, S; Ashari, SE; Salim, N; Samiun, WS, 2020)	2.24
"Aripiprazole is a quinolinone derivative. "	( Electrophilic Aromatic Synthesis of Radioiodinated Aripiprazole: Experimental and DFT Investigations. Anouar, EH; Farag, ZR; Geesi, MH; Moustapha, ME, 2020)	2.25
"Aripiprazole is an atypical antipsychotic commonly used in the treatment of childhood disorders, such as bipolar disorder, psychosis, and irritability associated with autism spectrum disorder. "	( Low-dose Aripiprazole Induced Enuresis Continuum in a Child. Karatoprak, S; Uzun, N, )	1.99
"Aripiprazole lauroxil (AL) is a long-acting injectable antipsychotic approved for treatment of schizophrenia in adults. "	( Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ, 2020)	2.21
"Aripiprazole is a third generation antipsychotic approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia. "	( A safety evaluation of aripiprazole in the treatment of schizophrenia. Preda, A; Shapiro, BB, 2020)	2.31
"Aripiprazole is a generally well-tolerated third-generation antipsychotic with low rates of motor side effects and metabolic adverse effects that occur commonly with several alternative antipsychotics. "	( A safety evaluation of aripiprazole in the treatment of schizophrenia. Preda, A; Shapiro, BB, 2020)	2.31
"Aripiprazole lauroxil (AL) is a long-acting atypical antipsychotic approved for the treatment of schizophrenia in adults. "	( Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals. Du, Y; Faldu, S; Rege, B; Sommi, RW; Wehr, A; Weiden, PJ, 2022)	3.61
"Aripiprazole is known to be a prolactin-sparing antipsychotic; however, data regarding its effects on prolactin and estrogens in postmenopausal women are lacking."	( Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression. Hartz, SM; Lenze, EJ; Ma, C; Mulsant, BH; Nicol, GE; Patrick, C; Rahman, T; Reynolds, CF; Yingling, M, )	1.09
"Aripiprazole is an atypical antipsychotic commonly used in the treatment of psychiatric disorders, such as schizophrenia, bipolar disorder, and irritability associated with autism spectrum disorder. "	( Low-Dose Aripiprazole-Induced Nocturnal Enuresis in a 9-Year-Old Boy: A Case Report and the Possible Underlying Mechanism. Özdemir, YE; Tanir, Y, )	1.99
"Aripiprazole is a third-generation atypical antipsychotic drug that acts as a stabilizer of the dopaminergic and serotonergic system. "	( Resolution of enuresis with aripiprazole in children with psychiatric disorders: two case reports. Capizzi, M; Gliubizzi, C; Guccione, F; Mangano, S; Marino, A; Nardello, R, 2021)	2.36
"Aripiprazole is an atypical antipsychotic drug that is metabolized by cytochrome P450 (CYP) 2D6 and CYP3A4, which mainly form its active metabolite dehydro-aripiprazole. "	( Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. Abad-Santos, F; Hempel, G; Kneller, LA; Koller, D; Zubiaur, P, 2021)	2.31
"Aripiprazole monotherapy is a recommended option for the treatment of mania in BD."	( Gamma oscillations predict treatment response to aripiprazole in bipolar disorder. Arıkan, MK; Günver, G; İlhan, R; Metin, B; Öksüz, Ö, 2021)	1.6
"Aripiprazole lauroxil is an extended-release prodrug of aripiprazole for intramuscular injection, approved for schizophrenia treatment. "	( Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Citrome, L; Hard, ML; Mills, RJ; Sadler, BM; Turncliff, RZ, 2017)	3.34
"Aripiprazole is a newer atypical antipsychotic that displays a unique pharmacological profile, including partial D2 agonism and functionally selective properties. "	( Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Holahan, MR; Tuplin, EW, 2017)	3.34
"Aripiprazole is an atypical antipsychotic agent commonly used in the management of schizophrenia. "	( Aripiprazole-induced hypersensitivity pneumonitis. Gunasekaran, K; Jennings, J; Lone, N; Murthi, S, 2017)	3.34
"Aripiprazole lauroxil (AL) is a long-acting injectable medication approved for the treatment of schizophrenia. "	( Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY; Weiden, PJ, 2017)	2.15
"Aripiprazole is an atypical antipsychotic with dopaminergic and serotonergic effects. "	( Aripiprazole-Related Diurnal Enuresis in Children: 2 Cases (Aripiprazole-Related Enuresis). Gunes, S, )	3.02
"Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic that was evaluated for the treatment of schizophrenia in a randomized, placebo-controlled, Phase 3 study. "	( Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. Citrome, L; Cutler, AJ; Du, Y; Nasrallah, HA; Risinger, R; Silverman, BL; Zummo, J, 2018)	2.33
"Aripiprazole is a second generation antipsychotic widely prescribed for the treatment of psychiatric diseases. "	( Aripiprazole-induced Asymptomatic Hypertension: A Case Report. Ayhan, MG; Eren, İ; Kürkcü, A; Özbek, S; Seven, H, 2017)	3.34
"Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for treatment of schizophrenia on the basis of a large-scale trial of two doses of AL versus placebo. "	( Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison. Cameron, C; Desai, DN; Drake, C; Hutton, B; Kotb, A; Weiden, PJ; Zummo, J, )	3.02
"Aripiprazole is an atypical antipsychotic which used for the treatment of schizophrenia and bipolar disorder."	( Aripiprazole prevents renal ischemia/reperfusion injury in rats, probably through nitric oxide involvement. Gholampour, H; Moezi, L; Shafaroodi, H, 2017)	2.62
"Aripiprazole lauroxil (AL) is an FDA-approved treatment for schizophrenia. "	( A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. Hard, M; Risinger, R; Weiden, PJ, 2017)	2.11
"Aripiprazole is a dopamine D2 receptor partial agonist that exhibits partial agonistic activity against serotonin-1A (5-HT1A) receptors and full antagonistic activity against 5-HT2A receptors."	( [Efficacy of low-Dose Aripiprazole to Treat Clozapine-Associated Tardive Dystonia in a Patient with Schizophrenia]. Huh, L; Lee, BJ, 2017)	1.49
"Aripiprazole is a dopamine D2- and serotonin 5-hydroxytryptamine (5-HT)"	( Aripiprazole in treatment of Gilles de la Tourette syndrome - New therapeutic option. Janik, P; Szejko, N, )	3.02
"Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for the treatment of schizophrenia."	( Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. Cameron, C; Desai, D; Drake, C; Hutton, B; Kotb, A; Weiden, PJ; Zummo, J, 2018)	2.23
"Aripiprazole is a new drug for the treatment of adults with schizophrenia. "	( Aripiprazole-induced transient myopia: A rare entity. Alam, MS; Chiranjeevi, P; Praveen Kumar, KV, 2018)	3.37
"Aripiprazole is a second-generation antipsychotics, acting as a partial dopamine D2 receptor agonist. "	( Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study. Chan, CH; Chan, HY; Chen, YC, 2018)	2.2
"Aripiprazole is an effective and safe augmentation for treatment resistance."	( Advances in Pharmacotherapy of Late-Life Depression. Beyer, JL; Johnson, KG, 2018)	1.2
"Aripiprazole is an atypical antipsychotic drug approved worldwide for treatment of acute and long term schizophrenia in adults. "	( Aripiprazole Nanocrystal Impregnated Buccoadhesive Films for Schizophrenia. Al-Dhubiab, BE, 2017)	3.34
"Aripiprazole is a third-generation atypical antipsychotic medication, which is widely used for various psychiatric disorders across the lifespan. "	( Aripiprazole-Induced Neutropenia: Case Report and Literature Review. Chaudhary, AM; Felin, T; Naveed, S, 2018)	3.37
"Aripiprazole is an atypical antipsychotic with a long half-life. "	( Prolonged QRS Widening After Aripiprazole Overdose. Dewey, K; Mazer-Amirshahi, M; Porter, R, 2019)	2.25
"Aripiprazole is a second generation antipsychotic medication that has been a useful addition to the treatment of severe mental illness due to its low metabolic and sedation risk profile. "	( Aripiprazole and pregnancy: A retrospective, multicentre study. Frayne, J; Galbally, M; Snellen, M; Watson, SJ, 2018)	3.37
"Aripiprazole is an atypical antipsychotic drug with a polypharmacological mechanism of action and a favorable tolerability profile. "	( Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors. Anastasia, A; D'Urso, G; de Bartolomeis, A; Patti, S; Toscano, E, 2018)	3.37
"Aripiprazole lauroxil is an LAI that offers multiple dosing options but requires oral treatment overlap during initiation for the first 21 consecutive days."	( Aripiprazole Lauroxil NanoCrystal Clark, C; Davis, E; Ehret, MJ; Luttrell, SE, )	2.3
"Aripiprazole is an atypical antipsychotic drug that is commonly used in children and adolescents."	( Aripiprazole-Induced Hoarseness: A Case Report. Çam Ray, P; Işik, Ü, )	3.02
"Aripiprazole is an interesting psychoactive compound acting as a dopamine D2 partial agonist, serotonin 5-HT(1A) partial agonist and serotonin 5-HT(2A) antagonist. "	( Aripiprazole-induced persistent hiccup: a case report and review of the literature. Amore, M; Belvederi Murri, M; Cervetti, A; Monacelli, F; Piccinini, G; Pompili, M; Serafini, G; Visimberga, S, 2019)	3.4
"Aripiprazole is an atypical antipsychotic with partial agonism at dopamine and serotonin receptors. "	( Aripiprazole Toxicity With a Biphasic Course of Somnolence. Gupta, D; OʼHara, C, 2019)	3.4
"Aripiprazole is a new drug applied in schizophrenia treatment. "	( [Application of HPLC-UV method for aripiprazole determination in serum]. Florek, E; Gomółka, E; Piekoszewski, W; Synowiec, A; Zieba, A; Zyss, T, 2012)	2.1
"Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile."	( Aripiprazole versus other atypical antipsychotics for schizophrenia. El-Sayeh, HG; Hunger, H; Khanna, P; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S, 2013)	2.55
"Aripiprazole LAI (ALAI) is a lyophilized powder that needs to be reconstituted with sterile water to form an injectable suspension without affecting the original molecule."	( Long-acting injectable aripiprazole: how might it fit in our tool box? Aggarwal, A; Gopalakrishna, G; Lauriello, J, 2013)	1.42
"Aripiprazole is an atypical antipsychotic drug which belongs to the benzisoxazole derivatives. "	( Aripiprazole. Ardiana, F; Indrayanto, G; Lestari, ML, 2013)	3.28
"Aripiprazole is a second-generation antipsychotic that is increasingly being prescribed to children and adolescents. "	( Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats. Charntikov, S; Crawford, CA; Der-Ghazarian, T; Lee, RJ; McDougall, SA; Varela, FA, 2014)	2.26
"Aripiprazole is an effective treatment for mania in a population that includes adults, children and adolescents, although its use leads to gastrointestinal disturbances and movement disorders. "	( Aripiprazole alone or in combination for acute mania. Brown, R; Geddes, J; Taylor, MJ, 2013)	3.28
"Aripiprazole is a drug with partial agonist activity at the level of dopamine receptors D2, which may be effective for antipsychotic- induced hyperprolactinemia."	( Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Cavuto, M; De Berardis, D; Di Giannantonio, M; Fornaro, M; Girinelli, G; Iasevoli, F; Marini, S; Martinotti, G; Mazza, M; Perna, G; Piersanti, M; Serroni, N; Valchera, A, 2014)	1.33
"Aripiprazole is an antipsychotic drug with an important adverse effect profile."	( Aripiprazole versus other atypical antipsychotics for schizophrenia. El-Sayeh, HG; Khanna, P; Komossa, K; Leucht, S; Ma, H; Rummel-Kluge, C; Suo, T; Xia, J, 2014)	2.57
"Aripiprazole (Abilify(®)) is an atypical antipsychotic that is widely used in the treatment of psychiatric conditions. "	( Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder. McKeage, K, 2014)	3.29
"Aripiprazole is a partial agonist at dopamine (D2) and serotonin (5-HT1a) receptors and 5-HT2 antagonist. "	( Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. Campbell, C; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2014)	3.29
"Aripiprazole (ARI) is an atypical antipsychotic drug, which has also been shown to have a beneficial effect on cognitive function."	( Evaluation of antidepressant and memory-improving efficacy of aripiprazole and fluoxetine in alcohol-preferring rats. Burda-Malarz, K; Czubak, A; Jędrzejewski, L; Kus, K; Nowakowska, E; Ratajczak, P; Sadowski, C, 2014)	1.36
"Aripiprazole (ABILIFY(®)) is an atypical antipsychotic drug that is proposed to act via partial agonism of dopamine D2 receptors. "	( Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Perry, CM; Shirley, M, 2014)	3.29
"Aripiprazole (ARI) is a second-generation antipsychotic acting as a dopamine-serotonin system stabilizer and partial agonist at D2 receptors. "	( A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. Gentile, S, 2014)	2.16
"Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors, with a favorable pharmacological profile. "	( The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice. Aguiar, DC; Almeida-Santos, AF; Duarte, ID; Ferreira, RC; Gobira, PH; Moreira, FA; Romero, TR; Souza, DP, 2014)	2.18
"Aripiprazole lauroxil is a linker lipid ester of aripiprazole for extended-release intramuscular (IM) injection. "	( Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Du, Y; Ehrich, EW; Hard, M; Risinger, R; Turncliff, R, 2014)	2.11
"Aripiprazole is an antipsychotic drug that shows a partial agonistic activity at D2 receptors."	( Severe exacerbation of psychosis after sudden withdrawal of chlorpromazine in the treatment of methamphetamine-associated psychosis with aripiprazole and chlorpromazine: 2 case reports. Devi Thakoor, JP; Hao, W; Wang, G; Wang, X, )	1.06
"Aripiprazole is a second-generation antipsychotic drug with partial dopamine agonistic activity. "	( Aripiprazole induced non-cardiogenic pulmonary edema: a case report. Cakıcı, M; Celik, M; Cetin, M; Polat, M; Suner, A, 2014)	3.29
"Aripiprazole is an atypical antipsychotic with proven efficacy in schizophrenia and bipolar I disorder, with a pharmacological profile distinct from other available antipsychotics and a side-effect profile that is different from other agents in the class; these characteristics make it a possible alternative in patients requiring a change in antipsychotic treatment due to lack of efficacy or persistent side-effects."	( Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Brugnoli, R; De Filippis, S; Di Sciascio, G; Fagiolini, A; Maina, G, 2015)	1.41
"Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 receptors. "	( Aripiprazole-Induced Hypoprolactinemia in an Adult Male with First-Episode Psychosis. Jarvis, GE; Margolese, HC; Propst, AJ, 2016)	3.32
"Aripiprazole is a novel atypical antipsychotic."	( The Effects of Sub-Chronic Treatment with Aripiprazole on Pentylenetetrazole- and Electroshock-Induced Seizures in Mice: The Role of Nitric Oxide. Hosseini, M; Moezi, L; Niknahad, H; Oveisi, S; Shafaroodi, H, 2015)	1.4
"Aripiprazole is an antipsychotic drug which acts through dopamine and serotonin receptors. "	( The effect of acute aripiprazole treatment on chemically and electrically induced seizures in mice: The role of nitric oxide. Hosseini, M; Moezi, L; Niknahad, H; Oveisi, S; Shafaroodi, H, 2015)	2.18
"Aripiprazole is a wide-used antipsychotic drug with therapeutic effects on both positive and negative symptoms of schizophrenia, and reduced side-effects. "	( Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats. Chen, J; Deng, C; Huang, XF; Lian, J; Pan, B, 2015)	2.17
"Aripiprazole is a low-risk antipsychotic regarding cardiac safety in healthy patients. "	( The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Graff, C; Kanters, JK; Meyer, J; Nielsen, J; Polcwiartek, C; Sneider, B; Taylor, D, 2015)	2.17
"Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. "	( Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum. Aguiar, DC; Batista, LA; Moreira, FA; Silveira, VT; Viana, TG, 2016)	2.27
"Aripiprazole is an antipsychotic that acts by multiple mechanisms, including partial agonism at dopamine D2 and serotonin 5-HT1A receptors. "	( The antipsychotic aripiprazole induces antinociceptive effects: Possible role of peripheral dopamine D2 and serotonin 5-HT1A receptors. Aguiar, DC; Almeida-Santos, AF; Duarte, ID; Ferreira, RC; Moreira, FA; Romero, TR, 2015)	2.19
"Aripiprazole is a third-generation antipsychotic with a dopamine receptor-binding profile distinct from other second-generation antipsychotics."	( Aripiprazole. Prommer, E, 2017)	2.62
"Aripiprazole is a partial D2 receptor agonist, whereas DRT includes full D2 receptor agonist."	( Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. Challet-Bouju, G; Derkinderen, P; Etcheverrigaray, F; Gaboriau, L; Grall-Bronnec, M; Jolliet, P; Leboucher, J; Perrouin, F; Sauvaget, A; Victorri-Vigneau, C, 2016)	1.43
"Aripiprazole is a D2 receptor partial agonist hypothesised to enhance PFC dopamine functioning, possibly improving working memory."	( An investigation into aripiprazole's partial D₂ agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. Deakin, JF; Dursun, S; Elliott, R; McKie, S; Murphy, A, 2016)	1.47
"Aripiprazole is a partial dopamine agonist with low sedation, relatively favourable metabolic profile and a tendency to lower, rather than raise, prolactin. "	( Aripiprazole long-acting injection: promising but more evidence needed. Culhane, C; Hope, J; Keks, NA, 2016)	3.32
"Aripiprazole is a first or second line treatment frequently used because it has reduced side effects such as weight gain, sleepiness, dyslipidemia, insulin resistance, hyperprolactinemia and extrapyramidal symptoms."	( [Aripiprazole, gambling disorder and compulsive sexuality]. Dafreville, C; Mété, D; Paitel, V; Wind, P, 2016)	2.07
"Aripiprazole is an antipsychotic associated with reduced side effects compared to other antipsychotics. "	( [Aripiprazole, gambling disorder and compulsive sexuality]. Dafreville, C; Mété, D; Paitel, V; Wind, P, 2016)	2.79
"Aripiprazole is a third generation antipsychotic drug that possesses a unique pharmacodynamic profile, which in conjunction with recently published scientific data on the drugs' influence on antidepressant, anxiolytic and cognitive functions, suggests a highly positive future potential for restorative cognitive treatment and ongoing healthy function."	( Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole. Getova, DP; Topolov, MK, 2016)	1.38
"Aripiprazole is an atypical antipsychotic approved for the treatment of irritability and aggression in children and adolescents aged 6-17 years with autism spectrum disorder."	( Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders. Pavone, P; Rizzo, R, 2016)	3.32
"Aripiprazole is a D2-like receptor (D2R) partial agonist with a favourable clinical profile. "	( Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats. Deng, C; Huang, XF; Pan, B, 2016)	2.18
"Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. "	( Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole. Bruhn, CH; Fink-Jensen, A; Jakobsen, KD; Nielsen, J; Pagsberg, AK, 2016)	2.09
"Aripiprazole augmentation is an efficacious strategy in older depressed adults who fail to remit with two or more adequate antidepressant trials, including a course of venlafaxine."	( Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation. Blumberger, DM; Hsu, JH; Karp, JF; Lavretsky, H; Lenze, EJ; Mulsant, BH; Reynolds, CF; Roose, SP, 2016)	2.1
"Aripiprazole is a unique atypical antipsychotic with partial agonist activity on the dopamine-2 (D2) receptor. "	( Risk of Extrapyramidal Adverse Events With Aripiprazole. Carleton, BC; Etminan, M; Procyshyn, RM; Samii, A, 2016)	2.14
"Aripiprazole once-monthly is a second generation antipsychotic recently developed."	( Aripiprazole once-monthly as treatment for psychosis in Turner syndrome: literature review and case report. Carlone, C; Nicolò, G; Pompili, E; Silvestrini, C, )	2.3
"Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. "	( Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole. Chouinard, S; Huot, P; Selfani, K; Soland, VL, 2017)	2.14
"Aripiprazole (ARP) is a popular antipsychotic drug that has demonstrated ameliorative effects on hyperprolactinemia. "	( Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series. Abe, H; Funahashi, H; Ishida, Y; Naono, H; Naono-Nagatomo, K; Takeda, R; Uchimura, D, 2017)	2.18
"Aripiprazole is a partial agonist for the dopamine D2, serotonin 5-HT1A receptors, and an antagonist for 5HT2A receptors."	( [Acute Dystonia due to Aripiprazole Use in Two Children with Autism Spectrum Disorder in the First Five Years of Life]. Kabukçu Başay, B; Küçükköse, M, 2017)	1.49
"Aripiprazole, which acts as a dopamine/5-HT system stabilizer, approaches the optimal characteristics sought in medication to be considered for testing in the treatment of alcohol dependence."	( Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. Di Giannantonio, M; Di Nicola, M; Janiri, L; Martinotti, G, 2009)	2.52
"Aripiprazole is a second-generation antipsychotic that seems to have a favorable side-effect profile."	( The safety of the electroconvulsive therapy-aripiprazole combination: four case reports. Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR; Zervas, IM, 2008)	1.33
"Aripiprazole is a fairly new atypical antipsychotic substance. "	( Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Bachmann, CJ; Heinzel-Gutenbrunner, M; Hiemke, C; Remschmidt, H; Rieger-Gies, A; Theisen, FM, 2008)	2.11
"Aripiprazole is a first next-generation atypical antipsychotic drug with dopamine system stabilizing, serotonin (5-hydroxytryptamine, 5-HT) 5-HT1A receptor partial agonistic, and 5-HT2A receptor antagonistic properties. "	( Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms. Abe, M; Egashira, N; Fujiwara, M; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Oishi, R; Okuno, R, 2008)	3.23
"Aripiprazole is a relatively new antipsychotic drug, said to be the prototype of a new third generation of antipsychotics; the so-called dopamine-serotonin system stabilisers. "	( Aripiprazole versus typical antipsychotic drugs for schizophrenia. Bhattacharjee, J; El-Sayeh, HG, 2008)	3.23
"Aripiprazole is a new antipsychotic agent that has proven safe and efficacious in controlled clinical trials. "	( Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients. Barbero, JD; Benito, N; Cobo Gómez, JV; Coronas, R; Domenech, C; Fuste, G; García-Parés, G; Gómez, JV, 2008)	2.14
"Aripiprazole is a novel atypical antipsychotic drug with neuroprotective properties. "	( Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Wang, SJ; Yang, TT, 2008)	3.23
"Aripiprazole is a dopamine partial agonist approved for use in adults for short- and long-term treatment of schizophrenia and bipolar disorder. "	( A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Carson, WH; Findling, RL; Forbes, RA; Ivanova, S; Iwamoto, T; Jin, N; Marcus, R; McQuade, RD; Nyilas, M; Robb, A, 2008)	2.02
"Aripiprazole is an efficacious and well-tolerated add-on treatment for sertraline-resistant BPD patients."	( Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Bellino, S; Bogetto, F; Paradiso, E, 2008)	1.36
"Aripiprazole is a new dopaminergic agent and has been reported to be clinically useful as an antipsychotic drug with reduced extrapyramidal motor side effects."	( Aripiprazole-induced rabbit syndrome: a case report. Caykoylu, A; Deniz, O; Ekinci, O; Kuloglu, M, 2010)	2.52
"Aripiprazole is a second-generation antipsychotic that is increasingly prescribed in a variety of psychiatric disorders. "	( Predictors of aripiprazole treatment continuation in hospitalized patients. Ammerman, DK; Coley, KC; Fabian, TJ; Ganguli, R; Kim, E; Kim, MS; Saul, MI; Scipio, TM; Whitehead, R, 2008)	2.15
"Aripiprazole is an effective antipsychotic in the long-term treatment of both positive and negative symptoms. "	( Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY, 2009)	2.08
"Aripiprazole is a new generation antipsychotic drug with a partial agonist effect on dopamine D2 and D3 receptors. "	( Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. Adan-Manes, J; Garcia-Parajua, P, 2009)	3.24
"Aripiprazole is an atypical antipsychotic drug primarily characterized by partial agonist activity at dopamine(DA) D2 receptors and serotonin-1A (5-hydroxytryptamine, 5-HT1A) receptors and minimal side effects.Based on its pharmacological profile, including stabilization of mesocorticolimbic DA activity (a pathway implicated in drug addiction), we investigated the effects of aripiprazole on relapse to morphine seeking in rats. "	( Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats. Li, SX; Liu, LJ; Lu, L; Wu, P; Zou, Y, 2009)	3.24
"Aripiprazole acts as a partial agonist at dopamine D2 and D3 and serotonin 1A receptors and as an antagonist at serotonin 2A receptors (HTR2A). "	( HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Chen, CH; Chen, SF; Shen, YC, 2009)	2.02
"Aripiprazole (ABILIFY) is an effective antipsychotic used in a dose range from 10 to 30 mg, administered once daily. "	( Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study. Bergmann, F; Ebrecht, M; Kungel, M; Modell, S; Nass, A; Spevakné-Göröcs, T; Urban, R; Werner, C; Zacher, A, 2009)	2.03
"Aripiprazole is a potent (high-affinity) partial agonist at D2 and 5-HT1A receptors and a potent antagonist at 5-HT2A receptor and is associated with less weight gain than olanzapine."	( Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B, 2009)	2.52
"Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. "	( Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. Bernardi, S; Edito, F; Meco, G; Purcaro, C; Stirpe, P; Valente, M; Vanacore, N, 2009)	3.24
"Aripiprazole (ARI) is an atypical antipsychotic approved by the Food and Drug Administration for use in major depressive disorder as an adjunct to antidepressants. "	( Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Blier, P; Chernoloz, O; El Mansari, M, 2009)	2.04
"Aripiprazole is an atypical antipsychotic that has been shown to be more effective than placebo and at least as effective as haloperidol and risperidone in the treatment of schizophrenia and schizoaffective disorder. "	( Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. Mace, S; Taylor, D, 2009)	3.24
"Aripiprazole (Abilify) is an atypical antipsychotic drug characterized by partial agonist activity at dopamine (DA) D(2)/D(3) receptors and a low side-effect profile. "	( Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse. Do, PH; Feltenstein, MW; See, RE, 2009)	2.21
"Aripiprazole is an atypical antipsychotic with a pharmacological profile, different from other atypical antipsychotics. "	( [Aripiprazole induced Parkinsonism: A case report]. Germain, C; Pasquier de Franclieu, S; Petitjean, F, 2009)	2.71
"Aripiprazole is an atypical antipsychotic that is a partial agonist at the D2 and 5HT1a receptors and an antagonist at 5HT2a receptors. "	( Movement disorders associated with aripiprazole use: a case series. Agarwal, P; Griffith, A; Hall, DA; Seeberger, LC; Segro, V, 2009)	2.07
"Aripiprazole appears to be a safe and tolerable treatment in children and adolescents with TD that appears to reduce tics; it should be further investigated as a treatment option in controlled trials."	( Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. Coffey, BJ; Goldman, R; Hirsch, S; Jummani, R; Lyon, GJ; Samar, S; Spirgel, A, 2009)	3.24
"Aripiprazole acts as a potential dopamine partial agonist and the dopamine blockade in the basal ganglia might be one of the causes of urinary incontinence and enuresis."	( Use of aripiprazole in clozapine induced enuresis: report of two cases. Kim, CE; Lee, MJ, 2010)	1.54
"Aripiprazole is an atypical antipsychotic that has been found to improve positive and negative symptoms of schizophrenia with a favorable adverse-effect profile."	( Aripiprazole in schizophrenia and schizoaffective disorder: A review. Stip, E; Tourjman, V, 2010)	2.52
"Aripiprazole is a 3(rd) generation atypical antipsychotic U.S."	( Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. Anton, RF; Vergne, DE, 2010)	2.52
"Aripiprazole is a relatively new therapeutic option due to its partial D2 agonism."	( Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine. Asenbaum, S; Barnas, C; Fischer, P; Mossaheb, N; Spindelegger, C, 2010)	1.31
"Aripiprazole is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia. "	( Trial of aripiprazole in the treatment of first-episode schizophrenia. Hahn, SW; Ham, BJ; Kang, RH; Lee, HY; Lee, MS; Paik, JW, 2010)	2.22
"Aripiprazole is an effective and well-tolerated antipsychotic agent in patients with first-episode schizophrenia. "	( Trial of aripiprazole in the treatment of first-episode schizophrenia. Hahn, SW; Ham, BJ; Kang, RH; Lee, HY; Lee, MS; Paik, JW, 2010)	2.22
"Aripiprazole is an atypical or newer generation antipsychotic with a unique mechanism of action impacting dopaminergic and serotonergic neurotransmission."	( Aripiprazole in autism spectrum disorders and fragile X syndrome. Erickson, CA; McDougle, CJ; Posey, DJ; Stigler, KA, 2010)	2.52
"Aripiprazole is a unique antipsychotic that seems to act as a partial agonist at dopamine D2-receptors, contrasting with other drugs in this class, which are silent antagonists. "	( Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety. Biojone, C; Casarotto, PC; Guimarães, FS; Moreira, FA; Resstel, LB; Zangrossi, H, 2011)	2.06
"Aripiprazole is a dopamine D2/D3 receptor partial agonist that is currently used as an antipsychotic drug in clinical settings."	( Repetitive administration of aripiprazole enhances locomotor response to methamphetamine in mice. Chen, CH; Cheng, MC; Hsu, SH, 2011)	1.38
"Aripiprazole is a dopamine D(2) receptor partial agonist undergoing evaluation as a pharmacotherapy for stimulant-use disorders. "	( Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. Glaser, PE; Hays, LR; Lile, JA; Rush, CR; Stoops, WW, 2011)	2.03
"Aripiprazole is a novel, third-generation antipsychotic with comparable efficacy to SGAs, but a more favorable side effect profile."	( Aripiprazole as a viable alternative for treating delusions of parasitosis. Bhutani, T; Busse, KL; Koo, JY; Ladizinski, B, 2010)	2.52
"Aripiprazole is an atypical antipsychotic that acts as a partial D2 dopamine and a serotonin 5-HT₁(A) agonist and a serotonin 5-HT₂(A) antagonist."	( Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole. Bäckström, P; Etelälahti, TJ; Hyytiä, P, 2011)	1.32
"Aripiprazole is an atypical neuroleptic with a unique mechanism of action. "	( Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report. Gumus, S; Kamberyan, K; Saatcioglu, O; Yanik, M, 2010)	2.12
"Aripiprazole is a partial agonist at dopamine D(2) and D(3) and serotonin 5-HT(1A) receptors, and is an antagonist at 5-HT(2A) receptors."	( Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. Forbes, A; Pae, CU; Patkar, AA, 2011)	2.53
"aripiprazole has proven to be an effective medication for the acute treatment of manic and mixed episodes, as well as for the prophylactic-maintenance phase of bipolar disorder in patients recovering from a manic/mixed episode. "	( Aripiprazole for the treatment of bipolar disorder: a review of current evidence. Casamassima, F; Fagiolini, A; Forgione, RN; Marra, FS; Nitti, M, 2011)	3.25
"Aripiprazole is an atypical antipsychotic approved for the treatment of irritability associated with autistic disorder in pediatric patients aged 6-17 years. "	( Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients. Curran, MP, 2011)	3.25
"Aripiprazole, which is a partial dopamine D2 receptor agonist, may have an impact on cognitive dysfunction in patients with schizophrenia."	( Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N, 2012)	1.38
"Aripiprazole appears to be an alternative for children and adolescents who are vulnerable to these side effects and are having trouble coping with them."	( [Aripiprazole use in children and adolescent psychiatric patients]. Bentué-Ferrer, D; Chevreuil, C; Guillemot, P; Lemonnier, E; Polard, E, )	1.76
"Aripiprazole is a drug belonging to the group of atypical antipsychotics. "	( Aripiprazole induced transient myopia: a case report and review of literature. Biswas, J; Gandhi, RA; George, RJ; Nair, AG, 2012)	3.26
"Aripiprazole is an antipsychotic agent to treat schizophrenia, which acts through dopamine D(2) partial agonism, serotonin 5-HT(1A) partial agonism and 5-HT(2A) antagonism. "	( Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice. Camacho, LR; Celso, F; Da Rosa, KM; Da Silva, TG; Dos Santos, Bde J; Freitas, TM; Monteiro, JD; Pereira, P; Picada, JN; Pontes, VM; Vieira, LR, 2011)	2.05
"Aripiprazole is an eff ective and well-tolerated treatment for ADHD and CD symptoms; however, additional studies (specifically, placebo-controlled and double-blind studies) are needed to better defi ne the clinical use of aripiprazole in children and adolescents with ADHD-CD."	( Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study. Akyol Ardic, U; Ardıc, UA; Ercan, E; Ercan, ES; Uysal, T, 2012)	3.26
"Aripiprazole is a new, atypical antipsychotic with a unique mechanism of action, which may have positive effects on cognitive functions."	( Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Burda, K; Czubak, A; Kus, K; Nowakowska, E; Ratajczak, P; Zin, J, 2011)	1.46
"Aripiprazole is an atypical antipsychotic with a pharmacological and clinical profile distinct from other atypical antipsychotics."	( Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance. Abbar, M; Ågren, H; Altamura, AC; Bellivier, F; Fountoulakis, KN; Goodwin, GM; Grunze, H; Holsboer-Trachsler, E; Licht, RW; Pitchot, W; Schlaepfer, TE; Vieta, E, 2011)	3.25
"Aripiprazole is a neuroleptic to consider in the treatment of delusional parasitosis."	( [Delusional parasitosis associated with dialysis treated with aripiprazole]. Choi, KM; Duarte, C; Li, CL, )	1.09
"Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. "	( Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Dhillon, S, 2012)	3.26
"Aripiprazole is a new generation antipsychotic drug that shows a partial agonistic activity at D(2) and 5-HT(1A) receptors. "	( Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone. Grohmann, R; Holl, AK; Letmaier, M; Painold, A; Vergin, H, 2012)	2.06
"Aripiprazole is an important antipsychotic drug. "	( Determination of aripiprazole in rat plasma and brain using ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Bartlett, MG; Liang, F; Terry, AV, 2012)	2.16
"Oral aripiprazole (Abilify®) is an atypical antipsychotic agent that is approved worldwide for use in adult patients with schizophrenia. "	( Aripiprazole: a review of its use in the management of schizophrenia in adults. Croxtall, JD, 2012)	2.34
"Aripiprazole is an atypical antipsychotic with unique pharmacological properties, used for a variety of indications, including psychotic and mood disorders in youth. "	( Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review. Doey, T, 2012)	3.26
"Aripiprazole is a dopamine D/D3 and serotonin 5-HT1A receptor partial agonist which is approved for treatment of schizophrenia. "	( [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Kikuchi, T; Tadori, Y, 2012)	1.82
"Aripiprazole is a partial dopamine D2-receptor antagonist that blocks dopamine at higher dopamine concentrations and augments/releases prefrontal cortex dopamine at lower concentrations."	( Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions. Khemiri, L; Moreira, T; Runeson, L, 2011)	1.36
"Aripiprazole is an atypical neuroleptic with agonistic and antagonistic dopaminergic and serotonergic effects. "	( Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. Bokemeyer, S; Kleimann, A; Müller-Vahl, KR; Wenzel, C, 2012)	3.26
"Aripiprazole is an effective first-line treatment for acute bipolar mania with a favorable safety/tolerability profile."	( A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania. Bobmanuel, S; Davies, W; Dratcu, L; Farmer, A; George, M; Rana, T; Singh, M; Turner, M, 2012)	2.09
"Aripiprazole is an atypical antipsychotic approved for pediatric use in schizophrenia, bipolar I disorder, and autistic disorder."	( The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. Caldwell, RL; Erickson, CA; Ho, JG; McDougle, CJ; Orsagh-Yentis, DK; Posey, DJ; Stigler, KA, 2012)	1.45
"Aripiprazole is an atypical antipsychotic drug approved for the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder and autism. "	( Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole. Hashimoto, K; Ishima, T; Iyo, M, 2012)	2.04
"Aripiprazole (ARI) is an antipsychotic drug that is metabolized to dehydroaripiprazole (DARI) by CYP2D6. "	( High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients. de Andrés, F; de la Rubia, A; Dorado, P; González, AP; González, I; Llerena, A; Naranjo, ME; Peñas-Lledó, EM, 2012)	2.04
"Aripiprazole is an atypical antipsychotic used for schizophrenia, manic and mixed episodes associated with bipolar I disorder and as adjunctive therapy for major depressive disorder. "	( Aripiprazole, alcohol and substance abuse: a review. Brunetti, M; Dezi, S; Di Tizio, L; Grandinetti, P; Martinotti, G; Pozzi, G, 2012)	3.26
"Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine receptors. "	( Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice. Aguiar, DC; Almeida-Santos, AF; Moreira, FA; Viana, TG, 2013)	2.22
"Aripiprazole is an atypical antipsychotic medication that is a partial dopamine D(2) and serotonin 5-hydroxytryptamine (1A) receptor agonist and 5-hydroxytryptamine (2A) receptor antagonist. "	( Aripiprazole-induced seizure in a 3-year-old child: a case report and literature review. Joseph, SA; Sweis, RT; Thabet, FI, )	3.02
"Aripiprazole is a D2 and D3 receptor partial agonist that is unlike other second generation antipsychotics. "	( The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. Okamoto, Y; Sato, G; Yamashita, H; Yamawaki, S; Yoshimura, S, 2012)	2.11
"Aripiprazole is a newer atypical antipsychotic drug with partial agonist activity at dopamine receptors and antagonist activity at 5-HT(2A) receptors, with a low side-effect profile."	( Aripiprazole in the treatment of Alzheimer's disease. De Deyn, PP; Drenth, AF; Kremer, BP; Oude Voshaar, RC; Van Dam, D, 2013)	2.55
"Aripiprazole is a second-generation antipsychotic that may be selected for patients with prolonged QTc intervals and at risk for TdP. "	( Torsades de pointes after administration of low-dose aripiprazole. Leung, JG; Nelson, S, 2013)	2.08
"Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile. "	( Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002)	2.07
"Aripiprazole is a quinolinone derivative and the first of a new class of atypical antipsychotics. "	( Aripiprazole. Goa, KL; McGavin, JK, 2002)	3.2
"Aripiprazole is a new atypical antipsychotic with a unique receptor binding profile that combines partial agonist activity at D2 and 5HT1A receptors with potent antagonism at 5HT2A receptors."	( Aripiprazole: a review of its pharmacology and clinical use. Taylor, DM, )	2.3
"Aripiprazole is a dopamine partial agonist and a serotonin-2A antagonist; it is dosed 10-30 mg/d, with no initial titration necessary. "	( Aripiprazole: a new atypical antipsychotic drug. Bowles, TM; Levin, GM, 2003)	3.2
"Aripiprazole is a novel antipsychotic with a unique mechanism of action. "	( Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E, 2003)	3.2
"Aripiprazole is a dopamine D2 receptor partial agonist with partial agonist activity at serotonin 5HT1A receptors and antagonist activity at 5HT2A receptors. "	( Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J, 2003)	3.2
"Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. "	( Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A, 2003)	2.07
"Aripiprazole is a novel antipsychotic for the management of schizophrenia. "	( Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Carson, WH; Ingenito, GG; Pigott, TA; Saha, AR; Stock, EG; Torbeyns, AF, 2003)	3.2
"Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug with a low incidence of side effects. "	( Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Marona-Lewicka, D; Nichols, DE, 2004)	3.21
"Aripiprazole is a third-generation antipsychotic agent indicated for use in the treatment of schizophrenia."	( Aripiprazole. Winans, E, 2003)	2.48
"Aripiprazole is an antipsychotic drug with high affinity for D(2)- and D(3)-receptors and the dopamine autoreceptor."	( Focus on aripiprazole. Green, B, 2004)	1.46
"Aripiprazole is a novel antipsychotic with a unique mechanism of action, which differs from currently marketed typical and atypical antipsychotics. "	( The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Aihara, K; Burris, KD; Horie, M; Kikuchi, T; Miwa, T; Shimada, J; Tottori, K; Yocca, FD, 2004)	2.07
"Aripiprazole is a valuable new therapeutic option in the management of patients with schizophrenia."	( Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Perry, CM; Swainston Harrison, T, 2004)	2.49
"Aripiprazole is an atypical antipsychotic agent with an intrinsic dopamineagonist activity of 30 %. "	( [Aripiprazole: a new atypical antipsychotic drug]. Davids, E; Fischer, B; Gastpar, M, 2004)	2.68
"Aripiprazole is a new atypical antipsychotic with a mode of action that is distinct from currently available antipsychotic drugs. "	( Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Lambert, M; Naber, D, 2004)	3.21
"Aripiprazole (Abilify) is an atypical antipsychotic drug that has been recently introduced for clinical use in the treatment of schizophrenia. "	( Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. Davies, MA; Roth, BL; Sheffler, DJ, 2004)	3.21
"Aripiprazole is a newly available atypical antipsychotic for the treatment of schizophrenia."	( Aripiprazole in schizophrenia: consensus guidelines. Burns, T; Dursun, S; Fahy, T; Frangou, S; Gray, R; Haddad, PM; Hunter, R; Taylor, DM; Travis, MJ; Young, AH, 2005)	2.49
"Aripiprazole is a new psychotropic agent that possesses a unique pharmacologic profile. "	( Atypical experience: a case series of pediatric aripiprazole exposures. Klein-Schwartz, W; Lofton, AL, 2005)	2.03
"Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. "	( Aripiprazole: pharmacology, efficacy, safety and tolerability. Kinghorn, WA; McEvoy, JP, 2005)	3.21
"Aripiprazole is an atypical antipsychotic that is approved for the treatment of mania and that has a novel mechanism of action, acting as a dopamine-2 receptor partial agonist, thereby increasing dopamine release in some parts of the brain and decreasing dopa-mine release in other brain regions."	( Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Beard, L; Brown, ES; Garza, M; Jeffress, J; Liggin, JD, 2005)	1.26
"Aripiprazole is an atypical antipsychotic that has partial agonist activity at D2 receptors."	( Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Glaser, PE; Hays, LR; Lile, JA; Rush, CR; Stoops, WW; Vansickel, AR, 2005)	2.49
"Aripiprazole is an agent for treating schizophrenia. "	( Aripiprazole in psychosis associated with Parkinson's disease. López-Meza, E; Ramirez-Bermudez, J; Ruiz-Chow, A, 2005)	3.21
"Aripiprazole is a new chemical entity with a unique pharmacological profile. "	( Aripiprazole. Fleischhacker, WW, 2005)	3.21
"Aripiprazole is an effective augmentation strategy for improving therapeutic response in patients with treatment-resistant major depressive disorder when administered in combination with standard antidepressant therapy. "	( Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. Nemeroff, CB; Simon, JS, 2005)	3.21
"Aripiprazole is an effective treatment for hostility in patients with schizophrenia or schizoaffective disorder."	( Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J, 2005)	2.15
"Aripiprazole is a unique atypical antipsychotic drug with an excellent side-effect profile presumed, in part, to be due to lack of typical D(2) dopamine receptor antagonist properties. "	( Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Mailman, RB; Urban, JD; Vargas, GA; von Zastrow, M, 2007)	3.23
"Aripiprazole is a dopamine partial agonist and a serotonin(2A) antagonist with a favorable adverse effect profile."	( Acute dystonia with low-dosage aripiprazole in Tourette's disorder. Fountoulakis, KN; Iacovides, A; Kantartzis, S; Kaprinis, GS; Panagiotidis, P; Siamouli, M, 2006)	1.34
"Aripiprazole is a relatively new atypical antipsychotic agent that has been successfully employed in therapy for schizophrenia and schizoaffective disorders. "	( Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Anvar, J; Bachler, E; Buschmann, W; Egger, C; Fartacek, R; Kaplan, P; Kettler, C; Loew, TH; Muehlbacher, M; Nickel, C; Nickel, MK; Pedrosa Gil, F; Rother, N; Rother, WK, 2006)	3.22
"Aripiprazole appears to be a safe and effective agent in the treatment of patients with borderline personality disorder."	( Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Anvar, J; Bachler, E; Buschmann, W; Egger, C; Fartacek, R; Kaplan, P; Kettler, C; Loew, TH; Muehlbacher, M; Nickel, C; Nickel, MK; Pedrosa Gil, F; Rother, N; Rother, WK, 2006)	3.22
"Aripiprazole (Abilify) is an atypical antipsychotic drug primarily characterized by partial agonist activity at dopamine (DA) D2 receptors and low side effects. "	( Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Altar, CA; Feltenstein, MW; See, RE, 2007)	3.23
"Aripiprazole is a newer atypical antipsychotic agent used for effective treatment of schizophrenia. "	( Aripiprazole-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH). Bachu, K; Gasparyan, A; Godkar, D; Niranjan, S; Sircar, P; Yakoby, M, )	3.02
"Aripiprazole is an oral atypical antipsychotic drug used in the treatment of schizophrenia and potentially other behavior disorders. "	( Aripiprazole exposures reported to Texas poison control centers during 2002-2004. Forrester, MB, 2006)	3.22
"Aripiprazole is an atypical antipsychotic that is reported to be effective in the treatment of schizophrenia."	( Aripiprazole for schizophrenia. Systematic review. Adams, CE; El-Sayeh, HG; Morganti, C, 2006)	3.22
"Aripiprazole is a novel antipsychotic quinolone derivative that has been approved for the treatment of schizophrenia in adults."	( Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series. Alla, L; Sabaratnam, M; Shastri, M, 2006)	2.5
"Aripiprazole is a novel antipsychotic drug, which displays partial agonist activity at the dopamine D(2) receptor. "	( Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Clarke, K; Davies, CH; Forbes, IT; Gribble, A; Hill, M; Jones, DN; Newson, M; Reavill, C; Rourke, C; Scott, C; Westaway, J; Wood, MD, 2006)	3.22
"Aripiprazole is a new atypical antipsychotic drug with a partial agonist activity at dopamine 2 and serotonin 1A receptors. "	( Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Lunde, H; Lunder, N; Molden, E; Refsum, H, 2006)	2.06
"Aripiprazole is a recently released antipsychotic medication that differs from other atypical antipsychotic agents by its mode of action as a dopamine D2 partial agonist."	( Role of aripiprazole in treating mood disorders. García-Amador, M; Goikolea, JM; Pacchiarotti, I; Sanchez, RF; Valentí, M; Vieta, E, 2006)	1.49
"Aripiprazole is a recently introduced antipsychotic with a unique pharmacological profile, a dopamine partial agonist. "	( Unique pharmacological profile of aripiprazole as the phasic component buster. Hamamura, T; Harada, T, 2007)	2.06
"Aripiprazole is an atypical antipsychotic drug with high in vitro affinity for 5-HT(1A), 5-HT(2A) and dopamine (DA) D2 receptors. "	( In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Artigas, F; Bortolozzi, A; Celada, P; Díaz-Mataix, L; Toth, M, 2007)	2.11
"Aripiprazole appears to be an effective and relatively safe agent in the long-term treatment of patients with BPD."	( Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Loew, TH; Nickel, MK; Pedrosa Gil, F, 2007)	3.23
"Aripiprazole is a dopamine (DA) D(2) receptor partial agonist, approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia. "	( Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Koob, GF; Pulvirenti, L; Wang, Z; Wee, S; Woolverton, WL, 2007)	2.18
"Aripiprazole is a psychotropic agent with a novel pharmacologic profile. "	( Aripiprazole: pharmacology and evidence in bipolar disorder. Konarski, JZ; McIntyre, RS; Miranda, A; Soczynska, JK; Woldeyohannes, HO, 2007)	3.23
"Aripiprazole is an effective atypical antipsychotic for the treatment of schizophrenia, demonstrating better effectiveness than SOC agents used in this study in patients for whom a switch in antipsychotic medication was warranted."	( A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Banki, CM; Beuzen, JN; Hanssens, L; Herman, E; Kerwin, R; L'Italien, G; Lublin, H; McQuade, RD; Millet, B; Pans, M, 2007)	2.02
"Aripiprazole is a novel antipsychotic drug for the treatment of schizophrenia and schizoaffective disorders. "	( Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients. Chiu, HJ; Hu, TM; Huang, HC; Lan, TH; Liu, CH; Tseng, YL; Wu, YC, 2007)	2.07
"Aripiprazole acts as a partial agonist of D2 receptors as well as a partial agonist of 5HT1A and an antagonist of 5HT2A. "	( [Clinical impact of aripiprazole in patients suffering from schizophrenia]. Drapier, D; Fadier-Salicé, G; Levoyer, D; Millet, B, )	1.9
"Aripiprazole is a novel antipsychotic with a mechanism of action different from those of traditional first- and second-generation antipsychotics. "	( Agitation associated with aripiprazole initiation. Lafollette, J; Lea, JW; Stoner, SC, 2007)	2.08
"Aripiprazole is a novel second-generation antipsychotic approved for the treatment of bipolar disorder in adults but there is no systematic data available in pediatric bipolar disorder."	( An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. Aleardi, M; Biederman, J; Doyle, R; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Spencer, T; Wozniak, J, 2007)	2.09
"Aripiprazole is an atypical antipsychotic drug which is metabolized by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6). "	( Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Hendset, M; Hermann, M; Lunde, H; Molden, E; Refsum, H, 2007)	2.02
"Aripiprazole is an atypical antipsychotic that acts as a partial agonist at the dopamine D(2) receptor. "	( Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Guimarães, FS; Leite, JV; Moreira, FA, 2008)	3.23
"Aripiprazole is a novel atypical antipsychotic that is approved in the US for use in adolescents with schizophrenia. "	( Aripiprazole: in adolescents with schizophrenia. Keating, GM; Sanford, M, 2007)	3.23
"Aripiprazole (OPC-14597) is an antipsychotic with a unique pharmacology as a dopamine D2 receptor partial agonist, which has been demonstrated to reduce symptoms of schizophrenia. "	( Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Freichel, C; Künnecke, B; Maco, M; Moreau, JL; Nordquist, RE; Riemer, C; Risterucci, C; Spooren, W; von Kienlin, M, 2008)	2.18
"Aripiprazole is a relatively new antipsychotic drug, said to be the prototype of a new third generation of antipsychotics; the so-called dopamine-serotonin system stabilisers. "	( Aripiprazole versus typicals for schizophrenia. Bhattacharjee, J; El-Sayeh, HG, 2008)	3.23
"Aripiprazole is an atypical antipsychotic with partial agonist activity at D(2) receptors, which could reduce the reinforcing effects of alcohol. "	( Effects of aripiprazole on subjective and physiological responses to alcohol. Arias, AJ; Chan, G; Covault, J; Douglas, K; Kranzler, HR; Oncken, C; Pierucci-Lagha, A, 2008)	2.18
"Aripiprazole is an atypical anti-psychotic associated with a reduction in prolactin level in anti-psychotic-induced hyperprolactinemia."	( Change in sexual dysfunction with aripiprazole: a switching or add-on study. Aitchison, KJ; McAllister, V; Mir, A; O'Keane, V; Shivakumar, K; Williamson, RJ, 2008)	1.35
"Aripiprazole is an atypical antipsychotic compound that is approved by the U.S."	( Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M, 2008)	2.51
"Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT."	( The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008)	1.36
"Aripiprazole also acts as a dopamine D2 partial receptor agonist, and has a possible action at adrenergic receptors."	( Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. Masand, PS; Pae, CU; Patkar, AA; Serretti, A, 2008)	2.51
"Aripiprazole is a novel atypical antipsychotic, which is a high-affinity dopamine D(2) receptor partial agonist."	( Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. Hashioka, S; Horikawa, H; Iwaki, T; Kanba, S; Kato, T; Mizoguchi, Y; Monji, A; Seki, Y; Suzuki, SO, 2008)	1.38
"Aripiprazole is an effective medication for treating patients with schizophrenia and bipolar disorder , and as an adjunct in patients with major depressive disorder and an inadequate response to antidepressant treatment, that is generally safe and well tolerated. "	( Proposed strategies for successful clinical management with aripiprazole. Mago, R, 2008)	2.03
"Aripiprazole is a dopamine partial agonist antipsychotic drug that has just been approved in Europe for its use in the treatment of acute mania and for the prevention of manic episodes in bipolar disorder. "	( [Advances in the treatment of mania: aripiprazole]. Franco, C; Vieta, E, )	1.85
"Aripiprazole (OPC 14597) is an antipsychotic drug that has high affinity for dopamine D2 and D3 receptors and the dopamine autoreceptor. "	( Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Biziere, K; Bramer, S; Dannals, RF; Dogan, AS; Gründer, G; Ravert, H; Stephane, M; Suri, A; Wong, DF; Yokoi, F, 2002)	1.98

Excerpt	Reference	Relevance
"Aripiprazole has a high affinity for the D2 receptor, but may have a lesser reduction of psychotic symptoms compared to other antipsychotics."	( Aripiprazole: examining the clinical implications of D2 affinity. Anam, A; Gekhman, D; Lynch, S; Mosharraf, N; Soukas, C, 2023)	3.07
"Aripiprazole; however, has a potential risk of inducing severe rebound psychosis in patients who have already developed dopamine supersensitivity."	( The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. Fujita, Y; Honma, M; Iyo, M; Kanahara, N; Komatsu, N; Noda, S; Saiga, T; Sasaki, T; Simoyama, T; Suzuki, H; Tadokoro, S; Takase, M; Yamanaka, H; Yanahashi, S, 2020)	1.54
"Aripiprazole has a low risk for causing extrapyramidal syndrome and can remit neuroleptic-induced tardive dyskinesia (TD). "	( Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder. Chan, HY; Tan, HK; Wu, WY, 2014)	2.09
"Aripiprazole, which has a unique pharmacological mechanism of action distinct from other atypical antipsychotics and an excellent safety profile, may be effective in the treatment of some schizophrenic patients with stupor, which sometimes carries a risk of physical debilitation and requires special attention due to the risk of adverse drug reactions."	( Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Kirino, E, 2010)	1.33
"Aripiprazole has a favorable efficacy/safety profile in ESS and appeared to be superior to haloperidol on a number of efficacy and safety outcomes."	( Aripiprazole versus haloperidol treatment in early-stage schizophrenia. Girgis, RR; Lieberman, JA; Merrill, DB; Pikalov, A; Vorel, SR; Whitehead, R; You, M, 2011)	2.53
"Aripiprazole has a lower risk of raised prolactin and prolongation of the QTc interval."	( Aripiprazole versus placebo for schizophrenia. Belgamwar, RB; El-Sayeh, HG, 2011)	2.53
"Aripiprazole has a low risk of extrapyramidal symptoms. "	( Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. Endo, T; Fukui, N; Ono, S; Shindo, M; Someya, T; Sugai, T; Suzuki, Y, 2012)	2.06
"Aripiprazole has a more benign side effect profile (weight gain, blood sugar level, lipid profile) as compared to olanzapine in the short-term treatment of schizophrenia."	( Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India. Jindal, KC; Munjal, V; Singh, GP, 2013)	2.55
"Aripiprazole (APZ) has a unique pharmacological profile, as a partial agonist at the dopamine D2 and serotonin 5HT1A receptors and an antagonist at the serotonin 5HT2A receptor; this drug has few side effects (such as extrapyramidal syndrome, hyperprolactinemia, weight gain, metabolic disorders, and sedation) which are typical problems with other antipsychotic drugs. "	( Efficacy and safety of aripiprazole in child and adolescent patients. Kirino, E, 2012)	2.13
"Aripiprazole has a unique mechanism of action as a dopamine D2 partial agonist, serotonin 5-HT(1A) partial agonist and serotonin 5-HT(2A) antagonist."	( Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Keck, PE; McElroy, SL, 2003)	2.48
"Aripiprazole has a low propensity to cause clinically significant bodyweight gain, hyperprolactinaemia or corrected QT interval prolongation in patients with schizophrenia or schizoaffective disorder."	( Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Perry, CM; Swainston Harrison, T, 2004)	2.49
"Aripiprazole has a unique pharmacologic profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [especially dopamine (D2) and 5-HT1A] and antagonistic action at others (especially 5-HT2A)."	( Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. Davies, MA; Roth, BL; Sheffler, DJ, 2004)	2.49
"Aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play in the management of schizophrenia."	( Partial dopamine agonists in schizophrenia. Launer, M, 2005)	1.05
"Aripiprazole has a favorable safety and tolerability profile, with minimal propensity for clinically significant weight gain and metabolic disruption."	( Aripiprazole: pharmacology and evidence in bipolar disorder. Konarski, JZ; McIntyre, RS; Miranda, A; Soczynska, JK; Woldeyohannes, HO, 2007)	2.5
"Aripiprazole has a unique pharmacological profile that includes partial agonism at D(2) receptors, antagonism at 5-HT(2) receptors, and partial agonism at 5-HT(1A) receptors. "	( Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM, 2007)	2.09
"Aripiprazole has highest affinity for h5-HT(2B)-, hD(2L)-, and hD(3)-dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT(1A), 5-HT(2A), 5-HT(7)), as well as alpha(1A)-adrenergic and hH(1)-histamine receptors."	( Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Arrington, E; Chiodo, LA; Liu, LX; Mailman, R; Renock, S; Roth, BL; Shapiro, DA; Sibley, DR, 2003)	2.48
"Aripiprazole has extremely high binding affinity for the dopamine D2 receptor, which is the receptor thought to be responsible for the antipsychotic effect, although Aripiprazole is not the most potent of the second generation antipsychotics."	( Aripiprazole: examining the clinical implications of D2 affinity. Anam, A; Gekhman, D; Lynch, S; Mosharraf, N; Soukas, C, 2023)	3.07
"Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive-compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization."	( Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review. Benites-Zapata, VA; Campos-Rodriguez, SK; Fernández, MF; Ortiz-Saavedra, B; Pino-Zavaleta, DA; Valdivieso-Jiménez, G, 2023)	1.94
"Aripiprazole has been implicated in pathological gambling and other impulse control behaviours, likely due to partial dopamine agonist activity (there have been no reports with brexpiprazole and cariprazine)."	( Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. Copolov, D; Hope, J; Keks, N; McLennan, H; Meadows, G; Schwartz, D, 2020)	1.28
"Aripiprazole; however, has a potential risk of inducing severe rebound psychosis in patients who have already developed dopamine supersensitivity."	( The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. Fujita, Y; Honma, M; Iyo, M; Kanahara, N; Komatsu, N; Noda, S; Saiga, T; Sasaki, T; Simoyama, T; Suzuki, H; Tadokoro, S; Takase, M; Yamanaka, H; Yanahashi, S, 2020)	1.54
"Aripiprazole has one of the fewest side-effects among the second-generation antipsychotics."	( Aripiprazole reduces liver cell division. Bulc Rozman, K; Kramar, B; Milisav, I; Pirc Marolt, T; Šuput, D, 2020)	2.72
"Aripiprazole (APZ) has poor physicochemical properties and bitter taste. "	( Salt Engineering of Aripiprazole with Polycarboxylic Acids to Improve Physicochemical Properties. Afrooz, H; Barakh Ali, SF; Dharani, S; Khan, MA; Mohamed, EM; Nutan, MTH; Rahman, Z, 2021)	2.39
"Aripiprazole has become one of the most commonly prescribed psychotropics, making a more comprehensive understanding of its reproductive safety profile a priority. "	( Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Caplin, PS; Chitayat, D; Church, TR; Cohen, LS; Freeman, MP; Góez-Mogollón, L; Hernández-Díaz, S; McElheny, SA; Viguera, AC; Young, AV, 2021)	2.37
"Aripiprazole has been linked to cases of problem gambling (PBG), but evidence supporting this association remains preliminary. "	( Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program. Carmichael, PH; Corbeil, O; Corbeil, S; Demers, MF; Dorval, M; Giroux, I; Jacques, C; Roy, MA, 2021)	2.35
"Aripiprazole has been reported to preserve hippocampal volume and to reduce inflammation."	( Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia. Ardekani, BA; Bello, I; Cather, C; Diminich, ED; Fan, X; Freudenreich, O; Goff, DC; Hart, KL; Holt, D; Li, C; Marx, J; Qi, W; Tang, Y; Wang, J; Worthington, M; Wu, R; Zeng, B; Zhao, J, )	1.21
"Aripiprazole has not been reported to have an association with interstitial lung disease."	( Aripiprazole-induced hypersensitivity pneumonitis. Gunasekaran, K; Jennings, J; Lone, N; Murthi, S, 2017)	2.62
"Aripiprazole has been considered as a dopamine stabilizer and was the first atypical antipsychotic agent approved by the US Food and Drug Administration as an adjunctive to the treatment of unipolar MDD."	( Killing two birds with one stone: the potential role of aripiprazole for patients with comorbid major depressive disorder and nicotine dependence via altering brain activity in the anterior cingulate cortex. Chang, CC; Chang, HA; Chen, TY; Chu, CS; Tzeng, NS, 2014)	1.37
"Aripiprazole has a low risk for causing extrapyramidal syndrome and can remit neuroleptic-induced tardive dyskinesia (TD). "	( Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder. Chan, HY; Tan, HK; Wu, WY, 2014)	2.09
"Aripiprazole (ARP) has been shown to be effective in the treatment of bipolar disorder (BD). "	( A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. Baglivo, V; Balestrieri, M; Brambilla, P; Gregoraci, G; Isola, M; Meduri, M, 2016)	2.14
"Aripiprazole has unique DLPFC actions attributed to its prefrontal D2 agonist action. "	( An investigation into aripiprazole's partial D₂ agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. Deakin, JF; Dursun, S; Elliott, R; McKie, S; Murphy, A, 2016)	2.19
"Aripiprazole also has 5-HT1A partial agonist and 5-HT2A antagonist properties that may promote sexual activity."	( [Aripiprazole, gambling disorder and compulsive sexuality]. Dafreville, C; Mété, D; Paitel, V; Wind, P, 2016)	2.07
"Aripiprazole has been associated with a low prevalence of metabolic side effects as compared to other second generation antipsychotic (SGA) medications mostly in patients with long standing illness. "	( Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study. Abadi, S; Joober, R; Lepage, M; Malla, A; Mustafa, S; Rho, A, 2016)	2.14
"Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small."	( Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use. Cocker, KE; Reese, TR; Thiel, DJ, 2016)	1.16
"Aripiprazole has been reported to ameliorate behavioral abnormalities in polyI:C-induced mice."	( Aripiprazole inhibits polyI:C-induced microglial activation possibly via TRPM7. Hayakawa, K; Horikawa, H; Inamine, S; Kanba, S; Kato, TA; Kyuragi, S; Mizoguchi, Y; Monji, A; Ohgidani, M; Sagata, N; Sato-Kasai, M; Seki, Y; Shimokawa, N, 2016)	2.6
"Aripiprazole has been used in the treatment of tardive syndrome, with some reports of a good response."	( A Review of Differences in Clinical Characteristics between Tardive Syndrome Induced or Improved by Aripiprazole Treatment. Chen, YW; Tseng, PT, 2016)	1.37
"Aripiprazole has been reported to exert variable effects on cognitive function in patients with schizophrenia. "	( Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia. Atake, K; Beppu, H; Hori, H; Igata, R; Katsuki, A; Konishi, Y; Tominaga, H; Yoshimura, R, 2017)	2.15
"As aripiprazole has been available in the USA for bipolar mania since 2004, clinical experience-sharing from clinical and research use of this agent can assist with initiation and administration in practice. "	( Practical guidance for prescribing with aripiprazole in bipolar disorder. Fagiolini, A, 2008)	1.23
"Aripiprazole has the unique pharmacology of being a partial dopamine agonist serving to stabilize brain dopamine systems in both frontal cortical and subcortical areas."	( Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Anton, R; Myrick, H; Randall, P; Voronin, K, 2008)	2.51
"Aripiprazole has recently received approval for the treatment of moderate to severe manic episodes in bipolar I disorder and prevention of new manic episodes in aripiprazole-responsive patients. "	( A UK consensus on the administration of aripiprazole for the treatment of mania. Aitchison, KJ; Bienroth, M; Cookson, J; Goodwin, GM; Gray, R; Haddad, PM; Moore, B; Ratna, L; Sullivan, G; Taylor, D; Taylor, M, 2009)	2.06
"Aripiprazole has been used effectively to treat schizophrenia in the clinic; however, its mechanisms of action are not clear. "	( Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Deng, C; Han, M; Huang, XF, 2009)	3.24
"Aripiprazole has demonstrated a relatively favorable side effect profile compared to other commonly prescribed antipsychotics, including a low propensity for treatment-limiting extrapyramidal symptoms, hyperprolactinemia, and body weight gain."	( Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Forbes, RA; Kikuchi, T; McQuade, RD; Tadori, Y, 2009)	1.07
"Aripiprazole has high affinity for dopamine D2 and D3 receptors (DRD2 and DRD3)."	( Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Chen, CH; Chen, SF; Shen, YC, 2009)	1.34
"Aripiprazole has also received approval for the treatment of bipolar disorder as adjunctive therapy or monotherapy (manic or mixed episodes) as well as an augmentation therapy of major depressive disorder (MDD) by the US FDA."	( A review of the safety and tolerability of aripiprazole. Pae, CU, 2009)	1.34
"Aripiprazole has unique properties that differ from other atypical antipsychotics and fill up the missing gaps, as it is associated with minimal metabolic complications and extrapyramidal side effects that are more commonly seen in other atypical agents."	( The use of aripiprazole in early onset schizophrenia: safety and efficacy. Hamidin, A; Normala, I, 2009)	1.46
"Aripiprazole, which has a unique pharmacological mechanism of action distinct from other atypical antipsychotics and an excellent safety profile, may be effective in the treatment of some schizophrenic patients with stupor, which sometimes carries a risk of physical debilitation and requires special attention due to the risk of adverse drug reactions."	( Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Kirino, E, 2010)	1.33
"Aripiprazole has a favorable efficacy/safety profile in ESS and appeared to be superior to haloperidol on a number of efficacy and safety outcomes."	( Aripiprazole versus haloperidol treatment in early-stage schizophrenia. Girgis, RR; Lieberman, JA; Merrill, DB; Pikalov, A; Vorel, SR; Whitehead, R; You, M, 2011)	2.53
"aripiprazole has proven to be an effective medication for the acute treatment of manic and mixed episodes, as well as for the prophylactic-maintenance phase of bipolar disorder in patients recovering from a manic/mixed episode. "	( Aripiprazole for the treatment of bipolar disorder: a review of current evidence. Casamassima, F; Fagiolini, A; Forgione, RN; Marra, FS; Nitti, M, 2011)	3.25
"Aripiprazole has been associated with fewer adverse effects compared with other atypicals; however, little is known about its tolerability profile in the TS population."	( Tolerability profile of aripiprazole in patients with Tourette syndrome. Cavanna, AE; Eddy, CM; Luoni, C; Rickards, H; Selvini, C; Termine, C, 2012)	1.41
"Aripiprazole has a lower risk of raised prolactin and prolongation of the QTc interval."	( Aripiprazole versus placebo for schizophrenia. Belgamwar, RB; El-Sayeh, HG, 2011)	2.53
"Aripiprazole has a low risk of extrapyramidal symptoms. "	( Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. Endo, T; Fukui, N; Ono, S; Shindo, M; Someya, T; Sugai, T; Suzuki, Y, 2012)	2.06
"Aripiprazole has a more benign side effect profile (weight gain, blood sugar level, lipid profile) as compared to olanzapine in the short-term treatment of schizophrenia."	( Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India. Jindal, KC; Munjal, V; Singh, GP, 2013)	2.55
"Aripiprazole (APZ) has a unique pharmacological profile, as a partial agonist at the dopamine D2 and serotonin 5HT1A receptors and an antagonist at the serotonin 5HT2A receptor; this drug has few side effects (such as extrapyramidal syndrome, hyperprolactinemia, weight gain, metabolic disorders, and sedation) which are typical problems with other antipsychotic drugs. "	( Efficacy and safety of aripiprazole in child and adolescent patients. Kirino, E, 2012)	2.13
"Aripiprazole has been reported to be effective in small case series with short follow-up periods."	( Effectiveness of aripiprazole in the treatment of adult Tourette patients up to 56 months. Kawohl, W; Neuner, I; Nordt, C; Schneider, F, 2012)	1.44
"Aripiprazole has demonstrated efficacy in the management of behavioral disturbances and has improved some of impaired cognitive functions."	( [Efficacy of aripiprazole on cognitive and behavioral changes in a young woman with systemic lupus erythematosus]. Attademo, L; Moretti, P; Quartesan, R, 2012)	1.47
"Aripiprazole has a unique mechanism of action as a dopamine D2 partial agonist, serotonin 5-HT(1A) partial agonist and serotonin 5-HT(2A) antagonist."	( Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Keck, PE; McElroy, SL, 2003)	2.48
"Aripiprazole has been shown to be a partial agonist at the D(2) family of dopamine (DA) receptors in biochemical and pharmacological studies."	( The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Aihara, K; Burris, KD; Horie, M; Kikuchi, T; Miwa, T; Shimada, J; Tottori, K; Yocca, FD, 2004)	1.35
"Aripiprazole has extensive extravascular distribution and more than 99% of"	( Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Perry, CM; Swainston Harrison, T, 2004)	2.49
"Aripiprazole has a low propensity to cause clinically significant bodyweight gain, hyperprolactinaemia or corrected QT interval prolongation in patients with schizophrenia or schizoaffective disorder."	( Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Perry, CM; Swainston Harrison, T, 2004)	2.49
"Aripiprazole has a unique pharmacologic profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [especially dopamine (D2) and 5-HT1A] and antagonistic action at others (especially 5-HT2A)."	( Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. Davies, MA; Roth, BL; Sheffler, DJ, 2004)	2.49
"Aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play in the management of schizophrenia."	( Partial dopamine agonists in schizophrenia. Launer, M, 2005)	1.05
"Aripiprazole has demonstrated superiority to placebo in clinical studies of the treatment of both schizophrenia and acute bipolar mania."	( Aripiprazole: an overview of a novel antipsychotic. Folnegović-Smalc, V; Kozumplik, O; Mimica, N; Uzun, S, 2005)	2.49
"Aripiprazole, however, has not yet been tested for this disorder, and the goal of this study was to determine whether aripiprazole is effective in the treatment of several domains of symptoms of borderline personality disorder."	( Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Anvar, J; Bachler, E; Buschmann, W; Egger, C; Fartacek, R; Kaplan, P; Kettler, C; Loew, TH; Muehlbacher, M; Nickel, C; Nickel, MK; Pedrosa Gil, F; Rother, N; Rother, WK, 2006)	2.5
"Aripiprazole has been licensed despite the fact that few reliable data on this drug are publicly available. "	( Aripiprazole for schizophrenia. Systematic review. Adams, CE; El-Sayeh, HG; Morganti, C, 2006)	3.22
"Aripiprazole has been extensively studied pre-clinically, both in vitro and in vivo, and these results have been correlated with clinical findings."	( Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Clarke, K; Davies, CH; Forbes, IT; Gribble, A; Hill, M; Jones, DN; Newson, M; Reavill, C; Rourke, C; Scott, C; Westaway, J; Wood, MD, 2006)	2.5
"Aripiprazole has demonstrated efficacy in treatment of bipolar mania, as well as in the maintenance treatment of bipolar disorder. "	( Adjunctive aripiprazole in bipolar I depression. Sokolski, KN, 2007)	2.17
"Aripiprazole has a favorable safety and tolerability profile, with minimal propensity for clinically significant weight gain and metabolic disruption."	( Aripiprazole: pharmacology and evidence in bipolar disorder. Konarski, JZ; McIntyre, RS; Miranda, A; Soczynska, JK; Woldeyohannes, HO, 2007)	2.5
"Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. "	( Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Reavill, C; Wood, M, 2007)	3.23
"Aripiprazole has higher affinity to dopamine D(2) receptors than haloperidol, which is the likely cause of this observation."	( Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH, 2007)	1.31
"Aripiprazole has a unique pharmacological profile that includes partial agonism at D(2) receptors, antagonism at 5-HT(2) receptors, and partial agonism at 5-HT(1A) receptors. "	( Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM, 2007)	2.09

Excerpt	Reference	Relevance
"Aripiprazole does not cause an excessive blockade of DRD2 and is less likely to upregulate DRD2 by aripiprazole's dopamine partial agonistic profile."	( The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. Fujita, Y; Honma, M; Iyo, M; Kanahara, N; Komatsu, N; Noda, S; Saiga, T; Sasaki, T; Simoyama, T; Suzuki, H; Tadokoro, S; Takase, M; Yamanaka, H; Yanahashi, S, 2020)	1.54
"Aripiprazole can cause side effects including headache, insomnia, agitation, nervousness, lightheadedness, dizziness, somnolence, akathisia, and weight gain."	( Aripiprazole-Induced Neutropenia: Case Report and Literature Review. Chaudhary, AM; Felin, T; Naveed, S, 2018)	2.64
"Aripiprazole may cause EPS at clinical dosages by augmenting cholinergic effects via AChE inhibition, in addition to its suppressive effect on dopaminergic neurons."	( Inhibition of Recombinant Human Acetylcholinesterase Activity by Antipsychotics. Arie, C; Fujii, A; Harada, N; Matsuo, K; Obara, K; Tanaka, Y; Yamaki, F; Yoshio, T, 2019)	1.96
"Aripiprazole had a lower incidence of extrapyramidal reactions than haloperidol (P<0.05), but the overall incidence of side effects of aripiprazole was not lower than traditional drugs for treatment of TD."	( [Efficacy and safety of aripiprazole in the treatment of childhood tic disorders: a Meta analysis]. Chen, L; Chen, QB; Fang, Q; Yang, F, 2015)	1.45
"Aripiprazole can cause irreversible tardive dystonia in some individuals, and additional intervention is sometimes needed. "	( Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report. Ahn, J; Joe, S; Lim, J; Park, C; Park, J, 2015)	2.16
"Aripiprazole failed to produce a significant effect on overall nicotine withdrawal symptoms after awakening and after lunch."	( Long-term treatment with aripiprazole on the waking and postprandial urges to smoke in Chinese heavy smokers. Bao, YP; Beveridge, TJ; Di, XL; Li, SX; Liu, Y; Lu, L; Sun, HQ; Yang, FD, 2010)	1.39
"Aripiprazole proved to inhibit the •O(2)(-) generation through the cascade of protein kinase C (PKC) activation, intracellular Ca(2+) regulation and NADPH oxidase activation via cytosolic p47(phox) translocation to the plasma/phagosomal membranes."	( Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia. Han, YH; Hashioka, S; Hirata, E; Horikawa, H; Inoguchi, T; Kanba, S; Kasai, M; Kato, TA; Maeda, Y; Mizoguchi, Y; Monji, A; Seki, Y; Sonoda, N; Utsumi, H; Yasukawa, K, 2011)	2.53
"Aripiprazole appears to cause less weight gain than many other antipsychotics."	( Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Basu, R; Brar, JS; Chang, CC; Ganguli, R; Garbut, R, 2011)	1.31
"Aripiprazole has a lower risk of raised prolactin and prolongation of the QTc interval."	( Aripiprazole versus placebo for schizophrenia. Belgamwar, RB; El-Sayeh, HG, 2011)	2.53
"Aripiprazole seems not to cause significant EPSE, hyperprolactinaemia, excessive weight gain or cardiac rhythm disturbance."	( Aripiprazole: a review of its pharmacology and clinical use. Taylor, DM, )	2.3
"Aripiprazole does not cause significant prolactin elevation and is associated with a low rate of clinically significant weight gain compared with other atypical antipsychotics."	( Aripiprazole, a novel atypical antipsychotic drug. Argo, TR; Carnahan, RM; Perry, PJ, 2004)	2.49
"Aripiprazole did however cause more insomnia than perphenazine (n=300, 1 RCT, RR 2.23 CI 1.57 to 3.18, NNH 4 CI 3 to 9) and less need for antiparkinson drugs than 10-20mg/day haloperidol (n=1854, 4 RCTs, RR 0.45 CI 0.33 to 0.60, NNT 4 CI 3 to 5)."	( Aripiprazole for schizophrenia. El-Sayeh, HG; Morganti, C, 2004)	2.49
"Aripiprazole did not inhibit physostigmine- or norepinephrine-induced lethality in rats."	( Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. Altar, CA; Burris, KD; Hirose, T; Kikuchi, T; Kitagawa, H; Miwa, T; Nabeshima, T; Uwahodo, Y; Yamada, S, 2004)	1.36
"Aripiprazole displays properties of an agonist and antagonist in animal models of dopaminergic hypoactivity and hyperactivity, respectively."	( Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Burris, KD; Kikuchi, T; Molinoff, PB; Molski, TF; Ryan, E; Tottori, K; Xu, C; Yocca, FD, 2002)	2.48

Excerpt	Reference	Relevance
"Aripiprazole can be a treatment option for temper outbursts in people with PWS. "	( Aripiprazole treatment for temper outbursts in Prader-Willi syndrome. Bleich, S; Deest, M; Deest-Gaubatz, S; Eberlein, CK; Frieling, H; Groh, A; Jakob, MM; Seifert, J; Toto, S; Wieting, J, 2022)	3.61
"Aripiprazole treatment decreased activation of the middle frontal, superior frontal and occipital gyrus (ToL) and medial temporal and inferior frontal gyrus, putamen and cuneus (WoF), while activation increased after risperidone."	( Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study. Aleman, A; Knegtering, H; Liemburg, EJ; van Es, F, 2017)	1.57
"Aripiprazole treatment also decreased the volume of kidney necrosis."	( Aripiprazole prevents renal ischemia/reperfusion injury in rats, probably through nitric oxide involvement. Gholampour, H; Moezi, L; Shafaroodi, H, 2017)	2.62
"Aripiprazole treatment was associated with significant BMI-Z increase, higher in children than in adolescents."	( Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. Bernardini, R; Biganzoli, E; Bravaccio, C; Capuano, A; Carnovale, C; Clementi, E; Marano, G; Molteni, M; Nobile, M; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Rizzo, R; Rossi, F, 2019)	1.46
"In aripiprazole-treated PC12 cells, we previously showed that the mitochondrial membrane potential (Δψm) was rather increased in spite of lowered cytochrome c oxidase activity. "	( Aripiprazole increases NADPH level in PC12 cells: the role of NADPH oxidase. Hamada, Y; Itoh, M; Kaneko, YS; Kodani, Y; Kondo, K; Nagasaki, H; Nagatsu, T; Nakashima, A; Ota, A; Ota, M; Takayanagi, T, 2014)	2.47
"Aripiprazole-treated AN subjects were more likely than PAE subjects to report somnolence (11.9% vs."	( Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Forbes, RA; Mankoski, R; Manos, G; Marcus, R; Marler, S; McQuade, R; Stockton, G, 2013)	2.55
"Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia."	( A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Addington, J; Bennett, N; Braga, RJ; Correll, CU; Gallego, JA; Greenberg, J; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Lopez, L; Malhotra, AK; Naraine, M; Petrides, G; Robinson, DG; Sevy, SM; Tohen, M; Zhang, JP, 2015)	1.44
"Aripiprazole-treated patients also had significantly more akathisia (p=0.03) and agitation (p=0.02) than risperidone-treated patients."	( Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients. Chawarski, MC; Chen, H; Hao, W; Schottenfeld, RS; Wang, G; Xu, Z; Zhang, S; Zhang, Y, 2016)	2.6
"Aripiprazole treatment produced a decrease of BP (9.3 mm Hg on systolic and 6.2 mm Hg on diastolic pressure) and an increase in HR (12.1 beats per minute) and QTc interval (9.1 milliseconds)."	( Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers. Abad-Santos, F; Belmonte, C; Cabaleiro, T; Ochoa, D; Román, M; Sánchez-Rojas, SD; Talegón, M, 2016)	1.39
"Aripiprazole showed less treatment emerged weight gain."	( A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia. Kumar C, N; Kumar P B, S; Kumar P T, S; Pandey, RS; Thirthalli, J, 2017)	1.43
"Aripiprazole treatment was generally well tolerated, with criteria for tolerability met for all doses tested."	( Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. Boulton, DW; Carson, WH; Findling, RL; Forbes, RA; Kauffman, RE; Mallikaarjun, S; Nyilas, M; Pikalov, A; Sallee, FR; Shoaf, SE, 2008)	1.34
"Aripiprazole treatment had no effect on cue-induced Meth craving, or on daily baseline craving assessed over the course of medication treatment, although aripiprazole treatment was associated with increased craving independent of Meth dosing."	( Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Abad, A; Anderson, A; Condos, R; De La Garza, R; Elkashef, A; Halkitis, PN; Li, SH; Mahoney, JJ; Mojisak, J; Newton, TF; Palamar, J; Reid, MS, 2008)	1.34
"In aripiprazole-treated patients, symptomatic remission rates were consistent at Weeks 8, 16, and 26; sustained remission rates at Week 8 were retained at Weeks 16 and 26."	( Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010). Carlson, BX; Eudicone, J; Marcus, RN; Masand, PS; McQuade, RD; Pikalov, A; Vester-Blokland, E, 2008)	1.07
"Aripiprazole treatment for 12 months (P = 0.027) and stopping clozapine or olanzapine treatment (P = 0.038) predicted weight loss (> or =3 kg)."	( A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole. Bruggeman, R; Postema, R; Schilthuis, M; Schorr, SG; Slooff, CJ; Taxis, K; Van Oven, W, 2008)	1.3
"Aripiprazole-treated patients also showed significant decreases versus placebo in 26 of the 30 PANSS items (all p<0.05)."	( The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Kane, JM; Pikalov, A; Whitehead, R, 2008)	1.41
"Aripiprazole- and lithium-treated patients remained on blinded treatment for 9 additional weeks."	( Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. Carson, WH; Cutler, AJ; Keck, PE; Marcus, RN; McQuade, RD; Orsulak, PJ; Sanchez, R; Torbeyns, A, 2009)	2.52
"Aripiprazole-treated patients had smaller increases in glucose and lipids, but no difference was observed between treatments in the proportion of patients experiencing categorical shifts in these measures."	( Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL, 2008)	1.4
"Aripiprazole treatment resulted in improvement from baseline on all efficacy outcome measures, including Positive and Negative Syndrome Scale total, positive, negative, and general subscale, and CGI-Severity scores."	( A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Chung, S; Jeon, YW; Jeong, B; Jun, TY; Jung, HY; Kim, CE; Kim, CY; Kim, DH; Kwon, JS; Lee, JN; Lee, MS, 2009)	1.31
"Aripiprazole-treated patients also showed BMI (median reduction 0.8 kg/m(2)) and waist circumference reduction (median reduction 2.0 cm) vs."	( Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Dewaele, P; Fleischhacker, WW; Heikkinen, ME; Hennicken, D; Kerselaers, W; Landsberg, W; Loze, JY; McQuade, RD; Olié, JP, 2010)	1.35
"Aripiprazole-treated subjects, compared with placebo-treated subjects, also had significantly less heavy drinking during the 14-day medication period."	( The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. Anton, RF; Henderson, S; Li, X; Myrick, H; Randall, PK; Voronin, K, 2010)	1.44
"Aripiprazole pre-treatment resulted in bidirectional effects on amphetamine self-administration."	( Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole. Bäckström, P; Etelälahti, TJ; Hyytiä, P, 2011)	1.32
"Aripiprazole treatment at 3 mg/day improved tardive oromandibular dystonia without worsening Parkinsonism."	( Efficacy of aripiprazole in sulpiride-induced tardive oromandibular dystonia. Ikawa, M; Imai, N, 2011)	1.47
"Aripiprazole treatment generally did not increase bodyweight to a clinically relevant extent; however, more patients receiving aripiprazole monotherapy than placebo had clinically significant bodyweight gain during 100 weeks' treatment."	( Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Dhillon, S, 2012)	2.54
"Aripiprazole treatment resulted in no significant difference from placebo in change in mean body weight from baseline (-0.4 vs."	( A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). Ishigooka, J; Kanba, S; Kawasaki, H; Kinoshita, T; Kuroki, T; Sakamoto, K, 2014)	1.36
"Aripiprazole treatment led to significantly more akathisia incidence in the AD group, compared with the SCZ group."	( Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Moteshafi, H; Stip, E, 2012)	1.34
"Aripiprazole treatment was well tolerated in both short- and long-term studies, showing a low liability for EPS and hyperprolactinemia, a lack of QTc prolongation, and minimal weight gain or sedation."	( Dopamine partial agonists: a new class of antipsychotic. Lieberman, JA, 2004)	1.04
"Aripiprazole-treated patients showed significantly greater improvements from baseline in BPRS Psychosis and BPRS Core subscale scores at end point compared with placebo."	( Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. Breder, C; Carson, WH; De Deyn, P; Iwamoto, T; Jeste, DV; Kostic, D; Swanink, R, 2005)	2.49
"Aripiprazole-treated patients demonstrated significantly greater improvement from baseline to endpoint in mean YMRS total scores compared with placebo-treated patients as early as Day 4 and sustained through Week 3."	( Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Abou-Gharbia, N; Carson, W; Impellizzeri, C; Iwamoto, T; Kaplita, S; Marcus, R; McQuade, R; Rollin, L; Sachs, G; Sanchez, R; Stock, E, 2006)	2.5
"Aripiprazole-treated patients had significantly fewer relapses (25%) than placebo patients (43%; p = .013)."	( A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. Calabrese, JR; Carlson, BX; Carson, WH; Keck, PE; Marcus, RN; McQuade, RD; Rollin, LM; Sanchez, R, 2006)	1.29
"Aripiprazole treatment (n=268) resulted in significantly better effectiveness than SOC treatment (n=254; P<0.001; Week 26 LOCF) as evidenced by the IAQ total score beginning at Week 4 (the first assessment point) and sustained through Week 26. "	( A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Banki, CM; Beuzen, JN; Hanssens, L; Herman, E; Kerwin, R; L'Italien, G; Lublin, H; McQuade, RD; Millet, B; Pans, M, 2007)	2.02
"Aripiprazole treatment was associated with clinically and statistically significant improvement in mean Young Mania Rating Scale scores (-18.0+/-6.9, P<.0001)."	( An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. Aleardi, M; Biederman, J; Doyle, R; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Spencer, T; Wozniak, J, 2007)	1.37
"One aripiprazole-treated patient discontinued due to an AE (akathisia)."	( Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Carlson, BX; Eudicone, JM; Marcus, RN; McQuade, RD; Momah, C; Muzina, DJ; Pikalov, A; Sanchez, R, 2008)	2.27
"Aripiprazole-treated patients had more favorable changes in lipids, glucose, and body weight versus SoC. "	( Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. Blonde, L; Gutterman, EM; Hanssens, L; Kan, HJ; Kim, MS; L'Italien, GJ; McQuade, RD, 2008)	2.01
"Aripiprazole-treated patients had more favorable changes in metabolic parameters compared with SoC, leading to a reduced risk of diabetes and CHD, based on validated models."	( Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. Blonde, L; Gutterman, EM; Hanssens, L; Kan, HJ; Kim, MS; L'Italien, GJ; McQuade, RD, 2008)	2.01
"Treatment with aripiprazole suppressed the growth of head and neck cancer cells in a concentration-dependent manner, as evidenced by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay."	( Aripiprazole sensitizes head and neck cancer cells to ionizing radiation by enhancing the production of reactive oxygen species. Jeong, HJ; Jung, CW; Kim, HJ; Kim, JY; Moon, Y; Park, B; Park, MJ, 2022)	2.5
"Treatment with aripiprazole was only effective at preventing the reinstatement of ethanol-induced CPP when paired with the ethanol-associated environment, but not when administered in the home-cage."	( Role of the treatment environment in the effects of aripiprazole on ethanol-induced behavioral sensitization and conditioned place preference in female mice. Baldaia, MA; Barros-Santos, T; Berro, LF; Borges, ALN; Cata-Preta, EG; de Santana Santos, ACG; Frussa-Filho, R; Hollais, AW; Libarino-Santos, M; Marinho, EAV; Nunes Brandão, NR; Oliveira-Lima, AJ; Santos-Baldaia, R, 2020)	1.15
"Co-treatment with aripiprazole and an ineffective dose of escitalopram also abolished the behavioral deficits in the studied tests."	( Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague-Dawley rats exposed to glutathione deficit during early postnatal development of the brain. Kamińska, K; Lech, MA; Leśkiewicz, M; Lorenc-Koci, E; Rogóż, Z, 2021)	1.19
"Treatment with aripiprazole was associated with a significantly longer time to exacerbation of psychotic symptoms/impending relapse compared with placebo (hazard ratio, 0.46 [95% CI = 0.24-0.88]; p = .016)."	( Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. Baker, RA; Carson, W; Correll, CU; Kohegyi, E; McQuade, R; Nyilas, M; Salzman, PM; Sanchez, R; Zhao, C, 2017)	1.31
"Treatment with aripiprazole once-monthly, at any dose, did not result in any clinically meaningful changes from baseline in extrapyramidal symptom scales, clinical laboratory tests, vital signs, or electrocardiogram parameters."	( Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Bricmont, P; Carson, W; Fleischhacker, WW; Forbes, RA; Kane, JM; Mallikaarjun, S; McQuade, R; Sanchez, R, 2013)	0.99
"Treatment with aripiprazole resulted in significant improvement in the PANSS and Clinical Global Impression scores over time."	( The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis. Cho, DH; Chung, YC; Hahn, SW; Jeong, B; Kim, JH; Kim, SW; Koo, MS; Lee, SH; Lee, SJ; Lee, YH; Park, JI; Rho, SH, 2014)	0.99
"Pretreatment of aripiprazole and minocycline suppressed apoptosis of oligodendrocytes in the co-culture model with interferon-γ (IFN-γ)-activated microglia, while haloperidol, a traditional antipsychotic drug, did not."	( Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model. Horikawa, H; Kanba, S; Kato, TA; Mizoguchi, Y; Monji, A; Sato-Kasai, M; Seki, Y; Yoshiga, D, 2013)	1.07
"Treatment with aripiprazole was associated with no changes of mean QTc, even if a small increase of QTd, (40.6+6.5 ms vs 46.3+7.2 ms, p<0.01) was observed."	( ECG parameters in children and adolescents treated with aripiprazole and risperidone. Calabrò, MP; D'Amico, G; Gagliano, A; Germanò, E; Guerriero, L; Ingrassia, M; Italiano, D; Lamberti, M; Privitera, C; Siracusano, R; Spina, E, 2014)	0.99
"Treatment with aripiprazole lauroxil resulted in decreases in agitation and hostility in patients with schizophrenia and this antihostility effect appears to be independent of a general antipsychotic effect."	( Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. Bose, A; Citrome, L; Claxton, A; Du, Y; Ehrich, EW; Risinger, R; Silverman, BL; Stankovic, S; Zummo, J, 2016)	1.18
"Treatment with aripiprazole resulted in a reduction in the frequency, duration, and severity of episodes of alternating hemiplegia, along with other therapeutic benefits."	( Treatment of alternating hemiplegia of childhood with aripiprazole. Haffejee, S; Santosh, PJ, 2009)	0.94
"Treatment with aripiprazole at 10 microM increased the levels of BDNF by 85%, compared with control levels (p<0.01), whereas haloperidol had no effect."	( Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Cho, HY; Choi, SM; Ha, EK; Kim, YH; Lee, JG; Park, SW; Seo, MK, 2009)	1
"Treatment with aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks."	( Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Correll, CU; Kane, JM; Malhotra, AK; Manu, P; Napolitano, B; Olshanskiy, V, 2009)	0.71
"Pretreatment of aripiprazole (40 mg/kg) had a tendency to suppress MK-801 (1.0 mg/kg)-induced pMEK/MEK (Ser218/222) activation."	( Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. Hashimoto, K; Ishii, D; Iyo, M; Kanahara, N; Kohno, M; Matsuda, S; Matsuzawa, D; Nakazawa, K; Ohtsuka, H; Shimizu, E; Sutoh, C, 2010)	1.08
"Pretreatment with aripiprazole protected dopaminergic neurons in a concentration-dependent manner."	( Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures. Akaike, A; Izumi, Y; Kume, T; Matsuo, T; Sawada, H; Takada-Takatori, Y, 2010)	1
"Treatment with aripiprazole came at the total costs per remission of 30,970 Baht while treatment with placebo came at the total costs per remission of 28,409 Baht. "	( The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model. Leelahanaj, T, 2010)	1.01
"Treatment with aripiprazole dominates over olanzapine in both schizophrenia and bipolar disorder. "	( Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Eriksson, J; Kasteng, F; Lindgren, P; Sennfält, K, 2011)	0.98
"Treatment with aripiprazole for 8 weeks significantly increased plasma BDNF levels. "	( Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Tomita, M; Umene-Nakano, W; Yoshimura, R, 2012)	2.17
"Treatment with aripiprazole is associated with significant reduction of the Positive and Negative Symptom Scale (PANSS) scores in youth with schizophrenia, and reductions in items in the negative symptom scores at higher doses (30 mg/day). "	( Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review. Doey, T, 2012)	2.17
"Treatment with aripiprazole was well tolerated."	( Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. Aleardi, M; Biederman, J; Falzone, R; McDonnell, MA; Mick, E; Spencer, T; Wozniak, J, 2005)	2.11
"Pretreatment with aripiprazole shifted the dose-response function of methamphetamine to the right in both LgA and ShA rats."	( Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Koob, GF; Pulvirenti, L; Wang, Z; Wee, S; Woolverton, WL, 2007)	1.07
"Pre-treatment with aripiprazole was generally well tolerated, with tiredness being the most commonly reported adverse event."	( Effects of aripiprazole on subjective and physiological responses to alcohol. Arias, AJ; Chan, G; Covault, J; Douglas, K; Kranzler, HR; Oncken, C; Pierucci-Lagha, A, 2008)	1.05

Excerpt	Reference	Relevance
"Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder."	( Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002)	2.07
" This includes general adverse events, a low incidence of reported weight gain and a low liability for inducing movement disorders."	( Aripiprazole: profile on efficacy and safety. Goodnick, PJ; Jerry, JM, 2002)	1.76
" Safety assessments included adverse event (AE) reports, EPS scales, ECGs, weight, and prolactin, glucose and cholesterol levels."	( Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E, 2003)	1.76
" Discontinuations due to adverse events did not differ significantly between the aripiprazole and placebo groups."	( A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Ali, M; Ingenito, G; Keck, PE; Liebeskind, A; Marcus, R; Saha, A; Tourkodimitris, S, 2003)	0.78
"Aripiprazole had significantly greater efficacy than placebo for the treatment of bipolar disorder patients in acute manic or mixed episodes and was safe and well tolerated in this randomized controlled trial."	( A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Ali, M; Ingenito, G; Keck, PE; Liebeskind, A; Marcus, R; Saha, A; Tourkodimitris, S, 2003)	1.99
" Time to discontinuation due to adverse events or lack of efficacy was significantly greater with aripiprazole than with haloperidol (p=0."	( Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A, 2003)	0.85
" Adverse events were generally mild to moderate, were transient in nature, and commonly occurred within the first 3 days of dosing."	( Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. Bramer, SL; Mallikaarjun, S; Salazar, DE, 2004)	0.58
"Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics."	( The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Citrome, L; Volavka, J, 2004)	0.32
" However, there are still significant adverse effects and toxicities with this class of medications."	( Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois, D, 2005)	0.33
"Continued research to evaluate adverse effects and tolerability of atypical antipsychotics compared with first-generation antipsychotics and each other is reviewed."	( Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois, D, 2005)	0.33
"While new atypical antipsychotic medications may have a safer therapeutic and overdose profile than first-generation antipsychotic medications, many adverse and toxic effects still need to be considered in therapeutic monitoring and overdose management."	( Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois, D, 2005)	0.33
" Several clinical trials have not shown efficacy, and there have been concerns about adverse events."	( Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Dagerman, K; Insel, PS; Schneider, LS, 2006)	0.33
" Clinical and trials characteristics, outcomes, and adverse events were extracted."	( Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Dagerman, K; Insel, PS; Schneider, LS, 2006)	0.33
" Adverse events were mainly somnolence and urinary tract infection or incontinence across drugs, and extrapyramidal symptoms or abnormal gait with risperidone or olanzapine."	( Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Dagerman, K; Insel, PS; Schneider, LS, 2006)	0.33
" Dropouts and adverse events further limit effectiveness."	( Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Dagerman, K; Insel, PS; Schneider, LS, 2006)	0.33
" Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events were assessed as measures of safety and tolerability."	( Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. Chan, HY; Chiang, SC; Hwang, TJ; Hwu, HG; Lin, SK; Lin, WW; Su, TP, 2007)	0.65
" No patient discontinued the study because of treatment-emergent adverse events."	( Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. Auby, P; Marcus, RN; McQuade, RD; Oren, DA; Sack, DA; Tran-Johnson, TK, 2007)	0.61
" Extrapyramidal symptom-related adverse events were lower for aripiprazole (1."	( Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007)	0.87
"Acutely agitated patients with schizophrenia or schizoaffective disorder treated with aripiprazole IM or haloperidol IM demonstrated similar effective and safe transition to their respective oral formulations."	( Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007)	0.86
" Adverse events (AEs) that occurred in > or = 10% of patients with adjunctive placebo or adjunctive aripiprazole were akathisia (4."	( The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. Berman, RM; Carson, WH; Corey-Lisle, PK; Khan, A; Marcus, RN; McQuade, RD; Swanink, R, 2007)	0.85
" The treatment-emergent adverse events reported in >or=5% of patients aged 18-40 years receiving aripiprazole were similar to those reported for the overall population."	( Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. Carlson, B; Eudicone, J; McQuade, R; Pikalov, A; Suppes, T, 2008)	0.87
" Treatment-emergent adverse events occurring during the pivotal trials revealed statistically significant NNH versus placebo (or placebo equivalent) for aripiprazole for headache (NNH = 20, 95% CI = 11 to 170) and nausea (NNH = 17, 95% CI = 11 to 38), for ziprasidone in the treatment of headache (NNH = 15, 95% CI = 8 to 703), and for olanzapine in treatment-emergent hypotension (NNH = 50, 95% CI = 30 to 154)."	( Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Citrome, L, 2007)	0.78
" Adverse effects and their impact on treatment course were also evaluated."	( Aripiprazole: effectiveness and safety under naturalistic conditions. Amoretti, A; Di Lorenzo, R; Fiorini, F; Forghieri, M; Genedani, S; Rigatelli, M, 2007)	1.78
"7%) and treatment-related adverse events (82."	( A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. Anton, RF; Breder, C; Carson, WH; Han, J; Kranzler, H; Marcus, RN, 2008)	0.56
" Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4."	( The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008)	0.87
" Aripiprazole is a second-generation antipsychotic that seems to have a favorable side-effect profile."	( The safety of the electroconvulsive therapy-aripiprazole combination: four case reports. Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR; Zervas, IM, 2008)	1.52
" Combined application of clozapine and aripiprazole is in accordance with a neurobiological rationale and appears to be a safe and well tolerated."	( Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment. Libiger, J; Masopust, J; Tůma, I, 2008)	1.01
"Aripiprazole (15 mg/day) is safe and tolerable when combined with cocaine; however, the usefulness of aripiprazole as a treatment for cocaine-use disorders remains to be determined."	( The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. Hays, LR; Lile, JA; Rush, CR; Stoops, WW, 2008)	2
"Dopamine receptor antagonists are commonly used to counter the adverse effects of opioids such as hallucinations, delusions and emesis."	( Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. Amano, T; Asato, M; Hashimoto, K; Ikegami, D; Kuzumaki, N; Matsushima, Y; Nakamura, A; Narita, M; Niikura, K; Shiokawa, M; Suzuki, T; Takagi, S; Takei, D; Tsurukawa, Y, 2008)	0.59
" Tolerability and safety were assessed by monitoring the frequency and severity of treatment-emergent adverse events, extrapyramidal symptoms (EPS), vital signs, weight, and laboratory tests."	( Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY, 2009)	0.63
"Completion rates were between 84% and 90% and comparable across all subgroups, with low discontinuations due to adverse events."	( Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. Berman, RM; Carlson, BX; Fava, M; Marcus, RN; Nelson, CJ; Pikalov, A; Qi, Y; Thase, ME; Tran, QV; Trivedi, MH; Yang, H, 2008)	0.74
" Safety and tolerability evaluations included incidence of treatment-emergent adverse events and extrapyramidal symptom assessments (SAS, BARS, and AIMS), and metabolic profile changes including weight and BMI."	( The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. Assunção-Talbott, S; Eudicone, JM; Glick, ID; Mankoski, R; Marcus, RN; Tran, QV, 2009)	0.62
"Aripiprazole was generally well tolerated, with agitation/activation the most common side effect reported in elderly inpatients."	( Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients. Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM, 2009)	3.24
" Primary endpoint was rate of discontinuation due to adverse events (AEs) during the 12-week study."	( Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Kahn, JP; Kerselaers, W; Lissens, J; McQuade, RD; Modell, S; Ryckmans, V; Sanchez, R; Werner, C, 2009)	0.72
" The ultimate aim for this research is to determine whether this combination is safe and is superior to either drug taken alone in reducing alcohol use in alcohol dependent patients."	( A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. Kenna, GA; Leggio, L; Swift, RM, 2009)	0.59
" Participants reported adverse events (AEs) daily alcohol use and participated in an alcohol challenge session (ACS)."	( A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. Kenna, GA; Leggio, L; Swift, RM, 2009)	0.59
" Most common adverse effects included appetite increase and weight gain in 5 subjects, mild extrapyramidal effects in 7 subjects, and headaches and tiredness/fatigue in 7 subjects; 1 subject experienced akathisia and muscle cramps."	( Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. Coffey, BJ; Goldman, R; Hirsch, S; Jummani, R; Lyon, GJ; Samar, S; Spirgel, A, 2009)	1.8
"Aripiprazole appears to be a safe and tolerable treatment in children and adolescents with TD that appears to reduce tics; it should be further investigated as a treatment option in controlled trials."	( Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. Coffey, BJ; Goldman, R; Hirsch, S; Jummani, R; Lyon, GJ; Samar, S; Spirgel, A, 2009)	3.24
" Frequently reported adverse events (AEs) that occurred with ARI + LI vs."	( Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Baudelet, C; Marcus, RN; McQuade, RD; Owen, R; Sanchez, R; Vieta, E, 2010)	0.6
"Long-term aripiprazole adjunctive to lithium/valproate in bipolar mania was safe and well tolerated."	( Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Baudelet, C; Marcus, RN; McQuade, RD; Owen, R; Sanchez, R; Vieta, E, 2010)	1
" Early onset schizophrenia warrants effective pharmacological treatment that is safe and well tolerated by children and adolescent population."	( The use of aripiprazole in early onset schizophrenia: safety and efficacy. Hamidin, A; Normala, I, 2009)	0.74
" Akathisia was the most common adverse event in both the older (17."	( Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Andersson, C; Berman, RM; Carlson, BX; Eudicone, JM; Forbes, RA; Nelson, JC; Steffens, DC; Tran, QV; Yang, H, 2011)	0.65
" Safety and tolerability measures included incidences of adverse events, extrapyramidal symptoms, weight, metabolic measures, vital signs, and other clinical assessments."	( Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. Carson, WH; Findling, RL; Kamen, L; Mankoski, R; Manos, G; Marcus, RN; McQuade, RD; Owen, R, 2011)	0.67
" Adverse events were experienced by 286/330 subjects (86."	( Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. Carson, WH; Findling, RL; Kamen, L; Mankoski, R; Manos, G; Marcus, RN; McQuade, RD; Owen, R, 2011)	0.67
"Aripiprazole was generally safe and well tolerated in the long-term treatment of irritability associated with autistic disorder in pediatric subjects."	( Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. Carson, WH; Findling, RL; Kamen, L; Mankoski, R; Manos, G; Marcus, RN; McQuade, RD; Owen, R, 2011)	2.11
" The Systematic Assessment of Treatment Emergent Events-General Inquiry was used to assess adverse effects."	( The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial. Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW, 2012)	0.64
" The most common adverse events (> 15% of patients; aripiprazole vs."	( A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). Ishigooka, J; Kanba, S; Kawasaki, H; Kinoshita, T; Kuroki, T; Sakamoto, K, 2014)	0.89
" Treatment was generally safe and well tolerated."	( A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). Ishigooka, J; Kanba, S; Kawasaki, H; Kinoshita, T; Kuroki, T; Sakamoto, K, 2014)	0.64
"Primary metabolic markers (body mass index, blood pressure, fasting blood glucose, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), percentage of patients who stay on the randomly assigned atypical antipsychotic for at least 6 months, psychopathology, percentage of patients who develop metabolic syndrome, and percentage of patients who develop serious and nonserious adverse events."	( Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA, 2013)	0.39
"Because of a high incidence of serious adverse events, quetiapine was discontinued midway through the trial."	( Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA, 2013)	0.39
" Double-blind, randomized, controlled trials investigating the metabolic adverse effects (weight gain, lipid, glucose, and prolactin level abnormalities) associated with atypical antipsychotic use in children and adolescents aged ≤ 18 years were included, irrespective of whether the investigation of adverse effects was a primary or secondary endpoint."	( Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Aitchison, KJ; Almandil, NB; Besag, FM; Liu, Y; Murray, ML; Wong, IC, 2013)	0.39
" Safety was assessed across study phases by the time of first onset of adverse events, as were objective measures of extrapyramidal symptoms, fasting metabolic parameters, and body weight."	( Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Baker, RA; Carson, W; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, B; Kane, JM; McQuade, R; Sanchez, R, 2013)	0.66
"5%) in the SOC group discontinued due to adverse events (physician and subject decision combined, P = ."	( A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. Adams, DH; Baygani, S; Kinon, BJ; Kollack-Walker, S; Millen, BA; Velona, I; Walling, DP, 2013)	0.39
"These data provide further evidence that the potential antipsychotic LY2140023 monohydrate, with a glutamatergic mechanism of action, may have a unique tolerability profile characterized by a low association with some adverse events such as extrapyramidal symptoms and weight gain that may characterize currently available dopaminergic antipsychotics."	( A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. Adams, DH; Baygani, S; Kinon, BJ; Kollack-Walker, S; Millen, BA; Velona, I; Walling, DP, 2013)	0.39
" Adverse events were assessed."	( A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Berk, M; Ghanizadeh, A; Sahraeizadeh, A, 2014)	0.69
" Adverse events were similar irrespective of prior atypical antipsychotic and duration of oral antipsychotic overlap, suggesting that patients can be safely switched from their existing oral antipsychotic to aripiprazole once monthly without requiring an intermediate stabilization phase with oral aripiprazole."	( Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Baker, RA; Bricmont, P; Eramo, A; Kasper, W; Mallikaarjun, S; McQuade, R; Peters-Strickland, T; Potkin, SG; Raoufinia, A; Sanchez, R, 2013)	0.84
" The most common treatment-emergent adverse events were vomiting (13."	( Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Bricmont, P; Carson, W; Fleischhacker, WW; Forbes, RA; Kane, JM; Mallikaarjun, S; McQuade, R; Sanchez, R, 2013)	0.65
" Subjects were stratified by PAE; adverse events (AEs), and changes in weight, and metabolic measures were evaluated."	( Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Forbes, RA; Mankoski, R; Manos, G; Marcus, R; Marler, S; McQuade, R; Stockton, G, 2013)	1.83
"The purpose of this project was to provide evidence-based guidance concerning when and how it is appropriate to undertake elective changes in antipsychotic medications in order to reduce adverse effects, with a focus on those adverse effects associated with increased long-term health risks."	( Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. Buchanan, RW; Newcomer, JW; Weiden, PJ, 2013)	0.39
" The most common adverse events during phase 1 were weight increase (25."	( A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Amatniek, J; Eudicone, JM; Findling, RL; Lears, K; Mankoski, R; Marcus, RN; McCartney, T; McQuade, RD; Sheehan, JJ; Timko, K, 2014)	0.64
" Adverse events were assessed within each subgroup."	( Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis. Berman, RM; Hatch, A; Largay, K; Marler, SV; Nelson, JC; Sheehan, JJ; Stewart, TD, 2014)	0.65
" Common treatment-emergent adverse events included akathisia and restlessness."	( Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis. Berman, RM; Hatch, A; Largay, K; Marler, SV; Nelson, JC; Sheehan, JJ; Stewart, TD, 2014)	0.65
" Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events were also assessed as measures of safety and tolerability."	( Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W, 2014)	0.71
"The aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium."	( Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. Boettger, S; Breitbart, W; Jenewein, J, 2015)	0.87
"The Memorial Delirium Assessment Scale (MDAS), the Karnofsky Performance Status (KPS) scale, and a side-effect rating were recorded at baseline (T1), after 2-3 days (T2), and after 4-7 days (T3)."	( Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. Boettger, S; Breitbart, W; Jenewein, J, 2015)	0.68
"Haloperidol, risperidone, aripiprazole, and olanzapine were equally effective in the management of delirium; however, they differed in terms of their side-effect profile."	( Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. Boettger, S; Breitbart, W; Jenewein, J, 2015)	0.98
" The most common adverse events were injection site pain in 20 subjects (43."	( Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Du, Y; Ehrich, EW; Hard, M; Risinger, R; Turncliff, R, 2014)	0.67
" Risk assessment for the potential use of a drug, such as aripiprazole (Abilify), should not focus on any particular adverse effect, but rather should consider risk assessment in a broader context."	( Atypical antipsychotics are not all alike: side effects and risk assessment. Howland, RH, 2014)	0.65
"The reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from 1997 to 2011 were reviewed to assess serious adverse events induced by the administration of antipsychotics to children."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
" Signals in the data that signified a drug-associated adverse event were detected via quantitative data mining algorithms."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
" Significant signals of the QT prolongation adverse event were detected only for ziprasidone and risperidone."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
"It was suggested that there is a level of diversity in the strength of the association between various first- and second-generation antipsychotics with associated serious adverse events, which possibly lead to fatal outcomes."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
" The most common (>10% patients) treatment-emergent adverse events for paliperidone ER were akathisia, headache, somnolence, tremor, and weight gain, and for aripiprazole were worsening of schizophrenia and somnolence."	( Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. Gopal, S; Hough, D; Lane, R; Nuamah, I; Savitz, AJ, 2015)	0.61
" EPS were assessed at baseline and 4, 8, and 12 weeks after naturalistic SGA initiation for schizophrenia, mood, disruptive behavior, and autism spectrum disorders using the Simpson-Angus Scale (SAS), Barnes Akathisia Scale, Abnormal Involuntary Movement Scale (AIMS), and Treatment Emergent Side Effect Scale."	( Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E, 2015)	0.42
" Akathisia was the most common adverse effect of aripiprazole (reported in 24 [26%] of 91 participants on aripiprazole vs 11 [12%] of 90 on placebo)."	( Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Anderson, SJ; Begley, AE; Blumberger, DM; Butters, MA; Dew, MA; Karp, JF; Lenze, EJ; Mulsant, BH; Newcomer, JW; Reynolds, CF; Stack, JA, 2015)	0.9
" Case reports, case series, and prospective or cross-sectional studies including relevant data such as relative infant dose (RID), milk-to-plasma ratio (M/P ratio), infant drug plasma levels, and adverse events were identified."	( Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety. Uguz, F, 2016)	0.43
" Other than clozapine, adverse events were rarely reported in infants exposed to SGAs."	( Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety. Uguz, F, 2016)	0.43
"The current data suggest that SGAs seem to be relatively safe in the exposed breastfed infants for short-term usage."	( Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety. Uguz, F, 2016)	0.43
"Hyperprolactinemia is an important but often overlooked adverse effect of antipsychotics."	( Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study. Choi, WJ; Hong, CH; Kim, BR; Kim, TY; Lee, BO; Lee, JS; Lee, SK; Park, IH; Park, SJ; Roh, D; Seok, JH; Son, SJ; Yoon, HW, )	0.36
"Both the addition and switching strategies were effective in resolving antipsychotic-induced hyperprolactinemia and hyperprolactinemia-related adverse events, including menstrual disturbances and sexual dysfunction."	( Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study. Choi, WJ; Hong, CH; Kim, BR; Kim, TY; Lee, BO; Lee, JS; Lee, SK; Park, IH; Park, SJ; Roh, D; Seok, JH; Son, SJ; Yoon, HW, )	0.36
"Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders."	( Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole. Bruhn, CH; Fink-Jensen, A; Jakobsen, KD; Nielsen, J; Pagsberg, AK, 2016)	2.09
" The most common treatment-emergent adverse event (TEAE) was injection site pain (35."	( [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. Ishigooka, J; Nishiyama, K; Noda, T; Shima, T; Tadori, Y; Tamaru, N; Yamasaki, Y, 2016)	0.72
" The incidence of treatment-emergent adverse events (AEs) was evaluated."	( Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. Bose, A; Du, Y; Ehrich, EW; Nasrallah, HA; Newcomer, JW; Risinger, R; Silverman, BL; Stankovic, S; Zummo, J, 2016)	0.84
" Women and subjects with higher AUC and maximum plasma concentration values were more prone to experience adverse drug reactions and gastrointestinal adverse reactions."	( Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers. Abad-Santos, F; Belmonte, C; Cabaleiro, T; Ochoa, D; Román, M; Sánchez-Rojas, SD; Talegón, M, 2016)	0.67
" There is a directly proportional relationship between pharmacokinetic parameters and adverse drug reactions and effect on BP and HR."	( Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers. Abad-Santos, F; Belmonte, C; Cabaleiro, T; Ochoa, D; Román, M; Sánchez-Rojas, SD; Talegón, M, 2016)	0.67
" Adjunctive aripiprazole appears safe but better RCTs are needed to demonstrate efficacy."	( Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia: Meta-Analysis of Randomized Controlled Trials. de Leon, J; Li, XB; Tang, YL; Wang, CY; Xiang, YQ; Zheng, W; Zheng, YJ, 2016)	1.09
"Overall, both treatments significantly improved depressive symptoms without causing serious adverse events."	( Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. Cheon, EJ; Koo, BH; Lee, JH; Lee, KH; Lee, SJ; Park, YW; Sung, HM, 2017)	0.72
" Aripiprazole and bupropion may offer effective and safe augmentation strategies in patients with MDD who are unresponsive to SSRIs."	( Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. Cheon, EJ; Koo, BH; Lee, JH; Lee, KH; Lee, SJ; Park, YW; Sung, HM, 2017)	1.63
" The treatment-emergent adverse events (incidence > 5%) that were reported at higher rates with AOM 400 than placebo were weight increase, akathisia, insomnia, and anxiety."	( Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study. Amatniek, J; Calabrese, JR; Carson, WH; Cox, K; Hertel, P; Jin, N; Johnson, B; McQuade, RD; Nyilas, M; Perry, P; Salzman, PM; Sanchez, R; Such, P, 2017)	0.77
"AOM 400 delayed the time to and reduced the rate of recurrence of mood episodes and was generally safe and well tolerated."	( Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study. Amatniek, J; Calabrese, JR; Carson, WH; Cox, K; Hertel, P; Jin, N; Johnson, B; McQuade, RD; Nyilas, M; Perry, P; Salzman, PM; Sanchez, R; Such, P, 2017)	0.77
"The deltoid muscle is a safe alternative injection site for aripiprazole once-monthly 400 mg in patients with schizophrenia."	( Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. Baker, RA; Bricmont, P; Eramo, A; Hertel, P; Jin, N; Larsen, F; McQuade, RD; Nylander, AG; Peters-Strickland, T; Raoufinia, A; Repella, J, 2017)	2.14
" Common adverse events (>5%) were schizophrenia, akathisia, headache, insomnia, and anxiety."	( Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Bose, A; Du, Y; Ehrich, E; Potkin, SG; Risinger, R; Silverman, B; Stankovic, S; Zummo, J, 2017)	0.77
" In conclusion, these data provide moderate quality evidence that aripiprazole could be an effective and safe treatment option for TDs, and results from further trials are urgently needed to extend this evidence base."	( The efficacy and safety of aripiprazole for tic disorders in children and adolescents: A systematic review and meta-analysis. Cheng, YH; Wang, S; Wei, YZ; Yang, C; Yang, JH; Zheng, Y; Zhou, YM, 2017)	0.99
" Our results suggest that aripiprazole is effective and safe in treating bipolar mania."	( Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Carvalho, AF; Chang, HY; Chen, TY; Chen, YW; Chow, PC; Chu, CS; Fornaro, M; Li, DJ; Lin, PY; Solmi, M; Stubbs, B; Tseng, PT; Veronese, N; Vieta, E, 2017)	1.03
" The most common adverse events (AEs) were sedation (low dose, 8/44 [18."	( Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents. Carson, W; Cox, K; Kohegyi, E; Kurlan, R; McQuade, R; Nyilas, M; Sallee, F; Sanchez, R; van Beek, A; Zhao, J, 2017)	0.67
"This study indicates that oral aripiprazole is a safe and effective treatment for tics in children and adolescents with TD."	( Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents. Carson, W; Cox, K; Kohegyi, E; Kurlan, R; McQuade, R; Nyilas, M; Sallee, F; Sanchez, R; van Beek, A; Zhao, J, 2017)	0.96
" Antipsychotics have important adverse effects, and systematic monitoring of drug safety is infrequently performed."	( Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study. Hammer, T; Ho, J; Patten, S; Pringsheim, T; Sarna, JR, 2017)	0.46
" Children were monitored for extrapyramidal, metabolic, and hormonal adverse effects using the Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotic Medications guidelines."	( Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study. Hammer, T; Ho, J; Patten, S; Pringsheim, T; Sarna, JR, 2017)	0.46
" The most common adverse event (AE) for all groups was injection-site reaction (pain)."	( A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. Hard, M; Risinger, R; Weiden, PJ, 2017)	0.67
" The most common treatment-emergent adverse events (TEAE; ≥20%) included nasopharyngitis, somnolence, influenza, and increased weight."	( An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. Hiratani, M; Ichikawa, H; Ono, H; Oshimo, T; Tadori, Y; Tsujii, N; Yasuhara, A, 2018)	0.71
" The analysis indirectly compared AL and AOM treatment groups for efficacy by mean change in Positive and Negative Syndrome Scale (PANSS) total score and ≥30% reduction in PANSS total score, as well as tolerability including adverse events, akathisia, and weight gain."	( Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. Cameron, C; Desai, D; Drake, C; Hutton, B; Kotb, A; Weiden, PJ; Zummo, J, 2018)	0.79
" The most common (≥20% patients in any group) treatment-emergent adverse events (TEAE) were nausea, akathisia, insomnia, and somnolence."	( Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan. Ishigooka, J; Matsumoto, H; Ono, H; Tadori, Y, 2018)	0.7
"These study results suggest that aripiprazole would be safe and well tolerated in both short- and long-term treatment for adolescents with SCZ in Japan."	( Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan. Ishigooka, J; Matsumoto, H; Ono, H; Tadori, Y, 2018)	0.98
"Prolactin-related adverse effects contribute to nonadherence and adverse health consequences, particularly in women with severe mental illness."	( Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial. Adams, HA; Buchanan, RW; Buckley, PF; Dickerson, FB; Earl, AK; Feldman, SM; Hackman, AL; Kearns, AM; Kelly, DL; Koola, MM; Liu, F; Luttrell, SE; McEvoy, JP; McMahon, RP; Narang, S; Nichols, RB; Powell, MM; RachBeisel, JA; Richardson, CM; Sayer, MA; Sullivan, KM; Vyas, G; Wehring, HJ, 2018)	0.92
" Psychiatric symptoms and adverse effects were closely monitored."	( Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial. Adams, HA; Buchanan, RW; Buckley, PF; Dickerson, FB; Earl, AK; Feldman, SM; Hackman, AL; Kearns, AM; Kelly, DL; Koola, MM; Liu, F; Luttrell, SE; McEvoy, JP; McMahon, RP; Narang, S; Nichols, RB; Powell, MM; RachBeisel, JA; Richardson, CM; Sayer, MA; Sullivan, KM; Vyas, G; Wehring, HJ, 2018)	0.92
" No differences between groups in symptoms or adverse effects were noted."	( Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial. Adams, HA; Buchanan, RW; Buckley, PF; Dickerson, FB; Earl, AK; Feldman, SM; Hackman, AL; Kearns, AM; Kelly, DL; Koola, MM; Liu, F; Luttrell, SE; McEvoy, JP; McMahon, RP; Narang, S; Nichols, RB; Powell, MM; RachBeisel, JA; Richardson, CM; Sayer, MA; Sullivan, KM; Vyas, G; Wehring, HJ, 2018)	0.92
"Building upon prior studies, this rigorous evaluation confirms the utility of adjunctive aripiprazole as a strategy for improving prolactin and managing prolactin-related adverse effects in premenopausal women with psychosis."	( Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial. Adams, HA; Buchanan, RW; Buckley, PF; Dickerson, FB; Earl, AK; Feldman, SM; Hackman, AL; Kearns, AM; Kelly, DL; Koola, MM; Liu, F; Luttrell, SE; McEvoy, JP; McMahon, RP; Narang, S; Nichols, RB; Powell, MM; RachBeisel, JA; Richardson, CM; Sayer, MA; Sullivan, KM; Vyas, G; Wehring, HJ, 2018)	1.14
" Overall, adverse event (AE) rates experienced over 12 weeks were modest; no AEs were considered serious."	( Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. Du, Y; Liu, CC; Stanford, AD; Weiden, PJ, 2019)	0.74
" Safety endpoints included adverse events (AEs) and extrapyramidal symptoms (EPS) including akathisia, injection-site reactions (ISRs), and clinically relevant changes in metabolic and endocrine values."	( Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. Aquila, R; Claxton, A; Du, Y; Nasrallah, HA; Stanford, AD; Weiden, PJ, 2019)	0.79
" We further assess safety and tolerability and characterize adverse events (AEs) across the duration of aripiprazole exposure."	( The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study. Amatniek, J; Calabrese, JR; Carson, WH; Cox, K; Hertel, P; Jin, N; Johnson, B; McQuade, RD; Nyilas, M; Perry, PP; Sanchez, R; Such, P, 2018)	0.98
" Safety was assessed by monitoring adverse events."	( Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder. Fukuta, Y; Kamijima, K; Yamamura, K; Yasuda, M, 2018)	0.75
"8% of patients experienced at least one adverse event, but no new safety signals were identified."	( Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder. Fukuta, Y; Kamijima, K; Yamamura, K; Yasuda, M, 2018)	0.75
"Aripiprazole augmentation therapy appears to be effective and safe in Japanese patients with depression/depressive symptoms treated in everyday clinical practice, taking into account factors associated with achieving remission."	( Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder. Fukuta, Y; Kamijima, K; Yamamura, K; Yasuda, M, 2018)	2.19
"The scoring system is based on the following 6 safety parameters: reported total sample, reported maximum relative infant dose, reported sample size for relative infant dose, infant plasma drug levels, prevalence of reported any adverse effect, and reported serious adverse effects."	( A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation. Uguz, F, )	0.13
"The aim of the study is to find a relationship between the individual intervariability of CYP2D6 and the incidence of hyperprolactinemia as side effect of atypical antipsychotics."	( Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L, 2019)	0.51
"For the slow and intermediate metabolizers, atypical antipsychotics determined a significant increase of prolactinemia with high risk of adverse events."	( Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L, 2019)	0.51
" There was a significant difference between aripiprazole and placebo in the incidence rate of adverse events (AEs) for somnolence (RR = 6."	( Safety of aripiprazole for tics in children and adolescents: A systematic review and meta-analysis. Cui, H; Mao, J; Yang, C; Yi, Q; Zhang, L, 2019)	1.18
" Compared with other atypical antipsychotics, it has a favorable side effect profile, but overdose experience is limited."	( Aripiprazole Toxicity With a Biphasic Course of Somnolence. Gupta, D; OʼHara, C, 2019)	1.96
" The effect size, remission/response rate, and risk for discontinuation due to adverse events (AEs), weight gain (WG), nervous systems and gastrointestinal AEs were assessed and compared between two regions with Cohen's d or number needed to treat/harm."	( Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? Bai, Y; Chen, G; Gao, K; Yang, H, 2020)	0.56
" Adverse events (AEs) and laboratory data were monitored."	( Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study. Bidollari, I; Cash, E; Claxton, A; Du, Y; Keane, E; Kunovac, J; Walling, DP; Weiden, PJ; Yagoda, S; Yao, B, 2020)	0.81
" Overall incidence by group of any adverse events (AEs) throughout the study was 68."	( Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ, 2020)	0.77
" Safety metrics included adverse events (AEs), AEs leading to study discontinuations, physical examinations, laboratory parameters, and extrapyramidal symptom (EPS) rating scales."	( Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study. Claxton, A; Du, Y; Lauriello, J; Weiden, PJ, 2020)	0.81
"To assess adverse events (AEs) and safety of aripiprazole (ARI) and olanzapine (OLA) treatment."	( Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial. Abad-Santos, F; Almenara, S; Koller, D; Martín, S; Mejía, G; Navares-Gómez, M; Ochoa, D; Román, M; Romero-Palacián, D; Saiz-Rodríguez, M; Wojnicz, A; Zubiaur, P, 2021)	1.12
" The most frequent adverse drug reactions (ADRs) to ARI were somnolence, headache, insomnia, dizziness, restlessness, palpitations, akathisia and nausea while were somnolence, dizziness, asthenia, constipation, dry mouth, headache and nausea to OLA."	( Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial. Abad-Santos, F; Almenara, S; Koller, D; Martín, S; Mejía, G; Navares-Gómez, M; Ochoa, D; Román, M; Romero-Palacián, D; Saiz-Rodríguez, M; Wojnicz, A; Zubiaur, P, 2021)	0.86
"Aripiprazole is a generally well-tolerated third-generation antipsychotic with low rates of motor side effects and metabolic adverse effects that occur commonly with several alternative antipsychotics."	( A safety evaluation of aripiprazole in the treatment of schizophrenia. Preda, A; Shapiro, BB, 2020)	2.31
" Secondary evaluations were related to efficacy, treatment emergent adverse events (TEAEs), extrapyramidal symptoms, and corrected QT interval (QTc)."	( Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study. Aoki, K; Inada, K; Ishigooka, J; Iwashita, S; Kojima, Y; Niidome, K; Yamada, S, 2021)	0.62
" Patient-reported sexual and endocrine side effects were assessed on the UKU Side Effect Rating Scale sexual function subscale and analyzed in study completers."	( Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. Bidollari, I; Claxton, A; Du, Y; Kelly, DL, 2021)	0.83
"We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long-acting injectable second-generation antipsychotic (LAI-SGA) therapy due to adverse events (AEs)."	( Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review. Hatano, M; Iwata, N; Kishi, T; Okuya, M; Sakuma, K, 2021)	0.62
"In this systematic literature review (SLR), we qualitatively synthesized evidence on the comparative efficacy (based on neuropsychiatric inventory), tolerability (weight gain), and safety (cerebrovascular adverse events [CVAE], cardiovascular events, mortality, somnolence, extrapyramidal symptoms [EPS]) of AAPs used to treat DRP."	( Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review. Abler, V; Rajagopalan, K; Rashid, N; Yunusa, I, 2021)	0.62
" The incidence of treatment-emergent adverse events (TEAEs) was similar in both groups."	( Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study. Guan, N; Li, AN; Li, K; Liu, T; Sun, J; Tan, Y; Uki, M; Wang, G; Wang, L; Wu, B; Xian, M; Xiao, L; Xie, S; Xu, X; Zhang, H; Zhang, K; Zhang, R; Zhang, W; Zhao, Q, 2022)	1.03
"To report side effect frequency and severity in patients with major depressive disorder (MDD) receiving escitalopram and aripiprazole adjunctive therapy and to examine whether pretreatment anxious depression is associated with the number and presence of specific side effects."	( Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. Bhat, V; Demchenko, I; Espinola, CW; Frey, BN; Ho, K; Kennedy, SH; Khoo, Y; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Parmar, R; Ravindran, AV; Rotzinger, S, 2022)	1.14
" Our study investigated the FDA Adverse Event Reporting System and the pharmacodynamic CHEMBL database to further characterize TGA-induced ICDs."	( Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System. De Ponti, F; Fusaroli, M; Giunchi, V; Menchetti, M; Poluzzi, E; Raschi, E; Rimondini Giorgini, R, 2022)	0.72
"We downloaded and pre-processed the FDA Adverse Event Reporting System up to December 2020."	( Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System. De Ponti, F; Fusaroli, M; Giunchi, V; Menchetti, M; Poluzzi, E; Raschi, E; Rimondini Giorgini, R, 2022)	0.72
"Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials."	( Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. Byeon, SJ; Chung, SJ; Oh, S, 2022)	0.72
"Data were collected from the Korea Adverse Event Reporting System database between 2010 and 2019."	( Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. Byeon, SJ; Chung, SJ; Oh, S, 2022)	0.72
"In total, 5067 adverse events associated with antipsychotic drugs were reported."	( Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. Byeon, SJ; Chung, SJ; Oh, S, 2022)	0.72
" Although there are some reports in literature, the side effect profile in this population remains poorly defined and there is a need to raise awareness among clinicians across specialties."	( Recognising side effects of antipsychotics in children with intellectual disabilities. Anand, G; Lee, J; Shepperd, R; Smith, M, 2023)	0.91
" Primary safety endpoints included reported adverse events, injection site reactions, and extrapyramidal symptoms."	( A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. Harlin, M; Jan, M; Jin, N; Larsen, F; Madera-McDonough, J; Such, P; Watkin, S; Yildirim, M, 2023)	1.11
" The incidence of treatment-emergent adverse events (TEAEs) was similar between Ari 2MRTU 960 (71."	( A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. Harlin, M; Jan, M; Jin, N; Larsen, F; Madera-McDonough, J; Such, P; Watkin, S; Yildirim, M, 2023)	1.11
" The incidence of adverse events emerging during the treatment period was similar between Ari 2MRTU 960 and AOM 400 (71."	( A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. Harlin, M; Jan, M; Jin, N; Larsen, F; Madera-McDonough, J; Such, P; Watkin, S; Yildirim, M, 2023)	1.11
" This pharmacovigilance study aimed to investigate reporting of OCD/OCS in association with the use of antipsychotics in comparison to one another, as well as treatment failure using data derived from the FDA Adverse Event Reporting System (FAERS)."	( Antipsychotics and obsessive-compulsive disorder/obsessive-compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system. Birur, B; Burk, BG; DiGiacomo, T; Polancich, S; Pruett, BS; Sivaraman, S, 2023)	0.91
"Data from January 1st, 2010 to December 31st, 2020 on suspected adverse drug reactions (ADRs) including OCD/OCS was obtained."	( Antipsychotics and obsessive-compulsive disorder/obsessive-compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system. Birur, B; Burk, BG; DiGiacomo, T; Polancich, S; Pruett, BS; Sivaraman, S, 2023)	0.91
"In contrast to prior reports noting clozapine as the antipsychotic most commonly associated with de novo or exacerbated OCD/OCS, this pharmacovigilance study found aripiprazole was most frequently reported for this adverse effect."	( Antipsychotics and obsessive-compulsive disorder/obsessive-compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system. Birur, B; Burk, BG; DiGiacomo, T; Polancich, S; Pruett, BS; Sivaraman, S, 2023)	1.11
" The adverse effects were headache, insomnia, restlessness, tremor, and akathisia."	( Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review. Benites-Zapata, VA; Campos-Rodriguez, SK; Fernández, MF; Ortiz-Saavedra, B; Pino-Zavaleta, DA; Valdivieso-Jiménez, G, 2023)	1.22
" The primary outcome was occurrence of ADEs within 1 year, according to modified Common Terminology Criteria for Adverse Events (CTCAE)."	( The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial. Benson, EA; Callaghan, JT; Desta, Z; Dexter, PR; Eadon, MT; Fulton, CR; Gufford, BT; Gupta, SK; Haas, DM; Holmes, AM; Kreutz, RP; Levy, KD; Pierson, RC; Pratt, VM; Rosenman, MB; Shugg, T; Skaar, TC; Tillman, EM; Vuppalanchi, R; Zang, Y; Zhang, P, 2023)	0.91

Excerpt	Reference	Relevance
" Coadministration with lithium increased mean Cmax and AUC values of aripiprazole by about 19% and 15%, respectively, whereas the apparent oral clearance decreased by 15%."	( Pharmacokinetics of aripiprazole and concomitant lithium and valproate. Bark, N; Citrome, L; Josiassen, R; Mallikaarjun, S; Salazar, DE, 2005)	0.89
" The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined."	( Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Azuma, J; Fukuda, T; Inaba, A; Koue, T; Kubo, M; Maune, H; Takeda, H, 2005)	0.82
" Validated HPLC methods were successfully applied to pharmacokinetic study of aripiprazole in rats, demonstrating brain concentrations after oral administration five times higher than plasma concentrations."	( High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study. Akiyama, H; Kashiyama, E; Koga, T; Miyamoto, G; Shimokawa, Y, 2005)	0.79
" This study investigated the pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole on the basis of 155 drug monitoring samples from psychiatric patients treated with therapeutic doses of aripiprazole (10-30 mg/day)."	( Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Lunde, H; Lunder, N; Molden, E; Refsum, H, 2006)	0.86
" The half-life of aripiprazole following repeated administration was similar to that following single administration, suggesting that pharmacokinetics was constant during 14-day administration."	( Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Azuma, J; Fukuda, T; Koue, T; Kubo, M; Maune, H, 2007)	1
"The population pharmacokinetic parameters of aripiprazole in healthy Japanese males were estimated using a nonlinear mixed effects model (NONMEM) program."	( Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. Azuma, J; Fukuda, T; Funaki, T; Hashimoto, Y; Kayano, Y; Koue, T; Kubo, M; Takaai, M, 2007)	0.84
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"The noncompartmental pharmacokinetic parameters for plasma concentrations of aripiprazole and its active metabolite dehydro-aripiprazole were determined."	( Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Boulton, DW; Kollia, G; Komoroski, B; Kovalick, LJ; Mallikaarjun, S; Reeves, RA; Sharma, A, 2008)	0.81
" In study 2, the proportionality of the C(max) and AUC to doses ranging from 1 mg to 45 mg suggests a linear pharmacokinetic profile for intramuscular aripiprazole."	( Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Boulton, DW; Kollia, G; Komoroski, B; Kovalick, LJ; Mallikaarjun, S; Reeves, RA; Sharma, A, 2008)	0.78
" PHARMACOKINETIC ANALYSES: Noncompartmental pharmacokinetic analysis was performed using plasma aripiprazole and dehydro-aripiprazole concentration-time data."	( Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Boulton, DW; Bramer, SL; Mallikaarjun, S; Shoaf, SE, 2008)	0.8
"Study 1 (hepatic impairment study): apparent oral clearance of unbound drug (CL/Fu) and the maximum plasma concentration (Cmax) of aripiprazole; Study 2 (renal impairment study): CL/Fu, Cmax and renal clearance (CL(R))."	( Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Boulton, DW; Bramer, SL; Mallikaarjun, S; Shoaf, SE, 2008)	0.79
" Blood samples were collected for pharmacokinetic analysis of ADTs."	( The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K, 2010)	0.61
"The aims of this study were to develop a combined population pharmacokinetic model for both aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients and to identify to what extent the genetic polymorphisms of cytochrome P450 (CYP) enzymes contribute to the variability in pharmacokinetics (PK)."	( Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Bahk, WM; Cho, JY; Jang, IJ; Kang, DH; Kim, JR; Kim, YK; Kwon, JS; Seo, HB; Shin, SG; Yu, KS, 2008)	0.83
"A population pharmacokinetic analysis was performed using NONMEM software based on 141 plasma concentrations at steady state from 80 patients receiving multiple oral doses of aripiprazole (10-30 mg day(-1))."	( Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Bahk, WM; Cho, JY; Jang, IJ; Kang, DH; Kim, JR; Kim, YK; Kwon, JS; Seo, HB; Shin, SG; Yu, KS, 2008)	0.81
"This population pharmacokinetic model provided an adequate fit to the data for both aripiprazole and dehydroaripiprazole in psychiatric patients."	( Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Bahk, WM; Cho, JY; Jang, IJ; Kang, DH; Kim, JR; Kim, YK; Kwon, JS; Seo, HB; Shin, SG; Yu, KS, 2008)	0.84
" Blood samples were collected on Days -1 and 14 for determination of lamotrigine steady-state pharmacokinetic parameters."	( A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Balch, AH; Benson, J; Boulton, DW; Carlson, BX; Croop, R; Mallikaarjun, S; Schieber, FC, 2009)	0.58
"Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole were studied in 18 inpatients with schizophrenia being treated with aripiprazole."	( Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Suzuki, T, 2009)	0.81
" Plural simultaneously - operant pharmacodynamic mechanisms may explain catatonia of unclear etiology and reconcile a seemingly contradictory literature (e."	( Catatonia and CPK elevation in neurosyphilis: role of plural pharmacodynamic mechanisms. Carter, WG; Lauterbach, EC; Norris, BK; Shillcutt, SD, 2009)	0.35
" This method was applied to pharmacokinetic study in human volunteers and patients taking aripiprazole."	( A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. Akamine, Y; Inoue, Y; Kojima, M; Uno, T; Yasui-Furukori, N, 2010)	0.84
" The author provides the reader with knowledge of the fundamental pharmacokinetic characteristics and metabolic pathways of these new antipsychotics, emphasizing the clinically important common features and differences compared to other older agents."	( Pharmacokinetics and metabolism update for some recent antipsychotics. Caccia, S, 2011)	0.37
"Aripiprazole, perospirone, lurasidone and cariprazine share some of the pharmacokinetic characteristics of older, lipophilic antipsychotics and, like these, each has some distinct pharmacokinetic features that are clinically beneficial and some that are not."	( Pharmacokinetics and metabolism update for some recent antipsychotics. Caccia, S, 2011)	1.81
" Typically, studies of antipsychotics have applied pharmacodynamic (PD) modeling alone to characterize the relationship between antipsychotic dose and its effect on the brain."	( Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. Howes, OD; Jang, IJ; Jeong, JM; Kapur, S; Kim, BH; Kim, E; Kwon, JS; Lee, JS; Shin, SG; Turkheimer, FE, 2012)	0.38
" The main pharmacokinetic parameters were T(max) = (4."	( Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. Bapuji, AT; Mukkanti, K; Raju, DR; Ravikiran, HL; Ravinder, S; Reddy, DC, )	0.36
" The method was successfully applied to human pharmacokinetic study of urapidil and aripiprazole in healthy human male volunteers."	( Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of urapidil and aripiprazole in human plasma and its application to human pharmacokinetic study. Ambavaram, VB; Gajulapalle, M; Kalluru, GR; Nandigam, V; Vemula, M, 2013)	0.83
" Here we tested the pharmacodynamic consequences of these properties in a P-gp deficient mouse model by studying the effects of aripiprazole and of ziprasidone on motor coordination."	( Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties. Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U, 2013)	0.89
"Evidence was given that P-gp substrate properties have pharmacodynamic consequences for aripiprazole but not for ziprasidone and thus affect dopamine receptor related motor behaviour."	( Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties. Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U, 2013)	0.91
" In contrast, plasma concentrations following administration of aripiprazole once-monthly at a dose of 200mg were below the therapeutic range and pharmacokinetic parameters were not proportional to the administered dose compared with the 300 mg and 400mg doses."	( Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Bricmont, P; Carson, W; Fleischhacker, WW; Forbes, RA; Kane, JM; Mallikaarjun, S; McQuade, R; Sanchez, R, 2013)	0.89
" In dose response sessions, all doses were given 1 hr apart in ascending order for pharmacodynamic and pharmacokinetic assessment."	( Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. Campbell, C; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2014)	1.85
" Pharmacokinetic parameters were derived from plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole, obtained over 16 days after each aripiprazole administration."	( Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults. Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R, 2015)	0.87
"Of 36 subjects enrolled, 24 were evaluable for pharmacokinetic analysis."	( Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults. Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R, 2015)	0.64
" The multiple dose of 200 or 100 mg/kg resveratrol significantly increased the AUC and Cmax of APZ."	( The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. Cai, JP; Dai, DP; Gu, EM; Hu, GX; Li, XY; Liang, BQ; Zhan, YY, 2016)	0.69
"The main objective of this study was to compare the pharmacokinetic properties and relative bioavailability of two 15-mg aripiprazole formulations (an orally disintegrating tablet [ODT] as the test drug and a conventional tablet as the reference drug) in healthy middle-aged Korean subjects."	( Pharmacokinetics of a New Orally Disintegrating Tablet Formulation of Aripiprazole 15 mg Administered Without Water in Healthy Middle-aged Korean Subjects. Chung, YC; Jeon, JY; Kim, MG; Kim, Y, 2015)	0.86
" Data on the pharmacokinetic parameters were recorded, and the 90% CIs of the ratios of the geometric means of the parameters were determined from the logarithmically transformed data by using an ANOVA model."	( Pharmacokinetics of a New Orally Disintegrating Tablet Formulation of Aripiprazole 15 mg Administered Without Water in Healthy Middle-aged Korean Subjects. Chung, YC; Jeon, JY; Kim, MG; Kim, Y, 2015)	0.65
" This study aimed to develop a combined population pharmacokinetic model for aripiprazole in healthy Korean subjects and to identify the significant covariates in the pharmacokinetic variability of aripiprazole."	( Population pharmacokinetics of aripiprazole in healthy Korean subjects. Chae, SW; Jeon, JY; Kim, MG, 2016)	0.95
" The population pharmacokinetic parameters of aripiprazole were estimated using nonlinear mixed-effect modeling with first-order conditional estimation with interaction method."	( Population pharmacokinetics of aripiprazole in healthy Korean subjects. Chae, SW; Jeon, JY; Kim, MG, 2016)	0.98
" The bootstrap and visual predictive check results were evaluated, showing that the accuracy of the pharmacokinetic model was acceptable."	( Population pharmacokinetics of aripiprazole in healthy Korean subjects. Chae, SW; Jeon, JY; Kim, MG, 2016)	0.72
"A population pharmacokinetic model of aripiprazole was developed for Korean subjects."	( Population pharmacokinetics of aripiprazole in healthy Korean subjects. Chae, SW; Jeon, JY; Kim, MG, 2016)	0.99
" Increase in Cmax was observed which might help in dose reduction along with reduction in dose related side effects."	( Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. Pandey, A; Patel, S; Sawant, K, 2016)	1.88
" After the fifth AOM 400 injection, mean aripiprazole AUC(28d), C(max) and C(min) were 165 μg x h/ml, 331 ng/ml and 201 ng/ml, respectively, which were similar to previously published pharmacokinetic parameters after the fifth gluteal injection of AOM 400."	( [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. Ishigooka, J; Nishiyama, K; Noda, T; Shima, T; Tadori, Y; Tamaru, N; Yamasaki, Y, 2016)	0.98
" There is a directly proportional relationship between pharmacokinetic parameters and adverse drug reactions and effect on BP and HR."	( Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers. Abad-Santos, F; Belmonte, C; Cabaleiro, T; Ochoa, D; Román, M; Sánchez-Rojas, SD; Talegón, M, 2016)	0.67
" Multiple-dose pharmacokinetic results for the major metabolite, dehydro-aripiprazole, followed a similar pattern to that of the parent drug for both deltoid and gluteal injection sites."	( Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. Baker, RA; Bricmont, P; Eramo, A; Hertel, P; Jin, N; Larsen, F; McQuade, RD; Nylander, AG; Peters-Strickland, T; Raoufinia, A; Repella, J, 2017)	2.13
" We developed a population pharmacokinetic (PopPK) model to characterize aripiprazole lauroxil PK and evaluate dosing scenarios likely to be encountered in clinical practice."	( Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Citrome, L; Hard, ML; Mills, RJ; Sadler, BM; Turncliff, RZ, 2017)	2.13
"We examined the feasibility of a 2-month (every 8 weeks [q8wk]) dosing interval of AL in a phase I open-label pharmacokinetic study investigating AL 1064 mg administered q8wk for 24 weeks, followed by 20 weeks of safety and pharmacokinetic measurements (ClinicalTrials."	( Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY; Weiden, PJ, 2017)	0.7
" Pharmacokinetic samples were collected at various time points during the 24-week study period and the 20-week follow-up period."	( Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY; Weiden, PJ, 2017)	0.7
" Here, a 6-month pharmacokinetic study compared 2 different initiation regimens for starting AL."	( Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia. Du, Y; Hard, ML; von Moltke, L; Walling, D; Wehr, AY; Weiden, PJ, 2018)	0.7
" The pharmacokinetic profile of the 1-day initiation regimen was comparable to the 21-day initiation regimen; both achieved aripiprazole concentrations in the therapeutic range within 4 days and remained in a comparable concentration range during treatment initiation."	( Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia. Du, Y; Hard, ML; von Moltke, L; Walling, D; Wehr, AY; Weiden, PJ, 2018)	0.91
" The pharmacokinetic parameters were calculated using a non-compartmental analysis."	( Effect of sinapic acid on aripiprazole pharmacokinetics in rats: Possible food drug interaction. Ahad, A; Ahmad, A; Al-Mohizea, AM; Ali, N; Aljenobi, FI; Alkharfy, KM; Ansari, MA; Khan, A; Raish, M, 2019)	0.81
" Population pharmacokinetic approach, based on nonlinear mixed effects modeling, is a useful tool to identify covariates explaining pharmacokinetic variability, as well as to characterize and distinguish unexplained residual and between-subject (interindividual) variability."	( Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models. Jovanović, M; Miljković, B; Vučićević, K, 2020)	0.77
" Plasma concentration samples were obtained at regular intervals to provide pharmacokinetic data for the duration of AL exposure and to measure persistence of plasma aripiprazole concentrations after AL discontinuation."	( Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ, 2020)	0.96
" Models were verified by assessing goodness-of-fit plots and ratios of predicted-to-observed pharmacokinetic parameters."	( Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation. Jiang, X; Tang, R; Tang, S; Wang, L; Xu, M; Zheng, L, 2021)	0.9
" In this study, phenotype-related physiologically based pharmacokinetic models were developed and evaluated to suggest phenotype-guided dose adjustments."	( Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. Abad-Santos, F; Hempel, G; Kneller, LA; Koller, D; Zubiaur, P, 2021)	0.87
"Physiologically based pharmacokinetic models for single dose (oral and orodispersible formulation), multiple dose, and steady-state condition were built using trial data from genotyped healthy volunteers."	( Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. Abad-Santos, F; Hempel, G; Kneller, LA; Koller, D; Zubiaur, P, 2021)	0.87
"Physiologically based pharmacokinetic models were able to accurately predict the pharmacokinetics of aripiprazole and dehydro-aripiprazole according to CYP2D6 phenotypes, illustrated by a minimal bias and a good precision."	( Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. Abad-Santos, F; Hempel, G; Kneller, LA; Koller, D; Zubiaur, P, 2021)	1.08
" The rate of removal of LAIs is regulated by the slow rate of absorption in the site of injection and the phenomenon of their increased half-life is called flip-flop pharmacokinetics."	( [Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics]. Kyziridis, TC, 2022)	0.72
" Our study investigated the FDA Adverse Event Reporting System and the pharmacodynamic CHEMBL database to further characterize TGA-induced ICDs."	( Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System. De Ponti, F; Fusaroli, M; Giunchi, V; Menchetti, M; Poluzzi, E; Raschi, E; Rimondini Giorgini, R, 2022)	0.72
" A pilot pharmacokinetic (PK) open-labeled parallel study on healthy human volunteers was carried out to assess the PK of FDC of aripiprazole/divalproex sodium in comparison with its individual components with a view to rationalize therapeutic regimen and potentially improve compliance of bipolar patients in future."	( Fixed Dose Combination Tablets of Aripiprazole and Divalproex Sodium: a Pilot Pharmacokinetic Study in Human Volunteers. Ahmed, S; Ahmed, Z; Subhan, F, 2022)	1.21
" These results indicate P-gp-mediated pharmacokinetic interaction increases pimozide accumulation in AC16 cells, and the subsequent elevated pimozide levels within the cells may result in an increased risk of hERG channel inhibition."	( P-Glycoprotein-Mediated Pharmacokinetic Interactions Increase Pimozide hERG Channel Inhibition. Ito, MA; Mizoi, K; Morishita, H; Ogihara, T; Perera, LMB; Yano, K; Zhang, X, 2022)	0.72
" At the end of the study, aripiprazole concentrations were similar between treatment groups, based on the reported pharmacokinetic parameters."	( A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. Harlin, M; Jan, M; Jin, N; Larsen, F; Madera-McDonough, J; Such, P; Watkin, S; Yildirim, M, 2023)	1.41

Excerpt	Reference	Relevance
"To explore the efficacy and safety of Jieyu Anshen Decoction (JAD) combined with aripiprazole in treating chronic schizophrenia."	( [Clinical observation on effect of Jieyu Anshen Decoction combined with aripiprazole in treating chronic schizophrenia]. Fan, XW; Luo, JW; Zeng, DZ, 2007)	0.8
"All 100 patients with chronic schizophrenia diagnosed according to CCMD-3 criteria were equally randomly assigned to the study group (treated with JAD combined with aripiprazole) and the control group (treated with aripiprazole alone) for 12 weeks."	( [Clinical observation on effect of Jieyu Anshen Decoction combined with aripiprazole in treating chronic schizophrenia]. Fan, XW; Luo, JW; Zeng, DZ, 2007)	0.77
"JAD combined with aripiprazole has definite effect in treating chronic schizophrenia, shows advantages of quickly initiating effect, high safety and with no harm for increasing adverse reactions, so it is better than using aripiprazole alone."	( [Clinical observation on effect of Jieyu Anshen Decoction combined with aripiprazole in treating chronic schizophrenia]. Fan, XW; Luo, JW; Zeng, DZ, 2007)	0.91
" We conducted a randomized crossover trial with MPH and placebo (2 weeks each) combined with aripiprazole in children and adolescents (n = 16; 8-17 years old) with JBPD and ADHD who had a significant response in manic symptoms with aripiprazole but still presented clinically significant symptoms of ADHD."	( Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. Ketzer, CR; Pheula, GF; Rohde, LA; Tramontina, S; Zeni, CP, 2009)	0.86
" The risk of adverse drug-drug interaction(s) is present when metabolic inhibitors are combined with known or suspected substrates of a given enzyme."	( Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Appel, DI; Markowitz, JS; Peterson, YK; Wang, Z; Zhu, HJ, 2010)	0.36
" After acquiring the discrimination, the effects of cocaine (0, 25, 50, 100 and 200 mg) administered alone and in combination with aripiprazole (15 mg) were determined."	( Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. Glaser, PE; Hays, LR; Lile, JA; Rush, CR; Stoops, WW, 2011)	0.79
" Safety and tolerability results revealed no unexpected adverse events for ARI combination with LTG."	( Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Carlson, BX; Ketter, TA; Marcus, R; McQuade, RD; Sanchez, R; Sun, W; Timko, K; Vester-Blokland, E, 2012)	1.82
" For these people, a number of treatment strategies have emerged, including the prescription of a second anti-psychotic drug in combination with clozapine."	( Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017)	0.46
"Dietary supplements and foods can interact with various drugs, leading to possible clinical concerns."	( Effect of sinapic acid on aripiprazole pharmacokinetics in rats: Possible food drug interaction. Ahad, A; Ahmad, A; Al-Mohizea, AM; Ali, N; Aljenobi, FI; Alkharfy, KM; Ansari, MA; Khan, A; Raish, M, 2019)	0.81
" We describe a case of SILENT combined with NMS in this case report."	( Subcortical Structure Disruption in Diffusion Tensor Tractography of the Patient With the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity Combined With Neuroleptic Malignant Syndrome: A Case Report. Kim, HS; Rhee, SY, )	0.13
"This case suggests that the clinical use of diffusion tensor tractography could be helpful to explain the clinical features in the case of SILENT combined with NMS."	( Subcortical Structure Disruption in Diffusion Tensor Tractography of the Patient With the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity Combined With Neuroleptic Malignant Syndrome: A Case Report. Kim, HS; Rhee, SY, )	0.13
" In this study, we established schizophrenia mouse model with dizocilpine (MK-801); treated mice with ARI alone or in combination with NGF; assessed spontaneous activity and cognitive function using open field test and Morris water maze test; and measured brain-derived neurotrophic factor (BDNF) protein and mRNA expression levels using immunohistochemistry and molecular biology assays."	( Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. Bai, M; Chen, H; Kang, L; Li, Q; Li, S; Lin, Y; Lu, C; Tang, Z; Xiong, P; Zhang, H, 2023)	2.35

Excerpt	Reference	Relevance
" It may be less well absorbed and/or less effective than Clozaril, although evidence is conflicting."	( Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP, 2002)	0.31
" The mean time to peak plasma concentration is 3 hours following multiple-dose administration of aripiprazole 10 or 15 mg and the absolute oral bioavailability of the drug is 87%."	( Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Perry, CM; Swainston Harrison, T, 2004)	1.98
"Study 1 was an open-label, randomized, three-treatment crossover study in healthy subjects (n = 18) to assess the bioavailability and pharmacokinetics of intramuscular aripiprazole 5 mg and oral aripiprazole 5 mg relative to intravenous aripiprazole 2 mg."	( Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Boulton, DW; Kollia, G; Komoroski, B; Kovalick, LJ; Mallikaarjun, S; Reeves, RA; Sharma, A, 2008)	0.77
"P-glycoprotein (Pgp or ABCB1) is an ABC transporter protein involved in intestinal absorption, drug metabolism, and brain penetration, and its inhibition can seriously alter a drug's bioavailability and safety."	( A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. Broccatelli, F; Carosati, E; Cruciani, G; Frosini, M; Goracci, L; Neri, A; Oprea, TI, 2011)	0.37
" APZ nanosuspensions got maximum absorption rate and extent comparing with APZ commercial tablet and suspensions with relative bioavailability of 123."	( Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. Lian, R; Liu, X; Lu, Y; Wu, W; Xu, Y; Yin, Z; Zheng, S, 2012)	0.63
"98-fold) and bioavailability (3."	( Aripiprazole in an animal model of chronic alcohol consumption and dopamine D₂ receptor occupancy in rats. Abraham, R; Bhyrapuneni, G; Jayarajan, P; Kandikere, V; Muddana, N; Nirogi, R; Saralaya, R, 2013)	1.83
"Poor aqueous solubility and the unpleasant taste of aripiprazole (APZ) have been recurring problems, owing to its low bioavailability and low patient tolerance, respectively."	( Aripiprazole-montmorillonite: a new organic-inorganic nanohybrid material for biomedical applications. Chang, HC; Choi, G; Choy, JH; Choy, YB; Lee, HJ; Oh, YJ; Park, JH; Park, JW; Yoon, YJ, 2013)	2.08
" Bioavailability studies of the polymorphs of aripiprazole and their pharmaceutical preparations are very important to optimize the formulations of the dosage forms."	( Aripiprazole. Ardiana, F; Indrayanto, G; Lestari, ML, 2013)	2.09
"The main objective of this study was to compare the pharmacokinetic properties and relative bioavailability of two 15-mg aripiprazole formulations (an orally disintegrating tablet [ODT] as the test drug and a conventional tablet as the reference drug) in healthy middle-aged Korean subjects."	( Pharmacokinetics of a New Orally Disintegrating Tablet Formulation of Aripiprazole 15 mg Administered Without Water in Healthy Middle-aged Korean Subjects. Chung, YC; Jeon, JY; Kim, MG; Kim, Y, 2015)	0.86
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."	( Highly predictive and interpretable models for PAMPA permeability. Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)	0.46
" To enhance in vivo efficacy and oral bioavailability of aripiprazole, aripiprazole-loaded solid lipid nanoparticles (SLNs) were developed using tristearin as solid lipid."	( Enhancement of In Vivo Efficacy and Oral Bioavailability of Aripiprazole with Solid Lipid Nanoparticles. Sinha, VR, 2018)	0.97
"Dependence on antipsycotic drugs like aripriprazole (ARI) is increasing at alarming rate, hence, this study was undertaken to support the hypothesis that supplementation of Citrus paradisi (Grapefruit) juice having high concentration of polyphenols might potentiate and synergize the therapeutic effect of ARI, by increasing its bioavailability and inherent antioxidant potential."	( Potentiating and synergistic effect of grapefruit juice on the antioxidant and anti-inflammatory activity of aripiprazole against hydrogen peroxide induced oxidative stress in mice. Al-Majed, AA; Wani, TA; Zargar, S, 2018)	0.69
"43, respectively, indicating similar in vitro release and in vivo bioavailability of rats between the ALSI and Abilify Maintena®."	( Process control and in vitro/in vivo evaluation of aripiprazole sustained-release microcrystals for intramuscular injection. Cai, Q; Chu, W; Gou, J; He, H; He, L; Jiang, S; Liang, X; Ma, D; Pan, W; Tang, X; Wang, S; Yin, T; Zhang, L; Zhang, Y; Zhou, L, 2018)	0.73
"The objective of this study was to formulate aripiprazole (ARI)-loaded pH-modulated solid dispersions (SD) to enhance solubility, dissolution, and bioavailability via hot-melt extrusion (HME) technology."	( Formulation of aripiprazole-loaded pH-modulated solid dispersions via hot-melt extrusion technology: In vitro and in vivo studies. Bandari, S; Kim, DW; Kolter, K; Langley, N; McFall, H; Murthy, SN; Repka, MA; Sarabu, S; Shankar, V, 2019)	1.13
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The rate of removal of LAIs is regulated by the slow rate of absorption in the site of injection and the phenomenon of their increased half-life is called flip-flop pharmacokinetics."	( [Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics]. Kyziridis, TC, 2022)	0.72
" This antipsychotic drug has an inadequate therapeutic impact because of its minimal and idiosyncratic oral bioavailability to treat schizophrenia."	( Enhanced Solubility and Stability of Aripiprazole in Binary and Ternary Inclusion Complexes Using Hydroxy Propyl Beta Cyclodextrin (HPβCD) and L-Arginine. Afridi, M; Ahsan, H; Awais, S; El-Serehy, HA; Farooq, N; Ishtiaq, F; Muhammad, SA; Nadeem, T; Sultana, K; Ullah, A, 2023)	1.18

Excerpt	Relevance	Reference
"To investigate the efficacy, safety and tolerability of three dosing strategies for switching chronic, stable patients with schizophrenia from current oral antipsychotic monotherapy to once-daily oral aripiprazole monotherapy."	( Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Ali, MW; Carson, WH; Casey, DE; Ingenito, GG; Jody, D; Liebeskind, A; Saha, AR, 2003)	0.82
"Aripiprazole is a dopamine partial agonist and a serotonin-2A antagonist; it is dosed 10-30 mg/d, with no initial titration necessary."	( Aripiprazole: a new atypical antipsychotic drug. Bowles, TM; Levin, GM, 2003)	3.2
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of aripiprazole are discussed."	( Aripiprazole. Winans, E, 2003)	1.97
" Although a recent dose-finding study in 22 pediatric patients (> or = 6 yrs old) described weight-based dosages that were safe and well tolerated, dosing of aripiprazole in children has not been well established."	( Excessive somnolence from aripiprazole in a child. Buck, ML; Davenport, JD; McCarthy, MW, 2004)	0.82
" Dosage titration is not necessary and the drug is effective in the first few weeks of treatment."	( Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Perry, CM; Swainston Harrison, T, 2004)	1.77
" There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on weight, is indicated in this population."	( Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. Davies, MA; Roth, BL; Sheffler, DJ, 2004)	2.01
" Steady-state concentrations are attained within 14 days of dosing for both active moieties."	( Aripiprazole: an overview of a novel antipsychotic. Folnegović-Smalc, V; Kozumplik, O; Mimica, N; Uzun, S, 2005)	1.77
" Dosing could be reduced to 15 mg/day for tolerability and, subsequently, increased to 30 mg/day based on clinical response."	( Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Abou-Gharbia, N; Carson, W; Impellizzeri, C; Iwamoto, T; Kaplita, S; Marcus, R; McQuade, R; Rollin, L; Sachs, G; Sanchez, R; Stock, E, 2006)	1.78
" The SC medication was specifically selected for each patient by the clinician and dosed according to prescribing guidelines for that medication."	( A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Crandall, DT; Iwamoto, T; Kostic, D; Marcus, RN; McQuade, RD; Nyilas, M; Pans, M; Riera, LC; Stock, EG; Tandon, R, 2006)	0.56
" Also discussed are findings concerning the continuation of acute treatments, including antidepressants, into the maintenance phase; dosage adjustments for maintenance treatment; the rationale for combination treatments; and implications of comorbid substance abuse and strategies for its management."	( Maintenance treatment of bipolar disorder: Applying research to clinical practice. Chou, JC; Fazzio, L, 2006)	0.33
"A 57-year-old man with a 30 year history of schizophrenia had been taking olanzapine for 4 years, with the dosage titrated to 20 mg/day, to control the psychosis."	( Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances. Chavez, B; Poveda, RA, 2006)	0.64
" Our recommendations for dosage and administration of aripiprazole are in agreement with the manufacturer's prescribing information."	( Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Cassano, GB; Fagiolini, A; Lattanzi, L; Monteleone, P; Niolu, C; Sacchetti, E; Siracusano, A; Vita, A, 2007)	2.03
" After 15 sessions, the dose-response function of methamphetamine was determined under either a progressive- or a fixed-ratio schedule."	( Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Koob, GF; Pulvirenti, L; Wang, Z; Wee, S; Woolverton, WL, 2007)	0.74
" The dosage was increased to 10 mg daily two weeks later."	( Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities. Brahm, NC; Brown, RC; McElwain, DL, 2007)	0.74
"Twenty-four outpatients aged 7 to 18 years with DSM-IV-diagnosed tic disorders were treated with aripiprazole using an open-label, flexible dosing schedule for 8 weeks from January 2005 to August 2006."	( An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. Choi, SH; Hong, JP; Kim, CY; Park, S; Wang, HR; Yoo, HK, 2007)	0.8
" Haloperidol dose was fixed; aripiprazole was dosed at 15 mg/day for the first 4 weeks, then 30 mg/day for the following 4 weeks."	( Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH, 2007)	0.88
" The standard of care for treating schizophrenia is to first use monotherapy of adequate dosage and duration, including a trial of clozapine before adding a second agent."	( Augmentation of aripiprazole with low-dose clozapine. Berges, A; Dahmen, MM; Petry, WM; Stoner, SC, 2007)	0.69
"5) enrolled in an open-label, single-site trial with fixed-flexible dosing of aripiprazole (5-30 mg/day) for 8 weeks."	( Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Callahan, JL; Cohen, SJ; Hawkins, KA; Mathalon, DH; McGlashan, TH; Miller, TJ; Tully, EM; Walsh, BC; Woods, SW, 2007)	2.01
" Patients were randomized to placebo or aripiprazole (initiated at 10 mg/d, then flexibly dosed at 5-30 mg/d based on clinical effect and tolerability)."	( Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. Bowden, CL; Carson, WH; Jonas, A; Khan, A; Marcus, RN; McQuade, RD; Owen, R; Thase, ME; Wu, X, 2008)	2.06
" Aripiprazole was dosed flexibly up to a maximum of 30 mg daily, based on tolerability and efficacy."	( A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. Chriki, LS; Dunn, RT; Filkowski, MM; Ghaemi, SN; Stan, VA, 2008)	1.53
" At a mean dosage of 20."	( Combined antipsychotic treatment involving clozapine and aripiprazole. Englisch, S; Zink, M, 2008)	0.59
" We measured regional occupancy attained across a range of clinical dosing by the partial D(2) agonist aripiprazole using these methods."	( Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Abi-Dargham, A; Alvarez, B; Bae, SA; Frankle, WG; Gil, R; Gonzales, R; Hackett, E; Kegeles, LS; Kim, JH; Laruelle, M; Slifstein, M; Xu, X, 2008)	0.79
"A 12-week, open-label trial with flexible dosing strategy of aripiprazole was performed with 15 participants, aged 7-19 years."	( Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. Bai, DS; Sea, HS; Seo, WS; Sung, HM, 2008)	2.03
" Despite its potential clinical benefits, the management of aripiprazole-treated patients can be challenging due to the lack of a simple dosing strategy and guidelines for preventing and managing potential adverse effects."	( Proposed strategies for successful clinical management with aripiprazole. Mago, R, 2008)	0.83
"The dosing strategy recommendations are based on clinical experience and a PubMed database search conducted with no date restrictions for English-language literature."	( Proposed strategies for successful clinical management with aripiprazole. Mago, R, 2008)	0.59
"4 mg/kg, aripiprazole decreased rates of cocaine self-administration without shifting the peak of the dose-response function."	( Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Brennum, LT; Fink-Jensen, A; Hee Bengtsen, C; Petersen, JH; Sager, TN; Sørensen, G; Thomsen, M; Thøgersen, P; Woldbye, DP; Wörtwein, G, 2008)	2.21
" The main objective of the two clinical pharmacology studies reported here was to evaluate the pharmacokinetics of aripiprazole after intramuscular dosing in healthy subjects and in patients with schizophrenia, and after intravenous and oral dosing in healthy subjects."	( Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Boulton, DW; Kollia, G; Komoroski, B; Kovalick, LJ; Mallikaarjun, S; Reeves, RA; Sharma, A, 2008)	0.79
" The results have confirmed that the D-optimal experimental design technique can be successfully employed for designing the long acting microsphere dosage form."	( D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole. Nahata, T; Saini, TR, 2008)	0.56
" Following baseline Meth dosing (15 mg and 30 mg), participants received 2 wk treatment with aripiprazole (n=8) or placebo (n=8)."	( Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Abad, A; Anderson, A; Condos, R; De La Garza, R; Elkashef, A; Halkitis, PN; Li, SH; Mahoney, JJ; Mojisak, J; Newton, TF; Palamar, J; Reid, MS, 2008)	0.84
"This study joins several others in demonstrating the utility of subacute dosing laboratory paradigms for evaluating medication effects in alcoholics."	( Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Anton, R; Myrick, H; Randall, P; Voronin, K, 2008)	1.79
" Adverse effects were evaluated using the Dosage Record and Treatment Emergent Symptom Scale (DOTES)."	( Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Bellino, S; Bogetto, F; Paradiso, E, 2008)	0.64
" Clinical factors such as gender, age, illness duration, education level, diagnostic subtype, and medication dosage were also recorded."	( Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Chen, CH; Chen, SF; Chen, SJ; Chen, YJ; Lin, CC; Luu, SU; Shen, YC, 2009)	0.59
" Serotonergic antidepressants, used both continuously and with increased dosage in the late luteal phase, are believed to be effective for major depressive disorder with premenstrual exacerbation."	( Effective treatment of premenstrual violence in major depression: augmentation with aripiprazole. Chiang, PH; Hsiao, MC; Liu, CY; Yao, YC, )	0.36
" A high kinetic stability was observed for three metastable polymorphs which can be categorized as suitable candidates for the development of solid dosage forms."	( Conformational polymorphism in aripiprazole: Preparation, stability and structure of five modifications. Braun, DE; Gelbrich, T; Griesser, UJ; Kahlenberg, V; Tessadri, R; Wieser, J, 2009)	0.64
" Some principles for dosing and switching are provided to assist with a successful treatment outcome with aripiprazole in mania."	( A UK consensus on the administration of aripiprazole for the treatment of mania. Aitchison, KJ; Bienroth, M; Cookson, J; Goodwin, GM; Gray, R; Haddad, PM; Moore, B; Ratna, L; Sullivan, G; Taylor, D; Taylor, M, 2009)	0.83
" This 5-day, randomized, double-blind trial evaluated relative improvements in agitation in hospitalized patients who received orally dosed olanzapine (n = 306, 20 mg/d) or aripiprazole (n = 298, 15 mg/d, increasing to 30 mg/d as needed)."	( Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL, 2008)	0.87
" No dosage adjustment of lamotrigine is required and the combination was generally safe and well tolerated."	( A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Balch, AH; Benson, J; Boulton, DW; Carlson, BX; Croop, R; Mallikaarjun, S; Schieber, FC, 2009)	0.58
" Escitalopram and aripiprazole were flexibly dosed for 7 weeks, with maximum dosages of 20 and 30 mg/d, respectively."	( An open study of aripiprazole and escitalopram for psychotic major depressive disorder. Denninger, JW; Dording, C; Fava, M; Hilliker, S; Homberger, C; Matthews, JD; Park, L; Rooney, K; Siefert, C; Sklarsky, K; van Nieuwenhuizen, AO, 2009)	1.03
" To evaluate the role of P-glycoprotein (P-gp) in aripiprazole tissue distribution and penetration across the blood-brain barrier, mice deficient in the P-gp gene (Abcb1a/b-/-) were dosed intraperitoneally with 2 microg/g mouse of the antipsychotic drug aripiprazole."	( Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Devane, CL; Donovan, JL; Geesey, ME; Markowitz, JS; Wang, JS; Yuan, HJ; Zhu, HJ, 2009)	2.05
" Clinical factors such as gender, age, duration of illness, education level, diagnostic subtype and medication dosage were recorded."	( Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Chen, CH; Chen, SF; Shen, YC, 2009)	0.61
"This analysis examined dosing patterns and safety of aripiprazole in elderly inpatients."	( Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients. Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM, 2009)	2.05
"A total of 52 elderly inpatients treated with aripiprazole over 3 years were retrospectively identified to examine dosing patterns and side effects associated with use of aripiprazole."	( Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients. Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM, 2009)	2.05
" Clinical factors such as gender, age, duration of illness, education level, diagnostic subtype, and medication dosage were noted as well."	( HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Chen, CH; Chen, SF; Shen, YC, 2009)	0.58
" In addition, the clinical factors, including dosage of aripiprazole, age, duration of illness, and diagnostic subtype, were found to influence PANSS performance after aripiprazole treatment."	( HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Chen, CH; Chen, SF; Shen, YC, 2009)	0.83
" In such situations, clinicians may want to consider prescribing a different antipsychotic or adding another antipsychotic and decreasing the dosage of clozapine."	( Aripiprazole in treatment-refractory schizophrenia. Chiu, NY; Hsu, WY; Kahn, DA; Lee, CI, 2009)	1.8
" Dosing was determined by clinical judgment."	( Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. Ishigooka, J; Oshimo, T; Takahashi, H, )	0.42
" The mean dosage of aripiprazole was 17."	( Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. Ishigooka, J; Oshimo, T; Takahashi, H, )	0.75
" The mean daily dosage of aripiprazole in completers was 11."	( Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Albert, U; Bogetto, F; Maina, G; Pessina, E, 2009)	2.1
" The reasons for the change, course of illness, and types and dosage of antipsychotics previously used were collected."	( Switching of antipsychotics to aripiprazole in the treatment of schizophrenia. Chong, MY; Lee, Y; Lin, HC; Lin, PY; Yeh, WC, )	0.42
" In this review we examined the efficacy data from short-term studies of aripiprazole in relapsed schizophrenia or schizoaffective disorder, in order to establish a dose-response relationship for aripiprazole."	( Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. Mace, S; Taylor, D, 2009)	2.03
" Patients were randomly assigned (1:1) to flexibly dosed aripiprazole (target dosage: 5, 10, or 15 mg/day) or placebo."	( Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Carson, WH; Corey-Lisle, P; Findling, RL; Manos, G; Marcus, RN; McQuade, RD; Owen, R; Sikich, L, 2009)	2.04
" Medication and dosing decisions were made by treating psychiatrists, constrained to once-a-day dosing, low initial doses and no clozapine."	( Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study. Audino, B; Curtis, J; Donohue, AM; Filymer, DM; Finkel, N; Josiassen, RC; Kacso, M; Shaughnessy, RA; Skuban, N, 2010)	0.36
" Outpatients who met DSM-IV-TR criteria for schizophrenia, who were not optimally controlled while on stable dosage of clozapine for > or =3 months and had experienced weight gain of > or =2."	( Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Dewaele, P; Fleischhacker, WW; Heikkinen, ME; Hennicken, D; Kerselaers, W; Landsberg, W; Loze, JY; McQuade, RD; Olié, JP, 2010)	0.63
" Dopamine receptor occupancy appears to reach a plateau at doses above 10 mg, supporting the observation found in dose-response studies that 10 mg/d is the optimal dose for aripiprazole."	( A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. Kapur, S; Patel, MX; Sparshatt, A; Taylor, D, 2010)	0.86
" Mean effective dosage was 14."	( [Aripiprazole - a medical treatment alternative for Tourette Syndrome in childhood and adolescence]. Banaschewski, T; Frölich, J; Lehmkuhl, G; Starck, M, 2010)	1.27
"This was an 8-week, open-label trial with flexible dosing strategy of aripiprazole in children and adolescents with TD."	( Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: a pilot study in China. Cui, YH; Li, J; Liu, J; Yang, YP; Zheng, Y, 2010)	0.87
" The effect occurs even when a low dosage (3 mg/d) of aripiprazole was used and achieves a plateau at dosages beyond 6 mg/d."	( Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N, 2010)	0.86
" However, excessive dosing of the antipsychotic medications, in particular haloperidol, may have played an important role in accounting for the differences between aripiprazole and haloperidol in this study."	( Aripiprazole versus haloperidol treatment in early-stage schizophrenia. Girgis, RR; Lieberman, JA; Merrill, DB; Pikalov, A; Vorel, SR; Whitehead, R; You, M, 2011)	2.01
"This was a post hoc analysis of data from two 8-week, randomized, double-blind, multicenter trials to evaluate the efficacy of aripiprazole dosed flexibly (2-15 mg/day, n=47) or fixed (5, 10, or 15 mg/day, n = 166) versus placebo (flexibly dosed, n = 51; fixed dose, n = 52)."	( Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. Aman, MG; Kasper, W; Mankoski, R; Manos, G; Marcus, R; Mathew, S; Owen, R, 2010)	0.79
" A month after the aripiprazole dosage was increased to 50 mg daily, the patient developed confusion and loss of coordination."	( Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Aung, GL; Kawamoto, LS; O'Brien, JG; Tien, PG, 2010)	1.09
" The mean final aripiprazole dosage was 12."	( Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. Berloffa, S; Masi, G; Millepiedi, S; Pfanner, C, 2010)	2.15
" In addition, specific issues associated with the use of aripiprazole as an adjunctive therapy in patients with MDD, including possible early treatment effect, appropriate timing of therapy initiation, appropriate dosing and duration of treatment, possible differential effect on depressive subgroups and long-term tolerability, are also discussed."	( Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. Forbes, A; Pae, CU; Patkar, AA, 2011)	2.06
" Choosing the appropriate dosing and tapering strategy, addressing the side effects, controlling withdrawal symptoms from previous medications and using adjunctive medications when necessary are key to successful treatment with aripiprazole."	( Aripiprazole for the treatment of bipolar disorder: a review of current evidence. Casamassima, F; Fagiolini, A; Forgione, RN; Marra, FS; Nitti, M, 2011)	2
" A smoked cocaine dose-response curve (0, 12, 25, 50 mg) was determined twice under placebo and aripiprazole maintenance."	( Aripiprazole maintenance increases smoked cocaine self-administration in humans. Foltin, RW; Haney, M; Rubin, E, 2011)	2.03
"OCS were significantly more prevalent and severe in group I, in which OCS severity correlated with dosage of clozapine and duration of treatment."	( Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M, 2011)	0.37
" One patient required a dosage reduction of ropinirole because of sleepiness and one patient assigned to aripiprazole who reported moderate akathysia had the dosage reduced to 5 mg/day."	( Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study. Ameglio, M; Biasci, L; Cecconi, D; Cellesi, V; Forgione, RN; Meini, M; Moncini, M; Pellegrini, M; Rucci, P; Simoni, G, 2011)	2.03
"Patients with schizophrenia or schizoaffective disorder with a body mass index ≥ 27 and non-high-density lipoprotein (non-HDL) cholesterol ≥ 130 mg/dl who were on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to switch to ari-piprazole (N=109) for 24 weeks or stay on their current medication (N=106)."	( A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011)	0.58
"A 52-week, open-label, flexibly dosed (2-15 mg/d) study of the safety and tolerability of aripiprazole in outpatients with a DSM-IV-TR diagnosis of autistic disorder who either had completed 1 of 2 antecedent, 8-week randomized trials or were enrolled de novo (ie, not treated in the randomized trials)."	( Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. Carson, WH; Findling, RL; Kamen, L; Mankoski, R; Manos, G; Marcus, RN; McQuade, RD; Owen, R, 2011)	0.89
" There was no difference in baseline PANSS scores or the daily dosage used between responders (n = 28) and nonresponders (n = 17) (15."	( Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. Chen, CK; Lin, SK; Liu, YL, 2011)	1.81
" He was started on aripiprazole 15 mg po daily for 4 days; the dosage was then increased to 30 mg po daily, with Valproic Acid 500 mg po tid."	( Pituitary microadenoma treated with antipsychotic drug aripiprazole. Capote, E; Ezequiel, U; Paez, R; Wix-Ramos, RJ, 2011)	0.95
" The patients were assigned to two groups: aripiprazole group (n=98) and tiapride group (n=97), with the treatment dosage of 5-25 mg/d and 100-500 mg/d, respectively."	( [A multicenter controlled study on aripiprazole treatment for children with Tourette syndrome in China]. Chen, YH; Liao, JX; Liu, ZS; Sun, D; Wang, DB; Wang, H; Zhong, YQ; Zou, LP, 2011)	0.91
" The mean dosage of aripiprazole required was 18."	( An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. Boettger, S; Breitbart, W, 2011)	1.03
"The mean maximum daily dosage of aripiprazole in the completers was 10."	( A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Hayashida, K; Kiriike, N; Maebayashi, K; Matsunaga, H; Mito, H, 2011)	0.99
"Positron emission tomography (PET) studies of dopamine receptor occupancy can be used to assess dosing of antipsychotics."	( Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. Howes, OD; Jang, IJ; Jeong, JM; Kapur, S; Kim, BH; Kim, E; Kwon, JS; Lee, JS; Shin, SG; Turkheimer, FE, 2012)	0.38
" We conducted a prospective, open-label nonrandomized, 4-week flexibly dosed (2."	( The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial. Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW, 2012)	0.64
"We investigated the effects of the atypical antipsychotics risperidone, olanzapine, and aripiprazole on the cognitive functions of Japanese patients with schizophrenia with respect to dosage amounts and dosing schedules."	( The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Umene-Nakano, W; Yoshimura, R, 2012)	0.9
", PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial."	( An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. Bradford, DW; Butterfield, MI; Hertzberg, MA; Kilts, JD; Marx, CE; Naylor, JC; Strauss, JL; Youssef, NA; Zinn, S, 2012)	0.67
"4 weeks with a mean final aripiprazole dosage of 10."	( A retrospective review of the effectiveness of aripiprazole in the treatment of sensory abnormalities in autism. Bivas, R; Chahal, L; Fung, LK; Hardan, AY; Libove, RA, 2012)	0.94
"The panel agreed that aripiprazole is effective in treating bipolar mania when prescribed and dosed appropriately, in both the short and long term, as monotherapy or in combination with a mood stabilizer."	( A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania. Bobmanuel, S; Davies, W; Dratcu, L; Farmer, A; George, M; Rana, T; Singh, M; Turner, M, 2012)	0.96
" Despite the lack of evidence, experts recommend an overlap strategy that includes maintaining the current antipsychotic dosage while titrating to a therapeutic dose of aripiprazole."	( Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia. Robert, S; Wisniewski, CS, )	0.59
"Patients were treated with aripiprazole monotherapy at a dosage of 10-30 mg/day."	( Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study. Bervoets, C; Constant, E; de Patoul, A; Halkin, V; Kok, F; Morrens, M; Peuskens, J; Pitsi, D; Sabbe, B; Vansteelandt, K, 2012)	1.08
" The dosage of pre-existing atypical antipsychotics was fixed, while the dosage of aripiprazole ranged from 5 to 20 mg/day during the study period."	( Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Chen, CK; Hsiao, CC; Huang, YS; Ree, SC; Wang, LJ, 2013)	0.93
"All trials were industry supported, with some variability in dosage of haloperidol."	( Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013)	0.39
"The aim of this study was to investigate the dosing patterns of adjunctive quetiapine or adjunctive aripiprazole in the treatment of major depressive disorder from 2006 to 2010, and to evaluate the impact of Food and Drug Administration (FDA) approval on these dosing patterns."	( Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010). Forbes, RA; Guo, Z; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME, 2013)	0.93
" A flexible dosing strategy based on clinical improvement and tolerability with a target dose 15 mg/d by the end of the fourth week."	( Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study. Chien, YL; Hsieh, MH; Hwang, TJ; Hwu, HG; Liu, CC; Liu, CM, 2013)	1.83
" They responded well to the reduction in dosage or to withdrawal of the apparent causing agent."	( [Medication-related oculogyric crises: a description of four cases and a review of the literature]. Campistol, J; Darling, A; Perez-Duenas, B; Poo, P, 2013)	0.39
" Bioavailability studies of the polymorphs of aripiprazole and their pharmaceutical preparations are very important to optimize the formulations of the dosage forms."	( Aripiprazole. Ardiana, F; Indrayanto, G; Lestari, ML, 2013)	2.09
" This was the first 12-week prospective, multicentre, open-label study of the effectiveness and tolerability of flexibly dosed aripiprazole as an augmentation to ongoing antidepressant treatment in patients with chronic or recurrent MDD."	( Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study. Cho, SJ; Choi, JH; Hahn, SW; Han, C; Jeon, HJ; Jon, DI; Jun, TY; Kim, SG; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Park, EJ; Seo, HJ, 2013)	2.04
" Available experimental evidences and published patents are indicative of broadening the circle of the applications in point of both technological advantages and dosage forms."	( [Pharmaceutical applications of sulfobuthylether-beta-cyclodextrin]. Sebestyén, Z; Szabó, B; Szepesi, K, 2013)	0.39
" Lowering the dosage of aripiprazole or changing the antipsychotic medication might be helpful in this situation."	( Aripiprazole associated urine retention in a male schizophrenia patient. Chang, TG; Chiu, NY; Hsu, WY, )	1.88
"This was a 6-week prospective, multicenter, open-label study with flexibly dosed adjunctive aripiprazole."	( Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study. Bahk, WM; Jon, DI; Kim, DH; Kim, MD; Kwon, YJ; Min, KJ; Pae, CU; Seo, HJ; Suh, HS; Yang, JC, )	0.7
"This study investigated the dosing patterns for aripiprazole augmentation for major depressive disorder (MDD) in a naturalistic treatment setting."	( Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Han, C; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Wang, SM, 2014)	2.1
"A 65-year-old man developed severe hyponatremia after an aripiprazole dosage increase."	( Syndrome of inappropriate antidiuretic hormone associated with aripiprazole. Jackson, EA; Kwan, BK; Yam, FK, 2013)	0.87
" Ancillary analyses indicated that tolerability was less favourable in younger (10-12 years) than in older (≥13 years) subjects, and less favourable with the higher (30 mg/day) than the lower dosage (10 mg/day)."	( Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder. McKeage, K, 2014)	1.85
", self-administration) sessions and 1 dose-response session, were conducted (once during the lead-in and twice after randomization)."	( Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. Campbell, C; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2014)	1.85
" In phase 1, single-blind aripiprazole was flexibly dosed (2-15 mg/d) for 13-26 weeks."	( A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Amatniek, J; Eudicone, JM; Findling, RL; Lears, K; Mankoski, R; Marcus, RN; McCartney, T; McQuade, RD; Sheehan, JJ; Timko, K, 2014)	0.94
" All patients were titrated on iloperidone to 6mg BID by Day 4, then flexibly dosing between 6 and 12mg BID, as needed."	( A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A, 2014)	0.62
" Analyses were performed assuming dosing of clinical trials, real-world practice, PIs, and highest therapeutic dose available, because of variation in practice settings."	( Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Baker, RA; Bentley, TG; Citrome, L; Eramo, A; Gutierrez, B; Hansen, K; Kamat, SA; Ortendahl, J; Sapin, C, 2014)	0.72
" When PI dosing was assumed, this ICER increased to US$19,968/relapse averted."	( Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Baker, RA; Bentley, TG; Citrome, L; Eramo, A; Gutierrez, B; Hansen, K; Kamat, SA; Ortendahl, J; Sapin, C, 2014)	0.72
" Under various dosing scenarios, AOM results indicated fewer relapses at lower overall costs or a reasonable cost-effectiveness threshold (i."	( Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Baker, RA; Bentley, TG; Citrome, L; Eramo, A; Gutierrez, B; Hansen, K; Kamat, SA; Ortendahl, J; Sapin, C, 2014)	0.72
" This finding suggests the need to increase the dosage during pregnancy in order to maintain stable PLs."	( A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. Gentile, S, 2014)	0.71
" His TD always improved immediately after the dosage was shifted to aripiprazole."	( Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder. Chan, HY; Tan, HK; Wu, WY, 2014)	0.88
"The aim of this study is to assess urine levels of aripiprazole and metabolites among patients receiving steady-state dosing of aripiprazole."	( Quantitative levels of aripiprazole parent drug and metabolites in urine. Buckley, P; Corwin, MJ; Dretchen, K; McEvoy, J; Millet, RA; Morris, AA, 2014)	0.96
"One hundred fifty adults, judged compliant with a stable aripiprazole regimen, had observed dosing for 5 consecutive days."	( Quantitative levels of aripiprazole parent drug and metabolites in urine. Buckley, P; Corwin, MJ; Dretchen, K; McEvoy, J; Millet, RA; Morris, AA, 2014)	0.96
"In this multicenter, double-blind, phase 3 study (screening [≤3 weeks], with an acute treatment period [8 weeks] and a maintenance period [18 weeks]), adolescents (12-17 years old) with schizophrenia (DSM-IV diagnosis; Positive and Negative Symptom Score [PANSS] total score 60-120) were randomized (1:1) to once-daily paliperidone ER (6 mg per day [days 1-7], flexibly dosed 3, 6, or 9 mg per day from week 2 to end of study [EOS]), or to aripiprazole (2 mg per day [days 1 and 2], 5 mg per day [days 3 and 4], 10 mg per day [days 5-7], flexibly dosed 5, 10, or 15 mg per day [week 2 to EOS])."	( Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. Gopal, S; Hough, D; Lane, R; Nuamah, I; Savitz, AJ, 2015)	0.58
" In case of a drug inhibition and/or of a slow metabolizing profile, dosage adjustment is necessary."	( [Rational estimation of drug dosage through pharmacometric modeling: The case of a long-acting depot antipsychotic]. Azorin, JM; Simon, N, 2015)	0.42
" This study confirmed that new dosage forms of aripiprazole in gummi drugs can be developed as hospital formulations, which will contribute to improve medication adherence of patients."	( Development of gummi drugs of aripiprazole as hospital formulations. Hiraoka, S; Namiki, N; Uchida, S, 2015)	0.96
" However, the ideal dosing regimen for this purpose is unknown."	( Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Bian, QT; Chen, JX; Correll, C; Liu, YH; Soares, JC; Su, YA; Wang, SL; Wei, LH; Yang, FD; Zhang, RZ; Zhang, XY, 2015)	0.81
" An inadequate response to antidepressants was defined as a total score ≥ 14 on the Hamilton Depression Rating Scale-item 17 (HDRS-17) despite adequate antidepressant dosage for at least 6 weeks in the current depressive episode."	( Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study. Chang, CM; Han, C; Kwak, KP; Lee, H; Pae, CU; Tang, TC; Wang, SM; Won, WY, )	1.57
" Aripiprazole produced a U-shaped dose-response curve on MK-801-induced bar pressing behavior, a dose-dependent decrease in locomotor activity but no changes in IL pERK1/2 labeling."	( Attenuation of MK-801-induced behavioral perseveration by typical and atypical antipsychotic pretreatment in rats. Holahan, MR; Stocco, MR; Tuplin, EW, 2015)	1.33
" We evaluated the effect of daily dosing with armodafinil on the pharmacokinetics and safety of the CYP3A4 substrate aripiprazole, an atypical antipsychotic used to treat bipolar I disorder."	( Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults. Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R, 2015)	0.85
"Studies of the phase transitions in an active substance contained in a solid dosage form are very complicated but essential, especially if an active substance is classified as a BCS Class IV drug."	( Studies of phase transitions in the aripiprazole solid dosage form. Witkowska, A; Łaszcz, M, 2016)	0.71
" The pharmacokinetic profile of AL also led to approval of dosing intervals of every 6 weeks for the 882 mg dose."	( Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Citrome, L, 2016)	1.88
" Moreover, available tools that guide dosing in neuropsychiatric pediatric patients are scant, leading to the possibility of reduced efficacy and/or increased risks of toxicity."	( Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Auricchio, F; Baldelli, S; Bernardini, R; Bertella, S; Bravaccio, C; Capuano, A; Carnovale, C; Cattaneo, D; Clementi, E; Ferrajolo, C; Fucile, S; Guastella, G; Mani, E; Molteni, M; Pascotto, A; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Riccio, MP; Rizzo, R; Rossi, F; Scuderi, MG; Sperandeo, S; Sportiello, L; Villa, L, 2016)	0.43
" In this study, the aripiprazole dosage ranged between 3 and 9 mg/day."	( Aripiprazole Can Improve Apraxia of Eyelid Opening in Parkinson's Disease. Fukunaga, K; Nakanishi, R; Tokisato, K; Tokunaga, M; Watanabe, S; Yamanaga, H, 2015)	2.18
" Statistical analysis shows that in cases of complex diagnoses, dosage does not depend on age but depends on other factors."	( CLINICAL EXPERIENCE OF LONG-TERM TREATMENT WITH ARIPIPRAZOLE (ABILIFY) IN CHILDREN AND ADOLESCENTS AT THE CHILD AND ADOLESCENT PSYCHIATRIC CLINIC 1 IN ROSKILDE, DENMARK. Danilevičiütė, V; Diomšina, B; Rasmussen, PD, )	0.39
" Analyses were conducted assuming pooled dosing from randomised clinical trials included in the MTCs."	( Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M, 2015)	0.7
" The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period."	( Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Guo, Q; Li, C; Ouyang, Q; Qiao, Y; Shen, W; Sheng, J; Wen, H; Yang, F; Zhu, S, 2016)	0.96
" This open-label, parallel-group study was performed to compare finger-stick-based capillary with corresponding venous plasma concentrations for risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole and their major metabolites after repeated dosing in patients with schizophrenia or related illnesses."	( Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. Ariyawansa, J; De Meulder, M; Remmerie, B; Savitz, A, 2016)	0.82
" Patients received flexibly dosed aripiprazole (1-15 mg/day) or placebo."	( Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Ichikawa, H; Ishizaki, Y; Mikami, K; Okada, T; Ono, H; Tadori, Y; Tomoda, A; Usuki, C; Yamashita, Y, 2017)	2.18
" inverted U) association between changes in dentate gyrus/CA4 volume and cumulative antipsychotic dosage between the scans."	( Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis. Gallego, JA; Malhotra, AK; Rhindress, K; Robinson, DG; Szeszko, PR; Wellington, R, 2017)	0.46
" The finding of a non-linear relationship between changes in dentate gyrus/CA4 subregion volume and antipsychotic exposure may provide new avenues into understanding dosing strategies for therapeutic interventions relevant to neurobiological models of hippocampal dysfunction in psychosis."	( Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis. Gallego, JA; Malhotra, AK; Rhindress, K; Robinson, DG; Szeszko, PR; Wellington, R, 2017)	0.46
"The purpose of this study was to develop extemporaneously compounded oral liquid formulations of aripiprazole for use in pediatric patients and those patients unable to swallow the solid oral dosage forms."	( Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children. Davidow, LW; Funk, RS; Pramann, LA; van Haandel, L, )	0.61
" We developed a population pharmacokinetic (PopPK) model to characterize aripiprazole lauroxil PK and evaluate dosing scenarios likely to be encountered in clinical practice."	( Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Citrome, L; Hard, ML; Mills, RJ; Sadler, BM; Turncliff, RZ, 2017)	2.13
" The model was subsequently used to evaluate various dose levels and frequency and the impact of dosing delay on aripiprazole concentrations."	( Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Citrome, L; Hard, ML; Mills, RJ; Sadler, BM; Turncliff, RZ, 2017)	2.11
" Based on the PopPK model simulations, a dosing interval of 882 mg every 6 weeks results in aripiprazole concentrations that fall within the concentration range associated with the efficacious aripiprazole lauroxil dose range (441-882 mg dosed monthly)."	( Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Citrome, L; Hard, ML; Mills, RJ; Sadler, BM; Turncliff, RZ, 2017)	2.12
"This PopPK model and model-based simulations were effective means for evaluating aripiprazole lauroxil dosing regimens and management of missed doses."	( Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Citrome, L; Hard, ML; Mills, RJ; Sadler, BM; Turncliff, RZ, 2017)	2.12
"We examined the feasibility of a 2-month (every 8 weeks [q8wk]) dosing interval of AL in a phase I open-label pharmacokinetic study investigating AL 1064 mg administered q8wk for 24 weeks, followed by 20 weeks of safety and pharmacokinetic measurements (ClinicalTrials."	( Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY; Weiden, PJ, 2017)	0.7
" Study limitations included use of a fixed dose for initial oral aripiprazole and fixed monthly AL doses without the option to individualize the oral initiation dosing or injection frequency for efficacy, tolerability, or safety."	( Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. Citrome, L; Cutler, AJ; Du, Y; Nasrallah, HA; Risinger, R; Silverman, BL; Zummo, J, 2018)	1.12
" Comparable daily dose equivalents were achieved with two different formulations due to the Q3wks vs Q4wks dosing strategies, although the two agents have some differences in pharmacokinetic profiles."	( Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report. Bishop, JR; Brown, JT; Eum, S; Lee, AM; Schneiderhan, ME, 2017)	0.69
" Our case report suggests further investigations of altered dosing strategies and receptor genotype sensitivities to pharmacokinetic factors may be helpful in understanding symptom re-emergence observed in some patients taking LAI antipsychotics."	( Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report. Bishop, JR; Brown, JT; Eum, S; Lee, AM; Schneiderhan, ME, 2017)	0.69
" Well-known sources of secondary negative symptoms are psychotic symptoms, disorganisation, anxiety, depression, chronic abuse of illicit drugs and alcohol, an overly high dosage of antipsychotic medication, social deprivation, lack of stimulation and hospitalisation."	( Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review. de Haan, L; Schulte, PFJ; Veerman, SRT, 2017)	0.46
" The PK results from this study show that a dosing interval of every 8 weeks for the 1064 mg dose resulted in aripiprazole concentrations within the established therapeutic window for AL."	( A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. Hard, M; Risinger, R; Weiden, PJ, 2017)	0.88
"Second-generation long-acting injectable therapies (SGA-LAIs) may reduce health care resource utilization (HRU) and health care costs compared with daily oral atypical antipsychotics (OAAs) in patients with schizophrenia due to reduced dosing frequency, delivery/monitoring by a health care provider, and improved adherence."	( Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. Emond, B; Joshi, K; Kamstra, R; Lafeuille, MH; Lefebvre, P; Pilon, D; Tandon, N, 2017)	0.46
"In this open-label extension study, patients who had completed a previous randomized, double-blind, placebo-controlled 8-week study were enrolled and were flexibly dosed with aripiprazole (1-15 mg/day) until the new indication of irritability in pediatric autism spectrum disorder was approved in Japan."	( An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. Hiratani, M; Ichikawa, H; Ono, H; Oshimo, T; Tadori, Y; Tsujii, N; Yasuhara, A, 2018)	0.91
" Three months after the dosage increase, the patient was found to have an elevated IOP of 32 mm Hg and angle-closure with a plateau iris configuration in the left eye."	( Acute Angle-closure Glaucoma Associated With Aripiprazole in the Setting of Plateau Iris Configuration. Farukhi, S; Mosaed, S; Schmutz, M; Shen, E, 2018)	0.74
" These benefits together might decrease the daily dosage of the ARI and thus alleviate the possible side effects of drug."	( Potentiating and synergistic effect of grapefruit juice on the antioxidant and anti-inflammatory activity of aripiprazole against hydrogen peroxide induced oxidative stress in mice. Al-Majed, AA; Wani, TA; Zargar, S, 2018)	0.69
"Supplementing GFJ to ARI might increase an anti-oxidative potential of ARI due to inherent antioxidant and anti-inflammatory activity of GFJ and thus could alleviate the possible dosage dependent side effects of ARI."	( Potentiating and synergistic effect of grapefruit juice on the antioxidant and anti-inflammatory activity of aripiprazole against hydrogen peroxide induced oxidative stress in mice. Al-Majed, AA; Wani, TA; Zargar, S, 2018)	0.69
" The aim of the present study was to design a mucoadhesive dosage form for buccal delivery of aripiprazole which could provide a rapid drug delivery to the systemic circulation."	( Aripiprazole Nanocrystal Impregnated Buccoadhesive Films for Schizophrenia. Al-Dhubiab, BE, 2017)	2.12
"Concomitant administration of the 1-day initiation regimen with all approved AL dosing regimens (441, 662, or 882 mg monthly, 882 mg every 6 weeks, or 1064 mg every 2 months) is predicted to achieve aripiprazole concentrations associated with therapeutic doses of AL using the 21-day initiation regimen within 4 days, maintaining these concentrations until the next AL dose."	( Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil. Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY, 2018)	0.91
" Long-acting injectable (LAI) antipsychotics offer an extended dosing interval option for patients, although the current options may require an oral overlap at initiation."	( Aripiprazole Lauroxil NanoCrystal Clark, C; Davis, E; Ehret, MJ; Luttrell, SE, )	1.57
" With many advantages this method can be found as a new dosage form manufacturing technique, however low printing efficiency stays as one of the major limitations."	( 3D printing of tablets containing amorphous aripiprazole by filaments co-extrusion. Czech, A; Gawlak, K; Jachowicz, R; Jamróz, W; Kurek, M; Szafraniec, J, 2018)	0.74
" Aripiprazole and ceftriaxone were used in a single- or repeated dosing protocol."	( Interventional and preventive effects of aripiprazole and ceftriaxone used alone or in combination on oxaliplatin-induced tactile and cold allodynia in mice. Furgała, A; Sałat, K; Sałat, R, 2019)	1.69
"During a period of inflammation in patients taking quetiapine, according to our results, attention in dosing strategies is required to prevent toxic plasma concentrations."	( Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting. Deckert, J; Menke, A; Scherf-Clavel, M; Unterecker, S; Weidner, A, 2020)	0.76
" Department of Veterans Affairs (VA) Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) study, a multisite, randomized, single-blind trial of 1,522 Veterans Health Administration patients who did not have an adequate response to at least one course of antidepressant treatment meeting minimal standards for dosage and duration."	( General Predictors and Moderators of Depression Remission: A VAST-D Report. Chen, P; Davis, L; Hicks, P; Johnson, GR; Mohamed, S; Tal, I; Thase, M; Vertrees, J; Zhao, Y; Zisook, S, 2019)	0.51
" Pre-emptive CYP2D6 genotyping would be valuable for individualising risperidone and aripiprazole dosing and treatment optimisation."	( Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Haslemo, T; Ingelman-Sundberg, M; Jukic, MM; Molden, E; Smith, RL, 2019)	0.97
" At low dosage, aripiprazole outperformed ketoconazole in terms of inhibiting biofilm formation, hyphal filamentations, and yeast flocculation, whereas at higher dosage it mimicked ketoconazole."	( Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans. Lee, J; Lee, JH; Rajasekharan, SK, 2019)	2.3
" After treatment with aripiprazole long-acting injection at a dosage of 400 mg/mo intramuscularly, she has been relapse-free for over 2 years."	( Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long-acting injection: A case report. Hashimoto, T; Kurata, T; Suzuki, H, 2019)	1.05
"Tailoring medication dosing for the individual patient is complex, and many factors can influence drug exposure."	( Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. Correll, CU; Høiseth, G; Molden, E; Smith, RL; Tveito, M, 2020)	0.81
"The dose-response relationships of antipsychotic drugs for schizophrenia are not well defined, but such information would be important for decision making by clinicians."	( Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)	0.56
" Dose-response curves were constructed with random-effects dose-response meta-analyses and a spline model."	( Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)	0.56
" For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau."	( Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)	0.56
" Those with prior adequate trials were also more likely to require a higher dosage of venlafaxine to achieve remission."	( Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History. Blumberger, DM; Buchalter, ELF; Dixon, D; Karp, JF; Lenze, EJ; Miller, JP; Mulsant, BH; Oughli, HA; Reynolds, CF, 2019)	0.51
" Various factors may influence their pharmacokinetics, particularly elimination, leading to highly variable drug concentrations between individual patients following the same dosing regimen."	( Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models. Jovanović, M; Miljković, B; Vučićević, K, 2020)	0.77
" To evaluate the protocol, brain sections from mice dosed intraperitoneally with donepezil, tacrine, clozapine, haloperidol, and aripiprazole were used."	( Development of an Integrated Tissue Pretreatment Protocol for Enhanced MALDI MS Imaging of Drug Distribution in the Brain. Chen, Y; Gordon, A; Li, B; Tang, W, 2020)	0.76
" Approved AL doses and dosing regimens include 441 mg monthly, 662 mg monthly, and 882 mg monthly or every 6 weeks (q6wk), as well as the most recently approved dose, 1064 mg, administered every 2 months."	( Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ, 2020)	0.77
"This study evaluated pharmacokinetics of AL given at a higher dosage strength (1064 mg) and at a longer dose interval (every 8 weeks [q8wk]) than previously studied."	( Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ, 2020)	0.77
"AL 1064 mg q8wk provided continuous exposure to aripiprazole throughout the 8-week dosing interval and had a safety profile consistent with the 4- and 6-week regimens."	( Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ, 2020)	1.02
"Dopamine supersensitivity psychosis (DSP) in patients with schizophrenia is induced by treatment with a high dosage of antipsychotics for a long time period, and it is characterized by unstable psychotic symptoms."	( The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. Fujita, Y; Honma, M; Iyo, M; Kanahara, N; Komatsu, N; Noda, S; Saiga, T; Sasaki, T; Simoyama, T; Suzuki, H; Tadokoro, S; Takase, M; Yamanaka, H; Yanahashi, S, 2020)	0.82
" AL has five regimen options that offer three different injection intervals using four different dosage strengths."	( Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals. Du, Y; Faldu, S; Rege, B; Sommi, RW; Wehr, A; Weiden, PJ, 2022)	2.16
" Dosing strategies, discontinuation considerations, and side effects are discussed."	( The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia. Chen, A; Cloutier, A; Copeli, F; Metzger, E; Osser, DN, 2021)	0.62
"Delivering therapeutics to the brain using conventional dosage forms is always a challenge, thus the present study was aimed to formulate mucoadhesive nanoemulsion (MNE) of aripiprazole (ARP) for intranasal delivery to transport the drug directly to the brain."	( Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. Choudhury, H; Gorain, B; Kokare, CR; Kumbhar, SA; Shrivastava, B, 2021)	1.05
" Eventually, he agreed to a higher dosage of aripiprazole and thus titrate antipsychotic therapy that he rejected when prescribed by the dermatology and psychiatry specialists."	( Concurrent Delusions of Ocular Parasitosis and Complex Visual Hallucinations from Charles Bonnet Syndrome Treated Successfully with Aripiprazole in an Elderly Male: A Case Report. Krasniak, AE; Nguyen, HT; Whitfield, NT, 2020)	1.02
"In this post-marketing surveillance, patients were enrolled into the multicenter, prospective, non-interventional, observational study for 52 weeks, and were dosed with aripiprazole (1-15 mg/day) under daily clinical settings in Japan."	( Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance. Aoki, K; Fukuta, Y; Mikami, K; Sugimoto, Y; Takayama, T; Tomoda, A; Yamamura, K, 2021)	2.26
"This article aims to evaluate management options for antipsychotic-induced hyperprolactinemia and associated treatment considerations such as efficacy, tolerability, drug interactions, contraindications, and dosing regimens."	( Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Alabbasi, AY; Nelson, LA; Rusgis, MM, 2021)	0.62
" In conclusion, the limited data reported in this present study indicates that monitoring IS in the blood is a very important determinant in the dosage plan for the administration of site II drugs such as ARP, if the efficacy of the drug in renal disease is to be considered."	( The Binding of Aripiprazole to Plasma Proteins in Chronic Renal Failure Patients. Chuang, VTG; Hirata, K; Ikeda, T; Maruyama, T; Nishi, K; Otagiri, M; Sakurama, K; Tanaka, M; Uchida, Y; Watanabe, H; Yamasaki, K, 2021)	0.97
"Aripiprazole augmentation is proven effective for antidepressant-refractory depression, but its licensed dose range is wide and optimal dosage remains unclear."	( Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis. Cipriani, A; Furukawa, TA; Furukawa, Y; Hamza, T; Ostinelli, EG; Salanti, G, 2022)	2.51
"To find the optimal dosage of aripiprazole augmentation."	( Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis. Cipriani, A; Furukawa, TA; Furukawa, Y; Hamza, T; Ostinelli, EG; Salanti, G, 2022)	1.36
"Risperidone and aripiprazole with no dosage restrictions."	( Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews. Chen, MH; Escobar Liquitay, CM; Fieiras, C; Franco, JVA; Madrid, E; Meza, N; Rojas, V, 2023)	1.6
" They were administered aripiprazole 3 mg/day, with dosage increased or reduced as needed."	( Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease-Results of a multicenter open trial. Kashihara, K; Maeda, T; Yoshida, K, 2022)	1.33
" Despite no statistically significant differences between groups regarding clinical efficacy, aripiprazole required higher chlorpromazine equivalent dosage (χ 2 = 2."	( Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial. Ayesa-Arriola, R; Crespo-Facorro, B; Garrido-Sánchez, L; Gómez-Revuelta, M; Juncal-Ruiz, M; Mayoral-Van Son, J; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Ruiz-Veguilla, M; Vázquez-Bourgon, J, 2022)	2.38
"In this work, a novel environment-friendly stability indicating capillary zone electrophoresis (CZE) method has been developed and validated for assaying the aripiprazole (ARP) in tablet dosage form."	( Novel Eco-Friendly Stability Indicating Capillary Zone Electrophoresis Method for Determination of Aripiprazole in Tablet Dosage form: DoE Directed Optimization, Development and Method Validation. Fajardo, FAG; Prado, MSA; Rashid, A; Tavares, MFM, 2022)	1.14
" Our findings suggest that dosing based on CYP2C19 and CYP2D6 genotyping could improve safety and outcome in patients on ESC monotherapy."	( Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study. Blier, P; Farzan, F; Foster, JA; Frey, BN; Hassel, S; Islam, F; Kennedy, SH; Lam, RW; Leri, F; Magarbeh, L; Marshe, VS; Milev, RV; Müller, DJ; Parikh, SV; Placenza, F; Rotzinger, S; Soares, CN; Strother, SC; Taylor, VH; Turecki, G; Uher, R, 2022)	0.96
" In the TDM group, physicians will receive dosing advice based on plasma levels of risperidone and aripiprazole and its metabolites at 4 and 10 weeks."	( The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial. de Winter, BCM; Dierckx, B; Hermans, RA; Hillegers, MHJ; Kloosterboer, SM; Koch, BCP; Liang, K; Ringeling, LT, 2022)	1.18
" Tailor-made pharmaceutical formulations can provide a suitable dosage form to meet the specific needs of individual patients who exhibit poor adherence to industrially manufactured products."	( Palatability of Aripiprazole Gummies Prepared from Commercially Available Products: Pharmaceutical Formulation for Improving Patient Adherence. Hakamata, A; Inui, N; Kamiya, C; Kashiwagura, Y; Kawamoto, S; Miura, M; Namiki, N; Odagiri, K; Tanaka, S; Uchida, S; Watanabe, H, 2023)	1.26
"MK801 dose-response study was conducted in RHA and Roman Low-Avoidance (RLA) male rats."	( Atypical antipsychotics attenuate MK801-induced social withdrawal and hyperlocomotion in the RHA rat model of schizophrenia-relevant features. Cañete, T; Fernández-Teruel, A; Lavín, V; Oliveras, I; Río-Álamos, C; Sampedro-Viana, D; Sánchez-González, A; Sanna, F; Tapias-Espinosa, C; Tobeña, A; Torrecilla, P, 2023)	0.91
" Herein, a green and highly sensitive spectrofluorimetric method was developed for the determination of aripiprazole in pharmaceutical dosage form and plasma matrix."	( Application of a nucleophilic substitution reaction for spectrofluorimetric determination of aripiprazole in pharmaceutical dosage form and plasma matrix; greenness assessment. Abdullah, O; Alaqel, SL; Alharbi, A; Almalki, AH; Almrasy, AA; Althobaiti, YS; Alturki, MS; Ramzy, S, 2023)	1.34
" The intervention was a pharmacogenetic testing panel for 26 drugs with dosage and selection recommendations returned to the health record."	( The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial. Benson, EA; Callaghan, JT; Desta, Z; Dexter, PR; Eadon, MT; Fulton, CR; Gufford, BT; Gupta, SK; Haas, DM; Holmes, AM; Kreutz, RP; Levy, KD; Pierson, RC; Pratt, VM; Rosenman, MB; Shugg, T; Skaar, TC; Tillman, EM; Vuppalanchi, R; Zang, Y; Zhang, P, 2023)	0.91
" Evidence-based recommendations for female-specific pharmacotherapy for SSD consist of (1) female-specific dosing for antipsychotics (guided by therapeutic drug monitoring), (2) hormonal replacement with raloxifene in postmenopausal women, and (3) aripiprazole addition as best evidenced option in case of antipsychotic-induced hyperprolactinemia."	( Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders. Brand, BA; Hamers, IMH; Sommer, IE; Willemse, EJM, 2023)	1.09

Role	Description
H1-receptor antagonist	H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
serotonergic agonist	An agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
second generation antipsychotic	Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements.
drug metabolite	null
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
quinolone
N-arylpiperazine
N-alkylpiperazine
dichlorobenzene	Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
delta-lactam	A lactam in which the amide bond is contained within a six-membered ring, which includes the amide nitrogen and the carbonyl carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Aripiprazole metabolic pathway	0	2

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	39.8107	0.0040	23.8416	100.0000	AID485290
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	56.2341	0.6310	35.7641	100.0000	AID504339
acetylcholinesterase	Homo sapiens (human)	Potency	22.2215	0.0025	41.7960	15,848.9004	AID1347395; AID1347398
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	30.1065	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	29.3033	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	24.0732	0.1737	34.3047	61.8120	AID1346859; AID1346924
Fumarate hydratase	Homo sapiens (human)	Potency	31.1700	0.0030	8.7949	48.0869	AID1347053
USP1 protein, partial	Homo sapiens (human)	Potency	39.8107	0.0316	37.5844	354.8130	AID504865
PPM1D protein	Homo sapiens (human)	Potency	18.5569	0.0052	9.4661	32.9993	AID1347411
SMAD family member 3	Homo sapiens (human)	Potency	24.0732	0.1737	34.3047	61.8120	AID1346859; AID1346924
TDP1 protein	Homo sapiens (human)	Potency	15.4706	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	10.6612	0.0007	14.5928	83.7951	AID1259369; AID1259392
Microtubule-associated protein tau	Homo sapiens (human)	Potency	11.2202	0.1800	13.5574	39.8107	AID1460
AR protein	Homo sapiens (human)	Potency	13.9221	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743042; AID743053; AID743054
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	26.7797	0.0006	57.9133	22,387.1992	AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	16.5168	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	11.8832	0.0004	17.9460	75.1148	AID1346795
EWS/FLI fusion protein	Homo sapiens (human)	Potency	13.0463	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	26.8325	0.0002	14.3764	60.0339	AID720691
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	26.6032	0.0030	41.6115	22,387.1992	AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	0.8554	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	11.8348	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	21.1300	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	9.9132	0.0054	28.0263	1,258.9301	AID1346982; AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	24.2316	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	12.3018	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	3.0901	0.0010	8.3798	61.1304	AID1645840
polyprotein	Zika virus	Potency	31.1700	0.0030	8.7949	48.0869	AID1347053
67.9K protein	Vaccinia virus	Potency	14.1254	0.0001	8.4406	100.0000	AID720579
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	11.3872	0.0010	24.5048	61.6448	AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	26.6011	0.0010	19.4141	70.9645	AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	26.3620	0.0237	23.2282	63.5986	AID743222; AID743223; AID743241
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	8.3701	0.0355	20.9770	89.1251	AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Homo sapiens (human)	Potency	50.1187	0.0165	25.3078	41.3999	AID602332
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	33.4915	0.0016	28.0151	77.1139	AID1224843
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	23.9145	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	16.1998	0.0578	21.1097	61.2679	AID1159526; AID1159528
lysosomal alpha-glucosidase preproprotein	Homo sapiens (human)	Potency	1.7783	0.0366	19.6376	50.1187	AID1466; AID2242
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	29.0929	0.0041	9.9848	25.9290	AID504444
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	1.7783	0.0178	9.6374	44.6684	AID588834
transcriptional regulator ERG isoform 3	Homo sapiens (human)	Potency	7.9433	0.7943	21.2757	50.1187	AID624246
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	11.6595	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	29.8470	0.0420	27.3789	61.6448	AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	16.0822	0.0006	27.2152	1,122.0200	AID743202; AID743219
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	0.7079	0.0079	8.2332	1,122.0200	AID2546
geminin	Homo sapiens (human)	Potency	13.5937	0.0046	11.3741	33.4983	AID624296; AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	22.7936	0.0056	12.3677	36.1254	AID624032
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	28.1838	0.2512	15.8432	39.8107	AID504327
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	12.5893	0.0158	12.3113	615.5000	AID1461
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	26.6032	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	16.9931	0.0033	9.1582	39.8107	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	12.3018	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	31.6704	0.0023	19.5956	74.0614	AID651631; AID720552
Neuronal acetylcholine receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	1.7783	3.5481	18.0395	35.4813	AID1466
Neuronal acetylcholine receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	1.7783	3.5481	18.0395	35.4813	AID1466
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	26.6032	0.0015	51.7393	15,848.9004	AID1259244
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	29.4964	0.0096	10.5250	35.4813	AID1479145; AID1479148
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	7.9433	1.0000	10.4756	28.1838	AID1457
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	12.3018	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	12.3018	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 3E	Homo sapiens (human)	Ki	0.5012	0.0010	0.8835	9.9000	AID298488
Solute carrier family 22 member 2	Homo sapiens (human)	IC50 (µMol)	239.0000	0.4000	3.1000	9.7000	AID721751
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
5-hydroxytryptamine receptor 3A	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	630.0000	0.6900	4.1900	7.6900	AID1889692
5-hydroxytryptamine receptor 3B	Homo sapiens (human)	Ki	0.5012	0.0010	0.8711	9.9000	AID298488
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	0.7800	0.0002	2.3185	10.0000	AID598251
Cytochrome P450 3A4	Homo sapiens (human)	Ki	0.5740	0.0001	1.4162	9.9000	AID599884
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Ki	0.0093	0.0001	0.5326	10.0000	AID1169862; AID1309129; AID1393366; AID1512153; AID1517957; AID1693542; AID1756799; AID1762056; AID1782426; AID1865874; AID1889690; AID298481; AID516806; AID595498; AID723184
5-hydroxytryptamine receptor 2C	Rattus norvegicus (Norway rat)	Ki	0.0471	0.0002	0.6677	10.0000	AID1309133; AID1704720
D(2) dopamine receptor	Homo sapiens (human)	IC50 (µMol)	0.0158	0.0000	0.7472	8.0000	AID1153309; AID1301281; AID1373831; AID727074
D(2) dopamine receptor	Homo sapiens (human)	Ki	0.0020	0.0000	0.6518	10.0000	AID1153295; AID1153296; AID1169860; AID1232327; AID1245089; AID1309134; AID1393368; AID1442556; AID1442559; AID1443613; AID1447993; AID1447994; AID1464176; AID1464177; AID1512154; AID1517960; AID1693539; AID1756796; AID1762054; AID1769331; AID1782419; AID1865877; AID1889688; AID1889749; AID277677; AID298478; AID458632; AID458633; AID516804; AID595495; AID610678; AID698938; AID723179; AID727075
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	Ki	0.0091	0.0001	0.6017	10.0000	AID1704718; AID410335; AID457689; AID492640
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0132	0.0001	0.9490	10.0000	AID1704719; AID298478; AID723177
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	0.0379	0.0003	0.4834	10.0000	AID1865880
D	Rattus norvegicus (Norway rat)	Ki	0.9804	0.0001	0.6100	10.0000	AID410331; AID492643
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	0.0198	0.0001	0.7396	10.0000	AID1704717
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0001	1.0104	9.9280	AID1403798
D(1A) dopamine receptor	Homo sapiens (human)	Ki	0.5890	0.0001	0.8363	10.0000	AID1153294; AID1442557; AID1447992; AID1464175; AID1782424
D(4) dopamine receptor	Homo sapiens (human)	Ki	0.1576	0.0000	0.4362	10.0000	AID1153298; AID1232329; AID1442555; AID1447996; AID1464179; AID1693541; AID1756798; AID1782429; AID277674; AID298480; AID610680
D(1B) dopamine receptor	Homo sapiens (human)	Ki	1.6000	0.0003	0.4017	7.9000	AID1447997; AID1464180
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0132	0.0000	0.5751	10.0000	AID1704719; AID298478; AID723177
Alpha-1D adrenergic receptor	Homo sapiens (human)	Ki	0.0570	0.0000	0.3609	10.0000	AID1682829
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	IC50 (µMol)	1.9450	0.0001	0.8801	8.8500	AID1301283; AID1373833
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	Ki	0.0140	0.0000	0.3855	10.0000	AID1153300; AID1169863; AID1242908; AID1245094; AID1309130; AID1393364; AID1442561; AID1447999; AID1464182; AID1517959; AID1693543; AID1756800; AID1762057; AID1782427; AID1865875; AID1889689; AID298482; AID516805; AID595497; AID616781; AID723183
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	IC50 (µMol)	1.3800	0.0001	1.0302	9.0000	AID1301294; AID1373837; AID1403795
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	0.0829	0.0001	0.9549	10.0000	AID1169864; AID1693544; AID1756801; AID1762058; AID1782428; AID298485; AID599883
D(4) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.5100	0.0002	0.1887	2.0000	AID1309136
Histamine H1 receptor	Cavia porcellus (domestic guinea pig)	Ki	0.0489	0.0026	1.7832	10.0000	AID1704721
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	0.6739	0.0000	0.7048	8.1930	AID1309138; AID1693546; AID1756803; AID298489; AID616780
5-hydroxytryptamine receptor 7	Rattus norvegicus (Norway rat)	Ki	0.0894	0.0000	0.1480	3.1800	AID1704722
5-hydroxytryptamine receptor 7	Homo sapiens (human)	Ki	0.0235	0.0003	0.3806	10.0000	AID1309131; AID1393367; AID1693545; AID1756802; AID1889691; AID298487; AID6677; AID723182
Alpha-1A adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.1700	0.0002	0.5614	5.4000	AID1301292; AID1373835; AID1403797
Alpha-1A adrenergic receptor	Homo sapiens (human)	Ki	0.0329	0.0000	0.2726	10.0000	AID1682829; AID1762060
Histamine H1 receptor	Homo sapiens (human)	IC50 (µMol)	0.4200	0.0000	0.4436	5.1768	AID1301293; AID1373836; AID1403796
Histamine H1 receptor	Homo sapiens (human)	Ki	0.0400	0.0000	0.5110	10.0000	AID1309137; AID1682828; AID1762061; AID1865879
Alpha-1B adrenergic receptor	Homo sapiens (human)	Ki	0.0570	0.0000	0.4713	10.0000	AID1682829
D(3) dopamine receptor	Homo sapiens (human)	Ki	0.0054	0.0000	0.6020	10.0000	AID1153297; AID1169861; AID1232328; AID1309135; AID1442560; AID1443614; AID1447995; AID1464178; AID1693540; AID1756797; AID1762055; AID1769332; AID1782425; AID1865878; AID277673; AID298479; AID410333; AID610679; AID722917
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	Ki	0.0024	0.0003	0.7693	10.0000	AID1309132; AID1865876; AID298483
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0132	0.0000	0.9650	10.0000	AID1704719; AID298478; AID723177
5-hydroxytryptamine receptor 3A	Homo sapiens (human)	Ki	0.5012	0.0000	0.7411	9.9000	AID298488
5-hydroxytryptamine receptor 6	Homo sapiens (human)	Ki	0.2648	0.0002	0.5229	10.0000	AID1393365; AID1704723; AID1762059; AID298486; AID599884; AID723181
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Rattus norvegicus (Norway rat)	Ki	0.0220	0.0010	0.0163	0.0330	AID599883
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.0046	0.0000	0.4375	10.0000	AID1704716; AID410332; AID492642
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	1.8572	0.0009	1.9014	10.0000	AID1301295; AID1403799; AID1704724; AID1762063; AID539465; AID576612
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	Ki	0.8793	0.0021	1.8407	10.0000	AID410338; AID492638; AID516803
5-hydroxytryptamine receptor 3D	Homo sapiens (human)	Ki	0.5012	0.0010	0.8835	9.9000	AID298488
Multidrug and toxin extrusion protein 2	Homo sapiens (human)	IC50 (µMol)	500.0000	0.1600	3.9571	8.6000	AID721752
5-hydroxytryptamine receptor 3C	Homo sapiens (human)	Ki	0.5012	0.0010	0.8835	9.9000	AID298488
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	130.0000	0.0100	2.7656	10.0000	AID721754
Histamine H3 receptor	Homo sapiens (human)	Ki	2.3610	0.0001	0.3399	8.5110	AID1762062
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
mu-type opioid receptor isoform MOR-1	Homo sapiens (human)	EC50 (µMol)	92.4690	0.1320	3.3004	9.5690	AID624499
5-hydroxytryptamine receptor 2A	Mus musculus (house mouse)	EC50 (µMol)	8.3930	0.0038	1.3621	8.3930	AID624503
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	EC50 (µMol)	0.1545	0.0001	0.2571	8.0000	AID1301282; AID1373832
D(2) dopamine receptor	Homo sapiens (human)	EC50 (µMol)	0.8222	0.0000	0.1874	3.9000	AID1153305; AID1245096; AID1245098; AID1442562; AID1442568; AID1442570; AID1442571; AID1442574; AID1442576; AID1442578; AID1443616; AID1443620; AID1443624; AID1443628; AID1448003; AID1448005; AID1448008; AID1573431; AID1573433; AID1782420; AID1782422; AID698935; AID698937
D(3) dopamine receptor	Homo sapiens (human)	EC50 (µMol)	0.0197	0.0001	0.0247	0.6690	AID1153307; AID1442564
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of gene expression	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
monoatomic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 2	Homo sapiens (human)
body fluid secretion	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 2	Homo sapiens (human)
amine transport	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 2	Homo sapiens (human)
choline transport	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 2	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 2	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
amino acid import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
export across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
temperature homeostasis	D(2) dopamine receptor	Homo sapiens (human)
response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein phosphorylation	D(2) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(2) dopamine receptor	Homo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressure	D(2) dopamine receptor	Homo sapiens (human)
regulation of heart rate	D(2) dopamine receptor	Homo sapiens (human)
regulation of sodium ion transport	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
autophagy	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
neuron-neuron synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
axonogenesis	D(2) dopamine receptor	Homo sapiens (human)
synapse assembly	D(2) dopamine receptor	Homo sapiens (human)
sensory perception of smell	D(2) dopamine receptor	Homo sapiens (human)
long-term memory	D(2) dopamine receptor	Homo sapiens (human)
grooming behavior	D(2) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(2) dopamine receptor	Homo sapiens (human)
protein localization	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell population proliferation	D(2) dopamine receptor	Homo sapiens (human)
associative learning	D(2) dopamine receptor	Homo sapiens (human)
visual learning	D(2) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to light stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to toxic substance	D(2) dopamine receptor	Homo sapiens (human)
response to iron ion	D(2) dopamine receptor	Homo sapiens (human)
response to inactivity	D(2) dopamine receptor	Homo sapiens (human)
Wnt signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
striatum development	D(2) dopamine receptor	Homo sapiens (human)
orbitofrontal cortex development	D(2) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(2) dopamine receptor	Homo sapiens (human)
adenohypophysis development	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell migration	D(2) dopamine receptor	Homo sapiens (human)
peristalsis	D(2) dopamine receptor	Homo sapiens (human)
auditory behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(2) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
response to histamine	D(2) dopamine receptor	Homo sapiens (human)
response to nicotine	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of urine volume	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of renal sodium excretion	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of multicellular organism growth	D(2) dopamine receptor	Homo sapiens (human)
response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleep	D(2) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(2) dopamine receptor	Homo sapiens (human)
drinking behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(2) dopamine receptor	Homo sapiens (human)
response to morphine	D(2) dopamine receptor	Homo sapiens (human)
pigmentation	D(2) dopamine receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of innate immune response	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of insulin secretion	D(2) dopamine receptor	Homo sapiens (human)
acid secretion	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to ethanol	D(2) dopamine receptor	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	D(2) dopamine receptor	Homo sapiens (human)
response to axon injury	D(2) dopamine receptor	Homo sapiens (human)
branching morphogenesis of a nerve	D(2) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(2) dopamine receptor	Homo sapiens (human)
epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(2) dopamine receptor	Homo sapiens (human)
release of sequestered calcium ion into cytosol	D(2) dopamine receptor	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of synapse structural plasticity	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(2) dopamine receptor	Homo sapiens (human)
excitatory postsynaptic potential	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of growth hormone secretion	D(2) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	D(2) dopamine receptor	Homo sapiens (human)
regulation of locomotion involved in locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cellular response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor production	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	D(2) dopamine receptor	Homo sapiens (human)
hyaloid vascular plexus regression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of neuron migration	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(2) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
regulation of smooth muscle contraction	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2C adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2C adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2C adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
calcium-mediated signaling	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synaptic transmission, cholinergic	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of insulin secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein modification process	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
temperature homeostasis	D(1A) dopamine receptor	Homo sapiens (human)
conditioned taste aversion	D(1A) dopamine receptor	Homo sapiens (human)
behavioral fear response	D(1A) dopamine receptor	Homo sapiens (human)
regulation of protein phosphorylation	D(1A) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(1A) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(1A) dopamine receptor	Homo sapiens (human)
protein import into nucleus	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	D(1A) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
activation of adenylate cyclase activity	D(1A) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
synapse assembly	D(1A) dopamine receptor	Homo sapiens (human)
memory	D(1A) dopamine receptor	Homo sapiens (human)
mating behavior	D(1A) dopamine receptor	Homo sapiens (human)
grooming behavior	D(1A) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(1A) dopamine receptor	Homo sapiens (human)
visual learning	D(1A) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(1A) dopamine receptor	Homo sapiens (human)
astrocyte development	D(1A) dopamine receptor	Homo sapiens (human)
dopamine transport	D(1A) dopamine receptor	Homo sapiens (human)
transmission of nerve impulse	D(1A) dopamine receptor	Homo sapiens (human)
neuronal action potential	D(1A) dopamine receptor	Homo sapiens (human)
dentate gyrus development	D(1A) dopamine receptor	Homo sapiens (human)
striatum development	D(1A) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of cell migration	D(1A) dopamine receptor	Homo sapiens (human)
peristalsis	D(1A) dopamine receptor	Homo sapiens (human)
operant conditioning	D(1A) dopamine receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	D(1A) dopamine receptor	Homo sapiens (human)
regulation of dopamine metabolic process	D(1A) dopamine receptor	Homo sapiens (human)
vasodilation	D(1A) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(1A) dopamine receptor	Homo sapiens (human)
maternal behavior	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of potassium ion transport	D(1A) dopamine receptor	Homo sapiens (human)
glucose import	D(1A) dopamine receptor	Homo sapiens (human)
habituation	D(1A) dopamine receptor	Homo sapiens (human)
sensitization	D(1A) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	D(1A) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	D(1A) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(1A) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
long-term synaptic potentiation	D(1A) dopamine receptor	Homo sapiens (human)
long-term synaptic depression	D(1A) dopamine receptor	Homo sapiens (human)
cellular response to catecholamine stimulus	D(1A) dopamine receptor	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
amine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
choline transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
efflux transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(2) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(2) dopamine receptor	Homo sapiens (human)
protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(2) dopamine receptor	Homo sapiens (human)
dopamine binding	D(2) dopamine receptor	Homo sapiens (human)
ionotropic glutamate receptor binding	D(2) dopamine receptor	Homo sapiens (human)
identical protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterocyclic compound binding	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(2) dopamine receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signaling receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gs	D(1A) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(1A) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity	D(1A) dopamine receptor	Homo sapiens (human)
protein binding	D(1A) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(1A) dopamine receptor	Homo sapiens (human)
dopamine binding	D(1A) dopamine receptor	Homo sapiens (human)
arrestin family protein binding	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(1A) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(4) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity	D(4) dopamine receptor	Homo sapiens (human)
protein binding	D(4) dopamine receptor	Homo sapiens (human)
potassium channel regulator activity	D(4) dopamine receptor	Homo sapiens (human)
SH3 domain binding	D(4) dopamine receptor	Homo sapiens (human)
dopamine binding	D(4) dopamine receptor	Homo sapiens (human)
identical protein binding	D(4) dopamine receptor	Homo sapiens (human)
metal ion binding	D(4) dopamine receptor	Homo sapiens (human)
epinephrine binding	D(4) dopamine receptor	Homo sapiens (human)
norepinephrine binding	D(4) dopamine receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	D(4) dopamine receptor	Homo sapiens (human)
neurotransmitter receptor activity	D(4) dopamine receptor	Homo sapiens (human)
serotonin binding	D(4) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gs	D(1B) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity	D(1B) dopamine receptor	Homo sapiens (human)
protein binding	D(1B) dopamine receptor	Homo sapiens (human)
dopamine binding	D(1B) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(1B) dopamine receptor	Homo sapiens (human)
protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
identical protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1D adrenergic receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
virus receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein tyrosine kinase activator activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein-containing complex binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
histamine receptor activity	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H1 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H1 receptor	Homo sapiens (human)
protein binding	Alpha-1B adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(3) dopamine receptor	Homo sapiens (human)
protein binding	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(3) dopamine receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G-protein alpha-subunit binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
GTPase activator activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
histamine receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 6	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
histamine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 2	Homo sapiens (human)
presynapse	Solute carrier family 22 member 2	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
cell surface	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
Golgi membrane	D(2) dopamine receptor	Homo sapiens (human)
acrosomal vesicle	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cilium	D(2) dopamine receptor	Homo sapiens (human)
lateral plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
endocytic vesicle	D(2) dopamine receptor	Homo sapiens (human)
axon	D(2) dopamine receptor	Homo sapiens (human)
dendrite	D(2) dopamine receptor	Homo sapiens (human)
synaptic vesicle membrane	D(2) dopamine receptor	Homo sapiens (human)
sperm flagellum	D(2) dopamine receptor	Homo sapiens (human)
dendritic spine	D(2) dopamine receptor	Homo sapiens (human)
perikaryon	D(2) dopamine receptor	Homo sapiens (human)
axon terminus	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(2) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(2) dopamine receptor	Homo sapiens (human)
dopaminergic synapse	D(2) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(2) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(2) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basal plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basolateral plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nucleus	D(1A) dopamine receptor	Homo sapiens (human)
endoplasmic reticulum membrane	D(1A) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1A) dopamine receptor	Homo sapiens (human)
cilium	D(1A) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(1A) dopamine receptor	Homo sapiens (human)
dendritic spine	D(1A) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(1A) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(1A) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(1A) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(1A) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(1A) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1A) dopamine receptor	Homo sapiens (human)
centrosome	D(4) dopamine receptor	Homo sapiens (human)
plasma membrane	D(4) dopamine receptor	Homo sapiens (human)
membrane	D(4) dopamine receptor	Homo sapiens (human)
postsynapse	D(4) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(4) dopamine receptor	Homo sapiens (human)
plasma membrane	D(4) dopamine receptor	Homo sapiens (human)
dendrite	D(4) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1B) dopamine receptor	Homo sapiens (human)
cilium	D(1B) dopamine receptor	Homo sapiens (human)
brush border membrane	D(1B) dopamine receptor	Homo sapiens (human)
synapse	D(1B) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(1B) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(1B) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1B) dopamine receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
neurofilament	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
caveola	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
axon	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cytoplasmic vesicle	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neuronal cell body	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendritic shaft	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cell body fiber	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glutamatergic synapse	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
trans-Golgi network membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 7	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 7	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1A adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
synapse	Histamine H1 receptor	Homo sapiens (human)
dendrite	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
nucleus	Alpha-1B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1B adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
synapse	D(3) dopamine receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
nucleoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cytoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
cleavage furrow	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
cilium	5-hydroxytryptamine receptor 6	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 6	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 6	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
presynapse	Histamine H3 receptor	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
synapse	Histamine H3 receptor	Homo sapiens (human)
dendrite	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1704723	Displacement of [3H]lysergic acid diethylamide from human recombinant 5HT6 receptor stably expressed in CHO cell membranes measured after 30 mins by liquid scintillation counting method
AID458652	Reduction in amphetamine-induced locomotor activity in Sprague-Dawley rat striatum at 7.68 umol/kg, sc relative to control	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID1220560	Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1442607	Antagonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of quinpirole-induced EA-tagged beta-arrestin-2 recruitment at 10 uM incubated for 5 hrs measured after 60 mins by PathHunter assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1458650	Antagonist activity at human recombinant D2S receptor expressed in HEK-293 cells assessed as inhibition of dopamine-induced response at 1 x 10'-6 M by cellular dielectric spectroscopy	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1865875	Displacement of [3H]-ketanserin from human 5-HT2A receptor incubated for 1 hr by liquid scintillation counting method
AID610678	Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
AID457688	Displacement of [3H]-8-OH-DPAT from 5HT1A receptor in Wistar rat hippocampus homogenate	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
AID1152660	Antipsychotic-like activity in po dosed Wistar rat assessed as inhibition of DOI-induced head twitches measured after 60 mins	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
AID1442604	Effect on basal anxiety level in Sprague-Dawley rat at 1.5 mg//day for 7 days administered via osmotic Alzet mini pump measured 20 mins post dose by open field test	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1889691	Displacement of [3H]-5-CT from human 5-HT7b receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Novel D
AID1153300	Displacement of [3H]-ketanserin from human 5HT2A receptor expressed in HEK293 cells by competitive binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID516816	Antipsychotic activity in po dosed mouse assessed as inhibition of spontaneous locomotor activity	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID1693542	Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor by liquid scintillation counting	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	A study of the structure-affinity relationship in SYA16263; is a D
AID595495	Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
AID595494	Intrinsic activity at human dopamine D2 receptor expressed in CHO cells by [3H]-thymidine uptake assay relative to quinpirole	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
AID1309137	Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
AID1782424	Displacement of [3H]-SCH23390 from D1 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID6677	Binding affinity towards human 5-hydroxytryptamine 7 receptor	2003	Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID492646	Antipsychotic activity in NMRI mouse assessed as increase of PCP-induced locomotor activity at 3 mg/kg, ip administered 30 mins prior to testing measured for 60 mins	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
AID1703846	Antipsychotic activity in ICR mouse assessed as reduction of PCP induced hyperactivity at 3 mg/kg, ig pretreated with compound for 30 mins followed by PCP challenge for 10 mins and measured after 60 mins	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Automated design and optimization of multitarget schizophrenia drug candidates by deep learning.
AID330561	Displacement of [3H]mepyramine from H1R in rat brain	2007	Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9	From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
AID1782419	Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID1283242	Decrease in lanosterol levels in mouse Neuro2a cells by LC-MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID595520	Ratio of MED for catalepsy induction to in mouse to MED for inhibition of spontaneous locomotor activity in mouse	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
AID457689	Displacement of [3H]ketanserin from 5HT2A receptor in Wistar rat cortex homogenate	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
AID1517959	Displacement of [3H]-Ketanserin from human 5-HT2A receptor expressed in rat cortex tissue incubated for 30 mins by liquid scintillation counting method
AID113543	Induction of catalepsy in mice	1998	Journal of medicinal chemistry, Feb-26, Volume: 41, Issue:5	Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
AID1762063	Inhibition of human ERG by automated patch method relative to control	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1782438	Metabolic stability in mouse liver microsomes assessed as half life preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS analysis	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID458647	Reduction in spontaneous locomotor activity in Sprague-Dawley rat striatum at 7.68 umol/kg, sc relative to control	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID1704749	Antipsychotic activity in Kunming mouse assessed as inhibition of DOI-induced head twitch administered orally 60 mins prior to DOI challenge incubated for 5 mins and measured for 15 mins
AID516826	Ex vivo D2 receptor occupancy in po dosed rat striatum assessed as inhibition [3H]-raclopride binding at 158 ng/ml plasma concentration	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID1474756	Agonist activity at D2 long receptor (unknown origin) expressed in Flp-In-CHO cells co-expressing Rluc8-tagged GalphaoB assessed as change in transduction coefficient by measuring GalphaoB activation in presence of coelenterazine by BRET assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
AID1374517	Intrinsic clearance in mouse liver microsomes at 50 uM preincubated for 5 mins followed by NADPH addition measured up to 30 mins	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID1762054	Binding affinity to dopamine D2 receptor (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID234393	ratio between ED50 values of DA receptor antagonist activity and catalepsy.	1998	Journal of medicinal chemistry, Feb-26, Volume: 41, Issue:5	Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
AID1157846	Intrinsic activity at human D2L receptor expressed in FlpIn CHO cells assessed as inhibition of forskolin-stimulated cAMP production treated for 30 mins by AlphaScreen assay relative to control	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
AID1690414	Induction of memory deficit in CD-1 mouse assessed as effect on latency to enter dark compartment at 0.3125 to 2.5 mg/kg, ip administered 30 mins prior to acquisition trial by step-through passive avoidance test	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD).
AID1448009	Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay relative to quinpirole	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID113715	Inhibition of the GBL-induced increase in DOPA accumulation in mice(DA auto receptor agonist activity)	1998	Journal of medicinal chemistry, Feb-26, Volume: 41, Issue:5	Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
AID1301283	Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID1153295	Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1442585	Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1210213	Total drug level in mdr1a-deficient mouse brain at 3 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1373833	Antagonistic activity at human 5-HT2A receptor assessed as calcium flux after 10 mins by FLIPR assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.
AID458630	Reduction in 3,4-dihydroxyphenylacetic acid level in Sprague-Dawley rat striatum at 7.68 umol/kg, sc relative to saline treated control	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID599883	Displacement of [3H]mesulergine from human 5HT2C receptor in human tsA201 cells	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.
AID298486	Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID610683	Displacement of [3H](+)-pentazocine from guinea pig brain sigma-1 receptor after 90 mins by liquid scintillation counter	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
AID539464	Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1301296	Partial agonist activity at human dopamine D2 receptor assessed as intrinsic activity	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID1283241	Decrease in desmosterol levels in mouse Neuro2a cells by LC-MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1464181	Displacement of [3H]WAY100635 from 5-HT1AR in porcine cerebral cortex homogenates	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID301041	Antipsychotic activity in orally dosed Wistar rat assessed as inhibition of conditioned avoidance response after 1 hr	2007	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19	Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.
AID1442554	Displacement of [3H]prazosin from adrenergic alpha 1 receptor in porcine cerebral cortex after 2 hrs by scintillation counting analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID516805	Binding affinity to human 5HT2A receptor	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1403798	Antagonist activity at M3 receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assay
AID1153308	Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay relative to quinpirole	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1442558	Displacement of [3H]WAY100635 from 5-HT1A receptor in porcine cerebral cortex after 2 hrs by scintillation counting analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1443625	Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay relative to quinpirole
AID1403805	Inhibition of quipazine-induced head twitches in ICR mouse assessed as reduction in number of stereotyped head twitch movements at 3 mg/kg, ig administered 30 mins prior to quipazine challenge measured for 15 mins at 30 mins post quipazine challenge relat
AID1782423	Partial agonist activity at D2 receptor (unknown origin) expressed in HEK293T cells co-expressing GFP2-beta-arrestin2 assessed as beta-arrestin2 recruitment preincubated for 2 mins with coelenterazine followed by compound addition and measured after 2 min	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID1762086	Therapeutic index, ratio of ED50 for induction of catalepsy in po dosed mouse to ED50 for antipsychotic activity in po dosed mouse assessed as suppression of apomorphine-induced climbing	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1808020	Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1210178	Percentage unbound in Crl:NMRI(Han) mouse brain at 1 uM after 5 hrs by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID516818	Apparent intrinsic clearance in human liver microsomes	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID1442577	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1169862	Binding affinity to 5HT1A receptor (unknown origin)	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
AID1210177	Unbound brain to plasma partition coefficient of the compound in mdr1a-deficient rat at 6 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1157848	Ratio of intrinsic efficacy to KA for human D2L receptor expressed in FlpIn CHO cells assessed as inhibition of forskolin-stimulated cAMP production treated for 30 mins by AlphaScreen assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
AID516804	Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID492643	Displacement of [3H]SCH23390 from dopamine D1 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
AID1443613	Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis
AID1245099	Activity at dopamine D2S receptor (unknown origin) expressed in HEK293 cell membranes co-expressing Galpha protein subunit Galphai2 by [35S]GTPgammaS binding assay relative to quinpirole	2015	Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18	1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation.
AID1448005	Agonist activity at human D2S receptor expressed in HEK293T cell membranes coexpressing Galphao1 assessed as induction of nucleotide exchange preincubated for 30 mins followed by addition of [35S]GTPgammaS measured after 30 mins by [35S]GTPgammaS binding	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1233026	Antianxiety-like activity in Swiss albino mouse assessed as number of punished crossings at 0.06 to 0.5 mg/kg, ip by four-plate test	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
AID492638	Binding affinity to human ERG expressed in HEK293 cells	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
AID1703855	Toxicity in ICR mouse assessed as induction of sedation by measuring spontaneous locomotor activity at 3 mg/kg, po measured for 30 mins following drug administration	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Automated design and optimization of multitarget schizophrenia drug candidates by deep learning.
AID1373832	Agonistic activity at human 5-HT1A receptor measured after 60 mins by Ultra Lance cAMP assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.
AID1762061	Binding affinity to histamine H1 receptor (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1782428	Displacement of [3H]-LSD from 5HT2C receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID1210167	Unbound brain to plasma partition coefficient of the compound in mdr1a-deficient mouse at 3 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1458675	Inhibition of SERT expressed in rat brain synaptosomes assessed as decrease in incorporation of [3H]serotonin measured after 15 mins by scintillation counting method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID723182	Displacement of [3H]-5-CT from human 5HT7 receptor expressed in HEK293 after 1 hr	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID1210232	Total drug level in wild type Sprague-Dawley rat brain expressing Abcb1a at 6 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1393365	Displacement of [3H]-LSD from human 5-HT6R expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method
AID1865877	Displacement of [3H]-N-methylspiperone from human D2 receptor incubated for 1 hr by liquid scintillation counting method
AID1442556	Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1573432	Inverse agonist activity at dopamine D2 receptor (unknown origin) assessed as inhibition of forskolin-mediated cAMP accumulation after 20 mins by radiometric assay relative to control	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1447997	Displacement of [3H]SCH23390 from human D5R expressed in HEK293T cell membranes by radioligand binding assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1442584	Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1693545	Displacement of [3H]-LSD from human 5HT7 receptor by liquid scintillation counting	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	A study of the structure-affinity relationship in SYA16263; is a D
AID1301292	Antagonistic activity at alpha-1A adrenergic receptor (unknown origin) after 10 mins by FLIPR assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID1693543	Displacement of [3H]-ketanserin from human 5HT2A receptor by liquid scintillation counting	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	A study of the structure-affinity relationship in SYA16263; is a D
AID1659271	Antipsychotic activity in ICR mouse assessed as inhibition of quipazine-induced head-twitch response at 0.3 mg/kg, po administered with compound after quipazine administration measured for 15 mins	2020	Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8	Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
AID705598	Oral bioavailability in human	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1071695	Induction of catalepsy in albino mouse at 15 mg/kg, ip relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Design, synthesis, pharmacological evaluation and computational studies of 1-(biphenyl-4-yl)-2-[4-(substituted phenyl)-piperazin-1-yl]ethanones as potential antipsychotics.
AID298479	Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID516825	Ex vivo D2 receptor occupancy in po dosed rat striatum assessed as inhibition [3H]-raclopride binding at 21 ng/ml plasma concentration	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID1462322	Antipsychotic activity in PCP-induced hyperactivity ICR mouse model assessed as inhibition of hyper-locomotion administered ig incubated for 10 mins followed by PCP challenge measured after 10 mins for 75 mins	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
AID1659264	Antagonist activity at SERT receptor (unknown origin) at 400 nM by fluorescence based assay relative to control	2020	Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8	Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
AID1782421	Partial agonist activity at D2 receptor (unknown origin) expressed in HEK293T cells co-expressing Rluc8-tagged Galpahi1 assessed as Galphai1 dissociation preincubated for 2 mins with coelenterazine followed by compound addition and measured after 2 mins b	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID1153307	Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1157847	Agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
AID1309130	Displacement of [3H]Ketanserin from human 5-HT2A receptor expressed in cell membranes after 1 hr by liquid scintillation counting	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
AID722918	Toxicity in CD1 mouse assessed as induction of sedation at 1 mg/kg, ip	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID1782429	Displacement of [3H]-SCH23390 from D4 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1233027	Toxicity in ip dosed CD-1 mouse assessed as minimum dose required for induction of catalepsy by bar test	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
AID1762066	Induction of catalepsy in po dosed mouse by Horizontal grid and elevated bar test	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID705591	Lipophilicity, log D of the compound	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1448000	Displacement of [3H]prazosin from alpha1-adrenergic receptor in porcine cerebral cortex by radioligand binding assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1301291	Therapeutic index, ratio of ED50 for toxicity in orally dosed mouse by catalepsy test to ED50 for antipsychotic activity in mouse	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474758	Agonist activity at D2 long receptor (unknown origin) expressed in Flp-In-CHO cells assessed as change in transduction coefficient by measuring induction of ERK1/2 phosphorylation after 5 mins by Alphascreen assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1573431	Inverse agonist activity at dopamine D2 receptor (unknown origin) assessed as inhibition of forskolin-mediated cAMP accumulation after 20 mins by radiometric assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID723168	Antipsychotic activity in ip dosed Swiss albino mouse assessed as inhibition of (+/-)DOI-induced head twitch response after 20 mins	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID492634	Antipsychotic activity in ip dosed NMRI mouse assessed as reduction in spontaneous exploratory locomotor activity administered 30 mins prior to testing measured for 60 mins	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
AID1283240	Increase in 7-DHC levels in mouse Neuro2a cells at 100 nM by LC-MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1220556	Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1739156	Plasma protein binding in human	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Privileged scaffold-based design to identify a novel drug-like 5-HT
AID410532	Antipsychotic activity in NMRI mouse assessed as reduction in phencyclidine-induced locomotor activity administered 30 mins prior to testing measured for 60 mins	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
AID610679	Displacement of [125I]ABN from human recombinant D3 receptor expressed in HEK cells after 60 mins by gamma counter	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
AID1442592	Agonist activity at Dopamine D2L receptor (unknown origin) expressed in HEK293T cells coexpressing GFP-fused GIRK1/2 channels assessed as induction of inwardly rectifying K+ current at -70 mV holding potential at 1 uM measured up to 1.1 secs in presence o	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1704724	Inhibition of human ERG expressed in HEK293 cells by whole-cell patch clamp method
AID698934	Agonist activity at D2L receptor in human HTLA cells assessed as beta arrestin recruitment at 6 uM after 18 hrs by luminescence assay relative to Quinpirole	2012	Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16	Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
AID1220559	Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID516806	Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor expressed in HeLa cells	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID721752	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID727075	Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	Synthesis and SAR of aminothiazole fused benzazepines as selective dopamine D2 partial agonists.
AID1443624	Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay
AID539465	Inhibition of human ERG	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1782425	Displacement of [3H]-SCH23390 from D3 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID1458651	Agonist activity at human recombinant D2S receptor expressed in HEK-293 cells at 1 x 10'-6 M by cellular dielectric spectroscopy	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1782427	Displacement of [3H]-LSD from 5HT2A receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID1458670	Toxicity in CD-1 mouse assessed as effect on spontaneous locomotory activity by measuring number of areas crossed administered for 30 mins measured every 1 min for first 5 mins	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID610682	Selectivity ratio of Ki for human recombinant D4 receptor to Ki for human recombinant D2L receptor	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
AID410333	Displacement of [3H]7OH-DPAT from dopamine D3 receptor expressed in Sf9 cells by scintillation spectrometry	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
AID1782426	Displacement of [3H]-LSD from 5HT1A receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID1823849	Antipsychotic activity in ip dosed Wistar rat assessed as induction of MK801-induced hyperlocomotor activity by measuring minimum effective dose measured for 15 mins
AID1443614	Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D3 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis
AID1373831	Antagonistic activity at human dopamine D2 receptor measured after 60 mins by Lance Ultra cAMP assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.
AID1865876	Displacement of [3H]-LSD from human 5-HT2B receptor incubated for 1 hr by liquid scintillation counting method
AID1393366	Displacement of [3H]-8-OH-DPAT from human 5-HT1AR expressed in HEK293 cell membranes after 1 hr by microbeta counting method
AID1756801	Displacement of [3H]-Mesulergine from human 5-HT2C receptor incubated for 1 hr by liquid scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
AID1704753	Therapeutic index, ratio of ED50 for toxicity in po dosed Kunming mouse assessed as catalepsy to ED50 for antipsychotic activity in Kunming mouse assessed as inhibition of DOI-induced head twitch
AID1157845	Agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as inhibition of forskolin-stimulated cAMP production treated for 30 mins by AlphaScreen assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
AID1283243	Increase in 7-DHC levels in Dhcr7-deficient mouse Neuro2a cells at 200 nM after 24 hrs by by LC-MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1442576	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1157851	Biased agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as inhibition of forskolin-stimulated cAMP production treated for 30 mins by AlphaScreen assay relative to dopamine	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
AID1169869	Antipsychotic-like activity in sc dosed NMRI mouse assessed as reduction in methamphetamine-induced locomotor activity dosed 15 to 30 mins before administration of methamphetamine measured for 60 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
AID1808021	Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1762072	Toxicity in mouse assessed as effect on serum prolactin level at 0.05 to 1.35 mg/kg administered for 28 days	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID516803	Displacement of [3H]dofetilide from human ERG	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID1769331	Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method
AID1704751	Therapeutic index, ratio of ED50 for toxicity in po dosed Kunming mouse assessed as catalepsy to ED50 for antipsychotic activity in Kunming mouse assessed as inhibition of apomorphine-induced climbing behavior
AID1153299	Displacement of [3H]WAY-100635 from 5-HT1A receptor in pig cerebral cortex homogenates by competitive binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID457691	Selectivity index, ratio of Ki for Wistar rat striatum D2-like receptor to Ki for Wistar rat cortex 5HT2A receptor	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
AID1464179	Displacement of [3H]spiperone from human D4R expressed in CHO cell membranes	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID1373836	Antagonistic activity at histamine 1 receptor (unknown origin) after 10 mins by FLIPR assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.
AID1210248	Total brain to plasma partition coefficient of the compound in mdr1a-deficient rat at 6 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1196356	Effect on water consumption in intraperitoneally dosed Wistar rat by free drinking test	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID458634	Selectivity ratio of Ki for human dopamine D2 receptor at low affinity state to Ki for human dopamine D2 receptor at high affinity state	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID610681	Selectivity ratio of Ki for human recombinant D3 receptor to Ki for human recombinant D2L receptor	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
AID727076	Intrinsic agonist activity at human D2 dopamine receptor expressed in CHO cell membrane using cellular CD spectroscopy by Cell-Key assay	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	Synthesis and SAR of aminothiazole fused benzazepines as selective dopamine D2 partial agonists.
AID723184	Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor expressed in HEK293 after 1 hr	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID298489	Displacement of [3H]paraxetine from human 5HT transporter expressed in HEK293 cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID698935	Agonist activity at D2L receptor in human HTLA cells assessed as beta arrestin recruitment at 6 uM after 18 hrs by luminescence assay	2012	Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16	Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
AID1682828	Binding affinity to H1 histamine receptor (unknown origin)
AID1301294	Antagonistic activity at 5-HT2c receptor (unknown origin) after 10 mins by FLIPR assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID1889699	Cytotoxicity against HEK293 cells measured after 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Novel D
AID1458672	Cognitive enhancement activity in iv dosed CD-1 mouse assessed as increase in step-through latency time treated for 30 mins before training measured 24 hrs after training trial by passive avoidance test	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID410339	Sedative activity in NMRI mouse assessed as reduction in spontaneous locomotor activity administered 30 mins prior to testing	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
AID1442564	Agonist activity at human Dopamine D3 receptor expressed in HEK293T cell membranes coexpressing GalphaoA incubated for 30 mins measured after 75 mins by [35S]GTPgammaS binding assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1453901	Antipsychotic activity in CD-1 mouse assessed as inhibition of dizocilpine-induced hyperlocomotor activity at 0.5 mg/kg, ip pretreated with dizocilpine for 15 mins followed by compound administration for 60 mins
AID1762070	Cognitive enhancement effect in rat assessed as increase in novelty discrimination index at 0.3 mg/kg, po administered 1 hr prior to acquisition trial by novel object recognition test	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1403796	Antagonist activity at histamine H1 receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assay
AID492641	Displacement of [3H]8OH-DPAT from 5HT1A receptor in rat CRL:CD(SD)BR-COBS hippocampus by scintillation spectrometry	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
AID1782422	Partial agonist activity at D2 receptor (unknown origin) expressed in HEK293T cells co-expressing GFP2-beta-arrestin2 assessed as beta-arrestin2 recruitment preincubated for 2 mins with coelenterazine followed by compound addition and measured after 2 min	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
AID1393368	Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method
AID1210196	Total brain to plasma partition coefficient of the compound in wild type Crl:CF1 mouse expressing Abcb1a mutant at 3 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1442575	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID298490	Displacement of [3H]pirenzepine from human M1 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1762087	Therapeutic index, ratio of ED50 for induction of catalepsy in po dosed mouse to ED50 for antipsychotic activity in po dosed mouse assessed as reduction in MK-801-induced hyperlocomotor activity	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1442608	Antagonist activity at ARMS2-PK2 tagged D2L receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of quinpirole-induced EA-tagged beta-arrestin-2 recruitment at 10 uM incubated for 5 hrs measured after 60 mins by PathHunter assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID598252	Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 at 0.1 mM after 20 mins by FACS analysis relative to 5 mM sodium orthovanadate	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
AID595503	Induction of catalepsy in mouse	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
AID1301282	Agonistic activity at human 5-HT1A receptor measured after 60 mins by Ultra Lance cAMP assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID721751	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1153301	Displacement of [3Hprazosin from adrenergic alpha1 receptor in pig cerebral cortex homogenates by competitive binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID610684	Displacement of [3H]DTG from rat liver sigma-2 receptor in presence of (+)-pentazocine after 120 mins by liquid scintillation counter	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
AID1443616	Agonist activity at human dopamine D2 receptor expressed in HEK293 cells assessed as cAMP inhibition by BRET assay
AID516817	Selectivity ratio of Ki for human dopamine D2L receptor to Ki for human 5HT2A receptor	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID298491	Displacement of [3H]4-DAMP from human M4 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1442603	Antipsychotic activity in Sprague-Dawley rat assessed as inhibition of AMPH-induced rearing at 1.5 mg/kg/day administered via osmotic Alzet mini pump for 7 days post 6 days challenge with AMPH by open field test	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID298492	Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1233023	Anti-depressant like activity in Swiss albino mouse assessed as shortening of immobility time at 0.01 to 0.1 mg/kg, ip by forced swim test	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
AID410334	Displacement of [3H]8OH-DPAT from 5HT1A receptor in CRL:CD(SD)BR-COBS rat hippocampus by scintillation spectrometry	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
AID595504	In vivo antagonist activity at 5-HT2A receptor in rat assessed as inhibition of 2,5-dimethoxy-4-iodoamphetamine-induced head twitch at 3 x sLMA MED	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
AID113713	Inhibition of the APO-induced stereotyped behavior in mice	1998	Journal of medicinal chemistry, Feb-26, Volume: 41, Issue:5	Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
AID1153296	Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1474769	Agonist activity at D2 long receptor (unknown origin) expressed in Flp-In-CHO cells assessed as ratio of cellular impedance to GalphaoB activation at 90 mins post dose	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
AID1373839	Antipsychotic-like activity in ICR mouse assessed as inhibition of PCP-induced hyperlocomotion at 3 mg/kg, ig followed by animal habituation for 10 mins before 60 mins measurement period	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.
AID723169	Antipsychotic activity in ip dosed Swiss albino mouse assessed as inhibition of apomorphine-induced climbing behavior administered 10 mins before apomorphine-challenge measured after 2 mins	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID1756799	Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor incubated for 1 hr by liquid scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
AID457690	Selectivity index, ratio of Ki for Wistar rat striatum D2-like receptor to Ki for Wistar rat hippocampus 5HT1A receptor	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1865879	Displacement of [3H]-pyrilamine from human histamine H1 receptor incubated for 1 hr by liquid scintillation counting method
AID1442560	Displacement of [3H]spiperone from human Dopamine D3 receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1153305	Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphai2 after 30 mins by [35S]GTPgammaS binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1196350	Anti-depressant-like activity in intraperitoneally dosed >18-months old Wistar rat by Porsolt's forced swim test	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID1447999	Displacement of [3H]ketanserin from human 5-HT2AR expressed in HEK293T cell membranes by radioligand binding assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1464176	Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID1474754	Displacement of [3H]spiperone from D2 long receptor (unknown origin) expressed in Flp-In-CHO cell membranes assessed as transduction coefficient by measuring dissociation half life after 5 mins by liquid scintillation counter method	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
AID1442593	Agonist activity at Dopamine D2L receptor (unknown origin) expressed in HEK293T cells coexpressing GFP-fused GIRK1/2 channels assessed as induction of inwardly rectifying K+ current at -70 mV holding potential at 0.1 uM measured up to 1.1 secs by patch cl	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1373835	Antagonistic activity at alpha-1A adrenergic receptor (unknown origin) after 10 mins by FLIPR assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID723177	Displacement of [3H]-Prazosin from adrenergic alpha1 receptor in rat cortex after 30 mins by scintillation counting	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID1823851	Sedative activity in ip dosed Wistar rat assessed as effect on spontaneous locomotor activity measured for 10 mins by social interaction test
AID1153298	Displacement of [3H]Spiperone from human dopamine D4.4 receptor expressed in CHO cells by competitive binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1762059	Binding affinity to 5-HT6 receptor (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1210247	Total drug level in mdr1a-deficient rat brain at 6 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1676001	Intrinsic clearance in rat liver microsomes at 50 uM measured up to 45 mins by HPLC analysis
AID1374530	Drug metabolism in mouse liver microsomes assessed as hydroxylated main metabolite formation at 50 uM preincubated for 5 mins followed by NADPH addition measured after 30 mins by UPLC-MS analysis	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID1374518	Intrinsic clearance in rat liver microsomes at 50 uM preincubated for 5 mins followed by NADPH addition measured up to 30 mins	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID1889689	Displacement of [3H]-ketanserin from human 5-HT2A receptor expressed in CHO-K1 cells measured after 1.5 hrs by Microbeta plate reader method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Novel D
AID298487	Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1704747	Antipsychotic activity in Kunming mouse assessed as inhibition of apomorphine-induced climbing behavior administered orally 30 mins prior to apomorphine challenge and measured for 10 to 30 mins
AID1458667	Anxiolytic-like activity in Swiss albino mouse assessed as suppression of movement administered for 30 mins by four-plate test	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1411902	Oral bioavailability in human	2018	MedChemComm, May-01, Volume: 9, Issue:5	Schizophrenia: synthetic strategies and recent advances in drug design.
AID410335	Displacement of [3H]ketanserin from 5HT2A receptor in CRL:CD(SD)BR-COBS rat cortex by scintillation spectrometry	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
AID1403797	Antagonist activity at adrenergic alpha1A receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assay
AID330537	Increase in phospho-AMPK levels in H1RKO mouse hyphalamic slices at 500 nM after 30 mins by Western blotting	2007	Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9	From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
AID1447998	Displacement of [3H]WAY100635 from 5-HT1AR in porcine cerebral cortex by radioligand binding assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1309136	Displacement of [3H]N-methylspiperone from rat D4 receptor expressed in cell membranes after 1 hr by liquid scintillation counting	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
AID1443617	Agonist activity at human dopamine D2 receptor expressed in HEK293 cells assessed as cAMP inhibition by BRET assay relative to quinpirole
AID113720	Inhibition of the lethal effects of noradrenaline in mice (alpha-1 induced adrenoceptor antagonist activity)	1998	Journal of medicinal chemistry, Feb-26, Volume: 41, Issue:5	Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1704720	Displacement of [3H]mesulergine from rat cerebral cortex 5HT2C receptor measured after 15 mins by liquid scintillation counting method
AID1442605	Antipsychotic activity in Sprague-Dawley rat assessed as reversal of AMPH-induced anxiety level at 1.5 mg/kg/day administered via osmotic Alzet mini pump for 7 days post 6 days challenge with AMPH measured 20 mins after compound treatment by open field te	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1756797	Displacement of [3H]N-methylspiperone from human dopamine D3 receptor incubated for 1 hr by liquid scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
AID277677	Binding affinity to dopamine D2	2007	Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3	Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
AID1232329	Displacement of [3H]N-methylspiperone from human dopamine D4 receptor expressed in HEK293 cells	2015	Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14	Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
AID1573434	Inverse agonist activity at dopamine D2 receptor (unknown origin) assessed as increase in beta-arrestin-2 recruitment relative to control	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1447994	Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID298482	Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1762057	Binding affinity to 5-HT2A receptor (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1442568	Agonist activity at human Dopamine D2S receptor expressed in HEK293T cell membranes coexpressing Galphai2 incubated for 30 mins measured after 75 mins by [35S]GTPgammaS binding assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1169863	Binding affinity to 5HT2A receptor (unknown origin)	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
AID705599	Clearance in human	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID595501	Antipsychotic activity in po dosed mouse assessed as inhibition of spontaneous locomotor activity	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
AID1889742	Antipsychotic activity in male Wistar rat assessed as effect on non-anogenital social contact at 1 mg/kg, ip	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Novel D
AID1245100	Activity at pro-link-tagged D2S-ARMS2PK2 (unknown origin) expressed in HEK293 cells by beta-arrestin-2 recruitment assay	2015	Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18	1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation.
AID1309138	Displacement of [3H]Citalopram from human SERT expressed in cell membranes after 1 hr by liquid scintillation counting	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
AID1318827	Half life in ip dosed mouse	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Structural modifications of the serotonin 5-HT7 receptor agonist N-(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve in vitro microsomal stability: A case study.
AID1762069	Cognitive enhancement effect in rat assessed as increase in time spent in exploring novel object at 0.3 mg/kg, po administered 1 hr prior to acquisition trial by novel object recognition test	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID298480	Displacement of [3H]spiperone from human dopamine D4.4 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1301290	Toxicity in ig dosed mouse assessed as induction of catalepsy by horizontal bar method	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID1865880	Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1458659	Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time administered for 30 mins measured last 4 mins of 6 mins test by forced swimming test	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1704719	Displacement of [3H]prazosin from rat cerebral cortex alpha1 adrenergic receptor measured after 60 mins by liquid scintillation counting method
AID1210194	Total plasma concentration in wild type Crl:CF1 mouse expressing Abcb1a mutant at 3 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1373837	Antagonistic activity at 5-HT2c receptor (unknown origin) after 10 mins by FLIPR assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.
AID1442582	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1756800	Displacement of [3H]-Ketanserin from human 5-HT2A receptor incubated for 1 hr by liquid scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
AID298493	Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID298483	Displacement of [3H]LSD from 5HT2B receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1462325	Therapeutic index, ratio of ED50 for induction of catalepsy in ig dosed ICR mouse to ED50 for inhibition of PCP-induced hyper-locomotion in ig dosed ICR mouse	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
AID1447993	Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1153310	Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay relative to qunipirole	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1442559	Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1071697	Antipsychotic activity in albino mouse assessed as inhibition of apomorphine-induced climbing behaviour at 15 mg/kg, ip measured after 10 mins at 5 mins interval for 30 mins relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Design, synthesis, pharmacological evaluation and computational studies of 1-(biphenyl-4-yl)-2-[4-(substituted phenyl)-piperazin-1-yl]ethanones as potential antipsychotics.
AID1374521	Drug metabolism in human liver microsomes assessed as OPC-14857 formation at 50 uM preincubated for 5 mins followed by NADPH addition measured after 30 mins by UPLC-MS analysis	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID410535	Toxicity in sc dosed NMRI mouse assessed as cataleptogenic potential administered 30 mins prior to testing measured every 15 mins for 60 mins by horizontal bar test	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
AID1301289	Antipsychotic activity in ig dosed mouse assessed as inhibition of PCP-induced hyperactivity	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID1309129	Displacement of [3H]8-OH-DPAT from human 5-HT1A receptor expressed in cell membranes after 1 hr by liquid scintillation counting	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
AID1411907	Tmax in human at 9.75 mg, im administered as single dose	2018	MedChemComm, May-01, Volume: 9, Issue:5	Schizophrenia: synthetic strategies and recent advances in drug design.
AID1393364	Displacement of [3H]-ketanserin from human 5-HT2AR expressed in CHO-K1 cell membranes after 1.5 hrs by microbeta counting method
AID1442579	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1458660	Agonist activity at human recombinant 5-HT6 receptor expressed in CHO cells at 1 x 10'-6 M after 45 mins by HTRF method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1573433	Inverse agonist activity at dopamine D2 receptor (unknown origin) assessed as increase in beta-arrestin-2 recruitment	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID113717	Inhibition of the GBL-induced increase in DOPA synthesis in mice.	1998	Journal of medicinal chemistry, Feb-26, Volume: 41, Issue:5	Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
AID1309133	Displacement of [3H]Mesulergine from rat 5-HT2C receptor expressed in cell membranes after 1 hr by liquid scintillation counting	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
AID1210231	Total plasma concentration in wild type Sprague-Dawley rat expressing Abcb1a at 6 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1458673	Toxicity in ip dosed CD-1 mouse assessed as induction of catalepsy administered for 30 mins measured after 30 to 120 mins by bar test	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID114205	post-synaptic DA receptor antagonist activity was evaluated by inhibition of the apomorphine-induced stereotyped behavior in mice. inactive at single given dose	1998	Journal of medicinal chemistry, Feb-26, Volume: 41, Issue:5	Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
AID1196349	Anti-depressant-like activity in intraperitoneally dosed 3-months old Wistar rat by Porsolt's forced swim test	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID1157849	Intrinsic activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
AID1196355	Effect on pain threshold in intraperitoneally dosed Wistar rat by hot plate test	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID705600	Half life in human	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1512154	Displacement of [3H]methylspiperone from human D2 receptor by radio ligand binding assay	2019	Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21	Design, synthesis and biological evaluation of novel serotonin and dopamine receptor ligands being 6-bromohexyl saccharine derivatives.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1442562	Agonist activity at human Dopamine D2S receptor expressed in HEK293T cell membranes coexpressing GalphaoA incubated for 30 mins measured after 75 mins by [35S]GTPgammaS binding assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1889739	Antipsychotic activity in male Wistar rat assessed as restoration of prepulse inhibition of acoustic startle response at 1 mg/kg, ip	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Novel D
AID1704752	Therapeutic index, ratio of ED50 for toxicity in po dosed Kunming mouse assessed as catalepsy to ED50 for antipsychotic activity in Kunming mouse assessed as inhibition of MK801-induced locomotor activity
AID492645	Antipsychotic activity in NMRI mouse assessed as increase of PCP-induced locomotor activity at 10 mg/kg, ip administered 30 mins prior to testing measured for 60 mins	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
AID1210216	Percentage unbound in Sprague-Dawley rat brain at 1 uM after 5 hrs by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1769332	Displacement of [3H]N-methylspiperone from human D3 receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method
AID1442602	Antipsychotic activity in Sprague-Dawley rat assessed as inhibition of AMPH-induced locomotion at 1.5 mg/kg/day administered via osmotic Alzet mini pump for 7 days post 6 days challenge with AMPH by open field test	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID669782	Antibacterial activity against Staphylococcus aureus SA-1199B harboring grlA A116E mutant by microdilution techniques	2012	ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
AID1693539	Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	A study of the structure-affinity relationship in SYA16263; is a D
AID723179	Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 after 1 hr	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID1403795	Antagonist activity at 5-HT2C receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assay
AID1233019	Antipsychotic activity in ip dosed CD-1 mouse assessed as inhibition of D-amphetamine-induced hyperlocomotor activity	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
AID1442583	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1447996	Displacement of [3H]spiperone from human D4R expressed in CHO cell membranes by radioligand binding assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID698938	Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method	2012	Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16	Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
AID1153297	Displacement of [3H]Spiperone from human dopamine D3 receptor expressed in CHO cells by competitive binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID298494	Displacement of [3H]pyrilamine from histaminergic H1 receptor guinea pig cerebellum	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1865874	Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor incubated for 1 hr by liquid scintillation counting method
AID1196348	Anti-depressant-like activity in intraperitoneally dosed 3-months old Wistar rat assessed as reduction in saccharin self-administration	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID1245098	Activity at dopamine D2S receptor (unknown origin) expressed in HEK293 cell membranes co-expressing Galpha protein subunit Galphai2 by [35S]GTPgammaS binding assay	2015	Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18	1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation.
AID1517960	Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method
AID1442569	Agonist activity at human Dopamine D2S receptor expressed in HEK293T cell membranes coexpressing Galphai2 incubated for 30 mins measured after 75 mins by [35S]GTPgammaS binding assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1756802	Displacement of [3H]-LSD from human 5-HT7 receptor incubated for 1 hr by liquid scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
AID1442565	Agonist activity at human Dopamine D3 receptor expressed in HEK293T cell membranes coexpressing GalphaoA incubated for 30 mins measured after 75 mins by [35S]GTPgammaS binding assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1403799	Inhibition of human ERG by auomated patch clamp assay
AID1169861	Binding affinity to dopamine D3 receptor (unknown origin)	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
AID1762060	Binding affinity to alpha1 adrenoceptor (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1393473	Reversal of ketamine-induced working social withdrawal in ip dosed Sprague-Dawley rat pretreated for 60 mins followed by ketamine administration
AID722917	Displacement of [3H]-methylspiperone from human dopamine D3 receptor expressed in HEK293 after 1 hr	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID1210215	Percentage unbound in Sprague-Dawley rat plasma at 1 uM after 5 hrs by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1153304	Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay relative to quinpirole	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1762067	Antipsychotic activity in po dosed rat assessed as suppression in conditioned avoidance response by CAR test	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1210172	Unbound brain to plasma partition coefficient of the compound in wild type Sprague-Dawley rat expressing Abcb1a at 6 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1442578	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1210214	Total brain to plasma partition coefficient of the compound in mdr1a-deficient mouse at 3 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID516812	In vivo intrinsic activity at D2 receptor in mouse brain assessed as inhibition of gamma-butyrolactone-induced increase in DOPA synthesis at 30 mg/kg, po administered 60 mins before gamma-butyrolactone challenge measured after 30 mins	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID298478	Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1153294	Displacement of [3H]SCH23390 from human dopamine D1 receptor expressed in HEK293 cells by competitive binding assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1301295	Inhibition of human ERG after 10 mins	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID1693544	Displacement of [3H]-mesulergine from human 5HT2C receptor by liquid scintillation counting	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	A study of the structure-affinity relationship in SYA16263; is a D
AID1762064	Antipsychotic activity in po dosed mouse assessed as suppression of apomorphine-induced climbing behaviour	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID595497	Binding affinity to human 5HT2A receptor	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
AID1682829	Binding affinity to adrenergic alpha1 receptor (unknown origin)
AID516820	Induction of catalepsy in mouse at 30 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID1865878	Displacement of [3H]-N-methylspiperone from human D3 receptor incubated for 1 hr by liquid scintillation counting method
AID1232331	Selectivity index, ratio of Ki for human dopamine D4 receptor to KI for human dopamine D3 receptor	2015	Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14	Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
AID1245096	Activity at dopamine D2S receptor (unknown origin) expressed in HEK293 cell membranes co-expressing Galpha protein subunit Galphao1 by [35S]GTPgammaS binding assay	2015	Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18	1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation.
AID1210212	Total plasma concentration in mouse at 3 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1220558	Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1704748	Antipsychotic activity in Kunming mouse assessed as inhibition of MK801-induced locomotor activity administered orally 30 mins prior to MK801 challenge and measured for 90 mins
AID458633	Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID1309135	Displacement of [3H]N-methylspiperone from human D3 receptor expressed in cell membranes after 1 hr by liquid scintillation counting	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
AID1458663	Antagonist activity at human recombinant 5-HT7 receptor expressed in CHO cells assessed as inhibition of 5-HT induced response at 1 x 10'-6 M after 30 mins by HTRF method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1232328	Displacement of [3H]N-methylspiperone from human dopamine D3 receptor expressed in HEK293 cells	2015	Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14	Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
AID1196353	Anxiolytic activity in intraperitoneally dosed >18-months old Wistar rat by open-field test	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID698936	Agonist activity at human D2L receptor expressed in HEK293T cells coexpressing Gi subunit assessed as inhibition of isoproterenol-stimulated cAMP production by luminescence assay relative to quinpirole	2012	Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16	Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
AID516811	Intrinsic activity at human dopamine 5HT1A receptor expressed in HeLa cells by FLIPR assay	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID298485	Displacement of [3H]mesulergine from 5HT2C receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1756798	Displacement of [3H]N-methylspiperone from human dopamine D4 receptor incubated for 1 hr by liquid scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
AID595498	Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor expressed in HeLa cells	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
AID298488	Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1443628	Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay
AID1762102	Cognitive enhancement effect in rat assessed as effect on total exploration time at 0.05 to 0.3 mg/kg, po administered 1 hr prior to acquisition trial and by novel object recognition test	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1245094	Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK293 cell membranes by radioligand competition binding assay	2015	Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18	1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation.
AID616780	Binding affinity to SERT	2011	Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18	Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
AID1245089	Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay	2015	Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18	1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation.
AID1153309	Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Functionally selective dopamine D₂, D₃ receptor partial agonists.
AID1220555	Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID599884	Displacement of [3H]5-LSD from human 5HT6 receptor expressed in human HeLa cells	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.
AID114076	post-synaptic dopamine autoreceptor antagonist activity evaluated by inhibition of the apomorphine-induced stereotyped behavior in mice.	1998	Journal of medicinal chemistry, Feb-26, Volume: 41, Issue:5	Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
AID1458669	Antipsychotic activity in CD-1 mouse assessed as reduction in MK-801-induced hyperlocomotion administered 30 mins followed by 15 mins of MK-801 challenge	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1403801	Antipsychotic activity in ig dosed ICR mouse assessed as inhibition of PCP-induced hyper-locomotion pretreated for 45 mins followed by PCP challenge measured after 10 mins for 75 mins
AID410529	Antipsychotic activity in NMRI mouse assessed as reduction in methamphetamine-induced locomotor activity administered 30 mins prior to testing measured for 60 mins	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
AID1693540	Displacement of [3H]-N-methylspiperone from human dopamine D3 receptor by liquid scintillation counting	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	A study of the structure-affinity relationship in SYA16263; is a D
AID723183	Displacement of [3H]-ketanserin from human 5HT2A receptor expressed in HEK293 after 1.5 hrs	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID1462324	Induction of catalepsy in ig dosed ICR mouse assessed as incidence of unwanted extrapyramidal motor disturbances	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
AID1442591	Agonist activity at Dopamine D2L receptor (unknown origin) expressed in HEK293T cells coexpressing GFP-fused GIRK1/2 channels assessed as induction of inwardly rectifying K+ current at -70 mV holding potential at 1 uM measured up to 1.1 secs by patch clam	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID458632	Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID492642	Displacement of [3H]spiperone from dopamine D2 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
AID1309134	Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
AID1464178	Displacement of [3H]spiperone from human D3R expressed in CHO cell membranes	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID1889688	Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Novel D
AID410338	Binding affinity to human ERG expressed in HEK293 cells by whole cell patch clamp method	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
AID723181	Displacement of [3H]-LSD from human 5HT6 receptor expressed in HEK293 after 1 hr	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID595499	In vivo intrinsic activity at D2 receptor in po dosed mouse brain assessed as inhibition of gamma-butyrolactone-induced increase in DOPA synthesis	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
AID1474757	Agonist activity at D2 long receptor (unknown origin) expressed in Flp-In-CHO cells co-expressing Rluc8-tagged Galphai1 assessed as change in transduction coefficient by measuring Galphai1 activation after 5 mins in presence of coelenterazine by BRET assa	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
AID1808022	Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID516809	Intrinsic activity at human dopamine D2L receptor expressed in CHO cells by FLIPR assay relative to quinpirole	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
AID1762058	Binding affinity to 5-HT2C receptor (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1210233	Total brain to plasma partition coefficient of the compound in wild type Sprague-Dawley rat expressing Abcb1a at 6 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1393369	Selectivity index, ratio of pKi for 5-HT2AR to pKi for human D2LR
AID1704718	Displacement of [3H]ketanserin from rat cerebral cortex 5HT2A receptor measured after 15 mins by liquid scintillation counting method
AID410336	Displacement of [3H]mesulergine from 5HT2C receptor in CRL:(HA) BR albino guinea pig cortex by scintillation spectrometry	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
AID1704717	Displacement of [3H](+)8-OH-DPAT from rat cerebral cortex 5HT1A receptor measured after 30 mins by liquid scintillation counting method
AID1443615	Selectivity ratio of Ki for human dopamine D3 receptor expressed in HEK293 cell membranes to Ki for human dopamine D2 receptor expressed in HEK293 cell membranes
AID1442555	Displacement of [3H]spiperone from human Dopamine D4 receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1448008	Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1233028	Ratio of MED for catalepsy in CD-1 mouse to ED50 for antipsychotic activity in CD-1 mouse	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
AID463570	Partial agonistic activity at dopamine D2 receptor relative to aripiprazole	2010	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6	The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure.
AID1458664	Agonist activity at human recombinant 5-HT1A receptor expressed in HEK-293 cells at 1 x 10'-6 M by cellular dielectric spectroscopy	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1169867	Antipsychotic-like activity in sc dosed NMRI mouse assessed as reduction in MK801-induced locomotor activity dosed 15 to 30 mins before administration of MK801 measured for 60 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
AID1448006	Agonist activity at human D2S receptor expressed in HEK293T cell membranes coexpressing Galphao1 assessed as induction of nucleotide exchange at 0.1 pM to 100 uM preincubated for 30 mins followed by addition of [35S]GTPgammaS measured after 30 mins by [35	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1464175	Displacement of [3H]SCH23390 from human D1R expressed in HEK293T cell membranes	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID1220557	Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1442572	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1442597	Agonist activity at Dopamine D3 receptor (unknown origin) expressed in HEK293T cells coexpressing GFP-fused GIRK1/2 channels assessed as induction of inwardly rectifying K+ current at -70 mV holding potential at 1 uM measured up to 1.1 secs by patch clamp	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1245087	Selectivity index, ratio of Ki for human 5HT2A receptor to Ki for human dopamine D2 receptor	2015	Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18	1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation.
AID1169865	Effect on spontaneous exploratory locomotor activity in sc dosed NMRI mouse measured for 30 mins with activity counts each 5 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
AID1442557	Displacement of [3H]SCH23390 from human Dopamine D1 receptor expressed in HEK293T cell membranes after 2 hrs by scintillation counting analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1512153	Displacement of [3H]8-OH-DPAT from human 5HT1A receptor by radio ligand binding assay	2019	Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21	Design, synthesis and biological evaluation of novel serotonin and dopamine receptor ligands being 6-bromohexyl saccharine derivatives.
AID1762056	Binding affinity to 5-HT1A receptor (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
AID1442598	Increase in inwardly rectifying K+ current in human HEK293T cells coexpressing GFP-fused GIRK1/2 channels at -70 mV holding potential at 1 uM measured up to 1.1 secs by patch clamp electrophysiology assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1474768	Agonist activity at D2 long receptor (unknown origin) expressed in Flp-In-CHO cells assessed as ratio of GalphaoB activation to cellular impedance at 2 mins post dose	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1889692	Antagonist activity at 5-HT3 receptor in guinea-pig ileum assessed as inhibition of 5HT-induced contraction	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Novel D
AID1196352	Anxiolytic activity in intraperitoneally dosed 3-months old Wistar rat by open-field test	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID1210246	Total plasma concentration in mdr1a-deficient Sprague-Dawley rat at 6 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1442563	Agonist activity at human Dopamine D2S receptor expressed in HEK293T cell membranes coexpressing GalphaoA incubated for 30 mins measured after 75 mins by [35S]GTPgammaS binding assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1374529	Drug metabolism in mouse liver microsomes assessed as DM1451 formation at 50 uM preincubated for 5 mins followed by NADPH addition measured after 30 mins by UPLC-MS analysis	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID669781	Inhibition of human recombinant MDR1 expressed in mouse L5178Y cells assessed as inhibition of rhodamine-123 efflux at 10'-4 M preincubated for 10 mins measured after 20 mins by FACS analysis	2012	ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
AID1464182	Displacement of [3H]ketanserin from human 5-HT2AR expressed in HEK293T cell membranes1	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID1442561	Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK293T cell membranes after 2 hrs by scintillation counting analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID492640	Displacement of [3H]ketanserin from 5HT2A receptor in CRL:CD(SD)BR-COBS rat cortex by scintillation spectrometry	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
AID1442574	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1301293	Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1442580	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID616781	Binding affinity to 5-HT2A	2011	Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18	Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
AID1823850	Anxiolytic activity in stress-induced anxiety ip dosed Wistar rat model assessed as increase in open arm entry measured after 30 mins by elevated plus maze test
AID1704716	Displacement of [3H]spiperone from D2 receptor in rat striatum measured after 15 mins by liquid scintillation counting method
AID723175	Displacement of [3H]-citalopram from SERT in rat cerebral cortex after 1 hr by scintillation counting	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID1210218	Percentage unbound in Crl:NMRI(Han) mouse plasma at 1 uM after 5 hrs by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1210195	Total drug level in wild type Crl:CF1 mouse brain expressing Abcb1a mutant at 3 mg/kg/day administered through continuous minipump treatment for 3 days by UPLC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1693546	Displacement of [3H]-citalopram from human SERT by liquid scintillation counting	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	A study of the structure-affinity relationship in SYA16263; is a D
AID1152659	Antipsychotic-like activity in po dosed Wistar rat assessed as inhibition of MK-801-induced hyperlocomotion administered 45 mins prior to MK-801 challenge measured 60 mins post-drug administration	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
AID1442601	Effect on basal rearing in Sprague-Dawley rat at 1.5 mg/kg/day for 7 days administered via osmotic Alzet mini pump measured 20 mins post dose by open field test	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID298481	Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1756803	Displacement of [3H]-citalopram from human SERT receptor incubated for 1 hr by liquid scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
AID1474755	Agonist activity at Rluc8-tagged D2 long receptor (unknown origin) expressed in Flp-In-CHO cells co-expressing YFP-tagged beta-arrestin2 assessed as change in transduction coefficient by measuring beta-arrestin2 recruitment measured after 5 mins by BRET a	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
AID1889746	Antipsychotic activity in male Wistar rat assessed as effect on anogenital sniffing at 1 mg/kg, ip	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Novel D
AID1704722	Displacement of [3H]5-CT from rat cerebral cortex 5HT7 receptor measured after 30 mins by liquid scintillation counting method
AID1210184	Unbound brain to plasma partition coefficient of the compound in wild type Crl:CF1 mouse expressing Abcb1a mutant at 3 mg/kg/day administered through continuous minipump treatment for 3 days	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
AID1517957	Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor expressed in CHO-K1 cell membranes incubated for 60 mins by microbeta scintillation counting analysis
AID1464180	Displacement of [3H]SCH23390 from human D5R expressed in HEK293T cell membranes	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID576612	Inhibition of human ERG	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1443629	Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay relative to quinpirole
AID1447992	Displacement of [3H]SCH23390 from human D1R expressed in HEK293T cell membranes by radioligand binding assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1309132	Displacement of [3H]LSD from human 5-HT2B receptor expressed in cell membranes after 1 hr by liquid scintillation counting	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
AID277673	Displacement of [3H]spiperone from human dopamine D3 expressed in CHO cell membrane	2007	Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3	Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
AID1157850	Ratio of intrinsic efficacy to KA for human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
AID698937	Agonist activity at human D2L receptor expressed in HEK293T cells coexpressing Gi subunit assessed as inhibition of isoproterenol-stimulated cAMP production by luminescence assay	2012	Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16	Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
AID277674	Displacement of [3H]spiperone from human dopamine D4.4 expressed in CHO cell membrane	2007	Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3	Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
AID1442600	Effect on basal locomotion in Sprague-Dawley rat at 1.5 mg/kg/day for 7 days administered via osmotic Alzet mini pump measured 20 mins post dose by open field test	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.
AID1442573	Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay relative to quinpirole	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	15 (0.54)	18.2507
2000's	796 (28.82)	29.6817
2010's	1493 (54.06)	24.3611
2020's	458 (16.58)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	509 (17.03%)	5.53%
Reviews	462 (15.46%)	6.00%
Case Studies	772 (25.83%)	4.05%
Observational	28 (0.94%)	0.25%
Other	1,218 (40.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (369)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year [NCT02534363]	Phase 4	136 participants (Actual)	Interventional	2005-10-31	Completed
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With [NCT01119014]	Phase 4	300 participants (Anticipated)	Interventional	2010-05-31	Active, not recruiting
A Multicenter Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) [NCT00337571]	Phase 3	218 participants (Actual)	Interventional	2006-06-30	Completed
Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up [NCT02532491]	Phase 4	200 participants (Anticipated)	Interventional	2014-05-31	Enrolling by invitation
Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia [NCT00209027]		20 participants (Actual)	Interventional	2005-04-30	Terminated(stopped due to difficulty with technical aspect of fMRI, resources to complete the study ran out)
Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children [NCT00468130]		13 participants (Actual)	Interventional	2006-05-31	Completed
Easy Identification, Treatment Response Prediction, and Molecular Mechanism Exploration of Antipsychotic-related Metabolic Syndrome [NCT00956189]		132 participants (Actual)	Interventional	2009-11-30	Completed
Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up [NCT02526030]	Phase 4	203 participants (Actual)	Interventional	2008-10-31	Completed
A Twelve-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric H [NCT01193166]	Phase 4	0 participants (Actual)	Interventional	2010-08-31	Withdrawn(stopped due to This study was stopped due to an internal reconsideration of priorities of the product portfolio.)
The Relationship Between D2 Occupancy and Change in Frontal Metabolism and Working Memory Induced by Aripiprazole [NCT01562808]		15 participants (Actual)	Interventional	2009-01-31	Completed
A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adult Subjects With Schizophrenia, Schizoaffective Disorder, or First Episode Psychos [NCT03568500]	Phase 4	44 participants (Actual)	Interventional	2018-05-21	Completed
Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS): the Effects of D2 Antagonism on Candidate Endophenotypes [NCT01154829]		136 participants (Actual)	Interventional	2008-12-31	Completed
Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia [NCT01338298]		60 participants (Actual)	Interventional	2011-01-31	Completed
An Open-label, Single- and Multiple-dose, Pharmacokinetic, Safety, and Tolerability Trial of Aripiprazole Long-acting Injectable Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder [NCT03854409]	Phase 1	72 participants (Actual)	Interventional	2019-01-31	Completed
A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation [NCT03345979]	Phase 3	200 participants (Actual)	Interventional	2017-11-15	Completed
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI [NCT02334904]		60 participants (Anticipated)	Observational	2014-07-31	Recruiting
An Observational Drug Utilization Study of SYCREST^® (Asenapine) in the United Kingdom [NCT01498770]		42 participants (Actual)	Observational	2013-04-01	Completed
Biomarkers in Autism of Aripiprazole and Risperidone Treatment [NCT01333072]	Phase 4	80 participants (Actual)	Interventional	2011-07-31	Completed
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode [NCT04203056]	Phase 4	15 participants (Actual)	Interventional	2019-12-16	Terminated(stopped due to Withdraw of financial support by industry collaborator)
A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder [NCT03661983]	Phase 4	36 participants (Actual)	Interventional	2018-10-13	Terminated(stopped due to Lack of feasibility for completion of the trial within a reasonable time frame.)
Effectiveness of Antipsychotic Drugs to Treat Psychosis Syndrome: an Open Label, Controlled Study [NCT02137616]		300 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole and Risperidone Over 3 Years [NCT03883204]	Phase 4	115 participants (Anticipated)	Interventional	2015-01-01	Enrolling by invitation
Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer: a Double-blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, Amisulpride, Risperidone and Aripiprazole [NCT01185418]		80 participants (Actual)	Observational	2009-03-31	Completed
12- Week Open Label Treatment of Refractory Bipolar Depression (BD) With Combination of Depakote ER (DEP) and Aripiprazole (AZP) [NCT00223496]	Phase 4	32 participants (Actual)	Interventional	2004-09-30	Completed
EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL [NCT05868720]		42 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
Real-life Assessment of Aripiprazole Long-acting Injection (Abilify Maintena) Combined With Brexpiprazole (Rexulti) in Schizophrenia: a Naturalistic Non-interventional Prospective Follow-up Study [NCT05169268]		10 participants (Anticipated)	Observational	2022-02-01	Recruiting
Substance Misuse To Psychosis for Stimulants (SToP-S)--An Early Assertive Pharmacotherapy Intervention Study [NCT03485417]	Phase 2/Phase 3	240 participants (Anticipated)	Interventional	2019-06-01	Recruiting
Aripiprazole in Adolescents With Schizophrenia [NCT00102063]	Phase 3	302 participants (Actual)	Interventional	2004-07-31	Completed
Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine [NCT01047215]	Phase 4	120 participants (Anticipated)	Interventional	2009-08-31	Recruiting
A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia [NCT02320032]	Phase 1	140 participants (Actual)	Interventional	2014-12-31	Completed
Impact of Preoperative Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy: A Randomized Controlled Clinical Trial [NCT05103410]	Phase 4	80 participants (Actual)	Interventional	2021-11-10	Completed
A Multicenter, Randomized, Double-blind, Flexible-dosed, Placebo-controlled, Parallel-group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Autistic Disorder [NCT03487770]	Phase 3	111 participants (Actual)	Interventional	2018-04-09	Completed
A Randomized, Multi-site, Parallel-group, Rater-blind Study Comparing Response With Aripiprazole Once Monthly and Standard of Care Oral Antipsychotics in Non-adherent Outpatients With Schizophrenia Identified Using the Brief Adherence Rating Scale [NCT02282085]	Phase 4	200 participants (Anticipated)	Interventional	2014-12-31	Recruiting
A Phase 2, Multicenter, Double-Blind, Randomized, Fixed Dose, Parallel Group, 3-Week Inpatient Treatment Study To Evaluate The Dose-Response Relationship, Safety, Efficacy, And Pharmacokinetics Of PF-00217830 Compared With Placebo, Using Aripiprazole As A [NCT00580125]	Phase 2	164 participants (Actual)	Interventional	2007-11-30	Completed
A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder [NCT01123707]	Phase 3	173 participants (Actual)	Interventional	2010-11-18	Terminated(stopped due to The study was terminated early due to Sponsor decision; no safety issues.)
VA Aripiprazole vs. Esketamine for Treatment of Depression VAST-D II [NCT05554627]	Phase 4	940 participants (Anticipated)	Interventional	2023-12-07	Not yet recruiting
Efficacy and Safety of Aripiprazole in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study [NCT01026584]	Phase 4	55 participants (Actual)	Interventional	2009-10-31	Completed
Safety and Tolerability of Multiple Ascending Doses of LY2140023 in Subjects With Schizophrenia [NCT01354353]	Phase 1	75 participants (Actual)	Interventional	2011-05-31	Completed
A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia [NCT01129674]	Phase 2/Phase 3	1,210 participants (Anticipated)	Interventional	2010-06-30	Terminated(stopped due to The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.)
Efficacy of Aripiprazole in Combination With Lithium or Valproate in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients Partially Nonresponsive to Lithium or Valproate Monotherapy [NCT00261443]	Phase 4	1,270 participants (Actual)	Interventional	2005-09-30	Completed
A Long-Term, Phase 2, Multicenter, Randomized, Open-Label Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia [NCT00845026]	Phase 2	261 participants (Actual)	Interventional	2009-03-31	Completed
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset [NCT06128408]		300 participants (Anticipated)	Observational	2023-12-01	Not yet recruiting
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate L [NCT02431702]	Phase 3	337 participants (Actual)	Interventional	2015-07-08	Completed
A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Us [NCT03881449]	Phase 4	46 participants (Actual)	Interventional	2019-04-04	Active, not recruiting
Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning: A Pharmacological fMRI Study [NCT01161277]	Phase 4	54 participants (Actual)	Interventional	2010-08-31	Completed
Enhancing Adherence and Outcomes in Bipolar Disorder With Abilify Maintena + a Targeted Behavioral Approach to Promote Sustained Adherence and Behavioral Change [NCT03408873]	Phase 4	30 participants (Actual)	Interventional	2018-04-01	Completed
A Single-center, Open-label, Randomized, Two-treatment, Two-period Crossover Trial to Investigate Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and S [NCT03342963]	Phase 1	74 participants (Actual)	Interventional	2017-11-21	Completed
Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia [NCT01164059]	Phase 4	149 participants (Actual)	Interventional	2010-02-28	Completed
Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism [NCT03179787]		528 participants (Actual)	Observational	2017-04-01	Completed
A Multicenter, 180-day Pragmatic Clinical Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disord [NCT03643159]	Phase 4	2 participants (Actual)	Interventional	2018-06-28	Terminated(stopped due to Difficulty in participant recruitment)
A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia [NCT00706654]	Phase 3	937 participants (Actual)	Interventional	2008-09-30	Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]	Phase 4	104 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Difficulties in recruiting)
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals [NCT03790085]	Early Phase 1	2,700 participants (Anticipated)	Interventional	2018-09-01	Recruiting
A Randomized Clinical Trial of Response to Psychopharmacotherapy According to Multimodal Serum Biomarkers in Depressive Patients [NCT06054321]		400 participants (Anticipated)	Interventional	2022-08-03	Recruiting
Nautralsitic, Open-label, Single Arm Study Evaluating Effects of Aripiprazole LAI on Phychosocial&Congitive Functioning, Patient Reported Acceptability of Treatment Regarding QoL, Subjective Well-being Under Neuroleptic Medication in Sch [NCT02697045]	Phase 4	23 participants (Actual)	Interventional	2017-01-04	Completed
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder [NCT02918370]	Phase 3	132 participants (Anticipated)	Interventional	2016-11-30	Completed
Effect of add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia With Metabolic Syndrome: A Randomized Controlled Trial [NCT05766540]	Phase 4	60 participants (Anticipated)	Interventional	2023-08-20	Not yet recruiting
A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I) [NCT00689559]	Phase 1	52 participants (Anticipated)	Interventional	2008-03-31	Completed
A Randomized Placebo Controlled Clinical Trial of Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents Ages 6-17 With Bipolar Spectrum Disorder [NCT00592683]	Phase 4	20 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.)
Irritability in Children With ADHD and Emotion Dysregulation: Clinical Profiles, Neuropsychological Characteristics , and Pharmacological Treatment: A Cross-over Study [NCT05974241]	Phase 4	36 participants (Actual)	Interventional	2017-04-21	Completed
Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression [NCT04234776]	Phase 4	88 participants (Anticipated)	Interventional	2018-04-03	Enrolling by invitation
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia [NCT01663532]	Phase 3	340 participants (Actual)	Interventional	2012-10-31	Completed
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia [NCT00705783]	Phase 3	843 participants (Actual)	Interventional	2008-07-31	Completed
European Long-acting Antipsychotics in Schizophrenia Trial [NCT02146547]	Phase 4	536 participants (Actual)	Interventional	2015-02-28	Completed
Effectiveness of 6 Antipsychotic Drugs in the Treatment of Acute Exacerbations of Chronic Inpatients With Schizophrenia: a Randomized Double-blind Study [NCT02192723]		550 participants (Actual)	Interventional	2012-06-30	Completed
A Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Treatment of Major Depressive Episode Associ [NCT03423680]	Phase 3	390 participants (Anticipated)	Interventional	2018-02-22	Recruiting
A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify® 10 mg Tablet in Healthy Volunteers [NCT02501109]	Phase 1	36 participants (Actual)	Interventional	2015-10-31	Completed
An Open-label Study to Determine the Effect of Switching to Aripiprazole Once Monthly for Subjects With Schizophrenia Experiencing Worsening Sexual Dysfunction With Invega Sustenna or Risperdal Consta [NCT02472652]	Phase 4	2 participants (Actual)	Interventional	2015-06-30	Terminated(stopped due to Lack of adequate enrollment)
A Multinational, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Aripiprazole in Asian Pediatric Patients With Autism Spectrum Disorder and Behavior Problems [NCT02069977]	Phase 4	79 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Evaluation of Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation by Single Administration in Chinese Patients With Schizophrenia: a Single-center, Uncontrolled, Open -Label Trial [NCT03287505]	Phase 1	24 participants (Actual)	Interventional	2017-06-23	Completed
An Open-Label Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia [NCT02435836]	Phase 3	631 participants (Actual)	Interventional	1998-04-30	Terminated(stopped due to Study terminated when aripiprazole available commercially per protocol)
Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection [NCT02634320]	Phase 4	51 participants (Actual)	Interventional	2015-12-31	Completed
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone [NCT02087579]	Phase 1	305 participants (Actual)	Interventional	2014-02-28	Completed
A Double-Blind, Randomized, Multiple Dose Study of Weight Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects With Schizophrenia Suffering From Metabolic Dysregulation [NCT05542264]	Phase 1	60 participants (Anticipated)	Interventional	2022-11-15	Recruiting
A Randomized, Single Oral Dose, Two-way Crossover, Open-label, Laboratory Blind, Bioequivalence Study Comparing Aripiprazole From Two Different Drug Products After Oral Administration to Healthy Adult Subjects Under Fasting Conditions [NCT05532254]	Phase 1	31 participants (Actual)	Interventional	2021-02-14	Completed
RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT) [NCT05531591]	Phase 4	600 participants (Anticipated)	Interventional	2019-08-01	Active, not recruiting
Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia [NCT00509067]	Phase 2	43 participants (Actual)	Interventional	2007-11-30	Completed
A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia [NCT03198078]	Phase 3	316 participants (Actual)	Interventional	2017-06-30	Completed
Aripiprazole Treatment for Antipsychotic Induced Hyperprolactinaemia in Patients With Severe Mental Illness and Learning Disabilities [NCT01085383]	Phase 4	15 participants (Actual)	Interventional	2010-04-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode [NCT00338273]	Phase 3	0 participants (Actual)	Interventional	2006-12-31	Withdrawn
A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode [NCT00606229]	Phase 3	41 participants (Actual)	Interventional	2008-01-31	Completed
Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study [NCT00167817]	Phase 4	15 participants	Interventional	2003-07-31	Completed
A Canadian Non-interventional Study of Aripiprazole Once-Monthly (AOM) Administration in Hospitalized Patients With Schizophrenia, Schizoaffective Disorder and Bipolar I Disorder [NCT04907279]		200 participants (Anticipated)	Observational	2021-11-01	Recruiting
Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study [NCT00837707]	Phase 4	25 participants (Anticipated)	Interventional	2008-06-30	Recruiting
Aripiprazole Augmentation of SSRI Antidepressant Therapy in Treatment Refractory Depression: Assessment of Symptom Reduction, Psychosocial Function, and Cognitive Function [NCT00608543]	Phase 4	17 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia [NCT00088049]	Phase 4	560 participants	Interventional	2003-10-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group-Comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode [NCT00606281]	Phase 3	258 participants (Actual)	Interventional	2008-01-31	Completed
A Prospective Open-Label Trial of Aripiprazole Monotherapy in the Autism Spectrum Disorders (ASD) [NCT00308074]	Phase 2	14 participants (Actual)	Interventional	2006-02-28	Completed
Therapeutic Drug Monitoring (TDM) in Child & Adolescent Psychiatry [NCT01057329]		200 participants (Actual)	Observational	2010-01-31	Completed
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication [NCT03557931]	Phase 2	233 participants (Actual)	Interventional	2018-07-13	Completed
A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia [NCT00328367]	Phase 4	61 participants (Actual)	Interventional	2005-12-31	Completed
Investigating Metabolic Side Effects of Antipsychotic Medications in Children [NCT00746252]		5 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Due low rate of participation and lack of funding)
Augmenting Language Interventions in ASD: A Translational Approach (ACE Project 3) [NCT02574741]	Phase 2	58 participants (Actual)	Interventional	2012-06-30	Completed
Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data [NCT02582736]		725,489 participants (Actual)	Observational	2012-04-30	Completed
Broad Effectiveness: Study With Aripiprazole [NCT00036361]	Phase 3	444 participants	Interventional	2002-07-31	Completed
A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age [NCT01009047]	Phase 3	228 participants (Actual)	Interventional	2009-12-31	Completed
An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence [NCT00667875]	Phase 2	65 participants (Actual)	Interventional	2008-04-30	Completed
A Multicenter, Double-Blind, Randomized, Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia [NCT00712686]	Phase 3	690 participants (Actual)	Interventional	2000-06-30	Completed
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression: A Raclopride/F-DOPA Positron Emission Tomography and Functional MRI Study [NCT00953745]		43 participants (Actual)	Interventional	2009-05-31	Completed
Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone [NCT02634463]	Phase 1	81 participants (Actual)	Interventional	2015-11-30	Completed
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence [NCT00737256]	Phase 2	44 participants (Anticipated)	Interventional	2008-08-31	Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode [NCT00080314]	Phase 3	400 participants	Interventional	2004-01-31	Completed
Placebo-Controlled, Double-Blind, Parallel Group-Comparison Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder [NCT00876343]	Phase 3	586 participants (Actual)	Interventional	2009-03-31	Completed
A Four-Week Double Blind Multicenter Study Comparing The Efficacy And Safety Of Ziprasidone To Aripiprazole In Subjects With Schizophrenia Or Schizoaffective Disorder Needing Inpatient Care [NCT00634348]	Phase 4	256 participants (Actual)	Interventional	2004-04-30	Completed
Pharmacotherapy of Pervasive Developmental Disorders [NCT00870727]	Phase 3	33 participants (Actual)	Interventional	2009-02-28	Completed
An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Aripiprazole When Coadministered In Healthy Subjects [NCT01188668]	Phase 4	38 participants (Actual)	Interventional	2010-08-31	Completed
Post Marketing Clinical Study of Aripiprazole in Patients With Schizophrenia - Effects on Glucose Metabolism- [NCT00392197]	Phase 4	111 participants (Actual)	Interventional	2006-11-30	Completed
Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment Wit [NCT00545675]	Phase 4	146 participants (Anticipated)	Interventional	2007-12-31	Completed
Augmentation Therapy of Resistant Postpartum Depression With Aripiprazole [NCT01386086]	Phase 3	10 participants (Actual)	Interventional	2011-06-30	Completed
Efficacy and Safety of Aripiprazole 2.5mg Combine Sertraline 50mg in Major Depression [NCT00873795]		41 participants (Actual)	Interventional	2007-04-30	Completed
A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode [NCT00606177]	Phase 3	99 participants (Actual)	Interventional	2008-01-31	Completed
Metabolic Effects of Antipsychotics in Children [NCT00205699]	Phase 4	144 participants (Actual)	Interventional	2006-04-30	Completed
GiSAS Trial: Aripiprazole, Olanzapine, and Haloperidol in the Long Term Treatment of Schizophrenia. [NCT01052389]	Phase 4	300 participants (Actual)	Interventional	2007-07-31	Completed
A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode [NCT00606320]	Phase 3	59 participants (Actual)	Interventional	2008-01-31	Completed
A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients With Acute Schizoph [NCT00905307]	Phase 2	459 participants (Actual)	Interventional	2009-07-31	Completed
[NCT00036127]	Phase 2/Phase 3	0 participants	Interventional	2002-04-30	Completed
Incomplete Response in Late Life Depression: Getting to Remission [NCT00892047]	Phase 4	468 participants (Actual)	Interventional	2009-08-31	Completed
A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients [NCT00926835]	Phase 4	692 participants (Actual)	Interventional	2009-05-31	Terminated(stopped due to due to patient recruitment difficulties)
Comparative Randomized, Single Dose, Two-way Crossover Bioequivalence Study to Determine the Bioequivalence Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible [NCT05804721]	Phase 1	29 participants (Actual)	Interventional	2022-10-10	Completed
Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa [NCT00685334]	Phase 4	22 participants (Actual)	Interventional	2003-11-30	Completed
Sequenced Atypical Antipsychotics Therapy With Intensive or Basic Psychosocial Intervention for First-episode Schizophrenia: An Effectiveness Study [NCT01057849]		600 participants (Anticipated)	Interventional	2008-09-30	Recruiting
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated on Valproate or Lithium and in Need of Furth [NCT00665366]	Phase 3	493 participants (Actual)	Interventional	2008-06-30	Completed
A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic [NCT02600741]		296 participants (Actual)	Observational	2015-07-24	Completed
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults [NCT02960763]	Phase 4	742 participants (Actual)	Interventional	2017-02-24	Completed
Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia [NCT02040883]	Phase 4	100 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents [NCT00250705]	Phase 4	12 participants (Actual)	Interventional	2004-11-17	Completed
Reducing Medical Risks in Individuals With Bipolar Disorder: Enhancing Outcomes With Aripiprazole [NCT00665444]		3 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to The study was terminated by the sponser due to low study enrollment.)
An Open-Label Study of Aripiprazole (Abilify) as an Augmentation Agent in Patients With Treatment-Resistant Depression [NCT00174876]	Phase 2	20 participants	Interventional	2004-07-31	Completed
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia [NCT00731549]	Phase 3	1,081 participants (Actual)	Interventional	2008-12-31	Completed
Open-Label Pilot Study of Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder [NCT00181779]	Phase 4	20 participants	Interventional	2003-02-28	Completed
Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents: Combination of Pharmacogenomics and Therapeutic Drug Monitoring [NCT00545467]	Phase 4	79 participants (Actual)	Interventional	2007-08-31	Completed
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® [NCT03892889]	Phase 3	277 participants (Actual)	Interventional	2019-04-29	Terminated(stopped due to Study has stopped for having met the primary endpoint.)
A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD) [NCT00332241]	Phase 3	98 participants (Actual)	Interventional	2006-06-30	Completed
Aripiprazole (BMS-337039) for Outpatients With Schizophrenia Completing Aripiprazole Clinical Trials: A Non-Comparative Rollover Protocol [NCT00239356]	Phase 3	119 participants (Actual)	Interventional	2003-03-31	Completed
Abilify (Aripiprazole) as an Adjunctive Treatment for Refractory Unipolar Depression [NCT00220636]	Phase 4	15 participants (Actual)	Interventional	2005-03-31	Completed
Effects of Aripiprazole on Cocaine Craving and Self-Administration [NCT00373880]	Phase 2	26 participants (Actual)	Interventional	2005-04-30	Completed
Efficacy of Aripiprazole in the Treatment of Anorexia Nervosa in Teenagers: a Pilot, Randomised, Double Blind, Placebo-controlled Clinical Trial [NCT01082848]	Phase 3	60 participants (Anticipated)	Interventional	2010-03-31	Recruiting
A Study of Aripiprazole in Patients With Major Depressive Disorder [NCT00105196]	Phase 3	349 participants (Actual)	Interventional	2005-03-31	Completed
A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome [NCT00508157]	Phase 4	125 participants (Actual)	Interventional	2007-11-30	Terminated(stopped due to Slow Accrual)
A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia [NCT00299702]	Phase 4	355 participants (Actual)	Interventional	2006-02-28	Completed
A Multicenter, Double-blind, Study of the Efficacy and Safety of Aripiprazole in Combination With Lamotrigine in the Long-term Maintenance Treatment of Patients With Bipolar I Disorder With a Recent Manic or Mixed Episode [NCT00277212]	Phase 4	1,169 participants (Actual)	Interventional	2005-12-31	Completed
Aripiprazole in the Treatment of Tourette's Syndrome [NCT00282139]		40 participants (Anticipated)	Interventional	2004-01-31	Terminated
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine Versus Non-Clozapine Antipsychotics in Individuals With Treatment-resistant Schizophrenia [NCT05741502]	Phase 4	60 participants (Anticipated)	Interventional	2023-08-16	Recruiting
Phase 4 Study: An Open Prospective Study of the Safety and Effectiveness of Aripiprazole in the Treatment of Bipolar Depression [NCT00226317]		20 participants (Actual)	Interventional	2004-04-30	Completed
Aripiprazole in Children With Autism: A Pilot Study [NCT00208533]	Phase 2	11 participants (Actual)	Interventional	2004-02-29	Completed
A Comparison of Medication Augmentation and Problem Solving Therapy [NCT01942187]	Phase 4	0 participants (Actual)	Interventional	2013-08-31	Withdrawn(stopped due to No participants enrolled.)
Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse [NCT00208169]	Phase 4	30 participants (Actual)	Interventional	2005-03-31	Completed
A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices (Broad Effectiveness Trial With Aripiprazole- BETA) [NCT00237939]	Phase 3	1,200 participants	Interventional	2002-09-30	Completed
A Phase II Study to Test PK Tolerability in Children and Adolescents [NCT00102479]	Phase 2	0 participants	Interventional	2004-07-31	Completed
A Randomized, Open-Label, Single Dose, Cross-over Study of Gastric Emptying Rate: SEP-363856 vs Prior Antipsychotic Standard of Care in Subjects With Schizophrenia [NCT05402111]	Phase 1	31 participants (Actual)	Interventional	2022-06-13	Completed
Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications [NCT05473741]		180 participants (Anticipated)	Observational	2023-01-09	Recruiting
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole [NCT01981811]	Phase 2	0 participants (Actual)	Interventional	2014-03-31	Withdrawn(stopped due to The trial was terminated because it was determined that the usability of the MIND1 System in the intended population was necessary before conducting this trial.)
The Effect of Switching to Aripiprazole on Indices of Cardiovascular Health in Overweight and Obese Patients With Schizophrenia [NCT00222833]	Phase 4	30 participants	Interventional	2004-10-31	Completed
Do Patients Taking Aripiprazole Learn More in Vocational Skills Training Than Patients Taking Olanzapine? [NCT00223418]		43 participants (Actual)	Interventional	2004-01-31	Completed
"The Effects of Aripiprazole on Patients With Metabolic Syndrome: An Open-Label Trial" [NCT00224822]	Phase 4	27 participants (Actual)	Interventional	2004-03-31	Completed
Assessment of Incidence of Adverse Events in a Naive Pediatric Population Treated With an (Typical and Atypical) Antipsychotic Drug Over 12 Months Follow-up [NCT02007928]		200 participants (Actual)	Interventional	2013-04-30	Completed
The Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Acute Treatment of Psychotic Major Depression: Efficacy and Tolerability [NCT00556140]	Phase 3	16 participants (Actual)	Interventional	2003-06-30	Completed
Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study [NCT02013232]		120 participants (Anticipated)	Interventional	2013-02-28	Recruiting
Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole [NCT00567099]		20 participants (Anticipated)	Interventional	2003-08-31	Recruiting
A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia [NCT01149655]	Phase 3	252 participants (Actual)	Interventional	2011-07-31	Completed
Aripiprazole in At-Risk Children With Symptoms of Bipolar Disorder [NCT00194012]	Phase 3	62 participants (Actual)	Interventional	2004-08-31	Completed
Novel Pharmacological Strategies in Autism [NCT00198107]	Phase 3	81 participants (Actual)	Interventional	2005-09-30	Completed
A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral A [NCT00177164]	Phase 3	50 participants (Actual)	Interventional	2003-11-30	Completed
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia [NCT01129882]	Phase 3	709 participants (Actual)	Interventional	2010-06-24	Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]		1,037,352 participants (Actual)	Observational	2016-09-30	Completed
Comparison of Single-Dose Plasma and Blood Concentrations of Aripiprazole, Olanzapine, Quetiapine, Paliperidone and Risperidone After Capillary and Venous Blood Sample Collection [NCT01607762]	Phase 1	31 participants (Actual)	Interventional	2012-02-29	Completed
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder [NCT01111552]	Phase 3	237 participants (Actual)	Interventional	2010-07-29	Terminated(stopped due to The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.)
A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia [NCT01104766]	Phase 3	617 participants (Actual)	Interventional	2010-04-23	Completed
Double-blind Placebo Controlled Trial of Aripiprazole for Amphetamine [NCT00728312]	Phase 4	0 participants (Actual)	Interventional	2009-08-31	Withdrawn(stopped due to PI left the VA.)
Aripiprazole and Topiramate on Free-Choice Alcohol Use [NCT00884884]	Phase 2/Phase 3	90 participants (Actual)	Interventional	2007-09-30	Completed
A Phase 1b, Open-label, Multiple-dose, Randomized, Parallel-arm, Safety, Tolerability, and Pharmacokinetic Trial of Aripiprazole Intramuscular Depot Administered in the Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder [NCT04030143]	Phase 1/Phase 2	266 participants (Actual)	Interventional	2019-08-01	Completed
A Randomized Double-blind Trial of Aripiprazole and Risperidone in Schizophrenia: An Evaluation of Neuroimaging, Neuropsychological, and Pharmacogenomic Markers of Differential Treatment Response [NCT00712270]	Phase 4	21 participants (Actual)	Interventional	2005-04-30	Terminated(stopped due to Study terminated due to failure to meet sufficient enrollment for valid analysis)
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder [NCT00882362]	Phase 3	155 participants (Actual)	Interventional	2009-03-31	Completed
Safety and Efficacy of Aripiprazole in the Long-term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder [NCT01227668]	Phase 4	215 participants (Actual)	Interventional	2011-03-31	Completed
A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated [NCT01157351]	Phase 4	450 participants (Actual)	Interventional	2010-05-31	Completed
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment [NCT02650102]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Metabolic Effects of Antipsychotic Substitution in Children [NCT00910780]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2009-11-30	Withdrawn(stopped due to Study was not funded.)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder [NCT01111539]	Phase 3	211 participants (Actual)	Interventional	2010-07-13	Terminated(stopped due to The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.)
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder [NCT02636842]	Phase 1	47 participants (Actual)	Interventional	2015-12-31	Completed
Open Label Trial of Aripiprazole in Trichotillomania. [NCT00947154]		12 participants (Actual)	Interventional	2009-07-31	Completed
The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia [NCT05322031]	Phase 4	15 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Acute Impact of IM Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics [NCT01411930]	Phase 4	15 participants (Actual)	Interventional	2009-03-31	Completed
A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Board Range of Schizophrenic Patients [NCT00329810]	Phase 4	500 participants (Actual)	Interventional	2005-03-31	Completed
A Positron Emission Tomography Study in Healthy Male Subjects to Examine the Test-retest Reliability of the D2/3 Agonist Radiotracer [11C]PHNO [NCT01424449]	Phase 1	7 participants (Actual)	Interventional	2010-01-31	Completed
Aripiprazole for the Augmentation of Antidepressant Therapy: An Observational, Outpatients Study in Inadequate Responders Diagnosed With Major Depressive Disorder [NCT01429831]	Phase 4	300 participants (Actual)	Interventional	2011-09-30	Completed
Bioequivalence Study of Atazanavir Single 300 mg Capsule Relative to Two Atazanavir 150 mg Capsules in Healthy Subjects [NCT00393328]	Phase 1	46 participants	Interventional	2006-11-30	Completed
[NCT00036348]	Phase 3	0 participants	Interventional	2000-03-31	Completed
Preventing Cocaine Relapse: Developing Pharmacotherapies [NCT00276874]	Phase 1	41 participants (Actual)	Interventional	2006-01-31	Completed
Assessment of Interactions Between IV Methamphetamine and Aripiprazole [NCT00089440]	Phase 1	17 participants	Interventional	2004-06-30	Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. CN138-146 LT is the 26-week Open Label Extension Phase of the Above Titled Protocol, CN [NCT00094432]	Phase 3	650 participants	Interventional	2004-06-30	Completed
A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder [NCT00095524]	Phase 3	300 participants	Interventional	2004-03-31	Completed
A Safety & Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia [NCT00095719]	Phase 3	125 participants	Interventional	2003-12-31	Completed
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder [NCT00095758]	Phase 3	1,200 participants	Interventional	2004-09-30	Completed
A 16-Week, Randomized, Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Non-HDL Cholesterol Among Patients With Schizophrenia and Bipolar I Disorder Who Have Pre-existing Metabolic Syndrome [NCT00857818]	Phase 3	64 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Slow Accrual)
An Open- Label Rollover Study for Subjects With Schizophrenia Completing ABILIFY® (Aripiprazole) Clinical Study 31-03-241 [NCT01001702]	Phase 3	85 participants (Actual)	Interventional	2006-04-30	Completed
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety [NCT00177008]	Phase 4	18 participants	Interventional	2004-03-31	Completed
Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia. (BMS) [NCT00211302]		8 participants (Actual)	Interventional	2003-08-31	Terminated(stopped due to Enrollment too difficult)
Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia, (SFBRI). [NCT00211380]		8 participants (Actual)	Interventional	2003-08-31	Terminated(stopped due to Recruitment was too difficult)
Phase 1 Study of Insulin Sensitivity, Adjusted β-Cell Function and Adiponectin Among Lean Drug-naïve Schizophrenic Subjects Treated With Atypical Antipsychotic Drugs [NCT00528359]		36 participants (Actual)	Observational	2005-10-31	Completed
Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study [NCT01488266]		90 participants (Anticipated)	Interventional	2011-11-30	Active, not recruiting
Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters [NCT00438386]	Phase 4	0 participants	Interventional	2005-04-30	Completed
The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial [NCT00468533]	Phase 4	50 participants (Anticipated)	Interventional	2006-05-31	Recruiting
Health Evaluation of Abilify Long-term Therapy [NCT00520650]	Phase 4	245 participants (Actual)	Interventional	2006-08-31	Completed
Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile [NCT02949752]	Phase 4	67 participants (Actual)	Interventional	2016-08-31	Completed
The Cognitive Effects of Aripiprazole in Children [NCT00221962]	Phase 4	23 participants (Actual)	Interventional	2005-04-30	Completed
Pediatric Trials Network Long-term Antipsychotic Pediatric Safety Trial (LAPS) NICHD-2016-LAP01 Phase 4 Trial [NCT03522168]		509 participants (Actual)	Observational	2019-01-10	Active, not recruiting
Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder [NCT00545142]	Phase 4	280 participants (Anticipated)	Interventional	2007-10-31	Completed
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial [NCT00541554]	Phase 4	0 participants	Interventional	2007-10-31	Not yet recruiting
The Optimal Treatment for Treatment-resistant Schizophrenia [NCT02926976]		150 participants (Anticipated)	Interventional	2016-11-30	Recruiting
ARIQUELI: Potentiation of Quetiapine Treatment in Bipolar 1 Nonresponders Patients With Lithium or Aripiprazole [NCT01710163]	Phase 4	50 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Study on the Clinical Efficacy and Change of Life Quality Through Using the Comprehensive Behavioral Intervention Treatment for Tics (CBIT) [NCT04765085]		0 participants (Actual)	Interventional	2021-03-31	Withdrawn(stopped due to Lacking of funding)
A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder [NCT00097266]	Phase 3	615 participants	Interventional	2004-12-31	Completed
A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, Whil [NCT00232687]	Phase 4	450 participants (Actual)	Interventional	2005-06-30	Completed
Aripiprazole Treatment of Prodromal Patients [NCT00237874]	Phase 2/Phase 3	15 participants (Actual)	Interventional	2004-02-29	Completed
A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR) [NCT00237913]	Phase 3	700 participants	Interventional	2004-07-31	Completed
Metabolic Effects of Newer Antipsychotics in Older Patients [NCT00245206]	Phase 4	406 participants (Actual)	Interventional	2005-08-31	Completed
A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia [NCT00080327]	Phase 4	370 participants	Interventional	2003-11-30	Completed
A Randomized, Multicenter, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Aripiprazole in the Maintenance of Abstinence From Alcohol in Subjects With Alcoholism [NCT00082199]	Phase 4	400 participants	Interventional	2004-04-30	Completed
Investigation of Body Mass Index, Body Composition, Resting Energy Expenditure, Respiratory Quotient and Metabolic Changes Following a Switch From Olanzapine, Quetiapine or Risperidone to Aripiprazole [NCT00312598]		30 participants (Actual)	Observational	2005-08-31	Completed
A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder [NCT00347425]	Phase 3	286 participants (Actual)	Interventional	2006-12-31	Completed
An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease [NCT00095810]	Phase 4	50 participants	Interventional	2003-07-31	Completed
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia [NCT00103571]	Phase 4	600 participants	Interventional	2004-07-31	Completed
Phase 3 Study of Aripriprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms [NCT00440713]	Phase 3	40 participants	Interventional	2004-01-31	Completed
Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia [NCT00352339]	Phase 4	90 participants (Anticipated)	Interventional	2006-08-31	Recruiting
Aripiprazole in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Double Blind Placebo Controlled Trial [NCT00116259]		50 participants (Anticipated)	Interventional	2005-03-31	Completed
Pilot Study of the Effect of Aripiprazole Treatment in Autism Spectrum Disorders on Functional Magnetic Resonance Imaging (fMRI) Activation Patterns and Symptoms [NCT01028820]	Phase 4	13 participants (Actual)	Interventional	2009-08-31	Completed
Abilify Prolonged Release Aqueous Suspension for Intramuscular Injection Specified Drug-use Results Survey (Prevention of Recurrence/Relapse of Mood Episodes in Bipolar I Disorder) [NCT04812379]		535 participants (Actual)	Observational	2021-04-07	Active, not recruiting
Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD) [NCT02977299]	Phase 4	278 participants (Actual)	Interventional	2017-05-01	Completed
Open-Label Study of Aripiprazole in Individuals at Risk for Chronic Mental Illness [NCT00169949]		30 participants	Interventional	2004-01-31	Terminated(stopped due to The study was terminated due to low enrollment.)
Open Label Pilot Study of Aripiprazole Treatment of Difficult to Treat Bipolar Depression [NCT00198198]	Phase 4	10 participants	Interventional	2005-08-31	Completed
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder [NCT00216723]		3,000 participants (Anticipated)	Observational	2004-04-30	Completed
Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication [NCT01292057]	Phase 3	99 participants (Actual)	Interventional	2011-02-28	Completed
A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia or Child and Adolescent Patients With Bipolar I Disorder, [NCT01122927]	Phase 3	524 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational Plan was met and provided 2 years of safety data.)
Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study [NCT01520350]	Phase 3	2 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to recruitment issues)
Aripiprazole Oral Acceptability Trial [NCT00101569]	Phase 3	59 participants	Interventional	2004-03-31	Completed
Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients [NCT03839251]	Phase 4	82 participants (Actual)	Interventional	2018-06-01	Completed
[NCT00046384]	Phase 3	0 participants	Interventional	2002-06-30	Completed
A Phase 1, Open-label, Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Aripiprazole 2 Month Intramuscular Depot Administered Gluteally in Adult Subjects With Schizophrenia [NCT03150771]	Phase 1	36 participants (Actual)	Interventional	2017-06-14	Completed
Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Having Drug-induced Weight Gain [NCT00845988]	Phase 4	28 participants (Actual)	Interventional	2008-12-31	Completed
Aripiprazole Augmentation Therapy in Treatment-resistant Depression [NCT00276978]	Phase 3	0 participants (Actual)	Interventional	2005-06-30	Withdrawn(stopped due to Initiation of study was stopped due to administrative reasons before first subject was enrolled.)
"Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)." [NCT00374348]		10 participants (Actual)	Interventional	2005-03-31	Completed
[NCT00036114]	Phase 3	0 participants	Interventional	2000-03-31	Completed
Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial. [NCT00395915]	Phase 4	106 participants (Actual)	Interventional	2006-09-30	Active, not recruiting
[NCT00036101]	Phase 3	0 participants	Interventional	2002-02-28	Completed
[NCT00041678]	Phase 3	0 participants	Interventional	2000-01-31	Completed
Effectiveness of Aripiprazole to Reduce Craving for Alcohol and Drinking Under Natural Observation, During Cue Induced Brain Imaging, and During a Motivated Free Choice Drinking Procedure Compared to Placebo [NCT00183235]	Phase 2	30 participants	Interventional	2005-06-30	Completed
Aripiprazole in Late Life Bipolar Disorder [NCT00194038]	Phase 4	20 participants (Actual)	Interventional	2004-04-30	Completed
An Open-Label Study of Aripiprazole in Children and Adolescents With Autistic Disorder [NCT00198055]	Phase 2	25 participants (Actual)	Interventional	2005-01-31	Completed
An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder [NCT00221416]	Phase 3	30 participants (Anticipated)	Interventional	2005-06-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder [NCT00095511]	Phase 3	615 participants	Interventional	2004-06-30	Completed
A Multicenter, Long-Term, Open-label, Study to Assess the Safety and Tolerability of Aripiprazole as an Adjunctive Therapy in the Treatment of Outpatients With Major Depressive Disorder [NCT00095745]	Phase 3	1,002 participants (Actual)	Interventional	2004-09-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder. [NCT00095823]	Phase 3	1,200 participants	Interventional	2004-06-30	Completed
Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE) [NCT00330863]	Phase 4	357 participants (Actual)	Interventional	2006-05-31	Completed
Preventing Morbidity in First Episode Schizophrenia, Part II [NCT00320671]	Phase 4	198 participants (Actual)	Interventional	2005-12-31	Completed
CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) [NCT01421342]	Phase 3	1,522 participants (Actual)	Interventional	2012-12-31	Completed
CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness [NCT00216476]	Phase 3	753 participants (Actual)	Interventional	2004-10-31	Completed
A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder [NCT00706589]	Phase 3	61 participants (Actual)	Interventional	2008-10-31	Completed
A Cluster Randomized, Multi-center, Parallel-group, Rater-blind Study Comparing Treatment With Aripiprazole Once Monthly and Treatment as Usual on Effectiveness in First Episode and Early Phase Illness in Schizophrenia [NCT02360319]	Phase 4	489 participants (Actual)	Interventional	2014-12-11	Completed
Acute Impact of Antipsychotics on Insulin Sensitivity: A Novel Human Model [NCT00895921]	Phase 4	30 participants (Actual)	Interventional	2008-11-30	Completed
Aripiprazole in Children With Symptoms of Mania [NCT00194077]	Phase 3	60 participants (Actual)	Interventional	2004-08-31	Completed
Efficacy and Safety of Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia or Schizoaffective Disorder With Risperidone as an Active Control [NCT00283179]	Phase 3	83 participants (Actual)	Interventional	2004-03-31	Completed
Efficacy of Aripiprazole in Combination With Valproate or Lithium in the Treatment of Mania in Patients With Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy [NCT00257972]	Phase 3	400 participants	Interventional	2004-10-31	Completed
A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia. [NCT00300846]	Phase 4	200 participants	Interventional	2005-12-31	Completed
Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes [NCT00288353]	Phase 3	250 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to unable to secure additional funding)
Effects of Aripiprazole on the Steady-State Pharmacokinetics of Lamotrigine in Subjects With Bipolar I Disorder [NCT00321516]	Phase 1	20 participants	Interventional	2006-07-31	Completed
Comprehensive Treatment of Early Course Schizophrenia: A Nonrandomized Study of Long Acting Injectable Antipsychotic Medication Combined With Cognitive and Functional Skills Training [NCT05662306]	Phase 4	60 participants (Anticipated)	Interventional	2024-02-01	Recruiting
A Prospective Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices [NCT00292409]	Phase 3	400 participants (Anticipated)	Interventional	2005-03-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine o [NCT00325689]	Phase 4	323 participants (Actual)	Interventional	2006-07-31	Completed
Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial [NCT00305370]	Phase 4	20 participants (Anticipated)	Interventional	2005-08-31	Completed
A Multi-center, Randomized, Open, Treatment-switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients [NCT00304616]	Phase 4	500 participants	Interventional	2004-10-31	Completed
Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder. [NCT00304655]	Phase 4	300 participants	Interventional	2004-07-31	Completed
Integrated Biological Markers for the Prediction of Treatment Response in Depression [NCT01655706]	Phase 3	211 participants (Actual)	Interventional	2012-04-23	Completed
Early Detection and Intervention for the Prevention of Psychosis Project [NCT00531518]		292 participants (Actual)	Interventional	2007-10-31	Completed
Aripiprazole Augmentation of Antidepressants in PTSD [NCT00489866]	Phase 2	14 participants (Actual)	Interventional	2007-03-31	Completed
Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder [NCT01696617]	Phase 4	46 participants (Actual)	Interventional	2012-02-10	Completed
Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. [NCT01714011]	Phase 4	175 participants (Actual)	Interventional	2009-05-31	Completed
Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting [NCT01432444]	Phase 3	493 participants (Actual)	Interventional	2011-09-30	Completed
A Longitudinal Comparison of Aripiprazole vs. Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI [NCT01739127]		83 participants (Actual)	Observational	2012-11-30	Completed
[NCT01742390]	Phase 4	120 participants (Anticipated)	Interventional	2013-02-28	Recruiting
Randomized Multicentric Open-label Phase III Clinical Trial to Evaluate the Efficacy of Continual Treatment Versus Discontinuation Based in the Presence of Prodromes in a First Episode of Non-affective Psychosis. [NCT01765829]	Phase 3	104 participants (Anticipated)	Interventional	2012-11-30	Recruiting
A Multiple-Center, Randomized, Double-Blind Study of Comparison of Risperidone and Aripiprazole for Treatment [NCT01813643]	Phase 4	50 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to Effects of aripiprazole was not obvious and showed adverse reaction obviously)
A Multiple-Center, Randomized, Double-Blind Study of Aripiprazole for Treatment of Methamphetamine Dependence [NCT01813656]	Phase 4	10 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Aripiprazole arm had obvious adverse reactions,especially akathisia.)
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building [NCT04446234]	Phase 4	350 participants (Anticipated)	Interventional	2021-05-31	Not yet recruiting
A Double-Blind, Placebo Controlled Study of Aripiprazole in Body Focused Repetitive Behaviors [NCT05545891]	Phase 2	100 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
The Role of Antidepressants or Antipsychotics in Preventing Psychosis: Fluoxetine vs Aripiprazole Comparative Trial (FACT) [NCT02357849]	Phase 4	9 participants (Actual)	Interventional	2014-07-31	Terminated
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction in Patients Undergoing High-dose Antipsychotic Therapy [NCT03019887]		139 participants (Actual)	Interventional	2011-04-30	Completed
A Multi-Center, Randomized, Double-Blind Study, Comparing With Risperidone, to Evaluate the Efficacy and Safety of Aripiprazole in the Treatment of Patients With Schizophrenia [NCT00202007]	Phase 2	240 participants	Interventional	2005-02-28	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder [NCT01727700]	Phase 3	133 participants (Actual)	Interventional	2012-11-30	Completed
Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder [NCT02955654]		0 participants (Actual)	Interventional	2017-09-01	Withdrawn(stopped due to Loss of finacial support)
Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study [NCT01446328]	Phase 4	151 participants (Actual)	Interventional	2011-10-31	Completed
Effects of Aripiprazole on the Steady-State Pharmacokinetics of Venlafaxine in Healthy Subjects [NCT00362271]	Phase 1	38 participants	Interventional	2006-08-31	Completed
A Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD [NCT04539951]	Phase 2	1,600 participants (Anticipated)	Interventional	2020-09-22	Recruiting
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics [NCT03376763]	Phase 4	201 participants (Actual)	Interventional	2017-11-21	Completed
A Multi-Center, Open-Label, Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2 Mg-30 mg) in the Treatment of Adolescent Patients With Schizophrenia and Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or [NCT00102518]	Phase 3	325 participants (Actual)	Interventional	2004-09-30	Completed
A Single-dose, Two-treatment, Two-sequence, Two-period, Two Way Crossover Bioequivalence Study of Bosiqing Aripiprazole Orally Disintegrating Tablets and ABILIFY Under Fasting/Fed Condition [NCT03232710]		66 participants (Anticipated)	Interventional	2017-06-26	Recruiting
A Phase III Trial to Test the Safety and Efficacy of Two Doses of Aripiprazole in Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features [NCT00110461]	Phase 3	296 participants (Actual)	Interventional	2005-03-31	Completed
Efficacy of Biofeedback in the Treatment of Tic Disorder：A Randomized Controlled Trial [NCT05361993]	Phase 4	40 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
An Open Label Study of Aripiprazole in Children and Adolescents With Autism Spectrum Disorders [NCT00619190]	Phase 2	30 participants (Actual)	Interventional	2006-01-31	Completed
"Observational Study on the Effect of Switch to Lurasidone or Other Antipsychothics on Metabolic and Weight Changes in Subjects With Schizophrenia" [NCT04312503]		95 participants (Actual)	Observational	2020-07-13	Completed
An Open-label, Prospective, Randomized and Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug [NCT01592201]	Phase 4	13 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to This study was early terminated due to insufficient enrollment required for hypothesis testing.)
An Open-label, Multiple Dose, Safety and Tolerability Study of Aripiprazole IM Depot Administered in the Deltoid Muscle in Adult Subjects With Schizophrenia [NCT01909466]	Phase 1	141 participants (Actual)	Interventional	2013-07-31	Completed
OSMITTER 316-13-206A Substudy: A Substudy to Measure the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) System and Determine the Latency Period [NCT02091882]	Phase 4	30 participants (Actual)	Interventional	2014-03-21	Completed
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome [NCT00288366]		49 participants (Actual)	Interventional	2006-01-31	Completed
Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder [NCT00241176]	Phase 4	11 participants (Actual)	Interventional	2005-09-30	Completed
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia [NCT00351936]	Phase 4	16 participants (Actual)	Interventional	2005-12-31	Completed
"Developing More Efficacious Treatments for Children With ADHD Who Are Partial or Non-responders to Stimulants" [NCT00279409]	Phase 2	10 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to Recruitment Rate too slow)
A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry [NCT02462473]	Phase 2	9 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.)
A Long-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder [NCT01617460]	Phase 3	86 participants (Actual)	Interventional	2012-09-30	Completed
An Open-label, Randomized, Parallel Arm, Bioavailability Trial of Aripiprazole IM Depot Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Schizophrenia [NCT01646827]	Phase 1	37 participants (Actual)	Interventional	2012-05-31	Completed
A Multicenter, Double-blind, Randomized, Dose-comparison Study of Three Different Doses of Aripiprazole (2 mg/Day, 6-12 mg/Day, 24-30 mg/Day) Orally Administered Over 6 Weeks in Pediatric Patients (Aged 13-17 Years) With Schizophrenia [NCT01942161]	Phase 2/Phase 3	106 participants (Actual)	Interventional	2010-08-31	Completed
A Short-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder [NCT01617447]	Phase 3	92 participants (Actual)	Interventional	2012-07-31	Completed
Randomized, Open-Label, Multiple-Dose Study to Evaluate the Effect of Famotidine on the Pharmacokinetics of Atazanavir/Ritonavir/Tenofovir in Healthy Subjects [NCT00365339]	Phase 1	40 participants	Interventional	2006-04-30	Completed
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol [NCT05814640]	Phase 1/Phase 2	520 participants (Anticipated)	Interventional	2023-02-20	Recruiting
Effects on Aripiprazole on the Steady-State Pharmacokinetics of Escitalopram in Healthy Subjects [NCT00361790]	Phase 1	25 participants	Interventional	2006-08-31	Completed
[NCT00363337]	Phase 4	31 participants (Actual)	Interventional	2006-08-31	Completed
Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting, Europe, Canada and Asia [NCT01509053]	Phase 3	30 participants (Actual)	Interventional	2012-01-31	Terminated
Aripiprazole for Clozapine Associated Medical Morbidity [NCT00345033]	Phase 4	38 participants (Actual)	Interventional	2005-03-31	Completed
Pan European Collaboration on Antipsychotic Naïve Schizophrenia II [NCT02339844]	Phase 4	130 participants (Actual)	Interventional	2014-01-31	Completed
A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder [NCT00365859]	Phase 3	330 participants (Actual)	Interventional	2006-09-30	Completed
Aripiprazole in Fragile X Syndrome [NCT00420459]	Phase 2	12 participants (Actual)	Interventional	2007-04-30	Completed
A Multicenter, 8-week, Open-label, Single-Arm Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System by Adult Subjects With Schizophrenia, Major Depressive Disorder, or Bipolar 1 Treated With Oral Aripip [NCT02722967]	Phase 2	49 participants (Actual)	Interventional	2016-03-31	Completed
A Single-center, Uncontrolled, Open-label Clinical Trial Evaluating the Pharmacokinetic Characteristics and Safety of Aripiprazole IM Depot in Chinese Patients With Schizophrenia After Multi-dose Administration [NCT03285503]	Phase 1	12 participants (Actual)	Interventional	2018-08-17	Completed
A Randomized Controlled Trial of Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder [NCT04963257]	Phase 4	400 participants (Anticipated)	Interventional	2020-01-01	Recruiting
A Multicenter, Randomized, Double-blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Aripiprazole Intramuscular Depot in the Acute Treatment of Adults With Schizophrenia [NCT03172871]	Phase 3	436 participants (Actual)	Interventional	2017-05-15	Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 3-year Follow-up [NCT03090503]	Phase 4	200 participants (Anticipated)	Interventional	2014-06-30	Enrolling by invitation
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder [NCT01418352]	Phase 3	83 participants (Actual)	Interventional	2011-08-02	Completed
An Open-label, Safety and Tolerability Trial of Aripiprazole IM Depot Treatment Initiation in Adult Subjects With Schizophrenia Stabilized on Atypical Oral Antipsychotics Other Than Aripiprazole [NCT01552772]	Phase 1	60 participants (Actual)	Interventional	2012-01-31	Completed
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals [NCT00497055]	Phase 2	90 participants (Actual)	Interventional	2009-03-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder [NCT01418339]	Phase 3	135 participants (Actual)	Interventional	2011-07-27	Completed
The Role of Antidepressants or Antipsychotics in Preventing Psychosis [NCT01724372]		0 participants (Actual)	Interventional	2012-10-31	Withdrawn
A Randomized, Open Label, Parallel Group, Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism [NCT02237417]	Phase 4	47 participants (Actual)	Interventional	2014-09-01	Completed
52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder [NCT01567527]	Phase 3	731 participants (Actual)	Interventional	2012-08-31	Completed
An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder [NCT01416441]	Phase 3	170 participants (Actual)	Interventional	2011-10-19	Completed
Open-label, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Aripiprazole vs Paliperidone/Risperidone Using Multi-omics Data in Patients With a First Episode Psychosis [NCT06060886]	Phase 4	244 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
Striatal Connectivity and Clinical Outcome in Psychosis [NCT02822092]		170 participants (Anticipated)	Observational	2016-07-31	Recruiting
An Open-label Parallel Arm Multiple Dose Tolerability, Pharmacokinetics and Safety Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot Formulation Once Every Four Weeks [NCT01870999]	Phase 1	41 participants (Actual)	Interventional	2007-11-30	Completed
An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder [NCT01727713]	Phase 3	110 participants (Actual)	Interventional	2013-01-31	Completed
Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia [NCT01959035]	Phase 3	88 participants (Actual)	Interventional	2013-10-31	Completed
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder [NCT01710709]	Phase 3	748 participants (Actual)	Interventional	2012-11-30	Completed
Locus Coeruleus Neuroimaging of Antipsychotic/Modafinil Interactions on Cognition in Schizophrenia [NCT01913327]	Phase 4	4 participants (Actual)	Interventional	2013-04-30	Terminated(stopped due to Insufficient Funds and Inadequate Subject Recruitment)
A Multicenter, Open-label Study to Evaluate the Effectiveness and Safety of Aripiprazole in Patients With Acute Episode of Schizophrenia [NCT03289026]	Phase 4	770 participants (Actual)	Interventional	2017-09-01	Completed
A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder [NCT00484471]	Phase 4	127 participants (Actual)	Interventional	2007-10-31	Completed
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain [NCT01844700]	Phase 4	14 participants (Actual)	Interventional	2013-07-31	Terminated(stopped due to very slow recruitment, no sufficient results)
Metabolic Signatures and Biomarkers in First Episode and Recurrent Patients With Schizophrenia in Comparison to Healthy Controls [NCT00466310]	Phase 1	71 participants (Actual)	Interventional	2007-02-28	Completed
Clinical Management of Metabolic Problems in Patients With Schizophrenia [NCT00423878]	Phase 4	215 participants (Actual)	Interventional	2007-01-31	Completed
Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia [NCT05389046]		252 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior ADT [NCT00683852]	Phase 3	225 participants (Actual)	Interventional	2008-09-30	Completed
Comparison of Optimal Antipsychotic Treatments for Schizophrenia Pilot Study [NCT00802100]	Phase 4	21 participants (Actual)	Interventional	2008-12-31	Completed
Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT) [NCT00806234]	Phase 4	127 participants (Actual)	Interventional	2009-01-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type [NCT01438060]	Phase 3	232 participants (Actual)	Interventional	2000-08-31	Completed
A Multicenter, Open-label, Long-term Safety Study of Aripiprazole (Initial Dose 2 mg/Day, Maintenance Dose 6-24 mg/Day, Maximum Dose 30 mg/Day) Orally Administered Over 52 Weeks in Patients Who Complete a Short-term Treatment Study of Aripiprazole in Pedi [NCT01942148]	Phase 3	68 participants (Actual)	Interventional	2010-08-31	Completed
A 28-week, Randomised, Open-label Study Evaluating the Effectiveness of Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia [NCT01795547]	Phase 3	295 participants (Actual)	Interventional	2013-02-28	Completed
Aripiprazole, Abilify Maintena Collaborative Clinical Protocol [NCT02717130]		9 participants (Actual)	Interventional	2016-06-08	Terminated(stopped due to The study was terminated due to lack of enrollment.)
Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole [NCT04903353]	Phase 4	350 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Proof of Concept Study to Treat Negative Affect in Chronic Low Back Pain [NCT04747314]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2021-03-31	Recruiting
Clinical Psychopharmacology Division Institute of Mental Health, Peking University [NCT03148509]	Phase 4	300 participants (Anticipated)	Interventional	2017-06-01	Not yet recruiting
Estimating the Optimal Dynamic Antipsychotic Treatment Regime: Sequential Multiple-assignment Randomized Clinical Antipsychotic Trials in Chinese Patients With First-episode Psychosis. [NCT03510325]	Phase 4	1,260 participants (Anticipated)	Interventional	2018-10-01	Not yet recruiting
A Multicenter, Randomized, Double-Blind, Flexible-Dosed, Placebo-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Tourette's Syndrome [NCT03487783]	Phase 3	121 participants (Actual)	Interventional	2018-05-02	Completed
Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II) [NCT02305823]	Phase 4	203 participants (Actual)	Interventional	2005-10-31	Completed
[NCT02220712]	Phase 1	17 participants (Actual)	Interventional	2014-07-31	Completed
A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023 [NCT01328093]	Phase 3	678 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder [NCT01111565]	Phase 3	137 participants (Actual)	Interventional	2010-10-04	Terminated(stopped due to The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.)
A Phase III, Multicenter, Randomized, Double-blind, Active-Controlled Study (Aripiprazole Tablets) to Evaluate the Efficacy and Safety of Brexpiprazole in the Treatment of Adults With Acute Schizophrenia [NCT03874494]	Phase 3	371 participants (Actual)	Interventional	2019-11-27	Completed
A Multicenter, 8-week, Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adult Subjects With Schizophrenia Who Are Treated With Oral Aripiprazole [NCT02219009]	Phase 2	67 participants (Actual)	Interventional	2014-08-31	Completed
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder [NCT01490086]	Phase 2	234 participants (Actual)	Interventional	2011-12-31	Completed
Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia [NCT02054702]	Phase 3	97 participants (Actual)	Interventional	2014-02-28	Completed
Effectiveness of Switching Antipsychotic Medications [NCT00044655]	Phase 4	219 participants (Actual)	Interventional	2001-07-31	Completed
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia [NCT01683058]	Phase 3	74 participants (Actual)	Interventional	2013-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00044655 (1) [back to overview]	Number Who Discontinued Medication Within First 6 Study Months
NCT00102063 (8) [back to overview]	Clinical Global Impression (CGI) Improvement Score
NCT00102063 (8) [back to overview]	Patients Achieving Remission
NCT00102063 (8) [back to overview]	Change in Children's Global Assessment Scale (CGAS) Score
NCT00102063 (8) [back to overview]	Change in Clinical Global Impression (CGI) Severity Score
NCT00102063 (8) [back to overview]	Change in Pediatric Quality of Life Enjoyment and Satisfaction (PQLES) Questionnaire Total Score
NCT00102063 (8) [back to overview]	Change in Positive and Negative Syndrome Scale (PANSS) Negative Subscale Score
NCT00102063 (8) [back to overview]	Change in Positive and Negative Syndrome Scale (PANSS) Positive Subscale Score
NCT00102063 (8) [back to overview]	Change in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT00102518 (3) [back to overview]	Change in Change in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT00102518 (3) [back to overview]	Change in Young Mania Rating Scale (Y-MRS) Total Score
NCT00102518 (3) [back to overview]	Percentage of Subjects Experiencing SAEs
NCT00105196 (8) [back to overview]	Mean Change in SDS Item Score (Social Life)
NCT00105196 (8) [back to overview]	Mean Change in SDS Item Score (Family Life)
NCT00105196 (8) [back to overview]	MADRS Response
NCT00105196 (8) [back to overview]	MADRS Remission
NCT00105196 (8) [back to overview]	Clinical Global Impression (CGI)-Improvement Response
NCT00105196 (8) [back to overview]	Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS)
NCT00105196 (8) [back to overview]	Mean Change in Sheehan Disability Scale (SDS) Mean Score
NCT00105196 (8) [back to overview]	Mean Change in SDS Item Score (Work/School)
NCT00110461 (30) [back to overview]	Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 4
NCT00110461 (30) [back to overview]	Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 30
NCT00110461 (30) [back to overview]	Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 4
NCT00110461 (30) [back to overview]	Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 30
NCT00110461 (30) [back to overview]	Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 4
NCT00110461 (30) [back to overview]	Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 30
NCT00110461 (30) [back to overview]	Subject Response to Treatment at Week 4
NCT00110461 (30) [back to overview]	Subject Response to Treatment at Week 30
NCT00110461 (30) [back to overview]	Change in Young Mania Rating Scale (Y-MRS) Total Score at Week 4
NCT00110461 (30) [back to overview]	Change in Young Mania Rating Scale (Y-MRS) Total Score at Week 30
NCT00110461 (30) [back to overview]	Change in General Behavior Inventory Scale (GBI) Total Subject Version Mania Score at Week 4
NCT00110461 (30) [back to overview]	Change in General Behavior Inventory Scale (GBI) Total Subject Version Mania Score at Week 30
NCT00110461 (30) [back to overview]	Change in General Behavior Inventory Scale (GBI) Total Subject Version Depression Score at Week 4
NCT00110461 (30) [back to overview]	Change in General Behavior Inventory Scale (GBI) Total Subject Version Depression Score at Week 30
NCT00110461 (30) [back to overview]	Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Mania Score at Week 4
NCT00110461 (30) [back to overview]	Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Mania Score at Week 30
NCT00110461 (30) [back to overview]	Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Depression Score at Week 4
NCT00110461 (30) [back to overview]	Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Depression Score at Week 30
NCT00110461 (30) [back to overview]	Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 4
NCT00110461 (30) [back to overview]	Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 30
NCT00110461 (30) [back to overview]	Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 4
NCT00110461 (30) [back to overview]	Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 30
NCT00110461 (30) [back to overview]	Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 4
NCT00110461 (30) [back to overview]	Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 30
NCT00110461 (30) [back to overview]	Change in Children's Global Assessment Scale (CGAS) Total Score at Week 4
NCT00110461 (30) [back to overview]	Change in Children's Global Assessment (CGAS) Total Score at Week 30
NCT00110461 (30) [back to overview]	Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 4
NCT00110461 (30) [back to overview]	Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 30
NCT00110461 (30) [back to overview]	Change in Attention Deficit Hyperactivity Disorders Rating Scale (ADHD-RS-IV) Total Score at Week 4
NCT00110461 (30) [back to overview]	Change in Attention Deficit Hyperactivity Disorders Rating Scale (ADHD-RS-IV) Total Score at Week 30
NCT00177164 (4) [back to overview]	Evaluate the Number of Clinical Events (Pooled) Occurring Between 3-15 Months Following a Switch/Stabilization of the Antipsychotic Agents Among Patients Who Receive Either Risperidal Consta or One of the 4 Marketed 2nd Generation Antipsychotic Agents.
NCT00177164 (4) [back to overview]	Number of Participants With Treatment - Emergent Hyperglycemia
NCT00177164 (4) [back to overview]	Number of Participants With Treatment Emergent Hyperlipidemia
NCT00177164 (4) [back to overview]	BMI
NCT00194012 (15) [back to overview]	Clinical Global Impressions Scale (CGI-Severity)
NCT00194012 (15) [back to overview]	CDRS-R Children's Depression Rating Scale-Revised
NCT00194012 (15) [back to overview]	Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale IV or (ARS-IV)
NCT00194012 (15) [back to overview]	Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale IV or (ARS-IV)
NCT00194012 (15) [back to overview]	Young Mania Rating Scale (YMRS)
NCT00194012 (15) [back to overview]	Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale IV or (ARS-IV)
NCT00194012 (15) [back to overview]	Young Mania Rating Scale (YMRS)
NCT00194012 (15) [back to overview]	CDRS-R Children's Depression Rating Scale-Revised
NCT00194012 (15) [back to overview]	Young Mania Rating Scale (YMRS)
NCT00194012 (15) [back to overview]	Children's Depression Rating Scale-Revised (CDRS-R )
NCT00194012 (15) [back to overview]	Children's Global Assessment Scale (CGAS)
NCT00194012 (15) [back to overview]	Children's Global Assessment Scale (CGAS)
NCT00194012 (15) [back to overview]	Children's Global Assessment Scale (CGAS)
NCT00194012 (15) [back to overview]	Clinical Global Impressions Scale (CGI-Severity)
NCT00194012 (15) [back to overview]	Clinical Global Impressions Scale (CGI-Severity)
NCT00194077 (1) [back to overview]	Time in Weeks to Discontinuation
NCT00198107 (10) [back to overview]	Mean Post-baseline Score on a Modified Version of the Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT00198107 (10) [back to overview]	Mean Social Reciprocity Scale (SRS) Total Score, Week 8
NCT00198107 (10) [back to overview]	Mean Vineland Maladaptive Behavior Subscales Total Score, Week 8
NCT00198107 (10) [back to overview]	Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Score, Parent Report, Double-blind Phase
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Score, Parent Report, Double-blind Phase
NCT00198107 (10) [back to overview]	Mean Autism Diagnostic Observation Schedule (ADOS) Social Affect and Restricted and Repetitive Behaviors Total Score, Week 8
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Score, Parent Report, Double-blind Phase
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Stereotypy Score, Parent Report, Double-blind Phase
NCT00205699 (6) [back to overview]	Change in MRI-measured Visceral Abdominal Fat
NCT00205699 (6) [back to overview]	Change in MRI-measured Subcutaneous Abdominal Fat
NCT00205699 (6) [back to overview]	Change in Insulin-stimulated Glycerol Rate of Appearance (Glycerol Ra)
NCT00205699 (6) [back to overview]	Change in Insulin-stimulated Glucose Rate of Disappearance (Glucose Rd)
NCT00205699 (6) [back to overview]	Change in DEXA % Body Fat
NCT00205699 (6) [back to overview]	Change in Insulin-stimulated Glucose Rate of Appearance (Glucose Ra)
NCT00216476 (5) [back to overview]	Change From Baseline to Endpoint in Short-Form Health Survey 12 (SF-12) Scores
NCT00216476 (5) [back to overview]	Mean Relapse Free Period(Risperidone LAI Versus Quetiapine)
NCT00216476 (5) [back to overview]	Mean Relapse Free Period (Exploratory/Aripiprazole)
NCT00216476 (5) [back to overview]	Change From Baseline to Endpoint in Total Positive and Negative Syndrome Scale (PANSS) Score
NCT00216476 (5) [back to overview]	Change From Baseline to Endpoint in Clinical Global Impression Scale (CGI) Score
NCT00220636 (4) [back to overview]	Change in Global Assessment of Functioning Scale (GAFS)
NCT00220636 (4) [back to overview]	Change in Beck Depression Inventory (BDI) Score
NCT00220636 (4) [back to overview]	Hamilton Depression Rating Scale (HDRS)
NCT00220636 (4) [back to overview]	Clinical Global Impressions Improvement Scale (CGI)
NCT00223496 (1) [back to overview]	Primary Measure:Reduction in Depression Symptoms
NCT00239356 (7) [back to overview]	Mean Exposure to Aripiprazole at Days 541 to 630, Days 721 to 810 and Days 1081 to 1170 - Safety Population
NCT00239356 (7) [back to overview]	Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs), and Discontinuation Due to an AE - Safety Population
NCT00239356 (7) [back to overview]	Number of Participants With Potentially Clinically Relevant Chemistry Laboratory Abnormalities During Treatment - Safety Population
NCT00239356 (7) [back to overview]	Number of Participants With Potentially Clinically Relevant ECG Abnormalities During Treatment - Safety Population
NCT00239356 (7) [back to overview]	Number of Participants With Potentially Clinically Relevant Hematology Laboratory Abnormalities During Treatment - Safety Population
NCT00239356 (7) [back to overview]	Number of Participants With Potentially Clinically Relevant Vital Sign Abnormality During Treatment - Safety Population
NCT00239356 (7) [back to overview]	Mean Clinical Global Impression Severity Score (CGI-S) From Baseline Through End of Study- - Safety Population.
NCT00241176 (2) [back to overview]	Clinical Global Impression Severity Scores
NCT00241176 (2) [back to overview]	Calculating Difference Between Means (Baseline and Endpoint Scores on the Yale Global Tic Severity Scale Subscales)
NCT00250705 (5) [back to overview]	Children's Aggression Scale-Parent Version
NCT00250705 (5) [back to overview]	The Primary Outcome Efficacy Measure: Rating of Aggression Against People and/or Property Scale (RAAPP) (Kemph et al 1993)
NCT00250705 (5) [back to overview]	Overt Aggression Scale-Modified (OAS-M)
NCT00250705 (5) [back to overview]	Secondary Outcome Measures Were the Clinical Global Impression--Improvement (CGI-I) Scales (NIMH, 1985a).
NCT00250705 (5) [back to overview]	Secondary Outcome Measures Were the Clinical Global Impression-Severity (CGI-S) Scale (NIMH, 1985a).
NCT00261443 (124) [back to overview]	Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), and Discontinuations Due to AEs During Phase 2
NCT00261443 (124) [back to overview]	Deaths, Treatment-Emergent Serious Adverse Events (SAEs), Adverse Events (AEs) in >=2% of Participants, and AEs Leading to Discontinuation During Phase 3
NCT00261443 (124) [back to overview]	Extension Phase: Adverse Events (AEs), by Maximum Intensity
NCT00261443 (124) [back to overview]	Extension Phase: Deaths, Adverse Events (AES), Serious Adverse Events (SAEs), and Discontinuations
NCT00261443 (124) [back to overview]	Extension Phase: Mean Baseline and Mean Change From Baseline in CGI-BP (Mania)
NCT00261443 (124) [back to overview]	Extension Phase: Mean Baseline and Mean Change From Baseline in CGI-BP Severity of Illness (Depression) Through Extension Phase
NCT00261443 (124) [back to overview]	Extension Phase: Mean Baseline and Mean Change From Baseline in CGI-BP Severity of Illness (Overall) Through Extension Phase
NCT00261443 (124) [back to overview]	Extension Phase: Participants With Potentially Clinically Relevant ECG Abnormalities
NCT00261443 (124) [back to overview]	Extension Phase: Participants With Potentially Clinically Relevant Laboratory Abnormalities
NCT00261443 (124) [back to overview]	Extension Phase: Participants With Potentially Clinically Relevant Metabolic Laboratory Abnormalities During Extension Phase
NCT00261443 (124) [back to overview]	Extension Phase: Participants With Potentially Clinically Relevant Vital Sign Abnormalities
NCT00261443 (124) [back to overview]	Mean Baseline and Adjusted Mean Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score Through Phase 3
NCT00261443 (124) [back to overview]	Mean Baseline and Adjusted Mean Change From Baseline in Young-Mania Rating Scale (Y-MRS) Total Score Through Phase 3
NCT00261443 (124) [back to overview]	Mean Baseline and Unadjusted Mean Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score Through Phase 2 and at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Mean Baseline and Unadjusted Mean Change From Baseline in Young-Mania Rating Scale (Y-MRS) Total Score Through Phase 2
NCT00261443 (124) [back to overview]	Median Baseline Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK), and Lactate Dehydrogenase (LD), Phase 2 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline and Change From Baseline in Blood Pressure (BP) Vital Sign Measurements During Phase 2
NCT00261443 (124) [back to overview]	Median Baseline and Change From Baseline in Body Mass Index (BMI) During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline and Change From Baseline in Body Mass Index (BMI) Vital Sign Measurements at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Median Baseline and Change From Baseline in ECG Measurements During Phase 2
NCT00261443 (124) [back to overview]	Median Baseline and Change From Baseline in Heart Rate Measurements During Phase 2
NCT00261443 (124) [back to overview]	Median Baseline and Change From Baseline in Heart Rate Vital Sign Measurements During Phase 2
NCT00261443 (124) [back to overview]	Median Baseline and Change From Baseline in Weight Vital Sign Measurements At Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Median Baseline Blood Urea Nitrogen (BUN), Total Cholesterol-Fasting (TC), Creatine, Glucose, High Density Lipoprotein Cholesterol-Fasting (HDL-C), Low Density Lipoprotein Cholesterol-Fasting (LDL-C), Bilirubin-Total, Triglycerides, and Uric Acid
NCT00261443 (124) [back to overview]	Median Baseline Eosinophils (Relative) and Neutrophils (Relative)
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Value of Change in Leukocytes, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Values in Sitting Diastolic BP During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Values in Sitting Heart Rate During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Values in Sitting Systolic BP During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Values in Standing Diastolic BP During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Values in Standing Heart Rate During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Values in Standing Systolic BP During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Values in Supine Diastolic BP During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Values in Supine Heart Rate During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Values in Supine Systolic BP During Phase 3
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Change Value in LDL Cholesterol (Fasting), Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Alkaline Phosphatase (ALP), Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in ALT, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in AST, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in BUN, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Creatine Kinase, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Creatinine, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Eosinophils (Relative), Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Glucose (Fasting), Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Heart Rate, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in HOMA2-IR, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in HOMA2-Percent Beta, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Lactate Dehydrogenase, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Neutrophils (Relative), Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in PR, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Prolactin, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in QRS, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in QT Interval Corrected for Heart Rate (QTc) Bazett, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in QTc (0.33), Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in RR, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Total Bilirubin, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Total Cholesterol (Fasting), Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Triglycerides (Fasting), Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest Value of Change in Uric Acid, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Lowest Value of Change in HDL Cholesterol (Fasting), Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Lowest Value of Change in Hematocrit, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Lowest Value of Change in Hemoglobin, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK), and Lactate Dehydrogenase (LD) at the End of Phase 2
NCT00261443 (124) [back to overview]	Median Change From Baseline in BUN, TC, Creatine, Glucose, HDL-C, LDL-C, Bilirubin-Total, Triglycerides, and Uric Acid at the End of Phase 2
NCT00261443 (124) [back to overview]	Median Change From Baseline in Eosinophils (Relative) and Neutrophils (Relative)
NCT00261443 (124) [back to overview]	Number of Participants Maintaining Remission During Phase 3
NCT00261443 (124) [back to overview]	Number of Participants Showing Relevant Weight Gain During Phase 3
NCT00261443 (124) [back to overview]	Number of Participants Showing Relevant Weight Loss During Phase 3
NCT00261443 (124) [back to overview]	Number of Participants Taking Concomitant Medications for Potential Treatment of Extrapyramidal Syndrome (EPS) During Phase 3
NCT00261443 (124) [back to overview]	Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities During Phase 2
NCT00261443 (124) [back to overview]	Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities During Phase 3
NCT00261443 (124) [back to overview]	Number of Participants With Potentially Clinically Relevant Laboratory Abnormalities During Phase 2
NCT00261443 (124) [back to overview]	Number of Participants With Potentially Clinically Relevant Laboratory Abnormalities During Phase 3
NCT00261443 (124) [back to overview]	Number of Participants With Potentially Clinically Relevant Vital Sign Abnormalities During Phase 2
NCT00261443 (124) [back to overview]	Participants With Potentially Clinically Relevant Vital Sign Abnormalities During Phase 3
NCT00261443 (124) [back to overview]	Proportion of Participants Not Experiencing Relapse of Depressive Episode Through Week 52 During Phase 3
NCT00261443 (124) [back to overview]	Proportion of Participants Not Experiencing Relapse of Manic Episode Through Phase 3
NCT00261443 (124) [back to overview]	Proportion of Participants Not Experiencing Relapse to Any Mood Episode Through Week 52, Phase 3
NCT00261443 (124) [back to overview]	Treatment-Emergent Adverse Events in >=5 Percent of Participants, by Severity, During Phase 2
NCT00261443 (124) [back to overview]	Treatment-Emergent AEs in >=5% of Participants During Phase 3, by Age, Gender, Race, and Maximum Intensity
NCT00261443 (124) [back to overview]	Unadjusted Mean Baseline and Mean Change From Baseline in the CGI-BP Severity of Illness (Mania) Through Phase 2
NCT00261443 (124) [back to overview]	Unadjusted Mean Change Baseline and Mean Change From Baseline in the CGI-BP Severity of Illness (Depression) Through Phase 2
NCT00261443 (124) [back to overview]	Unadjusted Mean Change Baseline and Mean Change From Baseline in the CGI-BP Severity of Illness (Overall) Through Phase 2
NCT00261443 (124) [back to overview]	Unadjusted Mean Change From Preceding Phase in the CGI-BP (Depression) Through Phase 2
NCT00261443 (124) [back to overview]	Unadjusted Mean Change From Preceding Phase in the CGI-BP (Mania) Through Phase 2
NCT00261443 (124) [back to overview]	Unadjusted Mean Change From Preceding Phase in the CGI-BP (Overall) Through Phase 2
NCT00261443 (124) [back to overview]	Baseline Abnormal Involuntary Movement Scale (AIMS)
NCT00261443 (124) [back to overview]	Baseline in Barnes Akathisia Global Clinical Assessment
NCT00261443 (124) [back to overview]	Baseline in Simpson-Angus Scale (SAS) Total Score
NCT00261443 (124) [back to overview]	Extension Phase: Mean Change From Baseline in CGI-BP (Mania) Severity of Illness at Extension Phase Endpoint
NCT00261443 (124) [back to overview]	Extension Phase: Mean Change From Baseline in CGI-BP Severity of Illness (Depression) at Extension Phase Endpoint
NCT00261443 (124) [back to overview]	Extension Phase: Mean Change From Baseline in CGI-BP Severity of Illness (Overall) at Extension Phase Endpoint
NCT00261443 (124) [back to overview]	Median Baseline Hematocrit
NCT00261443 (124) [back to overview]	Median Baseline Hemoglobin
NCT00261443 (124) [back to overview]	Median Baseline Homeostasis Model Assessment 2 (HOMA2)-Percent Beta
NCT00261443 (124) [back to overview]	Median Baseline Homeostasis Model Assessment 2 HOMA2-Insulin Resistance (IR)
NCT00261443 (124) [back to overview]	Median Baseline Leukocytes
NCT00261443 (124) [back to overview]	Median Baseline Platelet Count
NCT00261443 (124) [back to overview]	Median Baseline, Change From Baseline, and Highest and Lowest Value of Change in Platelet Count, Phase 3 Safety Sample
NCT00261443 (124) [back to overview]	Median Baseline Prolactin
NCT00261443 (124) [back to overview]	Median Change From Baseline in Hematocrit
NCT00261443 (124) [back to overview]	Median Change From Baseline in Hemoglobin
NCT00261443 (124) [back to overview]	Median Change From Baseline in HOMA2 Model Assesses Insulin Resistance (HOMA2-IR) at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Median Change From Baseline in Homeostasis Model Assessment 2(HOMA2)-Percent Beta at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Median Change From Baseline in Leukocytes at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Median Change From Baseline in Platelet Count at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Median Change From Baseline in Prolactin at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Proportion of Participants Discontinuing For Any Reason Through Week 52 (During Phase 3)
NCT00261443 (124) [back to overview]	Unadjusted Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Unadjusted Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Unadjusted Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score at Phase 2 Endpoint
NCT00261443 (124) [back to overview]	Adjusted Mean Change From Baseline in AIMS Item 10 During Phase 3
NCT00261443 (124) [back to overview]	Adjusted Mean Change From Baseline in AIMS Item 8 During Phase 3
NCT00261443 (124) [back to overview]	Adjusted Mean Change From Baseline in AIMS Item 9 During Phase 3
NCT00261443 (124) [back to overview]	Adjusted Mean Change From Baseline in AIMS Total Score During Phase 3
NCT00261443 (124) [back to overview]	Adjusted Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment During Phase 3
NCT00261443 (124) [back to overview]	Adjusted Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score During Phase 3
NCT00261443 (124) [back to overview]	Adjusted Mean Change in CGI-BP From Preceding Phase (Depression) Through Phase 3
NCT00261443 (124) [back to overview]	Adjusted Mean Change in CGI-BP From Preceding Phase (Mania) Through Phase 3
NCT00261443 (124) [back to overview]	Adjusted Mean Change in CGI-BP From Preceding Phase (Overall) Through Phase 3
NCT00261443 (124) [back to overview]	Baseline and Adjusted Mean Change From Baseline in CGI-BP Severity of Illness (Depression) Score Through Phase 3
NCT00261443 (124) [back to overview]	Baseline and Adjusted Mean Change From Baseline in Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) Severity of Illness Score (Mania) Through Phase 3
NCT00261443 (124) [back to overview]	Baseline and Adjusted Mean Change From Baseline in the CGI-BP Severity of Illness (Overall) Through Phase 3
NCT00261443 (124) [back to overview]	Baseline and Adjusted Mean Change From Baseline in Weight
NCT00277212 (17) [back to overview]	Number of Participants Showing Clinically Relevant Weight Loss by Study Week
NCT00277212 (17) [back to overview]	Number of Participants With Potentially Clinically Relevant Laboratory Abnormalities Occurring During Double-Blind Treatment (Phase 2)
NCT00277212 (17) [back to overview]	Number of Participants Showing Clinically Relevant Weight Gain by Study Week
NCT00277212 (17) [back to overview]	Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities Occurring During Double-Blind Treatment
NCT00277212 (17) [back to overview]	Proportion of Participants Not Experiencing a Depressive Relapse in the Double-blind Relapse Assessment Phase (Phase 2)
NCT00277212 (17) [back to overview]	Proportion of Participants Not Experiencing Relapse (Manic, Mixed, Depressive) in the Double-blind Relapse Assessment Phase Phase 2
NCT00277212 (17) [back to overview]	Proportion of Participants Not Experiencing Relapse Through Week 52 in the Double-Blind Relapse Assessment Phase (Phase 2)
NCT00277212 (17) [back to overview]	Proportion of Participants Without Discontinuation for Any Reason in the Double-blind Relapse Assessment Phase (Phase 2)
NCT00277212 (17) [back to overview]	Summary of Concomitant Medications, Phase 1
NCT00277212 (17) [back to overview]	Summary of Concomitant Medications, Phase 2
NCT00277212 (17) [back to overview]	Number of Participants With Potentially Clinically Relevant Vital Sign Abnormalities Occurring During Double-Blind Treatment
NCT00277212 (17) [back to overview]	Adjusted Mean Change From Baseline in Body Weight, Phase 2
NCT00277212 (17) [back to overview]	Adjusted Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
NCT00277212 (17) [back to overview]	Adjusted Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment,
NCT00277212 (17) [back to overview]	Adjusted Mean Change From Baseline in BMI by Study Week
NCT00277212 (17) [back to overview]	Adjusted Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score
NCT00277212 (17) [back to overview]	Deaths, Treatment-Emergent Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation of Study Medication, Treatment-Emergent AEs and Treatment-Emergent Extrapyramidal Syndrome (EPS)-Related AEs
NCT00288366 (1) [back to overview]	HDL Ratio
NCT00299702 (2) [back to overview]	Time in Remission
NCT00299702 (2) [back to overview]	Time to Relapse
NCT00308074 (4) [back to overview]	Clinical Global Impressions-Improvement
NCT00308074 (4) [back to overview]	Brief Psychiatric Rating Scale for Children (BPRS-C)
NCT00308074 (4) [back to overview]	Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
NCT00308074 (4) [back to overview]	Aberrant Behavior Checklist-Irritability Subscale
NCT00320671 (1) [back to overview]	Percentage of Participants That Responded to Treatment
NCT00330863 (3) [back to overview]	Side Effects and Metabolic Measures
NCT00330863 (3) [back to overview]	Substantial Clinical Deterioration Measured by Psychotic Symptoms
NCT00330863 (3) [back to overview]	Number of Patients Discontinuing From the Study
NCT00332241 (8) [back to overview]	Mean Clinical Global Impressions Improvement Scale (CGI-I) Score
NCT00332241 (8) [back to overview]	Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)
NCT00332241 (8) [back to overview]	Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score
NCT00332241 (8) [back to overview]	Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)
NCT00332241 (8) [back to overview]	Change From Baseline in Body Weight
NCT00332241 (8) [back to overview]	Summary of Safety
NCT00332241 (8) [back to overview]	Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores
NCT00332241 (8) [back to overview]	Number of Participants With Response at Week 8
NCT00337571 (8) [back to overview]	Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)
NCT00337571 (8) [back to overview]	Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score
NCT00337571 (8) [back to overview]	Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)
NCT00337571 (8) [back to overview]	Mean Clinical Global Impressions Improvement Scale (CGI-I) Score
NCT00337571 (8) [back to overview]	Number of Participants With Response at Week 8
NCT00337571 (8) [back to overview]	Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores
NCT00337571 (8) [back to overview]	Summary of Safety
NCT00337571 (8) [back to overview]	Change From Baseline in Body Weight
NCT00345033 (6) [back to overview]	Change in Triglycerides
NCT00345033 (6) [back to overview]	Change in Body Mass Index (BMI)
NCT00345033 (6) [back to overview]	Change in Weight
NCT00345033 (6) [back to overview]	Change in Total Cholesterol
NCT00345033 (6) [back to overview]	Change in Insulin Resistance
NCT00345033 (6) [back to overview]	Change in Glucose Metabolism
NCT00351936 (7) [back to overview]	Change From Baseline in Triglycerides
NCT00351936 (7) [back to overview]	Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
NCT00351936 (7) [back to overview]	Change From Baseline in Fasting Total Cholesterol
NCT00351936 (7) [back to overview]	Change From Baseline in Body Mass Index (BMI)
NCT00351936 (7) [back to overview]	Change From Baseline in Low-density Lipoprotein (LDL)
NCT00351936 (7) [back to overview]	Change From Baseline in Waist-hip Ratio (WHR)
NCT00351936 (7) [back to overview]	Change From Baseline in Weight (Lbs)
NCT00365859 (21) [back to overview]	Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities
NCT00365859 (21) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs
NCT00365859 (21) [back to overview]	Number of Potentially Clinically Relevant Vital Sign Abnormalities
NCT00365859 (21) [back to overview]	CGI-Improvement Score at Week 52 (Endpoint, LOCF)
NCT00365859 (21) [back to overview]	Change From Baseline in ABC Stereotypy Subscale Score at Week 52 (Endpoint, LOCF)
NCT00365859 (21) [back to overview]	Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Score at Week 52 (Endpoint, LOCF)
NCT00365859 (21) [back to overview]	Mean Change From Baseline By Time Period in BMI Z-Score
NCT00365859 (21) [back to overview]	Mean Change From Baseline in Patient Body Mass Index (BMI)
NCT00365859 (21) [back to overview]	Mean Change From Baseline by Time Period in Body Weight Z-Score
NCT00365859 (21) [back to overview]	Mean Change From Baseline in ABC Hyperactivity Subscale Score at Week 52 (Endpoint, LOCF)
NCT00365859 (21) [back to overview]	Mean Change From Baseline in ABC Inappropriate Speech Subscale Score at Week 52 (Endpoint, LOCF)
NCT00365859 (21) [back to overview]	Mean Change From Baseline in ABC Social Withdrawal Scale At Week 52 (Endpoint, LOCF)
NCT00365859 (21) [back to overview]	Mean Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Score at Week 52 (Endpoint, LOCF)
NCT00365859 (21) [back to overview]	Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52
NCT00365859 (21) [back to overview]	Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment at Week 8, Week 26, Week 52, and Endpoint
NCT00365859 (21) [back to overview]	Mean Change From Baseline in Clinical Global Impression (CGI)-Severity Score at Week 52 (Endpoint, LOCF)
NCT00365859 (21) [back to overview]	Mean Change From Baseline in Patient Weight
NCT00365859 (21) [back to overview]	Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52
NCT00365859 (21) [back to overview]	Number of Participants With Potentially Clinically Relevant Eletrocardiograph (ECG) Abnormalities
NCT00365859 (21) [back to overview]	Number of Participants With Potentially Clinically Relevant Laboratory Chemistry Abnormalities
NCT00365859 (21) [back to overview]	Number of Participants With Potentially Clinically Relevant Laboratory Hematology Abnormalities
NCT00373880 (3) [back to overview]	Plasma Cocaine
NCT00373880 (3) [back to overview]	Subjective Effects of Cocaine
NCT00373880 (3) [back to overview]	Cocaine Self-administration
NCT00392197 (2) [back to overview]	HbA1c
NCT00392197 (2) [back to overview]	Fasting Blood Glucose (FBS) Level (if Fasting Blood Glucose Level Was Not Available, Non-fasting Blood Glucose (Non-FBS) Level)
NCT00420459 (4) [back to overview]	Aberrant Behavior Checklist
NCT00420459 (4) [back to overview]	The Children's Yale-Brown Obsessive Compulsive Scale
NCT00420459 (4) [back to overview]	Clinical Global Impressions- Severity
NCT00420459 (4) [back to overview]	Social Responsiveness Scale
NCT00423878 (2) [back to overview]	Efficacy Failure, Defined as Psychiatric Hospitalization, a 25 Percent Increase From Baseline on the Positive and Negative Syndrome Scale or Substantial Clinical Deterioration on the Clinical Global Impressions-Change (CGI-C)
NCT00423878 (2) [back to overview]	Change in Non-HDL Cholesterol Level for Patients Assigned to Stay and Patients Assigned to Switch Over 24 Weeks
NCT00466310 (1) [back to overview]	Total Plasmalogen Levels in the Lipid Profile
NCT00468130 (2) [back to overview]	Clinical Global Impression Improvement (CGI-AD)
NCT00468130 (2) [back to overview]	Aberrant Behavior Checklist
NCT00489866 (5) [back to overview]	Beck Depression Inventory, Second Edition (BDI-II)
NCT00489866 (5) [back to overview]	Clinician Administered PTSD Scale (CAPS)
NCT00489866 (5) [back to overview]	Connor-Davidson Resilience Scale (CD-RISC)
NCT00489866 (5) [back to overview]	Brief Assessment of Cognition in Affective Disorders (BAC-A)
NCT00489866 (5) [back to overview]	Positive and Negative Symptoms Scale (PANSS)
NCT00497055 (3) [back to overview]	To Measure the Safety and Tolerability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, as Determined by the Number of Adverse Clinical Events in the Aripiprazole and Placebo Arms.
NCT00497055 (3) [back to overview]	To Measure the Acceptability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, by Determining (Via Electronic Pill Caps [MEMS or Medication Event Monitoring System]) Medication Adherence to Aripiprazole and Placebo.
NCT00497055 (3) [back to overview]	To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals.
NCT00508157 (2) [back to overview]	Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (HDL) Cholesterol at Week 16
NCT00508157 (2) [back to overview]	Number of Participants Remaining on Metabolic Syndrome at Week 16
NCT00509067 (3) [back to overview]	MATRICS Verbal Learning and Memory
NCT00509067 (3) [back to overview]	Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)
NCT00509067 (3) [back to overview]	Clinical Global Impression
NCT00531518 (1) [back to overview]	Psychotic Symptoms
NCT00556140 (2) [back to overview]	Depression and Psychosis Response Rate
NCT00556140 (2) [back to overview]	Depression and Psychosis Remission Rate
NCT00592683 (2) [back to overview]	Change in Bipolar Symptoms as Assessed by Young-Mania Rating Scale (YMRS)
NCT00592683 (2) [back to overview]	DSM-IV Mania Symptom Checklist
NCT00606177 (2) [back to overview]	Young Mania Rating Scale (YMRS)
NCT00606177 (2) [back to overview]	Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)
NCT00606229 (2) [back to overview]	Young Mania Rating Scale (YMRS)
NCT00606229 (2) [back to overview]	Clinical Global Impression - Bipolar Version (CGI-BP) Sevirity of Illness Score (Mania)
NCT00606281 (2) [back to overview]	Clinical Global Impression - Bipolar Version (CGI-BP), Severity of Illness Score (Mania)
NCT00606281 (2) [back to overview]	Young Mania Rating Scale (YMRS)
NCT00606320 (2) [back to overview]	Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)
NCT00606320 (2) [back to overview]	Young Mania Rating Scale (YMRS)
NCT00608543 (6) [back to overview]	Stockings of Cambridge (SOC) Mean Initial Thinking Time for 5-move Problems
NCT00608543 (6) [back to overview]	Spatial Working Memory (SWM) Between Errors for 6-move Problems
NCT00608543 (6) [back to overview]	Change in Hamilton Rating Scale for Depression (HRSD - 17-item)
NCT00608543 (6) [back to overview]	Spatial Working Memory (SWM) Strategy Score
NCT00608543 (6) [back to overview]	Quality of Life Enjoyment and Satisfaction Questionnaire
NCT00608543 (6) [back to overview]	Stockings of Cambridge (SOC) Mean Initial Thinking Time for 3-move Problems
NCT00619190 (3) [back to overview]	Clinical Global Impressions Scale - Severity Score (CGI-S)
NCT00619190 (3) [back to overview]	Change From Baseline in the Aberrant Behavior Checklist -Lethargy/Social Withdrawal Subscale at 12 Weeks
NCT00619190 (3) [back to overview]	Change From Baseline in Aberrant Behavior Checklist-Irritability at 12 Weeks
NCT00665366 (12) [back to overview]	Percentage of Participants With Relevant Weight Gain or Weight Loss From Baseline at Week 12 (LOCF Data Set)
NCT00665366 (12) [back to overview]	Percentage of Participants Showing Remission in the Young Mania Rating Scale (YMRS) Score From Baseline (LOCF Data Set)
NCT00665366 (12) [back to overview]	Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Overall) Scale at Week 12 (LOCF Data Set)
NCT00665366 (12) [back to overview]	Change From Baseline in Total and Subscale Scores on the Functional Assessment Short Test (FAST)(LOCF Data Set)
NCT00665366 (12) [back to overview]	Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set)
NCT00665366 (12) [back to overview]	Change From Baseline to Week 12 in Body Mass Index (BMI) (LOCF Data Set)
NCT00665366 (12) [back to overview]	Change From Baseline in Participant Weight (OC Data Set and Week 12 LOCF Data Set)
NCT00665366 (12) [back to overview]	Percentage of Participants Showing A Response From Baseline on the Young Mania Rating Scale (YMRS)(OC Data Set)
NCT00665366 (12) [back to overview]	Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Depression) Scale (LOCF Data Set)
NCT00665366 (12) [back to overview]	Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Mania) Scale (LOCF Data Set)
NCT00665366 (12) [back to overview]	Participant Scores on Patient Global Impression Improvement (PGI-I) Scale (OC Data Set)
NCT00665366 (12) [back to overview]	Change From Baseline in Total Score on the Longitudinal Interval Follow-up Evaluation-Rating Impaired Functioning Tool (LIFE-RIFT)(OC Data Set and Week 12 LOCF Data Set)
NCT00667875 (4) [back to overview]	Percent Riboflavin Positive Urine Samples as a Measure of Medication Compliance
NCT00667875 (4) [back to overview]	Percent Heavy Drinking Days
NCT00667875 (4) [back to overview]	Pill Counts During Treatment
NCT00667875 (4) [back to overview]	Drinks Per Drinking Day
NCT00683852 (8) [back to overview]	Number of Patients With Treatment Emergent AEs in Two Treatment Groups - People Exclusively on Drug or Placebo Throughout the Study
NCT00683852 (8) [back to overview]	Number of Patients With Treatment Emergent AEs in Two Treatment Groups - Placebo Non-Responders
NCT00683852 (8) [back to overview]	Treatment Emergent AEs in Two Treatment Groups - Safety Sample
NCT00683852 (8) [back to overview]	Mean Change in Symptom Questionnaire (SQ)
NCT00683852 (8) [back to overview]	MADRS (Montgomery-Asberg Depression Rating Scale) Readmission Rate
NCT00683852 (8) [back to overview]	MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate
NCT00683852 (8) [back to overview]	Mean Change in Clinical Global Impression of Severity (CGI-S)
NCT00683852 (8) [back to overview]	Mean Change in MADRS (Montgomery-Asberg Depression Rating Scale) Score From Baseline to the End of Follow-up
NCT00685334 (2) [back to overview]	Change From Baseline in Weight (Lbs.) at 12 Weeks
NCT00685334 (2) [back to overview]	Tolerability
NCT00705783 (10) [back to overview]	Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score
NCT00705783 (10) [back to overview]	Mean Change From Baseline in the PANSS Negative Subscale Score
NCT00705783 (10) [back to overview]	Mean Change From Baseline in the PANSS Positive Subscale Score
NCT00705783 (10) [back to overview]	Mean Change From Baseline in the PANSS Total Score
NCT00705783 (10) [back to overview]	Mean Clinical Global Impression-Improvement (CGI-I) Score
NCT00705783 (10) [back to overview]	Percentage of Patients Achieving Remission
NCT00705783 (10) [back to overview]	Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria
NCT00705783 (10) [back to overview]	Percentage of Responders
NCT00705783 (10) [back to overview]	Time to Discontinuation
NCT00705783 (10) [back to overview]	Time to Exacerbation of Psychotic Symptoms/Impending Relapse
NCT00706589 (1) [back to overview]	Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)
NCT00706654 (4) [back to overview]	Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26
NCT00706654 (4) [back to overview]	Percentage of Patients Achieving Remission
NCT00706654 (4) [back to overview]	Percentage of Responders up to Week 38
NCT00706654 (4) [back to overview]	Time to Exacerbation of Psychotic Symptoms/Impending Relapse
NCT00712270 (1) [back to overview]	QTc Measurement
NCT00731549 (10) [back to overview]	Percentage of Participants With Time to First Exacerbation of Psychotic Symptoms/Impending Relapse.
NCT00731549 (10) [back to overview]	Percentage of Participants Who Discontinued Due to All Causes.
NCT00731549 (10) [back to overview]	Percentage of Participants Achieving Remission.
NCT00731549 (10) [back to overview]	Mean Change From Baseline to Endpoint in PANSS Positive and Negative Subscales.
NCT00731549 (10) [back to overview]	Mean Change From Baseline to Endpoint (Last Visit) in Positive and Negative Syndrome Scale (PANSS) Total Score.
NCT00731549 (10) [back to overview]	Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score.
NCT00731549 (10) [back to overview]	Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.
NCT00731549 (10) [back to overview]	Mean Clinical Global Impression of Improvement (CGI-I) Score.
NCT00731549 (10) [back to overview]	Percentage of Stable Participants at Baseline Who Remained Stable at Endpoint (Last Visit).
NCT00731549 (10) [back to overview]	Percentage of Participants Stable at Baseline and Remaining Stable at Week 28.
NCT00746252 (1) [back to overview]	Weight Gain
NCT00802100 (2) [back to overview]	Feasibility of Randomizing a Cohort of Participants Meeting the Inclusion and Exclusion Criteria of the Study
NCT00802100 (2) [back to overview]	Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment
NCT00806234 (4) [back to overview]	Change in Low Density Lipoprotein (LDL) Cholesterol Level
NCT00806234 (4) [back to overview]	Body Mass Index (BMI) Z-score Change
NCT00806234 (4) [back to overview]	Triglyceride Levels
NCT00806234 (4) [back to overview]	Change in Whole Body Insulin Sensitivity Index
NCT00845026 (26) [back to overview]	Percentage of Participants With Remission (Rate of Remission) at Week 24 Endpoint
NCT00845026 (26) [back to overview]	Number of Participants With Treatment-Emergent Change in Neurological Examination
NCT00845026 (26) [back to overview]	Number of Participants With Suicidal Behaviors and Ideations Baseline Through 52 Weeks
NCT00845026 (26) [back to overview]	Change From Baseline in Simpson-Angus Scale (SAS) Total Score at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Personal and Social Performance (PSP) at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Number of Psychiatric Visits at 24 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB): Overall Composite T-Score at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) Total Score at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Number of Participants With Potentially Clinical Significant Change in Lipids Level
NCT00845026 (26) [back to overview]	Number of Participants With Shift From Baseline to Maximum Post-Baseline Grading in Electroencephalograms (EEGs)
NCT00845026 (26) [back to overview]	Change From Baseline in University of California-San Diego (UCSD) Performance-Based Skills Assessment-B (UPSA-B) Total Score at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Percentage of Participants With Response (Rate of Response) at 6 and 24 Weeks Endpoints
NCT00845026 (26) [back to overview]	Change From Baseline in EuroQoL Questionnaire-5 Dimension (EQ-5D) at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Blood Pressure (BP) at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in 16-Item Negative Symptoms Assessment (NSA-16) Total Score at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Time to Discontinuation Due to Adverse Event (AE)
NCT00845026 (26) [back to overview]	Change From Baseline in Pulse Rate at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Barnes Akathisia Scale (BAS) Global Score at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) at 52 Weeks Endpoint
NCT00845026 (26) [back to overview]	Percentage of Participants With Relapse (Rate of Relapse)
NCT00845026 (26) [back to overview]	Number of Participants With Potentially Clinically Significant Changes in QT Intervals Electrocardiograms (ECGs)
NCT00845026 (26) [back to overview]	Number of Participants With Potentially Clinical Significant Change in Fasting Glucose Level
NCT00845026 (26) [back to overview]	Change From Baseline in Weight at 52 Weeks Endpoint
NCT00857818 (3) [back to overview]	Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and 1 or More AEs
NCT00857818 (3) [back to overview]	Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Levels
NCT00857818 (3) [back to overview]	Mean Baseline Fasting Non-HDL Levels
NCT00870727 (6) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Subscale Score, Parent Report, Double-blind Phase
NCT00870727 (6) [back to overview]	Number of Participants Improved as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)
NCT00870727 (6) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Subscale Score, Parent Report, Double-blind Phase
NCT00870727 (6) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Subscale Score, Parent Report, Double-blind Phase
NCT00870727 (6) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Stereotypy Subscale Score, Parent Report, Double-blind Phase
NCT00870727 (6) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Irritability Subscale Score, Parent Report, Double-blind Phase
NCT00876343 (3) [back to overview]	Mean Change in Sheehan Disability Scale (SDISS)
NCT00876343 (3) [back to overview]	MADRS Response Rate
NCT00876343 (3) [back to overview]	Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT00882362 (1) [back to overview]	Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00892047 (6) [back to overview]	Akathisia
NCT00892047 (6) [back to overview]	Weight
NCT00892047 (6) [back to overview]	QTc Prolongation on EKG (to Greater or Equal to 480 Msec)
NCT00892047 (6) [back to overview]	Percentage of Subjects Who Met Criteria for Remission Based on the Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00892047 (6) [back to overview]	Parkinsonism
NCT00892047 (6) [back to overview]	Emergent Suicidal Ideation in Those With no Ideation at the Start of Treatment
NCT00895921 (3) [back to overview]	Akathisia
NCT00895921 (3) [back to overview]	Change in Glucose Disposition
NCT00895921 (3) [back to overview]	Change in Percent of Insulin Suppression of Endogenous Glucose Production
NCT00905307 (8) [back to overview]	Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score (Double Blind Phase)
NCT00905307 (8) [back to overview]	Change From Baseline to Week 6 in PANSS Positive Subscale Score (Double Blind Phase)
NCT00905307 (8) [back to overview]	Response Rate at Week 6
NCT00905307 (8) [back to overview]	Mean Clinical Global Impression - Improvement (CGI-I) at Week 6
NCT00905307 (8) [back to overview]	Discontinuation Rate for Lack of Efficacy or Receipt of Open Label OPC-34712
NCT00905307 (8) [back to overview]	Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (Double Blind Phase)
NCT00905307 (8) [back to overview]	Change From Baseline to Week 6 in Personal and Social Performance Scale (PSP) (Double Blind Phase)
NCT00905307 (8) [back to overview]	Change From Baseline to Week 6 in PANSS Negative Subscale Score (Double Blind Phase)
NCT00947154 (4) [back to overview]	Mass General Hair Pulling Scale, Actual Pulling Subscale
NCT00947154 (4) [back to overview]	Mass General Hair Pulling Scale
NCT00947154 (4) [back to overview]	Clinical Global Impressions Improvement (CGI-I)
NCT00947154 (4) [back to overview]	CGI-I Score of 1 or 2 (Very Much or Much Improved)
NCT00953745 (2) [back to overview]	Fluorodopa Uptake Values in Brain Images of Aripiprazole Augmentation Responders
NCT00953745 (2) [back to overview]	Depression Symptom Change on The Montgomery-Åsberg Depression Rating (MADRS) Scale Between ARP Responders and Non-responders.
NCT01001702 (8) [back to overview]	Number of Participants With Clinically Significant Heart Rate
NCT01001702 (8) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths
NCT01001702 (8) [back to overview]	Change From Baseline in Clinical Global Impression Severity of Illness (CGI-S) Score
NCT01001702 (8) [back to overview]	Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01001702 (8) [back to overview]	Number of Participants Showing Significant Weight Gain or Loss
NCT01001702 (8) [back to overview]	Number of Participants With Clinical Significant Laboratory Tests
NCT01001702 (8) [back to overview]	Number of Participants With Clinically Abnormal Changes in Electrocardiograms (ECGs) Evaluations
NCT01001702 (8) [back to overview]	Number of Participants With Clinically Significant Blood Pressure
NCT01009047 (9) [back to overview]	Number of Participants With PANSS Response
NCT01009047 (9) [back to overview]	Number of Participants With Clinical Stability
NCT01009047 (9) [back to overview]	Change From Baseline in PANSS Total Score at Day 182
NCT01009047 (9) [back to overview]	Change From Baseline in Personal and Social Performance (PSP) Scores at Day 56 and 182
NCT01009047 (9) [back to overview]	Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56
NCT01009047 (9) [back to overview]	Change From Baseline in Other PANSS Factors and Subscales at Day 56 and 182
NCT01009047 (9) [back to overview]	Change From Baseline in Other Marder Factors Scores at Day 56 and 182
NCT01009047 (9) [back to overview]	Change From Baseline in Marder Factor Negative Symptoms Score at Day 56 and 182
NCT01009047 (9) [back to overview]	Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Days 56 and 182
NCT01028820 (2) [back to overview]	Baseline and Week 8scores on Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version
NCT01028820 (2) [back to overview]	Total Repetitive Behavior Scale - Revised (RBS_R)
NCT01104766 (2) [back to overview]	Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.
NCT01104766 (2) [back to overview]	Measurement of the Overall Severity of Illness: Change From Baseline in Clinical Global Impression-Severity (CGI-S)
NCT01111539 (3) [back to overview]	Phase C: Mean Clinical Global Impression - Improvement (CGI-I) Scale Score at the End of Phase C (Week 14)
NCT01111539 (3) [back to overview]	Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)
NCT01111539 (3) [back to overview]	Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)
NCT01111552 (3) [back to overview]	Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)
NCT01111552 (3) [back to overview]	Phase C: Clinical Global Impression - Improvement Scale (CGI-I) Score at The End of Phase C (Week 14)
NCT01111552 (3) [back to overview]	Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)
NCT01111565 (3) [back to overview]	Phase C: Clinical Global Impression - Improvement Scale (CGI-I) Score at the End of Phase C
NCT01111565 (3) [back to overview]	Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)
NCT01111565 (3) [back to overview]	Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)
NCT01122927 (23) [back to overview]	Number of Participants With Cognitive Impairment for Each New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)
NCT01122927 (23) [back to overview]	Mean Change From Baseline by Week in Simpson-Angus Scale (SAS) Total Score
NCT01122927 (23) [back to overview]	Mean Change From Baseline by Week in Abnormal Involuntary Movement Scale (AIMS)
NCT01122927 (23) [back to overview]	Incidence of Vital Signs of Potential Clinical Relevance
NCT01122927 (23) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01122927 (23) [back to overview]	Incidence of Laboratory Values of Potential Clinical Relevance
NCT01122927 (23) [back to overview]	Mean Change From Baseline in Children's Global Assessment Scale (CGAS) in Bipolar (de Novo Participants)
NCT01122927 (23) [back to overview]	Mean Change From Baseline for Columbia-Suicide Severity Rating Scale (C-SSRS) in Suicidal Ideation Intensity Total Score
NCT01122927 (23) [back to overview]	Incidence of Suicidality, Suicidal Behavior and Suicidal Ideation
NCT01122927 (23) [back to overview]	Mean Change From Baseline in PANSS Negative Subscale Score
NCT01122927 (23) [back to overview]	Baseline and Post-Baseline Tanner Staging
NCT01122927 (23) [back to overview]	Incidence of Physical Examination Findings of Potential Clinical Relevance
NCT01122927 (23) [back to overview]	Mean Change From Baseline in Clinical Global Impression Scale - Bipolar (CGI-BP) Version Severity Score
NCT01122927 (23) [back to overview]	Mean Change From Baseline in Clinical Global Impression Scale - Bipolar Version Improvement Score
NCT01122927 (23) [back to overview]	Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score
NCT01122927 (23) [back to overview]	Mean Change From Baseline in General Behavior Inventory (GBI) Scale Total Score for Mania and Depression in Both Parent/Guardian and Subject Version of the Scale
NCT01122927 (23) [back to overview]	Mean Change From Baseline in PANSS Positive Subscale Score
NCT01122927 (23) [back to overview]	Mean Change From Baseline in Positive and Negative Symptoms Score (PANSS) Total Score
NCT01122927 (23) [back to overview]	Mean Change From Baseline in the Attention Deficit Hyperactive Disorders Rating (ADHD-RS-IV) Scale Score
NCT01122927 (23) [back to overview]	Mean Change From Baseline in Young Mania Rating Scale (YMRS) Score
NCT01122927 (23) [back to overview]	Mean Change in Clinical Global Impression-Improvement (CGI-I) Score
NCT01122927 (23) [back to overview]	Percentage of Participants Who Discontinued Due to All Adverse Events
NCT01122927 (23) [back to overview]	Mean Change From Baseline by Week in Barnes Akathisia Rating Scale (BARS) Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Overall General Subscore
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Total Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
NCT01123707 (29) [back to overview]	Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
NCT01123707 (29) [back to overview]	Number of Participants With Potentially Clinically Significant Laboratory Test Abnormalities
NCT01123707 (29) [back to overview]	Number of Participants With Potentially Clinically Significant Physical Examination Findings
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Assessment of Akathisia (Item 4) Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Assessment of Akathisia (Item 4) Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Body Mass Index (BMI)
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Body Mass Index (BMI)
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Body Weight
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Body Weight
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Body Weight
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Each Item as Measured by Massachusetts General Hospital Sexual Functioning Inventory (MGH SFI) Subscale Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Laboratory Test Results: Hemoglobin A1c (HbA1c)
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Laboratory Test Results: Hemoglobin A1c (HbA1c)
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Laboratory Test Results: Prolactin
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Patient Global Impression - Severity of Depression Scale (PGI-S) Score
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Patient Global Impression - Severity of Depression Scale (PGI-S) Score
NCT01123707 (29) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs), Severe (Grade 3 or Higher) TEAEs, and Discontinuations From the Trial Due to TEAEs
NCT01123707 (29) [back to overview]	Percentage of Participants With Suicidal Ideation in Each Item as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01123707 (29) [back to overview]	Mean Change From Baseline in Laboratory Test Results: Prolactin
NCT01123707 (29) [back to overview]	Number of Participants With Potentially Clinically Significant Vital Sign Abnormalities
NCT01129882 (2) [back to overview]	Mean Change In Clinical Global Impression-Severity (CGI-S) of Illness Scale Score From Baseline To Last Visit
NCT01129882 (2) [back to overview]	Number Of Participants Reporting Severe Treatment-Emergent Adverse Events (TEAE)
NCT01149655 (11) [back to overview]	Mean Change From Baseline to Endpoint in PANSS Positive Subscale.
NCT01149655 (11) [back to overview]	Mean Change From Baseline to Endpoint in PANSS Total Score.
NCT01149655 (11) [back to overview]	Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.
NCT01149655 (11) [back to overview]	Percentage of Participants Who Discontinued Due to All Reasons Other Than Sponsor Discontinued Study.
NCT01149655 (11) [back to overview]	Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse.
NCT01149655 (11) [back to overview]	Mean Change From Baseline to Endpoint in CGI-S Score.
NCT01149655 (11) [back to overview]	Mean Change From Baseline to Endpoint in Children's Global Assessment Scale (CGAS).
NCT01149655 (11) [back to overview]	Mean Change From Baseline to Endpoint in PANSS Negative Subscale.
NCT01149655 (11) [back to overview]	Percentage of Responders in Each Treatment Group.
NCT01149655 (11) [back to overview]	Percentage of Participants Who Had Achieved Remission.
NCT01149655 (11) [back to overview]	Mean CGI-I Score at Endpoint.
NCT01157351 (6) [back to overview]	Time to First Treatment Failure
NCT01157351 (6) [back to overview]	Time to First Psychiatric Hospitalization or Arrest/Incarceration
NCT01157351 (6) [back to overview]	Time to First Psychiatric Hospitalization
NCT01157351 (6) [back to overview]	Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration
NCT01157351 (6) [back to overview]	Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration
NCT01157351 (6) [back to overview]	Percentage of Participants in Each Event Category of First Treatment Failure
NCT01188668 (12) [back to overview]	Aripiprazole Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Aripiprazole Apparent Clearance (CL/F) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Aripiprazole Apparent Volume of Distribution (Vz/F) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Dehydro-aripiprazole (Metabolite) Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Plasma Aripiprazole Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg + Aripiprazole 5 mg
NCT01188668 (12) [back to overview]	Dehydro-aripiprazole (Metabolite) Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Dehydro-aripiprazole (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Aripiprazole Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Dehydro-aripiprazole (Metabolite) Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Aripiprazole Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Plasma Dehydro-aripiprazole (Metabolite) Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg, Aripiprazole 5 mg
NCT01188668 (12) [back to overview]	Aripiprazole Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01227668 (5) [back to overview]	Percentage of Patients Relapsing by Week 16
NCT01227668 (5) [back to overview]	Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
NCT01227668 (5) [back to overview]	Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
NCT01227668 (5) [back to overview]	Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
NCT01227668 (5) [back to overview]	Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
NCT01292057 (2) [back to overview]	Total Number of Drinks Per Day During Natural (Usual Environment) Conditions
NCT01292057 (2) [back to overview]	Total Number of Drinks Consumed in Bar Lab
NCT01328093 (16) [back to overview]	Change From Baseline to 24 Weeks in Body Weight
NCT01328093 (16) [back to overview]	Change From Baseline up to 24 Weeks in 16-Item Negative Symptom Assessment (NSA-16)
NCT01328093 (16) [back to overview]	Change From Baseline up to 24 Weeks in Abnormal Involuntary Movement Scale (AIMS)
NCT01328093 (16) [back to overview]	Change From Baseline up to 24 Weeks in Barnes Akathisia Scale (BAS)
NCT01328093 (16) [back to overview]	Change From Baseline up to 24 Weeks in Clinical Global Impression-Severity Scale (CGI-S)
NCT01328093 (16) [back to overview]	Change From Baseline up to 24 Weeks in Personal and Social Performance (PSP) Score
NCT01328093 (16) [back to overview]	Change From Baseline up to 24 Weeks in Simpson-Angus Scale (SAS)
NCT01328093 (16) [back to overview]	Change From Baseline up to 24 Weeks in Subjective Well-Being Under Neuroleptic Treatment Scale- Short Form (SWN-SF) Total Score
NCT01328093 (16) [back to overview]	Number of Participants With 30% or Greater Decrease in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT01328093 (16) [back to overview]	Schizophrenia Resource Use Module (S-RUM) - Number of Sessions With a Psychiatrist
NCT01328093 (16) [back to overview]	Time to Discontinuation
NCT01328093 (16) [back to overview]	Change From Baseline up to 24 Weeks in Positive and Negative Syndrome Scale (PANSS) Total and Subscale Scores
NCT01328093 (16) [back to overview]	Number of Participants With Suicidal Behaviors and Ideations Measured by Columbia Suicide Severity Rating Scale (C-SSRS)
NCT01328093 (16) [back to overview]	Percentage of Participants With Clinically Significant Weight Change
NCT01328093 (16) [back to overview]	Schizophrenia Resource Utilization Module (S-RUM) - Number of Emergency Room (ER) or Equivalent Facility Visits and Outpatient Medical Visits
NCT01328093 (16) [back to overview]	Change From Baseline up to 24 Weeks in EuroQol-5 Dimensions Questionnaire (EQ-5D) Visual Analog Scale (VAS) Health State Score
NCT01333072 (1) [back to overview]	Changes in the Irritability Subscale of the Larger ABC (Abberent Behavior Checklist) That Occur From Baseline to 10 Weeks
NCT01338298 (2) [back to overview]	To Determine if Adjunct Aripiprazole Will Resolve or Improve Prolactin Related Hormonal Side Effects (Amenorrhea, Oligomenorrhea, Galactorrhea).
NCT01338298 (2) [back to overview]	To Test Whether Adjunctive Aripiprazole Will Improve Quality/Perceived Quality of Life.
NCT01354353 (8) [back to overview]	Percentage of Participants With Worsening Severity From Baseline to Day 17 in Extrapyramidal Symptoms as Measured by the Abnormal Involuntary Movement Scale (AIMS)
NCT01354353 (8) [back to overview]	Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests)
NCT01354353 (8) [back to overview]	Percentage of Participants With Worsening Symptoms From Baseline to Day 17 in Extrapyramidal Symptoms as Measured by the Barnes Akathisia Scale (BAS)
NCT01354353 (8) [back to overview]	Part A: Pharmacokinetics, Area Under the Concentration - Time Curve (AUC)
NCT01354353 (8) [back to overview]	Percentage of Participants With Increasing Impairment From Baseline to Day 17 in Extrapyramidal Symptoms as Measured by the Simpson-Angus Scale (SAS)
NCT01354353 (8) [back to overview]	Part A: Pharmacokinetics, Maximum Concentration (Cmax)
NCT01354353 (8) [back to overview]	Percentage of Participants With Increased Severity From Baseline to Day 17 in Clinical Global Impression- Severity Scale (CGI-S)
NCT01354353 (8) [back to overview]	Percentage of Participants With Worsening Symptoms From Baseline to Day 17 in Brief Psychiatric Rating Scale (BPRS)
NCT01416441 (21) [back to overview]	Number of Participants With Emergence of Suicidal Ideation, TEAEs Related to Suicide and Suicidality and Suicide Ideation From the Potential Suicide Events Recorded on the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01416441 (21) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs and TEAEs Leading Treatment Discontinuation
NCT01416441 (21) [back to overview]	Response Rates
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Body Weight
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Body Mass Index (BMI)
NCT01416441 (21) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Average Score of Attention-Deficit Disorder/Attention-Deficit Hyperactivity Disorder (ADD/ADHD) Sub-scale of the Swanson, Nolan and Pelham-IV (SNAP-IV)
NCT01416441 (21) [back to overview]	Treatment Discontinuation Rates
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Children's Depression Rating Scale Revised (CDRS-R) Total Score
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Total Score
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Clinical Global Impression for Tourette's Syndrome (CGI-TS) Severity of Illness Score
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Pediatric Anxiety Rating Scale (PARS) Total Severity Score
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Simpson Angus Scale (SAS) Score
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Total YGTSS Score
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Waist Circumference
NCT01416441 (21) [back to overview]	Mean Change From Baseline in Yale Global Tic Severity Scale (YGTSS) Total Tic Score
NCT01416441 (21) [back to overview]	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values
NCT01416441 (21) [back to overview]	Number of Participants With Clinically Significant Changes in Laboratory Parameter Values
NCT01416441 (21) [back to overview]	Number of Participants With Clinically Significant Changes in Vital Signs
NCT01418339 (3) [back to overview]	Change From Baseline in Clinical Global Impressions Scale for Tourette's Syndrome (CGI-TS) Score
NCT01418339 (3) [back to overview]	Change From Baseline in Gilles de la Tourette Syndrome - Quality of Life Scale (GTS-QOL) Total Score
NCT01418339 (3) [back to overview]	Change From Baseline in Yale Global Tic Severity Scale (YGTSS) - Total Tic Score (TTS)
NCT01418352 (3) [back to overview]	Mean Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score
NCT01418352 (3) [back to overview]	Mean Change From Baseline in Clinical Global Impressions Scale for Tourette's Syndrome (CGI-TS) Score
NCT01418352 (3) [back to overview]	Mean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score at Week 8
NCT01421342 (4) [back to overview]	Rate of Protocol Relapse of Symptoms of Major Depression After Achieving Remission in the Acute Phase
NCT01421342 (4) [back to overview]	Rate of Protocol Remission of Symptoms of Major Depressive Disorder
NCT01421342 (4) [back to overview]	Rate of Protocol Response as Reduction in Symptoms of Major Depression (>= 50% Reduction in QIDS-C)
NCT01421342 (4) [back to overview]	Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale
NCT01432444 (6) [back to overview]	Mean Clinical Global Impression-Improvement Score (CGI-I) by Week.
NCT01432444 (6) [back to overview]	Change From Baseline in PANSS Positive Subscale Score.
NCT01432444 (6) [back to overview]	Change From Baseline in PANSS Negative Subscale Score.
NCT01432444 (6) [back to overview]	Change From Baseline in PANSS (Positive and Negative Syndrome Scale) Total Score.
NCT01432444 (6) [back to overview]	Change From Baseline in Clinical Global Impression-Severity Score (CGI-S).
NCT01432444 (6) [back to overview]	Number of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6).
NCT01438060 (42) [back to overview]	Change in Simpson-Angus Scale (SAS) Total Score During Extension Phase
NCT01438060 (42) [back to overview]	Clinical Global Impression (CGI) Improvement Score During Extension Phase
NCT01438060 (42) [back to overview]	Participants Who Demonstrated a ≥ 50% Decrease From Baseline in the Total NPI Score in Acute Phase
NCT01438060 (42) [back to overview]	Participants Who Demonstrated a ≥ 50% Decrease From Baseline to Endpoint in the NPI Psychosis Subscale Score in Acute Phase
NCT01438060 (42) [back to overview]	Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AE During Extension Phase
NCT01438060 (42) [back to overview]	Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AE During Treatment Beyond 140 Weeks
NCT01438060 (42) [back to overview]	Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs in Acute Phase
NCT01438060 (42) [back to overview]	Participants With a Potentially Clinically Significant Vital Sign Abnormality During Extension Phase
NCT01438060 (42) [back to overview]	Participants With Extrapyramidal Symptoms (EPS) Related Adverse Events During Extension Phase
NCT01438060 (42) [back to overview]	Participants With Extrapyramidal Symptoms (EPS) Related Adverse Events in Acute Phase
NCT01438060 (42) [back to overview]	Participants With Potentially Clinically Significant (PCS) Vital Sign Abnormalities in Acute Phase
NCT01438060 (42) [back to overview]	Participants With Potentially Clinically Significant Electrocardiogram Abnormalities in Acute Phase
NCT01438060 (42) [back to overview]	Participants With Potentially Clinically Significant Laboratory Abnormalities During Extension Phase
NCT01438060 (42) [back to overview]	Participants With Potentially Clinically Significant Laboratory Abnormalities in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Psychosis Subscale Caregiver Distress Score in Acute Phase
NCT01438060 (42) [back to overview]	Participants With a Potentially Clinically Significant Electrocardiogram Abnormalities During Extension Phase
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Aberrant Motor Behavior
NCT01438060 (42) [back to overview]	CGI Improvement Score in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in Barnes Global Clinical Assessment of Akathisia in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Score in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in Clinical Global Impression (CGI) Severity of Illness Score in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in Mini Mental State Examination (MMSE) Total Score in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Agitation/Aggression
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Anxiety
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Apathy/Indifference
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Appetite/Eating Behaviors
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Delusions
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Depression/Dysphoria
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Disinhibition
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Elation/Euphoria
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Hallucinations
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Irritability/Lability
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Individual Item Scores in Acute Phase: Sleep
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Psychosis Subscale Score Through Week 8 in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Total Caregiver Distress Score in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in NPI Total Score in Acute Phase
NCT01438060 (42) [back to overview]	Change From Baseline in Simpson-Angus Scale (SAS) Total Score in Acute Phase
NCT01438060 (42) [back to overview]	Change in Abnormal Involuntary Movement Scale (AIMS) Total Score During Extension Phase
NCT01438060 (42) [back to overview]	Change in Barnes Global Clinical Assessment of Akathisia Score During Extension Phase
NCT01438060 (42) [back to overview]	Change in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score From Baseline During Extension Phase
NCT01490086 (5) [back to overview]	Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score
NCT01490086 (5) [back to overview]	Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS Positive Subscale
NCT01490086 (5) [back to overview]	Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS Negative Subscale
NCT01490086 (5) [back to overview]	Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS General Psychopathology Subscale
NCT01490086 (5) [back to overview]	Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the Clinical Global Impression Scale - Severity (CGI-S)
NCT01552772 (11) [back to overview]	Change From Baseline in PANSS Positive Sub-scale Score for LOCF Data.
NCT01552772 (11) [back to overview]	CGI-I Scale Score in LOCF Data.
NCT01552772 (11) [back to overview]	Change From Baseline in PANSS Negative Sub-scale Score for LOCF Data.
NCT01552772 (11) [back to overview]	Change From Baseline in Clinical Global Impression Severity (CGI-S) Score in OC Data.
NCT01552772 (11) [back to overview]	Change From Baseline in CGI-S Score in LOCF Data.
NCT01552772 (11) [back to overview]	Change From Baseline in PANSS Positive Sub-scale Score for OC Data.
NCT01552772 (11) [back to overview]	Change From Baseline in Total Score of PANSS for Last Observation Carried Forward (LOCF) Data.
NCT01552772 (11) [back to overview]	Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS) for Observed Cases (OC) Data.
NCT01552772 (11) [back to overview]	Clinical Global Impression Improvement (CGI-I) Scale Score in OC Data.
NCT01552772 (11) [back to overview]	Number of Participants With Adverse Events (AE).
NCT01552772 (11) [back to overview]	Change From Baseline in PANSS Negative Sub-scale Score for OC Data.
NCT01567527 (4) [back to overview]	Mean Change From Randomization to Endpoint in the CGI-BP-S (Mania) Score.
NCT01567527 (4) [back to overview]	Time From Randomization to Recurrence Defined by Hospitalization for a Mood Episode.
NCT01567527 (4) [back to overview]	Time From Randomization to Recurrence of Any Mood Episode During Double-bind Placebo-controlled Phase.
NCT01567527 (4) [back to overview]	Number of Subjects Meeting Criteria for Recurrence of Any Mood Episode.
NCT01617447 (1) [back to overview]	Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score
NCT01617460 (1) [back to overview]	Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score
NCT01646827 (12) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Aripriprazole
NCT01646827 (12) [back to overview]	Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale.
NCT01646827 (12) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Dehydro-Aripiprazole
NCT01646827 (12) [back to overview]	Number of Participants With Vital Signs of Potential Clinical Relevance-Temperature
NCT01646827 (12) [back to overview]	Area Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Aripiprazole
NCT01646827 (12) [back to overview]	Area Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Dehydro-Aripiprazole
NCT01646827 (12) [back to overview]	Number of Participants Reporting Treatment Emergent Adverse Events (TEAE).
NCT01646827 (12) [back to overview]	Number of Participants With Electrocardiogram (ECG) Measurements of Potential Clinical Relevance
NCT01646827 (12) [back to overview]	Number of Participants With Laboratory Values of Potential Clinical Relevance.
NCT01646827 (12) [back to overview]	Number of Participants With Vital Signs of Potential Clinical Relevance-Blood Pressure
NCT01646827 (12) [back to overview]	Number of Participants With Vital Signs of Potential Clinical Relevance-Heart Rate
NCT01646827 (12) [back to overview]	Visual Analog Scale (VAS) Score at Day 1, Day 14, Day 28 and Last Visit.
NCT01663532 (7) [back to overview]	Mean Change From Baseline to Endpoint in PANSS Positive Subscale Score.
NCT01663532 (7) [back to overview]	Mean Change From Baseline to Endpoint in Personal and Social Performance Scale (PSP) Score.
NCT01663532 (7) [back to overview]	Mean Clinical Global Impression-Improvement Scale (CGI-I) Score at Endpoint.
NCT01663532 (7) [back to overview]	Responder Rate Based on PANSS Total Score.
NCT01663532 (7) [back to overview]	Mean Change From Baseline to Endpoint in Clinical Global Impression-Severity Scale (CGI-S) Score.
NCT01663532 (7) [back to overview]	Mean Change From Baseline to Endpoint in PANSS Negative Subscale Score.
NCT01663532 (7) [back to overview]	Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score.
NCT01683058 (25) [back to overview]	Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Severe TEAEs, Discontinued Investigational Medicinal Product (IMP) Due to AEs, Serious TEAEs and Outcome of Death
NCT01683058 (25) [back to overview]	Number of Participants With Clinically Relevant Laboratory Values.
NCT01683058 (25) [back to overview]	Number of Participants With Clinically Relevant Physical Examination.
NCT01683058 (25) [back to overview]	Mean Change From Baseline by Week by EPS Evaluated Using Barnes Akathisia Rating Scale (BARS)
NCT01683058 (25) [back to overview]	Mean Change From Baseline by Week by EPS Evaluated Using the Abnormal Involuntary Movement Scale (AIMS)
NCT01683058 (25) [back to overview]	Mean Change From Baseline by Week by Extrapyramidal Symptoms (EPS) Evaluated Using the Simpson-Angus Scale (SAS)
NCT01683058 (25) [back to overview]	Mean Change From Baseline in Suicidal Ideation Intensity Total Score by the Columbia Suicide Severity Rating Scale (C-SSRS)
NCT01683058 (25) [back to overview]	Mean Change in Body Temperature From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Clinically Relevant Body Mass Index From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Clinically Relevant Body Weight Changes From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Clinically Relevant Waist Circumference From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Diastolic BP From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Diastolic Supine BP From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Heart Rate From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Heart Rate Supine From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in PR Interval From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in QRS Interval From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in QT Interval From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in QTcB Interval From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in QTcF Interval From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in QTcN Interval From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in RR Interval From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Systolic BP From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Systolic Supine Blood Pressure (BP) From Baseline in All Participants.
NCT01683058 (25) [back to overview]	Mean Change in Ventricular Rate From Baseline in All Participants.
NCT01710709 (9) [back to overview]	Number of Participants With Adverse Events
NCT01710709 (9) [back to overview]	Number of Participants Experiencing Suicidal Events and Their Classification According to the Completion of Columbia Suicide Severity Rating Scale (C-SSRS)
NCT01710709 (9) [back to overview]	Injection Site Pain Measured by the Visual Analog Scale (VAS)
NCT01710709 (9) [back to overview]	Number of Participants With Clinically Significant Abnormal Laboratory Test Results
NCT01710709 (9) [back to overview]	Number of Participants With Clinically Significant Abnormal Vital Signs
NCT01710709 (9) [back to overview]	Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating
NCT01710709 (9) [back to overview]	Extrapyramidal Symptoms Will be Assessed by Mean Change From Baseline on Abnormal Involuntary Movement Scale(AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS Only Used in Japan) and Barnes Akathisia Rating Scale (BARS)
NCT01710709 (9) [back to overview]	Percentage of Participants Who Remained Stable at End of Treatment in Phase C
NCT01710709 (9) [back to overview]	Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECGs)
NCT01727700 (6) [back to overview]	Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS).
NCT01727700 (6) [back to overview]	Change in Clinical Global Impressions Scale-Tourette's Syndrome (CGI-TS) Score at Week 8.
NCT01727700 (6) [back to overview]	Mean Change From Baseline to Endpoint (Week 8) in Total YGTSS Score
NCT01727700 (6) [back to overview]	Mean Change From Baseline to Endpoint (Week 8) in CGI-TS Severity Score
NCT01727700 (6) [back to overview]	Response Rate
NCT01727700 (6) [back to overview]	Treatment Discontinuation Rate
NCT01727713 (21) [back to overview]	Change From Baseline to Endpoint on the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS).
NCT01727713 (21) [back to overview]	Mean Change From Baseline in Body Mass Index (BMI).
NCT01727713 (21) [back to overview]	Mean Change From Baseline in Body Weight.
NCT01727713 (21) [back to overview]	Mean Change From Baseline in Waist Circumference.
NCT01727713 (21) [back to overview]	Mean Change From Baseline to Endpoint in Total YGTSS Score.
NCT01727713 (21) [back to overview]	Mean Clinical Global Impressions for Tourette's Syndrome (CGI-TS) Change Score at Endpoint.
NCT01727713 (21) [back to overview]	Percentage of Participants With Adverse Events.
NCT01727713 (21) [back to overview]	Percentage of Participants With Clinically Significant Abnormal Electrocardiogram (ECG).
NCT01727713 (21) [back to overview]	Percentage of Participants With Clinically Significant Abnormal Laboratory Test Results.
NCT01727713 (21) [back to overview]	Percentage of Participants With Clinically Significant Abnormal Vital Signs.
NCT01727713 (21) [back to overview]	Percentage of Participants With Response (Response Rate).
NCT01727713 (21) [back to overview]	Percentage of Participants With Treatment Discontinuation (Treatment Discontinuation Rate).
NCT01727713 (21) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score.
NCT01727713 (21) [back to overview]	Change From Baseline in Average Score of Attention Deficit Disorder/Attention-deficit Hyperactivity Disorder (ADD/ADHD) of Swanson, Nolan, and Pelham-IV Rating Scale (SNAP-IV).
NCT01727713 (21) [back to overview]	Change From Baseline in Barnes Akathisia Rating Scale (BARS) Total Score.
NCT01727713 (21) [back to overview]	Change From Baseline in Children's Depression Rating Scale - Revised (CDRS-R).
NCT01727713 (21) [back to overview]	Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS).
NCT01727713 (21) [back to overview]	Change From Baseline in Pediatric Anxiety Rating Scale (PARS).
NCT01727713 (21) [back to overview]	Change From Baseline in Simpson-Angus Scale (SAS) Total Score.
NCT01727713 (21) [back to overview]	Change From Baseline in Suicidal Ideation Intensity Total Score Based on Columbia-Suicide Severity Rating Scale (C-SSRS).
NCT01727713 (21) [back to overview]	Change From Baseline to Endpoint in CGI-TS Severity of Illness Score.
NCT01795547 (9) [back to overview]	Change From Baseline to Week 28 in the TooL Total Score
NCT01795547 (9) [back to overview]	Investigator's Assessment Questionnaire (IAQ) Total Score at Week 28
NCT01795547 (9) [back to overview]	Change From Baseline to Week 28 in the 'Instrumental Role' QLS Domain Score
NCT01795547 (9) [back to overview]	Change From Baseline to Week 28 in CGI-S Score
NCT01795547 (9) [back to overview]	Change From Baseline to Week 28 in Quality of Life Scale (QLS) Total Score
NCT01795547 (9) [back to overview]	Change From Baseline to Week 28 in the 'Common Objects and Activities' QLS Domain Score
NCT01795547 (9) [back to overview]	Change From Baseline to Week 28 in SWN-S Total Score
NCT01795547 (9) [back to overview]	Change From Baseline to Week 28 in the 'Interpersonal Relations' QLS Domain Score
NCT01795547 (9) [back to overview]	Change From Baseline to Week 28 in the 'Intrapsychic Foundations' QLS Domain Score
NCT01844700 (4) [back to overview]	Percent Weight Change Compared to Baseline Weight
NCT01844700 (4) [back to overview]	BMI Z-scores
NCT01844700 (4) [back to overview]	Weight Change
NCT01844700 (4) [back to overview]	BMI Percentile
NCT01870999 (17) [back to overview]	"Number of Participants Hospitalized for Adverse Event Worsening Schizophrenia"
NCT01870999 (17) [back to overview]	Aripiprazole Area Under the Concentration-time Curve at Steady-state (AUCτ)
NCT01870999 (17) [back to overview]	Aripiprazole Maximum (Peak) Plasma Concentration (Tmax)
NCT01870999 (17) [back to overview]	Aripiprazole Maximum Steady State Plasma Concentration (Css,Max)
NCT01870999 (17) [back to overview]	Aripiprazole Minimum Steady State Plasma Concentration (Css,Min)
NCT01870999 (17) [back to overview]	Aripiprazole Steady-state Plasma Concentration (Css,Avg)
NCT01870999 (17) [back to overview]	Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 and Week 24
NCT01870999 (17) [back to overview]	Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Positive Subscale Scores at Week 12 and Week 24
NCT01870999 (17) [back to overview]	Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Negative Subscale Scores at Week 12 and Week 24
NCT01870999 (17) [back to overview]	Change From Baseline in the Clinical Global Impression- Severity of Illness Score (CGI-S) at Week 12 and Week 24
NCT01870999 (17) [back to overview]	Number of Participants With Adverse Events as a Measure of Safety
NCT01870999 (17) [back to overview]	Dehydro-aripiprazole Maximum Steady State Plasma Concentration (Css,Max)
NCT01870999 (17) [back to overview]	Dehydro-aripiprazole Maximum (Peak) Plasma Concentration (Tmax)
NCT01870999 (17) [back to overview]	Dehydro-aripiprazole Area Under the Concentration-Time Curve at Steady-State (AUCτ)
NCT01870999 (17) [back to overview]	Aripiprazole Terminal-phase Elimination Half-life (t1/2,z)
NCT01870999 (17) [back to overview]	Dehydro-aripiprazole Minimum Steady State Plasma Concentration (Css,Min)
NCT01870999 (17) [back to overview]	Clinical Global Impression-Improvement Scale (CGI-I) at Week 12 and Week 24
NCT01909466 (17) [back to overview]	Number of Participants With Adverse Events (AEs).
NCT01909466 (17) [back to overview]	Mean Visual Analog Scale (VAS) Score for Rating of Pain at the Injection Site.
NCT01909466 (17) [back to overview]	Mean Change From Baseline Measured by EPS by Barnes Akathisia Rating Scale (BARS).
NCT01909466 (17) [back to overview]	Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score.
NCT01909466 (17) [back to overview]	Mean Change From Baseline in Emotional Regulation Score of SWN-S.
NCT01909466 (17) [back to overview]	Mean Change From Baseline in Mental Functioning Score of SWN-S.
NCT01909466 (17) [back to overview]	Mean Change From Baseline in Suicidal Ideation Intensity Total Score Via Columbia-suicide Severity Rating Scale (C-SSRS).
NCT01909466 (17) [back to overview]	Mean Change From Baseline in PANSS Negative Sub-scale Score.
NCT01909466 (17) [back to overview]	Mean Change From Baseline Measured by Extrapyramidal Symptoms (EPS) by Simpson-Angus Scale (SAS).
NCT01909466 (17) [back to overview]	Clinical Global Impression-Improvement (CGI-I) Score.
NCT01909466 (17) [back to overview]	Mean Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS).
NCT01909466 (17) [back to overview]	Mean Change From Baseline in Total Score of Subject Well-being Under Neuroleptic Treatment-Short Form (SWN-S).
NCT01909466 (17) [back to overview]	Mean Change From Baseline in Physical Functioning Score of SWN-S.
NCT01909466 (17) [back to overview]	Mean Change From Baseline Measured by EPS by Abnormal Involuntary Movement Scale (AIMS).
NCT01909466 (17) [back to overview]	Mean Change From Baseline in PANSS Positive Sub-scale Score.
NCT01909466 (17) [back to overview]	Mean Change From Baseline in Self Control Score of SWN-S.
NCT01909466 (17) [back to overview]	Mean Change From Baseline in Social Integration Score of SWN-S.
NCT01942148 (3) [back to overview]	Mean Change From Baseline at Final Assessment in Clinical Global Impression-Severity of Illness (CGI-S) Score
NCT01942148 (3) [back to overview]	Mean Change From Baseline at Final Assessment in Children's Global Assessment Score (CGAS)
NCT01942148 (3) [back to overview]	Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT01942161 (5) [back to overview]	Mean Change From Baseline at Final Assessment in Children's Global Assessment Scale (C-GAS) Score
NCT01942161 (5) [back to overview]	Mean Change From Baseline at Final Assessment in Clinical Global Impression-Severity of Illness (CGI-S) Score
NCT01942161 (5) [back to overview]	Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Positive Subscale Total Score
NCT01942161 (5) [back to overview]	Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT01942161 (5) [back to overview]	Mean Change From Baseline at Final Assessment in Clinical Global Impression-Improvement (CGI-I) Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in the 'Instrumental Role' QLS Domain Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in the 'Interpersonal Relations' QLS Domain Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in the 'Intrapsychic Foundations' QLS Domain Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in the TooL Total Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in the WoRQ Total Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in ASEX Total Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in CGI-S Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in QLS Total Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in SWN-S Total Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in the 'Common Objects and Activities' QLS Domain Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in the 'Instrumental Role' QLS Domain Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in the 'Interpersonal Relations' QLS Domain Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in the 'Intrapsychic Foundations' QLS Domain Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in the TooL Total Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 24 in the WoRQ Total Score
NCT01959035 (23) [back to overview]	Patients Categorised As Sexually Dysfunctional Measured at Week 12 on the ASEX Scale
NCT01959035 (23) [back to overview]	Patients Categorised As Sexually Dysfunctional Measured at Week 24 on the ASEX Scale
NCT01959035 (23) [back to overview]	Safety and Tolerability
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in ASEX Total Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in CGI-S Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in QLS Total Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in SWN-S Total Score
NCT01959035 (23) [back to overview]	Change From Baseline to Week 12 in the 'Common Objects and Activities' QLS Domain Score
NCT02054702 (12) [back to overview]	Change From Baseline in Cognitive Test Battery Composite Score
NCT02054702 (12) [back to overview]	Change From Baseline in Cognitive Test Battery of Early Phase Battery Score
NCT02054702 (12) [back to overview]	Change From Baseline in Cognitive Test Battery Scores of Detection Task
NCT02054702 (12) [back to overview]	Change From Baseline in Cognitive Test Battery Scores of Groton Maze Learning (GML)
NCT02054702 (12) [back to overview]	Response Rate by Study Week
NCT02054702 (12) [back to overview]	Change From Baseline in Cognitive Test Battery Scores of Identification Task
NCT02054702 (12) [back to overview]	Change From Baseline in Cognitive Test Battery Scores of One Card Learning Task
NCT02054702 (12) [back to overview]	Change From Baseline to Week 6 in Barratt Impulsiveness Scale (BIS-11 Item) Total Score
NCT02054702 (12) [back to overview]	Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT02054702 (12) [back to overview]	Change From Baseline to Week 6 in Specific Levels of Functioning Scale (SLOF) Total Score
NCT02054702 (12) [back to overview]	Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score
NCT02054702 (12) [back to overview]	Mean Change in Clinical Global Impression-Improvement (CGI-I) Score at Week 6
NCT02091882 (2) [back to overview]	Latency Period From Ingestion to Detection of IEM
NCT02091882 (2) [back to overview]	Percentage of Participants With Accuracy of Ingestible Event Marker (IEM) Detection
NCT02219009 (3) [back to overview]	Proportion of Participants Who Are Able to Pair & Apply a Patch Independently & Successfully by the End of the Week 8 Study Visit as Defined by a Score of 91 to 100 on the Subject Ability to Use System Scale - Healthcare Professional Version (SAUSS-HCP)
NCT02219009 (3) [back to overview]	Proportion of Participants Able to Pair & Apply a Patch Successfully, Independently, or With Minimum Assistance, by the End of the Week 8 Study Visit, as Defined by a SAUSS-HCP Score of 71 to 100.
NCT02219009 (3) [back to overview]	Proportion of Time During the Study Period When Participants Wear Their Patches
NCT02220712 (1) [back to overview]	OPC-14597 Plasma Concentration 672 Hours Postdose Following Multiple Administration of OPC-14597 IMD Injections
NCT02237417 (1) [back to overview]	Number of Participants With Changes in Fractional Anisotropy (FA)
NCT02360319 (5) [back to overview]	Total Number of Psychiatric Hospitalizations Per Treatment Arm
NCT02360319 (5) [back to overview]	Brief Psychotic Rating Scale (BPRS) Total Score
NCT02360319 (5) [back to overview]	Quality of Life (QLS) Total Score
NCT02360319 (5) [back to overview]	Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Sum of Scores
NCT02360319 (5) [back to overview]	Time to First Hospitalization
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Clinical Global Impression Severity (CGI-S) Score
NCT02431702 (31) [back to overview]	Part-2 (Disease Progression): Time to First Treatment Failure
NCT02431702 (31) [back to overview]	Part 3 (Extended Disease Progression [EDP]): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score
NCT02431702 (31) [back to overview]	Part 3 (EDP): Time to First Treatment Failure
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Working Memory Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Verbal Learning Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Medication Satisfaction Questionnaire (MSQ) Score
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Speed of Processing Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Social Cognition Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Functioning as Measured by the Personal and Social Performance (PSP) Total Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Number of Participants With Change From Baseline in Severity of Psychotic Symptoms, as Measured by Clinician-Rated Dimensions of Psychosis Symptom Severity Scale (CRDPSS)
NCT02431702 (31) [back to overview]	Part 3 (Disease Modification): Change From Baseline in Adjusted Intracortical Myelin Fraction Score as Measured by Inversion Recovery (IR) and Spin Echo Magnetic Resonance Imaging (SE MRI)
NCT02431702 (31) [back to overview]	Part 3 (Disease Modification): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score
NCT02431702 (31) [back to overview]	Part 3 (Disease Modification): Personal and Social Performance (PSP) Total Observed Score
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Adjusted Intracortical Myelin Fraction Score as Measured by Inversion Recovery (IR) and Spin Echo Magnetic Resonance Imaging (MRI)
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Attention/Vigilance Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Functioning as Measured by the Personal and Social Performance (PSP) Total Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Adjusted Intracortical Myelin (ICM) Fraction Score as Measured by Inversion Recovery (IR) and Spin Echo Magnetic Resonance Imaging (MRI)
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Reasoning and Problem Solving: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Attention/Vigilance Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Clinical Global Impression Severity (CGI-S) Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Medication Satisfaction Questionnaire (MSQ) Total Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Reasoning and Problem Solving: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Social Cognition Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Speed of Processing Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Verbal Learning Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Working Memory Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Visual Learning Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Visual Learning Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Number of Participants With Change From Baseline in Severity of Psychotic Symptoms, as Measured by CRDPSS
NCT02435836 (13) [back to overview]	Mean Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score
NCT02435836 (13) [back to overview]	Mean Change From Baseline in PANSS Negative Sub-scale Score by Week
NCT02435836 (13) [back to overview]	Mean Change From Baseline in PANSS Positive Sub-scale Score by Week
NCT02435836 (13) [back to overview]	Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score by Week
NCT02435836 (13) [back to overview]	Mean Change From Baseline in Barnes Akathisia Rating Scale Score (BARS) Total Score by Week
NCT02435836 (13) [back to overview]	Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score by Week
NCT02435836 (13) [back to overview]	Mean Clinical Global Impression of Improvement (CGI-I) by Week
NCT02435836 (13) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT02435836 (13) [back to overview]	Percentage of Participants With ECG Measurements of Potential Clinical Relevance
NCT02435836 (13) [back to overview]	Percentage of Participants With Vital Signs of Potential Clinical Relevance
NCT02435836 (13) [back to overview]	Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) by Week
NCT02435836 (13) [back to overview]	Percentage of Participants With Laboratory Values of Potential Clinical Relevance
NCT02435836 (13) [back to overview]	Mean Change From Baseline in Abnormal Involuntary Movement Scale Score (AIMS) Total Score by Week
NCT02462473 (8) [back to overview]	Patient Satisfaction Survey (PSS) Total Score at Week 0 and 12
NCT02462473 (8) [back to overview]	Number of Participants With Factors Considered in Clinical Decision as Assessed by Clinical Assessment of the Schizophrenia Patient (CASP)
NCT02462473 (8) [back to overview]	Dimensions of Psychosis Symptom Severity Scale (DPSS) Total Score at Week 0 and 12
NCT02462473 (8) [back to overview]	Clinician's Rating Scale of Adherence (CRS) Score at Week 0 and 12
NCT02462473 (8) [back to overview]	Number of Participants With Medication Treatment Modifications (MTM)
NCT02462473 (8) [back to overview]	Adherence to Antipsychotic Medication as Assessed by Brief Adherence Rating Scale (BARS) at Week 0 and 12
NCT02462473 (8) [back to overview]	Antipsychotic Medication Plasma Levels (AMPL) During the Active Assessment Phase at Week 12
NCT02462473 (8) [back to overview]	Clinical Global Impression-Severity (CGI-S) Score at Week 0 and 12
NCT02472652 (2) [back to overview]	Change in Arizona Sexual Experiences Scale (ASEX) Score
NCT02472652 (2) [back to overview]	Prolactin Concentrations ng/ml (Normal Range 4.0 - 15.2ng/ml)
NCT02634320 (6) [back to overview]	Characterization of Healthcare Burden Will be Measured Using the Treatment Services Review, Version 6-Modified for Mental Health (mTSR-6)
NCT02634320 (6) [back to overview]	Number of Participants With Adverse Events
NCT02634320 (6) [back to overview]	Change From Baseline to Last Treatment Visit in Brief Psychiatric Rating Scale (BPRS) Scores
NCT02634320 (6) [back to overview]	Change From Baseline to Last Treatment Visit in Clinical Global Impressions-Severity (CGI-S) Scores
NCT02634320 (6) [back to overview]	Characterization of Family Burden Will be Measured Using the Burden Assessment Scale (BAS)
NCT02634320 (6) [back to overview]	Daily and Social Functioning Will be Measured Using the Heinrichs-Carpenter Quality of Life Scale (QLS)
NCT02722967 (1) [back to overview]	Assessment of the Functionality of an Integrated Call Center for DMS by Adult Subjects With SCH, MDD, or BP1 Who Were Treated With Oral Aripiprazole.
NCT02960763 (3) [back to overview]	Number of Participants With Remission From Depression
NCT02960763 (3) [back to overview]	Psychological Well-Being
NCT02960763 (3) [back to overview]	Serious Adverse Events
NCT03019887 (1) [back to overview]	Number of Participants With Relapse
NCT03179787 (1) [back to overview]	Mean Changes of Aberrant Behavior Checklist-Japanese Version (ABC-J) Irritability Subscale Scores From Baseline.
NCT03198078 (22) [back to overview]	Percentage of Participants Achieving Response
NCT03198078 (22) [back to overview]	Percentage of Participants Achieving Remission
NCT03198078 (22) [back to overview]	Number of Participants With At Least One Occurrence of Suicidal Behavior or Suicidal Ideation as Recorded on Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT03198078 (22) [back to overview]	Change From Baseline to Week 6 in PANSS Positive and Negative Sub-Scales Scores
NCT03198078 (22) [back to overview]	Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 6
NCT03198078 (22) [back to overview]	Mean Change From Baseline in Weight
NCT03198078 (22) [back to overview]	Mean Change From Baseline in Waist Circumference
NCT03198078 (22) [back to overview]	Mean Change From Baseline in Height
NCT03198078 (22) [back to overview]	Mean Change From Baseline in Body Mass Index (BMI)
NCT03198078 (22) [back to overview]	Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT03198078 (22) [back to overview]	Change From Baseline to Week 6 in Clinical Global Impression Severity (CGI-S) Scale Score
NCT03198078 (22) [back to overview]	Number of Participants With Potentially Clinically Relevant Laboratory Test Values
NCT03198078 (22) [back to overview]	Number of Participants With Treatment-emergent AEs (TEAEs), Serious TEAEs, and TEAEs Graded by Severity
NCT03198078 (22) [back to overview]	Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters
NCT03198078 (22) [back to overview]	Number of Participants With Severe Psychotropic Side Effects as Assessed by Udvalg for Kliniske Undersogelser (UKU) Rating Scale
NCT03198078 (22) [back to overview]	Number of Participants With Adverse Events (AEs) and Trial Discontinuation Due to AEs
NCT03198078 (22) [back to overview]	Number of Participants With Cognitive Adverse Effects Assessed by New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)
NCT03198078 (22) [back to overview]	Number of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs
NCT03198078 (22) [back to overview]	Change From Baseline to Week 6 in Children's Global Assessment Scale (CGAS) Total Score
NCT03198078 (22) [back to overview]	Change From Baseline in Simpson Angus Scale (SAS) Total Score
NCT03198078 (22) [back to overview]	Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score
NCT03198078 (22) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
NCT03342963 (4) [back to overview]	Area Under the Plasma Concentration Versus Time Curve 168h (AUC168h) of Aripiprazole in Cohort 1
NCT03342963 (4) [back to overview]	Cmax of Aripiprazole and Sertraline in Cohort 2
NCT03342963 (4) [back to overview]	AUC168h of Aripiprazole and Sertraline in Cohort 2
NCT03342963 (4) [back to overview]	Peak Plasma Concentration (Cmax) of Aripiprazole in Cohort 1
NCT03345979 (7) [back to overview]	Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
NCT03345979 (7) [back to overview]	Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
NCT03345979 (7) [back to overview]	Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9
NCT03345979 (7) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events (AEs)
NCT03345979 (7) [back to overview]	Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9
NCT03345979 (7) [back to overview]	Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25
NCT03345979 (7) [back to overview]	Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25
NCT03408873 (15) [back to overview]	Change in Social and Occupational Functioning Assessment Scale (SOFAS) Score
NCT03408873 (15) [back to overview]	Change in Communication Styles Scale Score
NCT03408873 (15) [back to overview]	Change in Drug Attitude Inventory (DAI) Score
NCT03408873 (15) [back to overview]	Change in the Brief Psychiatric Rating Scale (BPRS) Score
NCT03408873 (15) [back to overview]	Change in Global Assessment of Functioning (GAF) Score
NCT03408873 (15) [back to overview]	Change in Montgomery Asberg Rating Scale (MADRS) Score
NCT03408873 (15) [back to overview]	Change in Oxford Bipolar Knowledge Questionnaires (OBQ) Score
NCT03408873 (15) [back to overview]	Change in Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES 8A) Score
NCT03408873 (15) [back to overview]	Change in Tablets Routine Questionnaire (TRQ, Past Month)
NCT03408873 (15) [back to overview]	Change in Tablets Routine Questionnaire (TRQ, Past Week)
NCT03408873 (15) [back to overview]	Change in The Self-Report Habit Index (SRHI) Score
NCT03408873 (15) [back to overview]	Change in Young Mania Rating Scale (YMRS) Score
NCT03408873 (15) [back to overview]	Change in Clinical Global Impressions (CGI) Score
NCT03408873 (15) [back to overview]	LAI Injection Adherence
NCT03408873 (15) [back to overview]	Change in Attitude Towards Medication Questionnaire (AMSQ) Score
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Barnes Akathisia Rating Scale (BARS) Values
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Simpson Angus Scale (SAS) Values
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Abnormal Involuntary Movement Scale (AIMS) Values
NCT03557931 (8) [back to overview]	Number of Participants With Adverse Event (AE)
NCT03557931 (8) [back to overview]	Concentration at Trough Level (Ctrough) for ASP4345
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Columbia-Suicide Severity Rating Scale (C-SSRS) Values
NCT03557931 (8) [back to overview]	Change From Baseline to Week 12/EoT in University of California San Diego Performance-based Skills Assessment-2 Extended Range (UPSA-2-ER) Total Score
NCT03557931 (8) [back to overview]	Change From Baseline to Week 12/End of Treatment (EoT) in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Neurocognitive Composite Score
NCT03568500 (2) [back to overview]	Participant Adherence
NCT03568500 (2) [back to overview]	Percentage Of Days With Good Patch Coverage
NCT03661983 (1) [back to overview]	Percentage of Participants With Relapse During the Double-blind Randomized Withdrawal Phase
NCT03892889 (2) [back to overview]	Percentage of Participants With Inpatient Psychiatric Hospitalization
NCT03892889 (2) [back to overview]	Percentage of Days With Improved Adherence
NCT04030143 (37) [back to overview]	Plasma Concentration of Aripiprazole 7 Days Post First Dose (C7) of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	Plasma Concentration of Aripiprazole 56 Days Postdose (C56) of Aripiprazole 2M LAI 960 mg After the Fourth Dose
NCT04030143 (37) [back to overview]	Plasma Concentration of Aripiprazole 28 Days Postdose (C28) of Aripiprazole IM Depot 400 mg After the Eighth Dose
NCT04030143 (37) [back to overview]	Plasma Concentration of Aripiprazole 28 Days (C28) After the First Dose of Aripiprazole IM Depot 400 mg
NCT04030143 (37) [back to overview]	Peak-to-Trough Percent Fluctuation (PTF%) After the Fourth Dose of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	Number of Participants With Suicidality as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT04030143 (37) [back to overview]	VAS Scores for Pain Perception of Aripiprazole IM Depot 400 mg
NCT04030143 (37) [back to overview]	Visual Analog Scale (VAS) Scores for Pain Perception of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	Number of Participants With Potentially Clinically Relevant Vital Signs Abnormalities
NCT04030143 (37) [back to overview]	Time to Reach the Maximum Plasma Concentration (Tmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time 0 to 56 Days (AUC0-56) of Aripiprazole After the Fourth Dose of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	AUC0-28 After the First Dose of Aripiprazole IM Depot 400 mg
NCT04030143 (37) [back to overview]	AUC0-28 After the Fourth Dose of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time 29 to 56 Days (AUC29-56) After the Fourth Dose of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	Tmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness Score
NCT04030143 (37) [back to overview]	AUC0-56 After the First Dose of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	Plasma Concentration of Aripiprazole 56 Days (C56) After the First Dose of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg
NCT04030143 (37) [back to overview]	Cmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg
NCT04030143 (37) [back to overview]	PTF% After the Eighth Dose of Aripiprazole IM Depot 400 mg
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Clinical Global Impression - Improvement Scale (CGI-I) Score
NCT04030143 (37) [back to overview]	Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities
NCT04030143 (37) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of Aripiprazole After the Seventh and Eighth Doses of Aripiprazole IM Depot 400 mg
NCT04030143 (37) [back to overview]	Plasma Concentration of Aripiprazole Post First Dose (C14) of Aripiprazole IM Depot 400 mg
NCT04030143 (37) [back to overview]	Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole IM Depot 400 mg Injection
NCT04030143 (37) [back to overview]	Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole 2M LAI 960 mg Injection
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Score
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Simpson-Angus Neurologic Rating Scale (SAS) Total Score
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Barnes Akathisia Rating Score (BARS) Global Score
NCT04030143 (37) [back to overview]	Number of Participants With Potentially Clinically Relevant Clinical Laboratory Abnormalities
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Positive and Negative Syndrome Scale Rating Criteria (PANSS) Total Score
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) Total Score
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
NCT04030143 (37) [back to overview]	Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)
NCT04030143 (37) [back to overview]	Mean Change From Baseline in Clinical Global Impression - Severity Scale (CGI-S) Score
NCT04203056 (3) [back to overview]	Change in Role Ratings on the Global Functioning Scale From Baseline to 12 Months
NCT04203056 (3) [back to overview]	Exacerbation or Relapse of Psychotic Symptoms
NCT04203056 (3) [back to overview]	"Change From Baseline to One-Year in the MATRICS Consensus Cognitive Battery (MCCB) Overall Composite T-Score."

Number Who Discontinued Medication Within First 6 Study Months

(NCT00044655)
Timeframe: Measured at Six Months

Intervention	participants (Number)
Stay	11
Switch	23

Intervention	points (Mean)
Aripiprazole 10 mg/Day Group	2.7
Aripiprazole 30 mg/Day Group	2.5
Placebo Group	3.1

Intervention	points (Mean)
Aripiprazole 10 mg/Day Group	14.7
Aripiprazole 30 mg/Day Group	14.8
Placebo Group	9.8

Intervention	points (Mean)
Aripiprazole 10 mg/Day Group	-1.2
Aripiprazole 30 mg/Day Group	-1.3
Placebo Group	-0.9

Intervention	points (Mean)
Aripiprazole 10 mg/Day Group	-6.9
Aripiprazole 30 mg/Day Group	-6.6
Placebo Group	-5.4

Intervention	points (Mean)
Aripiprazole 10 mg/Day Group	-7.6
Aripiprazole 30 mg/Day Group	-8.1
Placebo Group	-5.6

Intervention	points (Mean)
Aripiprazole 10 mg/Day Group	-26.7
Aripiprazole 30 mg/Day Group	-28.6
Placebo Group	-21.2

Intervention	participants (Number)
	Responders	Nonresponders
Aripiprazole + ADT	81	93
Placebo + ADT	45	124

Intervention	participants (Number)
	Remission	No remission
Aripiprazole + ADT	64	110
Placebo + ADT	32	137

Intervention	points (Mean)
Aripiprazole 10 mg/Day	2.48
Aripiprazole 30 mg/Day	2.41
Placebo	3.47

Intervention	points (Mean)
Aripiprazole 10 mg/Day	2.75
Aripiprazole 30 mg/Day	2.6
Placebo	3.38

Intervention	points (Mean)
Aripiprazole 10 mg/Day	2.4
Aripiprazole 30 mg/Day	2.32
Placebo	3.37

Intervention	points (Mean)
Aripiprazole 10 mg/Day	2.61
Aripiprazole 30 mg/Day	2.45
Placebo	3.26

Intervention	points (Mean)
Aripiprazole 10 mg/Day	2.96
Aripiprazole 30 mg/Day	3.06
Placebo	3.57

Intervention	percentage of participants (Number)
Aripiprazole 10 mg/Day	44.79
Aripiprazole 30 mg/Day	63.64
Placebo	26.09

Intervention	percentage of participants (Number)
Aripiprazole 10 mg/Day	50.00
Aripiprazole 30 mg/Day	55.56
Placebo	26.60

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-14.04
Aripiprazole 30 mg/Day	-16.16
Placebo	-8.67

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-13.91
Aripiprazole 30 mg/Day	-14.6
Placebo	-8.69

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-6.51
Aripiprazole 30 mg/Day	-6.52
Placebo	-4.57

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-6.82
Aripiprazole 30 mg/Day	-7.84
Placebo	-5.23

Intervention	points (Mean)
Aripiprazole 10 mg/Day	0
Aripiprazole 30 mg/Day	-3.24
Placebo	-3.11

aripiprazole

Description

Cross-References

Synonyms (162)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (6)

Pathways (1)

Protein Targets (109)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (566)

Molecular Functions (169)

Ceullar Components (92)

Bioassays (604)

Research

Studies (2,762)

Market Indicators

Research Demand Index: 126.92

Study Types

Clinical Trials (369)

Trial Overview

Trial Outcomes

Number Who Discontinued Medication Within First 6 Study Months

Clinical Global Impression (CGI) Improvement Score

Patients Achieving Remission

Change in Children's Global Assessment Scale (CGAS) Score

Change in Clinical Global Impression (CGI) Severity Score

Change in Pediatric Quality of Life Enjoyment and Satisfaction (PQLES) Questionnaire Total Score

Change in Positive and Negative Syndrome Scale (PANSS) Negative Subscale Score

Change in Positive and Negative Syndrome Scale (PANSS) Positive Subscale Score

Change in Positive and Negative Syndrome Scale (PANSS) Total Score

Change in Change in Positive and Negative Syndrome Scale (PANSS) Total Score

Change in Young Mania Rating Scale (Y-MRS) Total Score

Percentage of Subjects Experiencing SAEs

Mean Change in SDS Item Score (Social Life)

Mean Change in SDS Item Score (Family Life)

MADRS Response

MADRS Remission

Clinical Global Impression (CGI)-Improvement Response

Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS)

Mean Change in Sheehan Disability Scale (SDS) Mean Score

Mean Change in SDS Item Score (Work/School)

Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 4

Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 30

Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 4

Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 30

Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 4

Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 30

Subject Response to Treatment at Week 4

Subject Response to Treatment at Week 30

Change in Young Mania Rating Scale (Y-MRS) Total Score at Week 4

Change in Young Mania Rating Scale (Y-MRS) Total Score at Week 30

Change in General Behavior Inventory Scale (GBI) Total Subject Version Mania Score at Week 4

Change in General Behavior Inventory Scale (GBI) Total Subject Version Mania Score at Week 30

Change in General Behavior Inventory Scale (GBI) Total Subject Version Depression Score at Week 4

Change in General Behavior Inventory Scale (GBI) Total Subject Version Depression Score at Week 30

Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Mania Score at Week 4

Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Mania Score at Week 30

Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Depression Score at Week 4

Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Depression Score at Week 30

Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 4

Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 30

Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 4

Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 30

Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 4

Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 30

Change in Children's Global Assessment Scale (CGAS) Total Score at Week 4

Change in Children's Global Assessment (CGAS) Total Score at Week 30

Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 4

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-4.45
Aripiprazole 30 mg/Day	-4.38
Placebo	-2.7

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-9.66
Aripiprazole 30 mg/Day	-9.1
Placebo	-4.63

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-8.76
Aripiprazole 30 mg/Day	-8.48
Placebo	-5

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-6.12
Aripiprazole 30 mg/Day	-3.71
Placebo	-3.92

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-5.17
Aripiprazole 30 mg/Day	-3.71
Placebo	-3.03

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-1.6
Aripiprazole 30 mg/Day	-1.91
Placebo	-0.84

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-1.59
Aripiprazole 30 mg/Day	-1.75
Placebo	-0.91

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-1.63
Aripiprazole 30 mg/Day	-1.93
Placebo	-1.03

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-0.86
Aripiprazole 30 mg/Day	-0.9
Placebo	-0.57

Intervention	points (Mean)
Aripiprazole 10 mg/Day	-0.71
Aripiprazole 30 mg/Day	-0.94
Placebo	-0.47